

MULTIPLE CONGENITAL ANOMALIES GENE PANEL DG 2.7/DG 2.8

| <i>Gene</i> | <i>Median coverage</i> | <i>% covered > 10x</i> | <i>% covered > 20x</i> | <i>Associated Phenotype description and OMIM disease ID</i> |
|-------------|------------------------|---------------------------|---------------------------|--|
| A2M | 109.0 | 99% | 99% | Alpha-2-macroglobulin deficiency, 614036 {Alzheimer disease, susceptibility to}, 104300 |
| A4GALT | 123.7 | 100% | 100% | NOR polyagglutination syndrome, 111400 [Blood group, P1Pk system, P phenotype], 111400 [Blood group, P1Pk system, p phenotype], 111400 |
| AAAS | 77.2 | 100% | 97% | Achalasia-addisonianism-alacrimia syndrome, 231550 |
| AAGAB | 133.1 | 99% | 92% | Keratoderma, palmoplantar, punctate type IA, 148600 |
| AARS | 112.5 | 99% | 96% | Charcot-Marie-Tooth disease, axonal, type 2N, 613287 Epileptic encephalopathy, early infantile, 29, 616339 |
| AARS2 | 109.2 | 99% | 97% | Combined oxidative phosphorylation deficiency 8, 614096 Leukoencephalopathy, progressive, with ovarian failure, 615889 |
| AASS | 120.8 | 100% | 96% | Hyperlysinemia, 238700 Saccharopinuria, 268700 |
| ABAT | 79.3 | 100% | 100% | GABA-transaminase deficiency, 613163 |
| ABCA1 | 112.7 | 99% | 98% | HDL deficiency, type 2, 604091 Tangier disease, 205400 {Coronary artery disease in familial hypercholesterolemia, protection against}, 143890 |
| ABCA12 | 131.5 | 99% | 96% | Ichthyosis, autosomal recessive 4B (harlequin), 242500 Ichthyosis, congenital, autosomal recessive 4A, 601277 |
| ABCA3 | 109.2 | 99% | 98% | Surfactant metabolism dysfunction, pulmonary, 3, 610921 |
| ABCA4 | 106.1 | 100% | 97% | Cone-rod dystrophy 3, 604116 Fundus flavimaculatus, 248200 Retinal dystrophy, early-onset severe, 248200 Retinitis pigmentosa 19, 601718 Stargardt disease 1, 248200 {Macular degeneration, age-related, 2}, 153800 |
| ABCB11 | 150.3 | 100% | 98% | Cholestasis, benign recurrent intrahepatic, 2, 605479 Cholestasis, progressive familial intrahepatic 2, 601847 |

| | | | | |
|--------|-------|------|------|---|
| ABCB4 | 110.5 | 98% | 94% | Cholestasis, intrahepatic, of pregnancy, 3, 614972 Cholestasis, progressive familial intrahepatic 3, 602347 Gallbladder disease 1, 600803 |
| ABCB6 | 106.3 | 99% | 98% | Dyschromatosis universalis hereditaria 3, 615402 Microphthalmia, isolated, with coloboma 7, 614497 Pseudohyperkalemia, familial, 2, due to red cell leak, 609153 [Blood group, Langereis system], 111600 |
| ABCB7 | 170.5 | 100% | 97% | Anemia, sideroblastic, with ataxia, 301310 |
| ABCC2 | 132.7 | 100% | 100% | Dubin-Johnson syndrome, 237500 |
| ABCC6 | 86.5 | 92% | 90% | Arterial calcification, generalized, of infancy, 2, 614473 Pseudoxanthoma elasticum, 264800 Pseudoxanthoma elasticum, forme fruste, 177850 |
| ABCC8 | 128.1 | 100% | 99% | Diabetes mellitus, noninsulin-dependent, 125853 Diabetes mellitus, permanent neonatal, 606176 Diabetes mellitus, transient neonatal 2, 610374 Hyperinsulinemic hypoglycemia, familial, 1, 256450 Hypoglycemia of infancy, leucine-sensitive, 240800 |
| ABCC9 | 141.6 | 100% | 98% | Atrial fibrillation, familial, 12, 614050 Cardiomyopathy, dilated, 1O, 608569 Hypertrichotic osteochondrodysplasia, 239850 |
| ABCD1 | 95.4 | 73% | 68% | Adrenoleukodystrophy, 300100 Adrenomyeloneuropathy, adult, 300100 |
| ABCD4 | 123.5 | 100% | 98% | Methylmalonic aciduria and homocystinuria, cblJ type, 614857 |
| ABCG5 | 129.0 | 100% | 100% | Sitosterolemia, 210250 |
| ABCG8 | 140.8 | 100% | 96% | Sitosterolemia, 210250 {Gallbladder disease 4}, 611465 |
| ABHD12 | 89.3 | 100% | 88% | Polyneuropathy, hearing loss, ataxia, retinitis pigmentosa, and cataract, 612674 |
| ABHD5 | 206.1 | 100% | 100% | Chanarin-Dorfman syndrome, 275630 |
| ABL1 | 121.5 | 100% | 99% | Leukemia, Philadelphia chromosome-positive, resistant to imatinib |
| ACAD8 | 111.4 | 100% | 100% | Isobutyryl-CoA dehydrogenase deficiency, 611283 |
| ACAD9 | 113.4 | 98% | 94% | Mitochondrial complex I deficiency due to ACAD9 deficiency, 611126 |
| ACADM | 94.6 | 98% | 93% | Acyl-CoA dehydrogenase, medium chain, deficiency of, 201450 |
| ACADS | 113.7 | 99% | 96% | Acyl-CoA dehydrogenase, short-chain, deficiency of, 201470 |
| ACADSB | 111.4 | 96% | 87% | 2-methylbutyrylglycinuria, 610006 |

| | | | | |
|--------|-------|------|------|---|
| ACADVL | 103.2 | 100% | 95% | VLCAD deficiency, 201475 |
| ACAN | 105.3 | 91% | 82% | Osteochondritis dissecans, short stature, and early-onset osteoarthritis, 165800 Spondyloepimetaphyseal dysplasia, aggrecan type, 612813 Spondyloepiphyseal dysplasia, Kimberley type, 608361 |
| ACAT1 | 106.6 | 96% | 84% | Alpha-methylacetoacetic aciduria, 203750 |
| ACE | 98.6 | 92% | 87% | Renal tubular dysgenesis, 267430 [Angiotensin I-converting enzyme, benign serum increase] {Microvascular complications of diabetes 3}, 612624 {Myocardial infarction, susceptibility to} {SARS, progression of} {Stroke, hemorrhagic}, 614519 |
| ACO2 | 106.8 | 94% | 88% | Infantile cerebellar-retinal degeneration, 614559 ?Optic atrophy 9, 616289 |
| ACOX1 | 158.8 | 100% | 100% | Peroxisomal acyl-CoA oxidase deficiency, 264470 |
| ACP5 | 179.2 | 100% | 97% | Spondyloenchondrodysplasia with immune dysregulation, 607944 |
| ACSF3 | 123.6 | 100% | 98% | Combined malonic and methylmalonic aciduria, 614265 |
| ACSL4 | 136.5 | 98% | 89% | Mental retardation, X-linked 63, 300387 |
| ACSL6 | 109.9 | 100% | 98% | Myelodysplastic syndrome Myelogenous leukemia, acute |
| ACTA1 | 82.9 | 100% | 95% | Myopathy, actin, congenital, with cores, 161800 Myopathy, actin, congenital, with excess of thin myofilaments, 161800 Myopathy, congenital, with fiber-type disproportion 1, 255310 Nemaline myopathy 3, autosomal dominant or recessive, 161800 ?Myopathy, scapulohumeroperoneal, 616852 |
| ACTA2 | 126.5 | 100% | 98% | Aortic aneurysm, familial thoracic 6, 611788 Moyamoya disease 5, 614042 Multisystemic smooth muscle dysfunction syndrome, 613834 |
| ACTB | 90.3 | 100% | 90% | Baraitser-Winter syndrome 1, 243310 ?Dystonia, juvenile-onset, 607371 |
| ACTC1 | 143.2 | 100% | 99% | Atrial septal defect 5, 612794 Cardiomyopathy, dilated, 1R, 613424 Cardiomyopathy, hypertrophic, 11, 612098 Left ventricular noncompaction 4, 613424 |
| ACTG1 | 101.9 | 100% | 100% | Baraitser-Winter syndrome 2, 614583 Deafness, autosomal dominant 20/26, 604717 |

| | | | | |
|----------|-------|------|------|--|
| ACTG2 | 118.9 | 99% | 96% | Visceral myopathy, 155310 |
| ACTN1 | 128.7 | 100% | 99% | Bleeding disorder, platelet-type, 15, 615193 |
| ACTN2 | 132.6 | 100% | 100% | Cardiomyopathy, dilated, 1AA, with or without LVNC, 612158 Cardiomyopathy, hypertrophic, 23, with or without LVNC, 612158 |
| ACTN4 | 113.0 | 100% | 100% | Glomerulosclerosis, focal segmental, 1, 603278 |
| ACVR1 | 142.8 | 100% | 98% | Fibrodysplasia ossificans progressiva, 135100 |
| ACVR1B | 149.7 | 99% | 94% | Pancreatic cancer, somatic |
| ACVR2B | 125.8 | 95% | 90% | Heterotaxy, visceral, 4, autosomal, 613751 |
| ACVRL1 | 106.2 | 99% | 97% | Telangiectasia, hereditary hemorrhagic, type 2, 600376 |
| ACY1 | 121.8 | 99% | 95% | Aminoacylase 1 deficiency, 609924 |
| ADA | 96.3 | 98% | 95% | Adenosine deaminase deficiency, partial, 102700 Severe combined immunodeficiency due to ADA deficiency, 102700 |
| ADAM10 | 131.1 | 99% | 98% | Reticulate acropigmentation of Kitamura, 615537 {Alzheimer disease 18, susceptibility to}, 615590 |
| ADAM9 | 134.7 | 100% | 94% | Cone-rod dystrophy 9, 612775 |
| ADAMTS10 | 93.0 | 99% | 96% | Weill-Marchesani syndrome 1, recessive, 277600 |
| ADAMTS13 | 93.0 | 95% | 91% | Thrombotic thrombocytopenic purpura, familial, 274150 |
| ADAMTS17 | 105.9 | 88% | 87% | Weill-Marchesani-like syndrome, 613195 |
| ADAMTS18 | 140.7 | 100% | 98% | Microcornea, myopic chorioretinal atrophy, and telecanthus, 615458 |
| ADAMTS2 | 108.0 | 100% | 96% | Ehlers-Danlos syndrome, type VIIC, 225410 |
| ADAMTSL2 | 98.4 | 87% | 82% | Geleophysic dysplasia 1, 231050 |
| ADAMTSL4 | 77.7 | 99% | 98% | Ectopia lentis et pupillae, 225200 Ectopia lentis, isolated, autosomal recessive, 225100 |
| ADAR | 106.4 | 100% | 98% | Aicardi-Goutieres syndrome 6, 615010 Dyschromatosis symmetrica hereditaria, 127400 |
| ADAT3 | 66.4 | 100% | 97% | Mental retardation, autosomal recessive 36, 615286 |
| ADCK3 | 113.7 | 100% | 99% | Coenzyme Q10 deficiency, primary, 4, 612016 |
| ADCK4 | 84.7 | 100% | 99% | Nephrotic syndrome, type 9, 615573 |
| ADCY5 | 113.8 | 92% | 89% | Dyskinesia, familial, with facial myokymia, 606703 |
| ADD3 | 157.7 | 99% | 98% | Cerebral palsy, spastic quadriplegic, 3, 617008 |
| ADIPOQ | 113.0 | 100% | 100% | Adiponectin deficiency, 612556 |
| ADK | 84.1 | 99% | 93% | Hypermethioninemia due to adenosine kinase deficiency, 614300 |
| ADNP | 210.8 | 100% | 99% | Helsmoortel-van der Aa syndrome, 615873 |
| ADRA2B | 172.1 | 100% | 100% | Epilepsy, myoclonic, familial adult, 2, 607876 |

| | | | | |
|--------|-------|------|------|--|
| ADSL | 152.2 | 100% | 100% | Adenylosuccinase deficiency, 103050 |
| ADSSL1 | 109.3 | 98% | 90% | Myopathy, distal, 5, 617030 |
| AFF2 | 152.0 | 100% | 100% | Mental retardation, X-linked, FRAXE type, 309548 |
| AFF4 | 101.4 | 96% | 95% | CHOPS syndrome, 616368 |
| AFG3L2 | 96.0 | 89% | 78% | Ataxia, spastic, 5, autosomal recessive, 614487 Spinocerebellar ataxia 28, 610246 |
| AGA | 130.4 | 100% | 100% | Aspartylglucosaminuria, 208400 |
| AGBL1 | 120.0 | 99% | 99% | Corneal dystrophy, Fuchs endothelial, 8, 615523 |
| AGBL5 | 96.7 | 99% | 97% | Retinitis pigmentosa 75, 617023 |
| AGK | 113.9 | 98% | 94% | Cataract 38, autosomal recessive, 614691 Sengers syndrome, 212350 |
| AGL | 133.0 | 100% | 97% | Glycogen storage disease IIIa, 232400 Glycogen storage disease IIIb, 232400 |
| AGPAT2 | 103.0 | 99% | 94% | Lipodystrophy, congenital generalized, type 1, 608594 |
| AGPS | 49.4 | 94% | 78% | Rhizomelic chondrodysplasia punctata, type 3, 600121 |
| AGRN | 103.1 | 97% | 90% | Myasthenic syndrome, congenital, 8, with pre- and postsynaptic defects, 615120 |
| AGT | 157.6 | 100% | 100% | Renal tubular dysgenesis, 267430 {Hypertension, essential, susceptibility to}, 145500 {Preeclampsia, susceptibility to} |
| AGTR1 | 132.6 | 100% | 100% | Renal tubular dysgenesis, 267430 {Hypertension, essential}, 145500 |
| AGXT | 125.0 | 100% | 100% | Hyperoxaluria, primary, type 1, 259900 |
| AHCY | 106.4 | 100% | 98% | Hypermethioninemia with deficiency of S-adenosylhomocysteine hydrolase, 613752 |
| AHDC1 | 110.1 | 100% | 96% | Xia-Gibbs syndrome, 615829 |
| AHI1 | 123.6 | 99% | 91% | Joubert syndrome-3, 608629 |
| AICDA | 115.0 | 99% | 97% | Immunodeficiency with hyper-IgM, type 2, 605258 |
| AIFM1 | 143.5 | 100% | 100% | Combined oxidative phosphorylation deficiency 6, 300816 Cowchock syndrome, 310490 Deafness, X-linked 5, 300614 |
| AIMP1 | 84.3 | 97% | 91% | Leukodystrophy, hypomyelinating, 3, 260600 |
| AIP | 135.3 | 98% | 95% | Pituitary adenoma, ACTH-secreting, 219090 Pituitary adenoma, growth hormone-secreting, 102200 Pituitary adenoma, prolactin-secreting, 600634 |

| | | | | |
|----------|-------|------|------|---|
| AIPL1 | 107.4 | 100% | 100% | Cone-rod dystrophy, 604393 Leber congenital amaurosis 4, 604393 Retinitis pigmentosa, juvenile, 604393 |
| AIRE | 69.3 | 98% | 91% | Autoimmune polyendocrinopathy syndrome , type I, with or without reversible metaphyseal dysplasia, 240300 |
| AK1 | 95.6 | 100% | 100% | Hemolytic anemia due to adenylate kinase deficiency, 612631 |
| AK2 | 91.7 | 97% | 88% | Reticular dysgenesis, 267500 |
| AKR1C2 | 139.6 | 95% | 84% | 46XY sex reversal 8, 614279 Obesity, hyperphagia, and developmental delay |
| AKR1D1 | 89.3 | 93% | 87% | Bile acid synthesis defect, congenital, 2, 235555 |
| AKT1 | 148.4 | 100% | 98% | Breast cancer, somatic, 114480 Colorectal cancer, somatic, 114500 Cowden syndrome 6, 615109 Ovarian cancer, somatic, 167000 Proteus syndrome, somatic, 176920 {Schizophrenia, susceptibility to}, 181500 |
| AKT2 | 125.5 | 99% | 98% | Diabetes mellitus, type II, 125853 Hypoinsulinemic hypoglycemia with hemihypertrophy, 240900 |
| AKT3 | 69.2 | 99% | 89% | Megalencephaly-polymicrogyria-polydactyly-hydrocephalus syndrome 2, 615937 |
| ALAD | 99.9 | 100% | 100% | Porphyria, acute hepatic, 612740 {Lead poisoning, susceptibility to}, 612740 |
| ALAS2 | 110.7 | 100% | 96% | Anemia, sideroblastic, 1, 300751 Protoporphria, erythropoietic, X-linked, 300752 |
| ALB | 141.4 | 100% | 97% | Analbuminemia, 616000 [Dysalbuminemic hyperthyroxinemia], 615999 |
| ALDH18A1 | 115.4 | 100% | 99% | Cutis laxa, autosomal dominant 3, 616603 Cutis laxa, autosomal recessive, type IIIA, 219150 Spastic paraplegia 9A, autosomal dominant, 601162 Spastic paraplegia 9B, autosomal recessive, 616586 |
| ALDH1A3 | 101.2 | 94% | 91% | Microphthalmia, isolated 8, 615113 |
| ALDH2 | 108.7 | 100% | 98% | Alcohol sensitivity, acute, 610251 {Esophageal cancer, alcohol-related, susceptibility to} {Hangover, susceptibility to}, 610251 {Sublingual nitroglycerin, susceptibility to poor response to} |
| ALDH3A2 | 122.0 | 100% | 100% | Sjogren-Larsson syndrome, 270200 |

| | | | | |
|---------|-------|------|------|--|
| ALDH4A1 | 104.2 | 98% | 97% | Hyperprolinemia, type II, 239510 |
| ALDH5A1 | 71.5 | 90% | 80% | Succinic semialdehyde dehydrogenase deficiency, 271980 |
| ALDH6A1 | 113.1 | 100% | 100% | Methylmalonate semialdehyde dehydrogenase deficiency, 614105 |
| ALDH7A1 | 62.7 | 91% | 83% | Epilepsy, pyridoxine-dependent, 266100 |
| ALDOA | 148.8 | 100% | 96% | Glycogen storage disease XII, 611881 |
| ALDOB | 136.6 | 100% | 98% | Fructose intolerance, 229600 |
| ALG1 | 49.1 | 52% | 47% | Congenital disorder of glycosylation, type I κ , 608540 |
| ALG11 | 144.7 | 100% | 100% | Congenital disorder of glycosylation, type I ρ , 613661 |
| ALG12 | 132.7 | 100% | 100% | Congenital disorder of glycosylation, type I γ , 607143 |
| ALG13 | 105.4 | 100% | 96% | Epileptic encephalopathy, early infantile, 36, 300884 |
| ALG2 | 95.5 | 100% | 100% | Myasthenic syndrome, congenital, 14, with tubular aggregates, 616228 ?Congenital disorder of glycosylation, type I ι , 607906 |
| ALG3 | 99.2 | 100% | 99% | Congenital disorder of glycosylation, type I δ , 601110 |
| ALG6 | 90.4 | 95% | 94% | Congenital disorder of glycosylation, type I ϵ , 603147 |
| ALG8 | 118.3 | 95% | 92% | Congenital disorder of glycosylation, type I η , 608104 |
| ALG9 | 112.0 | 100% | 98% | Congenital disorder of glycosylation, type I ζ , 608776 Gillessen-Kaesbach-Nishimura syndrome, 263210 |
| ALMS1 | 157.8 | 99% | 99% | Alstrom syndrome, 203800 |
| ALOX12B | 118.1 | 100% | 98% | Ichthyosis, congenital, autosomal recessive 2, 242100 |
| ALOXE3 | 117.1 | 100% | 99% | Ichthyosis, congenital, autosomal recessive 3, 606545 |
| ALPL | 135.2 | 100% | 100% | Hypophosphatasia, adult, 146300 Hypophosphatasia, childhood, 241510 Hypophosphatasia, infantile, 241500 Odontohypophosphatasia, 146300 |
| ALS2 | 144.4 | 100% | 99% | Amyotrophic lateral sclerosis 2, juvenile, 205100 Primary lateral sclerosis, juvenile, 606353 Spastic paralysis, infantile onset ascending, 607225 |
| ALX3 | 102.9 | 82% | 69% | Frontonasal dysplasia 1, 136760 |
| ALX4 | 102.9 | 94% | 84% | Frontonasal dysplasia 2, 613451 Parietal foramina 2, 609597 {Craniosynostosis 5, susceptibility to}, 615529 |
| AMACR | 130.5 | 100% | 99% | Alpha-methylacyl-CoA racemase deficiency, 614307 Bile acid synthesis defect, congenital, 4, 214950 |
| AMBN | 142.2 | 94% | 88% | Amelogenesis imperfecta, type I β , 616270 |

| | | | | |
|---------|-------|------|------|--|
| AMELX | 99.8 | 100% | 99% | Amelogenesis imperfecta, type 1E, 301200 |
| AMER1 | 108.5 | 100% | 99% | Osteopathia striata with cranial sclerosis, 300373 |
| AMH | 32.1 | 96% | 67% | Persistent Mullerian duct syndrome, type I, 261550 |
| AMHR2 | 115.9 | 99% | 98% | Persistent Mullerian duct syndrome, type II, 261550 |
| AMN | 51.5 | 78% | 66% | Megaloblastic anemia-1, Norwegian type, 261100 |
| AMPD1 | 117.1 | 100% | 100% | Myopathy due to myoadenylate deaminase deficiency, 615511 |
| AMPD2 | 117.6 | 100% | 96% | Pontocerebellar hypoplasia, type 9, 615809 ?Spastic paraplegia 63, 615686 |
| AMT | 134.3 | 100% | 98% | Glycine encephalopathy, 605899 |
| ANG | 147.9 | 100% | 96% | Amyotrophic lateral sclerosis 9, 611895 |
| ANGPTL3 | 82.2 | 92% | 88% | Hypobetalipoproteinemia, familial, 2, 605019 |
| ANK1 | 118.9 | 100% | 98% | Spherocytosis, type 1, 182900 |
| ANK2 | 133.8 | 99% | 99% | Cardiac arrhythmia, ankyrin-B-related, 600919 Long QT syndrome 4, 600919 |
| ANKH | 97.5 | 100% | 100% | Chondrocalcinosis 2, 118600 Craniometaphyseal dysplasia, 123000 |
| ANKK1 | 120.0 | 100% | 98% | Dopamine receptor D2, reduced brain density of, 608774 |
| ANKRD11 | 87.9 | 94% | 90% | KBG syndrome, 148050 |
| ANKRD26 | 71.0 | 88% | 74% | Thrombocytopenia 2, 188000 |
| ANKS6 | 79.4 | 91% | 84% | Nephronophthisis 16, 615382 |
| ANLN | 129.3 | 98% | 91% | Focal segmental glomerulosclerosis 8, 616032 |
| ANO10 | 102.8 | 100% | 95% | Spinocerebellar ataxia, autosomal recessive 10, 613728 |
| ANO3 | 141.4 | 99% | 98% | Dystonia 24, 615034 |
| ANO5 | 128.6 | 99% | 95% | Gnathodiaphyseal dysplasia, 166260 Miyoshi muscular dystrophy 3, 613319 Muscular dystrophy, limb-girdle, type 2L, 611307 |
| ANO6 | 113.4 | 97% | 92% | Scott syndrome, 262890 |
| ANTXR1 | 113.9 | 98% | 95% | GAPO syndrome, 230740 {Hemangioma, capillary infantile, susceptibility to}, 602089 |
| ANTXR2 | 79.9 | 100% | 90% | Hyaline fibromatosis syndrome, 228600 |
| AP1S1 | 104.8 | 100% | 99% | MEDNIK syndrome, 609313 |
| AP1S2 | 77.4 | 74% | 70% | Mental retardation, X-linked syndromic 5, 304340 |
| AP2S1 | 132.4 | 88% | 88% | Hypocalciuric hypercalcemia, familial, type III, 600740 |
| AP3B1 | 90.0 | 93% | 86% | Hermansky-Pudlak syndrome 2, 608233 |

| | | | | |
|--------|-------|------|------|--|
| AP4B1 | 131.8 | 99% | 97% | Spastic paraplegia 47, autosomal recessive, 614066 |
| AP4E1 | 95.1 | 100% | 98% | Spastic paraplegia 51, autosomal recessive, 613744 Stuttering, familial persistent, 1, 184450 |
| AP4M1 | 98.9 | 99% | 97% | Spastic paraplegia 50, autosomal recessive, 612936 |
| AP4S1 | 58.7 | 68% | 68% | Spastic paraplegia 52, autosomal recessive, 614067 |
| AP5Z1 | 78.1 | 100% | 99% | Spastic paraplegia 48, autosomal recessive, 613647 |
| APC | 143.0 | 100% | 99% | Adenoma, periampullary, somatic Adenomatous polyposis coli, 175100 Brain tumor-polyposis syndrome 2, 175100 Colorectal cancer, somatic, 114500 Desmoid disease, hereditary, 135290 Gardner syndrome, 175100 Gastric cancer, somatic, 613659 Hepatoblastoma, somatic, 114550 |
| APCDD1 | 132.0 | 98% | 93% | Hypotrichosis 1, 605389 |
| APOA1 | 81.5 | 100% | 100% | Amyloidosis, 3 or more types, 105200 ApoA-I and apoC-III deficiency, combined Corneal clouding, autosomal recessive Hypoalphalipoproteinemia, 604091 |
| APOA2 | 103.4 | 81% | 81% | Apolipoprotein A-II deficiency, 107670 {Hypercholesterolemia, familial, modifier of}, 143890 |
| APOA5 | 121.2 | 100% | 100% | Hyperchylomicronemia, late-onset, 144650 {Hypertriglyceridemia, susceptibility to}, 145750 |
| APOB | 166.0 | 99% | 99% | Hypercholesterolemia, due to ligand-defective apo B, 144010 Hypobetalipoproteinemia, 615558 |
| APOC2 | 83.2 | 100% | 100% | Hyperlipoproteinemia, type Ib, 207750 |
| APOC3 | 75.8 | 100% | 100% | Apolipoprotein C-III deficiency, 614028 |
| APOE | 50.3 | 96% | 85% | Alzheimer disease-2, 104310 Hyperlipoproteinemia, type III Lipoprotein glomerulopathy, 611771 Sea-blue histiocyte disease, 269600 {?Macular degeneration, age-related}, 603075 {Myocardial infarction susceptibility} |
| APOPT1 | 69.1 | 87% | 86% | Mitochondrial complex IV deficiency, 220110 |

| | | | | |
|----------|-------|------|------|--|
| APP | 133.9 | 100% | 100% | Alzheimer disease 1, familial, 104300 Cerebral amyloid angiopathy, Dutch, Italian, Iowa, Flemish, Arctic variants, 605714 |
| APRT | 56.4 | 100% | 100% | Adenine phosphoribosyltransferase deficiency, 614723 |
| APTX | 108.5 | 94% | 91% | Ataxia, early-onset, with oculomotor apraxia and hypoalbuminemia, 208920 |
| AQP2 | 109.4 | 100% | 93% | Diabetes insipidus, nephrogenic, 125800 |
| AQP5 | 94.5 | 98% | 93% | Palmoplantar keratoderma, Bothnian type, 600231 |
| AR | 91.4 | 94% | 89% | Androgen insensitivity, 300068 Androgen insensitivity, partial, with or without breast cancer, 312300 Hypospadias 1, X-linked, 300633 Spinal and bulbar muscular atrophy of Kennedy, 313200 {Prostate cancer, susceptibility to}, 176807 |
| ARFGEF2 | 140.9 | 99% | 98% | Periventricular heterotopia with microcephaly, 608097 |
| ARG1 | 131.0 | 100% | 100% | Argininemia, 207800 |
| ARHGAP26 | 126.8 | 100% | 100% | Leukemia, juvenile myelomonocytic, somatic, 607785 |
| ARHGAP31 | 98.4 | 99% | 97% | Adams-Oliver syndrome 1, 100300 |
| ARHGDIA | 121.4 | 100% | 100% | Nephrotic syndrome, type 8, 615244 |
| ARHGEF6 | 169.9 | 95% | 93% | Mental retardation, X-linked 46, 300436 |
| ARHGEF9 | 106.1 | 100% | 99% | Epileptic encephalopathy, early infantile, 8, 300607 |
| ARID1A | 112.7 | 93% | 88% | Coffin-Siris syndrome 2, 614607 |
| ARID1B | 121.6 | 92% | 87% | Coffin-Siris syndrome 1, 135900 |
| ARL13B | 88.6 | 100% | 91% | Joubert syndrome 8, 612291 |
| ARL2BP | 63.3 | 86% | 76% | Retinitis pigmentosa with or without situs inversus, 615434 |
| ARL6 | 85.2 | 99% | 93% | Bardet-Biedl syndrome 3, 600151 ?Retinitis pigmentosa 55, 613575 {Bardet-Biedl syndrome 1, modifier of}, 209900 |
| ARMC4 | 113.7 | 90% | 89% | Ciliary dyskinesia, primary, 23, 615451 |
| ARMC5 | 99.8 | 100% | 99% | ACTH-independent macronodular adrenal hyperplasia 2, 615954 |
| ARSA | 91.7 | 100% | 100% | Metachromatic leukodystrophy, 250100 |
| ARSB | 115.5 | 98% | 94% | Mucopolysaccharidosis type VI (Maroteaux-Lamy), 253200 |
| ARSE | 109.5 | 100% | 98% | Chondrodysplasia punctata, X-linked recessive, 302950 |
| ARV1 | 122.2 | 100% | 98% | Epileptic encephalopathy, early infantile, 38, 617020 |

| | | | | |
|---------|-------|------|-----|---|
| ARX | 38.5 | 87% | 73% | Epileptic encephalopathy, early infantile, 1, 308350 Hydranencephaly with abnormal genitalia, 300215 Lissencephaly, X-linked 2, 300215 Mental retardation, X-linked 29 and others, 300419 Partington syndrome, 309510 Proud syndrome, 300004 |
| ASAHI | 109.1 | 99% | 84% | Farber lipogranulomatosis, 228000 Spinal muscular atrophy with progressive myoclonic epilepsy, 159950 |
| ASB10 | 97.0 | 100% | 99% | Glaucoma 1, open angle, F, 603383 |
| ASCC1 | 141.7 | 93% | 91% | Barrett esophagus/esophageal adenocarcinoma, 614266 ?Spinal muscular atrophy with congenital bone fractures 2,616867 |
| ASCL1 | 155.3 | 79% | 73% | Central hypoventilation syndrome, congenital, 209880 Haddad syndrome, 209880 |
| ASL | 91.7 | 100% | 98% | Argininosuccinic aciduria, 207900 |
| ASNS | 85.2 | 97% | 87% | Asparagine synthetase deficiency, 615574 |
| ASPA | 112.6 | 97% | 91% | Canavan disease, 271900 |
| ASPH | 105.2 | 97% | 91% | Traboulsi syndrome, 601552 |
| ASPM | 94.8 | 97% | 91% | Microcephaly 5, primary, autosomal recessive, 608716 |
| ASPSCR1 | 83.6 | 100% | 96% | Alveolar soft-part sarcoma, 606243 |
| ASS1 | 81.1 | 98% | 89% | Citrullinemia, 215700 |
| ASXL1 | 135.3 | 99% | 98% | Bohring-Opitz syndrome, 605039 Myelodysplastic syndrome, somatic, 614286 |
| ASXL3 | 139.1 | 99% | 98% | Bainbridge-Ropers syndrome, 615485 |
| ATCAY | 136.6 | 100% | 99% | Ataxia, cerebellar, Cayman type, 601238 |
| ATF6 | 122.4 | 100% | 99% | Achromatopsia 7, 616517 |
| ATIC | 104.3 | 100% | 98% | AICA-ribosiduria due to ATIC deficiency, 608688 |
| ATL1 | 162.1 | 99% | 93% | Neuropathy, hereditary sensory, type ID, 613708 Spastic paraparesis 3A, autosomal dominant, 182600 |
| ATL3 | 110.4 | 96% | 93% | Neuropathy, hereditary sensory, type IF, 615632 |
| ATM | 101.4 | 98% | 92% | Ataxia-telangiectasia, 208900 Lymphoma, B-cell non-Hodgkin, somatic Lymphoma, mantle cell, somatic T-cell prolymphocytic leukemia, somatic {Breast cancer, susceptibility to}, 114480 |

| | | | | |
|----------|-------|------|------|---|
| ATN1 | 98.3 | 98% | 94% | Dentatorubro-pallidoluysian atrophy, 125370 |
| ATOH7 | 82.8 | 91% | 80% | Persistent hyperplastic primary vitreous, autosomal recessive, 221900 |
| ATP13A2 | 106.7 | 100% | 98% | Kufor-Rakeb syndrome, 606693 ?Ceroid lipofuscinosis, neuronal, 12, 606693 |
| ATP1A2 | 170.2 | 100% | 100% | Alternating hemiplegia of childhood, 104290 Migraine, familial basilar, 602481 Migraine, familial hemiplegic, 2, 602481 |
| ATP1A3 | 161.8 | 100% | 100% | Alternating hemiplegia of childhood 2, 614820 CAPOS syndrome, 601338 Dystonia-12, 128235 |
| ATP2A1 | 136.4 | 100% | 100% | Brody myopathy, 601003 |
| ATP2A2 | 153.1 | 100% | 98% | Acrokeratosis verruciformis, 101900 Darier disease, 124200 |
| ATP2C1 | 113.4 | 100% | 97% | Hailey-Hailey disease, 169600 |
| ATP6AP1 | 128.2 | 100% | 100% | Immunodeficiency 47, 300972 |
| ATP6V0A2 | 122.9 | 100% | 100% | Cutis laxa, autosomal recessive, type IIA, 219200 Wrinkly skin syndrome, 278250 |
| ATP6V0A4 | 108.7 | 99% | 97% | Renal tubular acidosis, distal, autosomal recessive, 602722 |
| ATP6V1B1 | 158.9 | 100% | 100% | Renal tubular acidosis with deafness, 267300 |
| ATP6V1B2 | 133.9 | 100% | 99% | Deafness, congenital, with onychodystrophy, autosomal dominant, 124480 Zimmermann-Laband syndrome 2, 616455 |
| ATP7A | 159.5 | 99% | 98% | Menkes disease, 309400 Occipital horn syndrome, 304150 Spinal muscular atrophy, distal, X-linked 3, 300489 |
| ATP7B | 134.6 | 100% | 98% | Wilson disease, 277900 |
| ATP8B1 | 133.1 | 96% | 93% | Cholestasis, benign recurrent intrahepatic, 243300 Cholestasis, intrahepatic, of pregnancy, 1, 147480 Cholestasis, progressive familial intrahepatic 1, 211600 |
| ATPAF2 | 90.3 | 100% | 98% | Mitochondrial complex V (ATP synthase) deficiency, nuclear type 1, 604273 |
| ATR | 129.0 | 98% | 95% | Seckel syndrome 1, 210600 ?Cutaneous telangiectasia and cancer syndrome, familial, 614564 |
| ATRX | 96.7 | 99% | 97% | Alpha-thalassemia myelodysplasia syndrome, somatic, 300448 Alpha-thalassemia/mental retardation syndrome, 301040 Mental retardation-hypotonic facies syndrome, X-linked, 309580 |

| | | | | |
|----------|-------|------|------|--|
| ATXN1 | 125.8 | 100% | 100% | Spinocerebellar ataxia 1, 164400 |
| ATXN10 | 133.1 | 95% | 92% | Spinocerebellar ataxia 10, 603516 |
| ATXN2 | 87.7 | 91% | 79% | Spinocerebellar ataxia 2, 183090 {Amyotrophic lateral sclerosis, susceptibility to, 13}, 183090 {Parkinson disease, late-onset, susceptibility to}, 168600 |
| ATXN3 | 92.8 | 98% | 90% | Machado-Joseph disease, 109150 |
| ATXN7 | 110.3 | 95% | 91% | Spinocerebellar ataxia 7, 164500 |
| ATXN8OS | NC | NC | NC | Spinocerebellar ataxia 8, 608768 |
| AUH | 75.2 | 100% | 95% | 3-methylglutaconic aciduria, type I, 250950 |
| AURKC | 75.0 | 99% | 94% | Spermatogenic failure 5,243060 |
| AUTS2 | 89.7 | 96% | 93% | Mental retardation, autosomal dominant 26,615834 |
| AVP | 35.3 | 84% | 37% | Diabetes insipidus, neurohypophyseal, 125700 |
| AVPR2 | 139.2 | 100% | 97% | Diabetes insipidus, nephrogenic, 304800 Nephrogenic syndrome of inappropriate antidiuresis, 300539 |
| AXIN1 | 130.6 | 99% | 97% | Hepatocellular carcinoma, somatic, 114550 ?Caudal duplication anomaly, 607864 |
| AXIN2 | 102.6 | 100% | 98% | Colorectal cancer, somatic, 114500 Oligodontia-colorectal cancer syndrome, 608615 |
| B2M | 276.5 | 100% | 100% | Immunodeficiency 43, 241600 ?Amyloidosis, familial visceral, 105200 |
| B3GALNT2 | 102.7 | 92% | 91% | Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies, type A, 11, 615181 |
| B3GALT6 | 47.2 | 74% | 69% | Ehlers-Danlos syndrome, progeroid type, 2, 615349 Spondyloepimetaphyseal dysplasia with joint laxity, type 1, with or without fractures, 271640 |
| B3GALTL | 81.5 | 92% | 86% | Peters-plus syndrome, 261540 |
| B3GAT3 | 79.7 | 100% | 92% | Multiple joint dislocations, short stature, craniofacial dysmorphism, with or without congenital heart defects, 245600 |
| B3GNT1 | 103.0 | 100% | 100% | Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 13, 615287 |
| B4GALNT1 | 122.6 | 99% | 90% | Spastic paraplegia 26, autosomal recessive, 609195 |
| B4GALT1 | 114.6 | 100% | 98% | Congenital disorder of glycosylation, type II ^d , 607091 |
| B4GALT7 | 84.2 | 99% | 94% | Ehlers-Danlos syndrome with short stature and limb anomalies, 130070 |
| B9D2 | 82.6 | 100% | 100% | Meckel syndrome 10, 614175 |
| BAAT | 112.3 | 97% | 93% | Hypercholanemia, familial, 607748 |
| BAG3 | 110.6 | 100% | 98% | Cardiomyopathy, dilated, 1HH, 613881 Myopathy, myofibrillar, 6, 612954 |

| | | | | |
|--------|-------|------|------|--|
| BANF1 | 60.0 | 99% | 95% | Nestor-Guillermo progeria syndrome, 614008 |
| BAP1 | 118.9 | 100% | 98% | Tumor predisposition syndrome, 614327 |
| BAX | 70.4 | 85% | 84% | Colorectal cancer, somatic, 114500 T-cell acute lymphoblastic leukemia, somatic, 613065 |
| BBS1 | 134.0 | 100% | 100% | Bardet-Biedl syndrome 1, 209900 |
| BBS10 | 143.8 | 100% | 99% | Bardet-Biedl syndrome 10, 615987 |
| BBS12 | 175.6 | 100% | 100% | Bardet-Biedl syndrome 12, 615989 |
| BBS2 | 168.7 | 100% | 100% | Bardet-Biedl syndrome 2, 615981 Retinitis pigmentosa 74, 616562 |
| BBS4 | 129.9 | 100% | 98% | Bardet-Biedl syndrome 4, 615982 |
| BBS5 | 104.0 | 96% | 90% | Bardet-Biedl syndrome 5, 615983 |
| BBS7 | 113.1 | 93% | 87% | Bardet-Biedl syndrome 7, 615984 |
| BBS9 | 96.9 | 95% | 92% | Bardet-Biedl syndrome 9, 615986 |
| BCAP31 | 77.9 | 99% | 92% | Deafness, dystonia, and cerebral hypomyelination, 300475 |
| BCHE | 147.0 | 100% | 98% | Apnea, postanesthetic, 177400 |
| BCKDHA | 140.4 | 100% | 98% | Maple syrup urine disease, type Ia, 248600 |
| BCKDHB | 93.9 | 93% | 90% | Maple syrup urine disease, type Ib, 248600 |
| BCKDK | 144.0 | 100% | 100% | Branched-chain ketoacid dehydrogenase kinase deficiency, 614923 |
| BCL10 | 82.6 | 100% | 98% | Lymphoma, MALT, somatic, 137245 ?Immunodeficiency 37, 616098 {Lymphoma, follicular, somatic}, 605027 {Male germ cell tumor, somatic}, 273300, {Mesothelioma, somatic}, 156240 {Sezary syndrome, somatic}, |
| BCL11A | 121.7 | 98% | 97% | Intellectual development disorder with persistence of fetal hemoglobin, 617101 |
| BCL2 | 109.5 | 100% | 90% | Leukemia/lymphoma, B-cell, 2, 151430 |
| BCL7A | 127.0 | 100% | 100% | B-cell non-Hodgkin lymphoma, high-grade |
| BCMO1 | 151.4 | 100% | 100% | Hypercarotenemia and vitamin A deficiency, autosomal dominant, 115300 |
| BCOR | 135.5 | 100% | 98% | Microphthalmia, syndromic 2, 300166 |
| BCR | 93.8 | 88% | 82% | Leukemia, acute lymphocytic, somatic, 613065 Leukemia, chronic myeloid, somatic, 608232 |
| BCS1L | 145.9 | 100% | 100% | Bjornstad syndrome, 262000 GRACILE syndrome, 603358 Leigh syndrome, 256000 |

| | | | | |
|---------|-------|------|------|---|
| | | | | Mitochondrial complex III deficiency, nuclear type 1, 124000 |
| BDNF | 152.9 | 100% | 100% | Central hypoventilation syndrome, congenital, 209880 {Anorexia nervosa, susceptibility to}, 610269 {Bulimia nervosa, age of onset of weight loss in}, 607499 {Memory impairment, susceptibility to} {Obsessive-compulsive disorder, protection against}, 164230 |
| BEAN1 | 102.6 | 97% | 87% | Spinocerebellar ataxia 31,117210 |
| BEST1 | 120.9 | 97% | 92% | Bestrophinopathy, autosomal recessive, 611809 Macular dystrophy, vitelliform, 2, 153700 Microcornea, rod-cone dystrophy, cataract, and posterior staphyloma, 193220 Retinitis pigmentosa, concentric, 613194 Retinitis pigmentosa-50, 613194 Vitreoretinochoroidopathy, 193220 |
| BFSP1 | 90.5 | 99% | 85% | Cataract 33, 611391 |
| BFSP2 | 78.8 | 97% | 94% | Cataract 12, multiple types, 611597 |
| BGN | 136.1 | 100% | 100% | Spondyloepimetaphyseal dysplasia, X-linked, 300106 |
| BHLHA9 | 12.2 | 51% | 37% | Syndactyly, mesoaxial synostotic, with phalangeal reduction, 609432 ?Camptosynpolydactyly, complex, 607539 |
| BICD2 | 125.6 | 99% | 99% | Spinal muscular atrophy, lower extremity-predominant, 2, AD, 615290 |
| BIN1 | 98.2 | 100% | 93% | Myopathy, centronuclear, autosomal recessive, 255200 |
| BLK | 95.6 | 100% | 100% | Maturity-onset diabetes of the young, type 11, 613375 |
| BLM | 118.7 | 98% | 94% | Bloom syndrome, 210900 |
| BLNK | 96.2 | 92% | 88% | Agammaglobulinemia 4, 613502 |
| BLOC1S3 | 32.8 | 95% | 70% | Hermansky-Pudlak syndrome 8, 614077 |
| BLOC1S6 | 72.6 | 98% | 84% | Hermansky-pudlak syndrome 9, 614171 |
| BLVRA | 112.3 | 100% | 96% | Hyperbiliverdinemia, 614156 |
| BMP1 | 126.9 | 100% | 99% | Osteogenesis imperfecta, type XIII, 614856 |
| BMP15 | 129.3 | 100% | 100% | Ovarian dysgenesis 2, 300510 Premature ovarian failure 4, 300510 |
| BMP2 | 166.6 | 100% | 100% | Brachydactyly, type A2, 112600 {HFE hemochromatosis, modifier of}, 235200 |

| | | | | |
|--------|-------|------|------|--|
| BMP4 | 127.2 | 100% | 99% | Microphthalmia, syndromic 6, 607932 Orofacial cleft 11, 600625 |
| BMPER | 137.0 | 100% | 97% | Diaphanospondylodysostosis, 608022 |
| BMPR1A | 105.6 | 100% | 96% | Juvenile polyposis syndrome, infantile form, 174900 Polyposis syndrome, hereditary mixed, 2, 610069 Polyposis, juvenile intestinal, 174900 |
| BMPR1B | 157.2 | 100% | 100% | Acromesomelic dysplasia, Demirhan type, 609441 Brachydactyly, type A1, D, 616849 Brachydactyly, type A2, 112600 |
| BMPR2 | 167.3 | 100% | 100% | Pulmonary hypertension, familial primary, 1, with or without HHT, 178600 Pulmonary hypertension, primary, fenfluramine or dexfenfluramine-associated, 178600 Pulmonary venoocclusive disease 1, 265450 |
| BOLA3 | 44.3 | 94% | 76% | Multiple mitochondrial dysfunctions syndrome 2 with hyperglycinemia, 614299 |
| PGM | 98.9 | 100% | 100% | Erythrocytosis due to bisphosphoglycerate mutase deficiency, 222800 |
| BRAF | 64.8 | 85% | 76% | Adenocarcinoma of lung, somatic, 211980 Cardiofaciocutaneous syndrome, 115150 Colorectal cancer, somatic LEOPARD syndrome 3, 613707 Melanoma, malignant, somatic Nonsmall cell lung cancer, somatic Noonan syndrome 7, 613706 |
| BRAT1 | 87.3 | 100% | 96% | Rigidity and multifocal seizure syndrome, lethal neonatal, 614498 |
| BRCA2 | 89.3 | 97% | 95% | Fanconi anemia, complementation group D1, 605724 Wilms tumor, 194070 {Breast cancer, male, susceptibility to}, 114480 {Breast-ovarian cancer, familial, 2}, 612555 {Glioblastoma 3}, 613029 {Medulloblastoma}, 155255 {Pancreatic cancer 2}, 613347 {Prostate cancer}, 176807 |
| BRF1 | 91.2 | 95% | 89% | Cerebellofaciodental syndrome, 616202 |
| BRIP1 | 114.3 | 100% | 96% | Breast cancer, early-onset, 114480 Fanconi anemia, complementation group J, 609054 |
| BRWD3 | 126.1 | 98% | 95% | Mental retardation, X-linked 93, 300659 |

| | | | | |
|-----------|-------|------|------|---|
| BSCL2 | 99.3 | 100% | 100% | Encephalopathy, progressive, with or without lipodystrophy, 615924 Lipodystrophy, congenital generalized, type 2, 269700 Neuropathy, distal hereditary motor, type VA, 600794 Silver spastic paraplegia syndrome, 270685 |
| BSND | 135.5 | 100% | 99% | Bartter syndrome, type 4a, 602522 Sensorineural deafness with mild renal dysfunction, 602522 |
| BTD | 125.5 | 100% | 98% | Biotinidase deficiency, 253260 |
| BTK | 158.3 | 100% | 100% | Agammaglobulinemia and isolated hormone deficiency, 307200 Agammaglobulinemia, X-linked 1, 300755 |
| BUB1 | 126.5 | 99% | 94% | Colorectal cancer with chromosomal instability, somatic |
| BUB1B | 144.3 | 98% | 97% | Colorectal cancer, somatic, 114500 Mosaic variegated aneuploidy syndrome 1, 257300 [Premature chromatid separation trait], 176430 |
| C10orf11 | 128.5 | 99% | 99% | Albinism, oculocutaneous, type VII, 615179 |
| C10orf2 | 152.5 | 100% | 100% | Mitochondrial DNA depletion syndrome 7 (hepatocerebral type), 271245 Perrault syndrome 5, 616138 Progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal dominant 3, 609286 |
| C11orf73 | 52.0 | 93% | 76% | Leukodystrophy, hypomyelinating, 13, 616881 |
| C12orf57 | 126.7 | 100% | 100% | Temptamy syndrome, 218340 |
| C12orf65 | 80.1 | 97% | 91% | Combined oxidative phosphorylation deficiency 7, 613559 Spastic paraparesis 55, autosomal recessive, 615035 |
| C15orf41 | 117.6 | 100% | 99% | Dyserythropoietic anemia, congenital, type Ib, 615631 |
| C19orf12 | 92.2 | 100% | 99% | Neurodegeneration with brain iron accumulation 4, 614298 ?Spastic paraparesis 43, autosomal recessive, 615043 |
| C1GALT1C1 | 146.2 | 100% | 100% | Tn polyagglutination syndrome, somatic, 300622 |
| C1QA | 101.1 | 100% | 98% | C1q deficiency, 613652 |
| C1QB | 151.4 | 100% | 100% | C1q deficiency, 613652 |
| C1QC | 192.1 | 100% | 100% | C1q deficiency, 613652 |
| C1QTNF5 | 111.5 | 85% | 67% | Retinal degeneration, late-onset, autosomal dominant, 605670 |
| C1S | 126.0 | 100% | 100% | C1s deficiency, 613783 |
| C2 | 13.7 | 50% | 17% | C2 deficiency, 217000 {Macular degeneration, age-related, 14, reduced risk of}, 615489 |
| C21orf59 | 124.9 | 100% | 99% | Ciliary dyskinesia, primary, 26, 615500 |
| C2orf71 | 105.9 | 99% | 97% | Retinitis pigmentosa 54, 613428 |

| | | | | |
|---------|-------|------|------|---|
| C3 | 135.2 | 100% | 99% | C3 deficiency, 613779 {Hemolytic uremic syndrome, atypical, susceptibility to, 5}, 612925 {Macular degeneration, age-related, 9}, 611378 |
| C4A | 17.6 | 66% | 31% | C4a deficiency, 614380 [Blood group, Rodgers], 614374 |
| C4B | 14.0 | 61% | 17% | C4B deficiency, 614379 |
| C4orf26 | 177.7 | 100% | 100% | Amelogenesis imperfecta, type IIA4, 614832 |
| C5 | 121.5 | 96% | 91% | C5 deficiency, 609536 [Eculizumab, poor response to], 615749 |
| C5orf42 | 112.4 | 98% | 94% | Joubert syndrome 17, 614615 Orofaciodigital syndrome VI, 277170 |
| C6 | 145.5 | 100% | 99% | C6 deficiency, 612446 Combined C6/C7 deficiency |
| C7 | 126.2 | 100% | 90% | C7 deficiency, 610102 |
| C7orf10 | 112.5 | 95% | 91% | Glutaric aciduria III, 231690 |
| C8A | 102.6 | 100% | 99% | C8 deficiency, type I, 613790 |
| C8B | 120.4 | 100% | 98% | C8 deficiency, type II, 613789 |
| C8orf37 | 100.1 | 100% | 99% | Cone-rod dystrophy 16, 614500 Retinitis pigmentosa 64, 614500 |
| C9 | 126.8 | 100% | 99% | C9 deficiency, 613825 {Macular degeneration, age-related, 15, susceptibility to}, 615591 |
| C9orf72 | 104.5 | 100% | 95% | Frontotemporal dementia and/or amyotrophic lateral sclerosis 1, 105550 |
| CA12 | 103.4 | 100% | 100% | Hyperchlorhidrosis, isolated, 143860 |
| CA2 | 126.8 | 100% | 97% | Osteopetrosis, autosomal recessive 3, with renal tubular acidosis, 259730 |
| CA4 | 133.0 | 100% | 98% | Retinitis pigmentosa 17, 600852 |
| CA5A | 97.7 | 100% | 94% | Hyperammonemia due to carbonic anhydrase VA deficiency, 615751 |
| CA8 | 95.6 | 94% | 89% | Cerebellar ataxia and mental retardation with or without quadrupedal locomotion 3, 613227 |
| CABP2 | 76.5 | 99% | 95% | Deafness, autosomal recessive 93, 614899 |
| CABP4 | 93.4 | 100% | 99% | Cone-rod synaptic disorder, congenital nonprogressive, 610427 |
| CACNA1A | 82.3 | 94% | 89% | Episodic ataxia, type 2, 108500 Migraine, familial hemiplegic, 1, 141500 Migraine, familial hemiplegic, 1, with progressive cerebellar ataxia, 141500 Spinocerebellar ataxia 6, 183086 |
| CACNA1C | 134.1 | 100% | 98% | Brugada syndrome 3, 611875 |

| | | | | |
|----------|-------|------|------|--|
| | | | | Timothy syndrome, 601005 |
| CACNA1D | 135.8 | 100% | 99% | Primary aldosteronism, seizures, and neurologic abnormalities, 615474 Sinoatrial node dysfunction and deafness, 614896 |
| CACNA1F | 115.3 | 100% | 98% | Aland Island eye disease, 300600 Cone-rod dystrophy, X-linked, 3, 300476 Night blindness, congenital stationary (incomplete), 2A, X-linked, 300071 |
| CACNA1G | 115.8 | 99% | 97% | Spinocerebellar ataxia 42, 616795 |
| CACNA1H | 101.1 | 98% | 95% | Hyperaldosteronism, familial, type IV, 617027 {Epilepsy, childhood absence, susceptibility to, 6}, 611942 {Epilepsy, idiopathic generalized, susceptibility to, 6}, 611942 |
| CACNA1S | 120.7 | 100% | 99% | Hypokalemic periodic paralysis, type 1, 170400 {Malignant hyperthermia susceptibility 5}, 601887 {Thyrotoxic periodic paralysis, susceptibility to, 1}, 188580 |
| CACNA2D4 | 98.1 | 98% | 96% | Retinal cone dystrophy 4, 610478 |
| CACNB2 | 129.5 | 99% | 95% | Brugada syndrome 4, 611876 |
| CACNB4 | 105.0 | 98% | 94% | Episodic ataxia, type 5, 613855 {Epilepsy, idiopathic generalized, susceptibility to, 9}, 607682 {Epilepsy, juvenile myoclonic, susceptibility to, 6}, 607682 |
| CACNG2 | 130.8 | 100% | 100% | Mental retardation, autosomal dominant 10, 614256 |
| CALM1 | 124.2 | 100% | 100% | Long QT syndrome 14, 616247 Ventricular tachycardia, catecholaminergic polymorphic, 4, 614916 |
| CALM2 | 50.0 | 67% | 64% | Long QT syndrome 15, 616249 |
| CALR | 90.6 | 100% | 94% | Myelofibrosis, somatic, 254450 Thrombocythemia, somatic, 187950 |
| CAMTA1 | 148.8 | 100% | 99% | Cerebellar ataxia, nonprogressive, with mental retardation, 614756 |
| CANT1 | 125.1 | 100% | 100% | Desbuquois dysplasia 1, 251450 |
| CAPN1 | 130.2 | 100% | 100% | Spastic paraparesis 76, autosomal recessive, 616907 |
| CAPN3 | 106.5 | 99% | 94% | Muscular dystrophy, limb-girdle, type 2A, 253600 |
| CAPN5 | 132.0 | 100% | 93% | Vitreoretinopathy, neovascular inflammatory, 193235 |
| CARD11 | 135.0 | 98% | 97% | B-cell expansion with NFkB and T-cell anergy, 616452 Immunodeficiency 11, 615206 |
| CARD14 | 95.7 | 99% | 95% | Pityriasis rubra pilaris, 173200 Psoriasis 2, 602723 |
| CARD9 | 101.8 | 97% | 95% | Candidiasis, familial, 2, autosomal recessive, 212050 |

| | | | | |
|----------|-------|------|------|---|
| CARS2 | 108.9 | 100% | 100% | Combined oxidative phosphorylation deficiency 27, 616672 |
| CASC5 | 94.5 | 96% | 93% | Microcephaly 4, primary, autosomal recessive, 604321 |
| CASK | 123.8 | 100% | 99% | FG syndrome 4, 300422 Mental retardation and microcephaly with pontine and cerebellar hypoplasia, 300749 Mental retardation, with or without nystagmus, 300422 |
| CASP10 | 98.1 | 98% | 95% | Autoimmune lymphoproliferative syndrome, type II, 603909 Gastric cancer, somatic, 613659 Lymphoma, non-Hodgkin, somatic, 605027 |
| CASP8 | 141.5 | 100% | 99% | Hepatocellular carcinoma, somatic, 114550 ?Autoimmune lymphoproliferative syndrome, type IIB, 607271 {Breast cancer, protection against}, 114480 {Lung cancer, protection against}, 211980 |
| CASQ1 | 102.4 | 100% | 99% | Myopathy, vacuolar, with CASQ1 aggregates, 616231 |
| CASQ2 | 135.5 | 100% | 98% | Ventricular tachycardia, catecholaminergic polymorphic, 2, 611938 |
| CASR | 141.5 | 99% | 99% | Hypercalciuric hypercalcemia Hyperparathyroidism, neonatal, 239200 Hypocalcemia, autosomal dominant, 601198 Hypocalcemia, autosomal dominant, with Bartter syndrome, 601198 Hypocalciuric hypercalcemia, type I, 145980 {Calcium, serum level of} {Epilepsy idiopathic generalized, susceptibility to, 8}, 612899 |
| CAST | 97.4 | 94% | 91% | Peeling skin with leukonychia, acral punctate keratoses, cheilitis, and knuckle pads, 616295 |
| CAT | 141.3 | 100% | 100% | Acatalasemia, 614097 |
| CATSPER1 | 146.6 | 100% | 99% | Spermatogenic failure 7, 612997 |
| CAV1 | 209.7 | 100% | 100% | Pulmonary hypertension, primary, 3, 615343 ?Lipodystrophy, congenital generalized, type 3, 612526 ?Partial lipodystrophy, congenital cataracts, and neurodegeneration syndrome, 606721 |
| CAV3 | 219.6 | 100% | 100% | Cardiomyopathy, familial hypertrophic, 192600 Creatine phosphokinase, elevated serum, 123320 Long QT syndrome 9, 611818 Muscular dystrophy, limb-girdle, type IC, 607801 Myopathy, distal, Tateyama type, 614321 Rippling muscle disease, 606072 |
| CBL | 117.3 | 99% | 98% | Noonan syndrome-like disorder with or without juvenile myelomonocytic leukemia, 613563 ?Juvenile myelomonocytic leukemia, 607785 |

| | | | | |
|---------|-------|------|------|---|
| CBS | 97.6 | 96% | 89% | Homocystinuria, B6-responsive and nonresponsive types, 236200 Thrombosis, hyperhomocysteinemic, 236200 |
| CC2D1A | 102.1 | 100% | 98% | Mental retardation, autosomal recessive 3, 608443 |
| CC2D2A | 111.9 | 99% | 96% | COACH syndrome, 216360 Joubert syndrome 9, 612285 Meckel syndrome 6, 612284 |
| CCBE1 | 63.1 | 95% | 84% | Hennekam lymphangiectasia-lymphedema syndrome 1, 235510 |
| CCDC103 | 88.1 | 100% | 97% | Ciliary dyskinesia, primary, 17, 614679 |
| CCDC11 | 140.0 | 97% | 94% | Heterotaxy, visceral, 6, autosomal recessive, 614779 |
| CCDC114 | 106.5 | 100% | 99% | Ciliary dyskinesia, primary, 20, 615067 |
| CCDC115 | 69.5 | 89% | 88% | Congenital disorder of glycosylation, type Ilo, 616828 |
| CCDC151 | 105.7 | 100% | 98% | Ciliary dyskinesia, primary, 30, 616037 |
| CCDC174 | 102.3 | 95% | 91% | Hypotonia, infantile, with psychomotor retardation, 616816 |
| CCDC22 | 114.1 | 98% | 94% | Ritscher-Schinzel syndrome 2, 300963 |
| CCDC39 | 79.1 | 95% | 90% | Ciliary dyskinesia, primary, 14, 613807 |
| CCDC40 | 99.4 | 98% | 98% | Ciliary dyskinesia, primary, 15, 613808 |
| CCDC41 | 95.6 | 94% | 87% | Nephronophthisis 18, 615862 |
| CCDC65 | 79.0 | 100% | 81% | Ciliary dyskinesia, primary, 27, 615504 |
| CCDC78 | 97.4 | 100% | 100% | Myopathy, centronuclear, 4, 614807 |
| CCDC8 | 82.8 | 100% | 100% | 3-M syndrome 3, 614205 |
| CCDC88A | 71.6 | 95% | 83% | PEHO syndrome, 260565 |
| CCDC88C | 95.4 | 98% | 95% | Hydrocephalus, nonsyndromic, autosomal recessive, 236600 ?Spinocerebellar ataxia 40, 616053 |
| CCM2 | 132.2 | 97% | 97% | Cerebral cavernous malformations-2, 603284 |
| CCND2 | 143.1 | 100% | 100% | Megalencephaly-polymicrogyria-polydactyly-hydrocephalus syndrome 3, 615938 |
| CCNO | 75.2 | 99% | 94% | Ciliary dyskinesia, primary, 29, 615872 |
| CCT5 | 125.0 | 100% | 99% | Neuropathy, hereditary sensory, with spastic paraplegia, 256840 |
| CD151 | 116.9 | 100% | 100% | Nephropathy with pretibial epidermolysis bullosa and deafness, 609057 [Blood group, Raph], 179620 |
| CD19 | 77.8 | 100% | 98% | Immunodeficiency, common variable, 3, 613493 |
| CD27 | 84.2 | 99% | 92% | Lymphoproliferative syndrome 2, 615122 |
| CD2AP | 81.8 | 99% | 96% | Glomerulosclerosis, focal segmental, 3, 607832 |
| CD320 | 77.7 | 100% | 99% | Methylmalonic aciduria due to transcobalamin receptor defect, 613646 |

| | | | | |
|--------|-------|------|------|---|
| CD36 | 113.1 | 100% | 97% | Platelet glycoprotein IV deficiency, 608404 [Macrothrombocytopenia] {Coronary heart disease, susceptibility to, 7}, 610938 {Malaria, cerebral, reduced risk of}, 611162 {Malaria, cerebral, susceptibility to}, 611162 |
| CD3D | 166.1 | 100% | 100% | Immunodeficiency 19, 615617 |
| CD3E | 164.4 | 100% | 99% | Immunodeficiency 18, 615615 Immunodeficiency 18, SCID variant, 615615 |
| CD3G | 171.8 | 100% | 100% | Immunodeficiency 17, CD3 gamma deficient, 615607 |
| CD4 | 91.7 | 100% | 100% | OKT4 epitope deficiency, 613949 |
| CD40 | 160.1 | 100% | 96% | Immunodeficiency with hyper-IgM, type 3, 606843 |
| CD40LG | 174.2 | 99% | 99% | Immunodeficiency, X-linked, with hyper-IgM, 308230 |
| CD59 | 196.1 | 90% | 84% | Hemolytic anemia, CD59-mediated, with or without immune-mediated polyneuropathy, 612300 |
| CD79A | 122.0 | 100% | 97% | Agammaglobulinemia 3, 613501 |
| CD79B | 194.1 | 100% | 100% | Agammaglobulinemia 6, 612692 |
| CD81 | 129.0 | 100% | 99% | Immunodeficiency, common variable, 6, 613496 |
| CD8A | 89.8 | 98% | 97% | CD8 deficiency, familial, 608957 |
| CD96 | 148.5 | 100% | 99% | C syndrome, 211750 |
| CDAN1 | 89.1 | 96% | 94% | Dyserythropoietic anemia, congenital, type Ia, 224120 |
| CDC14A | 133.0 | 94% | 88% | Deafness, autosomal recessive 105, 616958 |
| CDC42 | 80.8 | 97% | 93% | Takenouchi-Kosaki syndrome, 616737 |
| CDC45 | 144.3 | 99% | 97% | Meier-Gorlin syndrome 7, 617063 |
| CDC6 | 148.5 | 100% | 99% | Meier-Gorlin syndrome 5, 613805 |
| CDC73 | 85.8 | 100% | 96% | Hyperparathyroidism, familial primary, 145000 Hyperparathyroidism-jaw tumor syndrome, 145001 Parathyroid adenoma with cystic changes, 145001 Parathyroid carcinoma, 608266 |
| CDCA7 | 85.3 | 98% | 95% | Immunodeficiency-centromeric instability-facial anomalies syndrome 3, 616910 |
| CDH1 | 94.4 | 99% | 97% | Endometrial carcinoma, somatic, 608089 Gastric cancer, familial diffuse, with or without cleft lip and/or palate, 137215 Ovarian carcinoma, somatic, 167000 {Breast cancer, lobular}, 114480 {Prostate cancer, susceptibility to}, 176807 |
| CDH15 | 107.3 | 99% | 95% | Mental retardation, autosomal dominant 3, 612580 |

| | | | | |
|----------|-------|------|-----|--|
| CDH23 | 167.6 | 100% | 99% | Deafness, autosomal recessive 12, 601386 Usher syndrome, type 1D, 601067 Usher syndrome, type 1D/F digenic, 601067 |
| CDH3 | 121.8 | 99% | 95% | Ectodermal dysplasia, ectrodactyly, and macular dystrophy, 225280 Hypotrichosis, congenital, with juvenile macular dystrophy, 601553 |
| CDHR1 | 130.3 | 100% | 98% | Cone-rod dystrophy 15, 613660 Retinitis pigmentosa 65, 613660 |
| CDK5RAP2 | 116.7 | 98% | 97% | Microcephaly 3, primary, autosomal recessive, 604804 |
| CDKL5 | 138.6 | 99% | 96% | Epileptic encephalopathy, early infantile, 2, 300672 |
| CDKN1B | 62.5 | 100% | 89% | Multiple endocrine neoplasia, type IV, 610755 |
| CDKN1C | 32.7 | 74% | 57% | Beckwith-Wiedemann syndrome, 130650 IMAGE syndrome, 614732 |
| CDKN2A | 63.1 | 92% | 90% | Melanoma and neural system tumor syndrome, 155755 Orolaryngeal cancer, multiple, Pancreatic cancer/melanoma syndrome, 606719 {Melanoma, cutaneous malignant, 2}, 155601 |
| CDON | 118.9 | 100% | 98% | Holoprosencephaly 11, 614226 |
| CDSN | 9.7 | 37% | 11% | Hypotrichosis 2, 146520 Peeling skin syndrome 1, 270300 |
| CDT1 | 69.2 | 93% | 88% | Meier-Gorlin syndrome 4, 613804 |
| CEACAM16 | 111.1 | 100% | 98% | Deafness, autosomal dominant 4B, 614614 |
| CEBPA | 41.3 | 86% | 61% | Leukemia, acute myeloid, somatic, 601626 ?Leukemia, acute myeloid, 601626 |
| CEBPE | 62.7 | 98% | 96% | Specific granule deficiency, 245480 |
| CECR1 | 85.9 | 100% | 97% | Polyarteritis nodosa, childhood-onset, 615688 ?Sneddon syndrome, 182410 |
| CEL | 109.2 | 84% | 81% | Maturity-onset diabetes of the young, type VIII, 609812 |
| CENPF | 121.4 | 99% | 97% | Stromme syndrome, 243605 |
| CENPJ | 129.4 | 99% | 95% | Microcephaly 6, primary, autosomal recessive, 608393 ?Seckel syndrome 4, 613676 |
| CEP104 | 106.2 | 98% | 96% | Joubert syndrome 25, 616781 |
| CEP120 | 117.4 | 100% | 98% | Short-rib thoracic dysplasia 13 with or without polydactyly, 616300 |
| CEP152 | 157.8 | 97% | 94% | Microcephaly 9, primary, autosomal recessive, 614852 Seckel syndrome 5, 613823 |

| | | | | |
|--------|-------|------|------|---|
| CEP164 | 74.4 | 98% | 93% | Nephronophthisis 15, 614845 |
| CEP19 | 173.5 | 100% | 100% | Morbid obesity and spermatogenic failure, 615703 |
| CEP290 | 64.3 | 85% | 74% | Joubert syndrome 5, 610188 Leber congenital amaurosis 10, 611755 Meckel syndrome 4, 611134 Senior-Loken syndrome 6, 610189 ?Bardet-Biedl syndrome 14, 615991 |
| CEP41 | 76.4 | 94% | 86% | Joubert syndrome 15, 614464 |
| CEP57 | 91.9 | 100% | 92% | Mosaic variegated aneuploidy syndrome 2, 614114 |
| CERKL | 80.8 | 97% | 88% | Retinitis pigmentosa 26, 608380 |
| CERS3 | 115.0 | 100% | 100% | Ichthyosis, congenital, autosomal recessive 9, 615023 |
| CES1 | 129.5 | 100% | 97% | Carboxylesterase 1 deficiency, 114835 |
| CETP | 122.3 | 100% | 100% | Hyperalphalipoproteinemia, 143470 [High density lipoprotein cholesterol level QTL 10], 143470 |
| CFC1 | 46.7 | 76% | 51% | Heterotaxy, visceral, 2, autosomal, 605376 |
| CFD | 72.2 | 85% | 81% | Complement factor D deficiency, 613912 |
| CFH | 156.9 | 98% | 95% | Basal laminar drusen, 126700 Complement factor H deficiency, 609814 {Hemolytic uremic syndrome, atypical, susceptibility to, 1}, 235400 {Macular degeneration, age-related, 4}, 610698 |
| CFHR5 | 92.7 | 98% | 92% | Nephropathy due to CFHR5 deficiency, 614809 |
| CFI | 140.4 | 97% | 96% | Complement factor I deficiency, 610984 {Hemolytic uremic syndrome, atypical, susceptibility to, 3}, 612923 {Macular degeneration, age-related, 13, susceptibility to}, 615439 |
| CFL2 | 118.3 | 85% | 84% | Nemaline myopathy 7, autosomal recessive, 610687 |
| CFP | 101.9 | 100% | 96% | Properdin deficiency,X-linked, 312060 |
| CFTR | 113.2 | 98% | 92% | Congenital bilateral absence of vas deferens, 277180 Cystic fibrosis, 219700 Sweat chloride elevation without CF {Bronchiectasis with or without elevated sweat chloride 1, modifier of}, 211400 {Hypertrypsinemia, neonatal} {Pancreatitis, idiopathic}, 167800 |
| CHAMP1 | 149.4 | 100% | 100% | Mental retardation, autosomal dominant 40, 616579 |
| CHAT | 110.9 | 90% | 83% | Myasthenic syndrome, congenital, 6, presynaptic, 254210 |

| | | | | |
|---------|-------|------|------|--|
| CHCHD10 | 22.1 | 39% | 33% | Frontotemporal dementia and/or amyotrophic lateral sclerosis 2, 615911 Spinal muscular atrophy, Jokela type, 615048 ?Myopathy, isolated mitochondrial, autosomal dominant, 616209 |
| CHCHD2 | 85.1 | 99% | 87% | Parkinson disease 22, autosomal dominant, 616710 |
| CHD2 | 118.6 | 99% | 95% | Epileptic encephalopathy, childhood-onset, 615369 |
| CHD7 | 126.0 | 99% | 98% | CHARGE syndrome, 214800 Hypogonadotropic hypogonadism 5 with or without anosmia, 612370 |
| CHEK2 | 88.1 | 83% | 76% | Li-Fraumeni syndrome, 609265 Osteosarcoma, somatic, 259500 {Breast and colorectal cancer, susceptibility to} {Breast cancer, susceptibility to}, 114480 {Prostate cancer, familial, susceptibility to}, 176807 |
| CHKB | 75.2 | 91% | 90% | Muscular dystrophy, congenital, megaconial type, 602541 |
| CHM | 132.9 | 99% | 97% | Choroideremia, 303100 |
| CHMP1A | 98.2 | 100% | 100% | Pontocerebellar hypoplasia, type 8, 614961 |
| CHMP2B | 74.5 | 94% | 70% | Amyotrophic lateral sclerosis 17, 614696 Dementia, familial, nonspecific, 600795 |
| CHMP4B | 113.2 | 100% | 98% | Cataract 31, multiple types, 605387 |
| CHN1 | 131.2 | 97% | 97% | Duane retraction syndrome 2, 604356 |
| CHRDL1 | 143.2 | 100% | 100% | Megalocornea 1, X-linked 309300 |
| CHRNA1 | 110.3 | 100% | 100% | Multiple pterygium syndrome, lethal type, 253290 Myasthenic syndrome, congenital, 1A, slow-channel, 601462 Myasthenic syndrome, congenital, 1B, fast-channel, 608930 |
| CHRNA2 | 193.8 | 100% | 100% | Epilepsy, nocturnal frontal lobe, type 4, 610353 |
| CHRNA4 | 134.3 | 96% | 95% | Epilepsy, nocturnal frontal lobe, 1, 600513 {Nicotine addiction, susceptibility to}, 188890 |
| CHRNB1 | 137.3 | 100% | 98% | Myasthenic syndrome, congenital, 2A, slow-channel, 616313 ?Myasthenic syndrome, congenital, 2C, associated with acetylcholine receptor deficiency, 616314 |
| CHRNB2 | 187.5 | 99% | 97% | Epilepsy, nocturnal frontal lobe, 3, 605375 |
| CHRND | 143.3 | 100% | 99% | Multiple pterygium syndrome, lethal type, 253290 Myasthenic syndrome, congenital, 3B, fast-channel, 616322 ?Myasthenic syndrome, congenital, 3A, slow-channel, 616321 ?Myasthenic syndrome, congenital, 3C, associated with acetylcholine receptor deficiency, 616323 |

| | | | | |
|--------|-------|------|------|--|
| CHRNE | 122.7 | 100% | 99% | Myasthenic syndrome, congenital, 4A, slow-channel, 605809 Myasthenic syndrome, congenital, 4B, fast-channel, 616324 Myasthenic syndrome, congenital, 4C, associated with acetylcholine receptor deficiency, 608931 |
| CHRNG | 153.5 | 100% | 100% | Escobar syndrome, 265000 Multiple pterygium syndrome, lethal type, 253290 |
| CHST14 | 145.0 | 94% | 93% | Ehlers-Danlos syndrome, musculocontractural type 1, 601776 |
| CHST3 | 83.9 | 100% | 95% | Spondyloepiphyseal dysplasia with congenital joint dislocations, 143095 |
| CHST6 | 262.4 | 100% | 100% | Macular corneal dystrophy, 217800 |
| CHSY1 | 119.9 | 94% | 93% | Temptamy preaxial brachydactyly syndrome, 605282 |
| CHUK | 115.6 | 100% | 95% | Cocoon syndrome, 613630 |
| CIB2 | 201.8 | 100% | 100% | Deafness, autosomal recessive 48, 609439 Usher syndrome, type IJ, 614869 |
| CIITA | 105.4 | 100% | 98% | Bare lymphocyte syndrome, type II, complementation group A, 209920 {Rheumatoid arthritis, susceptibility to}, 180300 |
| CIRH1A | 163.0 | 100% | 100% | Cirrhosis, North American Indian childhood type, 604901 |
| CISD2 | 122.8 | 83% | 83% | Wolfram syndrome 2, 604928 |
| CITED2 | 99.5 | 100% | 100% | Atrial septal defect 8, 614433 Ventricular septal defect 2, 614431 |
| CKAP2L | 162.4 | 99% | 94% | Filippi syndrome, 272440 |
| CLCF1 | 92.3 | 100% | 97% | Cold-induced sweating syndrome 2, 610313 |
| CLCN1 | 122.7 | 99% | 98% | Myotonia congenita, dominant, 160800 Myotonia congenita, recessive, 255700 Myotonia levior, recessive |
| CLCN2 | 93.2 | 100% | 97% | Leukoencephalopathy with ataxia, 615651 {Epilepsy, idiopathic generalized, susceptibility to, 11}, 607628 {Epilepsy, juvenile absence, susceptibility to, 2}, 607628 {Epilepsy, juvenile myoclonic, susceptibility to, 8}, 607628 |
| CLCN4 | 129.3 | 100% | 100% | Mental retardation, X-linked 49/15, 300114 |
| CLCN5 | 152.6 | 99% | 99% | Dent disease, 300009 Hypophosphatemic rickets, 300554 Nephrolithiasis, type I, 310468 Proteinuria, low molecular weight, with hypercalciuric nephrocalcinosis, 308990 |
| CLCN7 | 118.0 | 98% | 96% | Osteopetrosis, autosomal dominant 2, 166600 Osteopetrosis, autosomal recessive 4, 611490 |

| | | | | |
|---------|-------|------|------|--|
| CLCNKA | 89.0 | 97% | 90% | Bartter syndrome, type 4b, digenic, 613090 |
| CLCNKB | 88.1 | 96% | 89% | Bartter syndrome, type 3, 607364 Bartter syndrome, type 4b, digenic, 613090 |
| CLDN1 | 125.4 | 100% | 100% | Ichthyosis, leukocyte vacuoles, alopecia, and sclerosing cholangitis, 607626 |
| CLDN14 | 102.3 | 100% | 100% | Deafness, autosomal recessive 29, 614035 |
| CLDN16 | 135.0 | 100% | 99% | Hypomagnesemia 3, renal, 248250 |
| CLDN19 | 111.6 | 96% | 93% | Hypomagnesemia 5, renal, with ocular involvement, 248190 |
| CLEC7A | 119.3 | 100% | 98% | Candidiasis, familial, 4, autosomal recessive, 613108 {Aspergillosis, susceptibility to}, 614079 |
| CLMP | 93.1 | 100% | 98% | Congenital short bowel syndrome, 615237 |
| CLN3 | 104.9 | 100% | 96% | Ceroid lipofuscinosis, neuronal, 3, 204200 |
| CLN5 | 136.2 | 93% | 86% | Ceroid lipofuscinosis, neuronal, 5, 256731 |
| CLN6 | 110.2 | 95% | 92% | Ceroid lipofuscinosis, neuronal, 6, 601780 Ceroid lipofuscinosis, neuronal, Kufs type, adult onset, 204300 |
| CLN8 | 195.1 | 100% | 100% | Ceroid lipofuscinosis, neuronal, 8, 600143 Ceroid lipofuscinosis, neuronal, 8, Northern epilepsy variant, 610003 |
| CLP1 | 147.8 | 100% | 100% | Pontocerebellar hypoplasia, type 10, 615803 |
| CLPB | 118.3 | 96% | 96% | 3-methylglutaconic aciduria, type VII, with cataracts, neurologic involvement and neutropenia, 616271 |
| CLPP | 94.8 | 96% | 87% | Perrault syndrome 3, 614129 |
| CLRN1 | 126.0 | 100% | 100% | Retinitis pigmentosa 61, 614180 Usher syndrome, type 3A, 276902 |
| CNBP | 107.6 | 100% | 100% | Myotonic dystrophy 2, 602668 |
| CNGA1 | 102.3 | 84% | 80% | Retinitis pigmentosa 49, 613756 |
| CNGA3 | 139.4 | 100% | 97% | Achromatopsia-2, 216900 |
| CNGB1 | 90.5 | 98% | 94% | Retinitis pigmentosa 45, 613767 |
| CNGB3 | 98.5 | 99% | 87% | Achromatopsia-3, 262300 Macular degeneration, juvenile, 248200 |
| CNNM2 | 162.3 | 100% | 99% | Hypomagnesemia 6, renal, 613882 Hypomagnesemia, seizures, and mental retardation, 616418 |
| CNNM4 | 161.8 | 98% | 97% | Jalili syndrome, 217080 |
| CNTNAP1 | 137.7 | 98% | 96% | Lethal congenital contracture syndrome 7, 616286 |
| CNTNAP2 | 121.9 | 100% | 99% | Cortical dysplasia-focal epilepsy syndrome, 610042 Pitt-Hopkins like syndrome 1, 610042 {Autism susceptibility 15}, 612100 |

| | | | | |
|---------|-------|------|------|---|
| COA6 | 57.9 | 97% | 87% | Cardioencephalomyopathy, fatal infantile, due to cytochrome c oxidase deficiency 4, 616501 |
| COASY | 133.9 | 100% | 100% | Neurodegeneration with brain iron accumulation 6, 615643 |
| COCH | 191.2 | 99% | 99% | Deafness, autosomal dominant 9, 601369 |
| COG1 | 109.9 | 100% | 99% | Congenital disorder of glycosylation, type IIg, 611209 |
| COG4 | 113.3 | 100% | 99% | Congenital disorder of glycosylation, type IIj, 613489 |
| COG5 | 97.3 | 93% | 92% | Congenital disorder of glycosylation, type III, 613612 |
| COG6 | 76.5 | 92% | 79% | Congenital disorder of glycosylation, type III, 614576 Shaheen syndrome, 615328 |
| COG7 | 115.5 | 100% | 100% | Congenital disorder of glycosylation, type IIe, 608779 |
| COG8 | 103.5 | 99% | 88% | Congenital disorder of glycosylation, type IIh, 611182 |
| COL10A1 | 81.1 | 100% | 91% | Metaphyseal chondrodysplasia, Schmid type, 156500 |
| COL11A1 | 79.7 | 92% | 89% | Fibrochondrogenesis 1, 228520 Marshall syndrome, 154780 Stickler syndrome, type II, 604841 {Lumbar disc herniation, susceptibility to}, 603932 |
| COL11A2 | 10.1 | 41% | 11% | Deafness, autosomal dominant 13, 601868 Deafness, autosomal recessive 53, 609706 Fibrochondrogenesis 2, 614524 Otospondylomegaepiphyseal dysplasia, 215150 Stickler syndrome, type III, 184840 Weissenbacher-Zweymuller syndrome, 277610 |
| COL12A1 | 122.2 | 99% | 97% | Bethlem myopathy 2, 616471 ?Ullrich congenital muscular dystrophy 2, 616470 |
| COL13A1 | 75.1 | 100% | 96% | Myasthenic syndrome, congenital, 19, 616720 |
| COL17A1 | 97.4 | 97% | 93% | Epidermolysis bullosa, junctional, localisata variant, 226650 Epidermolysis bullosa, junctional, non-Herlitz type, 226650 Epithelial recurrent erosion dystrophy, 122400 |
| COL18A1 | 75.9 | 93% | 85% | Knobloch syndrome, type 1, 267750 |
| COL1A1 | 118.0 | 97% | 94% | Caffey disease, 114000 Ehlers-Danlos syndrome, classic, 130000 Ehlers-Danlos syndrome, type VIIA, 130060 Osteogenesis imperfecta, type I, 166200 Osteogenesis imperfecta, type II, 166210 Osteogenesis imperfecta, type III, 259420 |

| | | | | |
|---------|-------|------|-----|---|
| | | | | Osteogenesis imperfecta, type IV, 166220 {Bone mineral density variation QTL, osteoporosis}, 166710 |
| COL1A2 | 90.7 | 95% | 91% | Ehlers-Danlos syndrome, cardiac valvular form, 225320 Ehlers-Danlos syndrome, type VIIIB, 130060 Osteogenesis imperfecta, type II, 166210 Osteogenesis imperfecta, type III, 259420 Osteogenesis imperfecta, type IV, 166220 {Osteoporosis, postmenopausal}, 166710 |
| COL25A1 | 109.3 | 99% | 92% | Fibrosis of extraocular muscles, congenital, 5, 616219 |
| COL2A1 | 92.2 | 100% | 98% | Achondrogenesis, type II or hypochondrogenesis, 200610 Avascular necrosis of the femoral head, 608805 Czech dysplasia, 609162 Epiphyseal dysplasia, multiple, with myopia and deafness, 132450 Kniest dysplasia, 156550 Legg-Calve-Perthes disease, 150600 Osteoarthritis with mild chondrodysplasia, 604864 Otospondylomegaepiphyseal dysplasia, 215150 Platyspondylic skeletal dysplasia, Torrance type, 151210 SED congenita, 183900 SMED Strudwick type, 184250 Spondyloepiphyseal dysplasia, Stanescu type, 616583 Spondyloperipheral dysplasia, 271700 Stickler syndrome, type I, nonsyndromic ocular, 609508 Stickler syndrome, type I, 108300 Vitreoretinopathy with phalangeal epiphyseal dysplasia |
| COL3A1 | 94.9 | 96% | 86% | Ehlers-Danlos syndrome, type IV, 130050 |
| COL4A1 | 79.5 | 97% | 88% | Angiopathy, hereditary, with nephropathy, aneurysms, and muscle cramps, 611773 Brain small vessel disease with or without ocular anomalies, 607595 Porencephaly 1, 175780 ?Retinal arteries, tortuosity of, 180000 |

| | | | | |
|----------|-------|------|-----|--|
| | | | | {Hemorrhage, intracerebral, susceptibility to}, 614519 |
| COL4A2 | 85.6 | 98% | 93% | Porencephaly 2, 614483 {Hemorrhage, intracerebral, susceptibility to}, 614519 |
| COL4A3 | 77.4 | 97% | 95% | Alport syndrome, autosomal dominant, 104200 Alport syndrome, autosomal recessive, 203780 Hematuria, benign familial, 141200 |
| COL4A3BP | 111.2 | 98% | 92% | Mental retardation, autosomal dominant 34, 616351 |
| COL4A4 | 72.4 | 97% | 91% | Alport syndrome, autosomal recessive, 203780 Hematuria, familial benign |
| COL4A5 | 61.5 | 95% | 81% | Alport syndrome, 301050 |
| COL5A1 | 105.4 | 99% | 95% | Ehlers-Danlos syndrome, classic type, 130000 |
| COL5A2 | 74.2 | 99% | 95% | Ehlers-Danlos syndrome, classic type, 130000 |
| COL6A1 | 128.3 | 99% | 97% | Bethlem myopathy 1, 158810 Ullrich congenital muscular dystrophy 1, 254090 |
| COL6A2 | 132.4 | 100% | 98% | Bethlem myopathy 1, 158810 Ullrich congenital muscular dystrophy 1, 254090 ?Myosclerosis, congenital, 255600 |
| COL6A3 | 145.4 | 100% | 99% | Bethlem myopathy 1, 158810 Dystonia 27, 616411 Ullrich congenital muscular dystrophy 1, 254090 |
| COL7A1 | 114.8 | 99% | 97% | EBD inversa, 226600 EBD, Bart type, 132000 EBD, localisata variant Epidermolysis bullosa dystrophica, AD, 131750 Epidermolysis bullosa dystrophica, AR, 226600 Epidermolysis bullosa pruriginosa, 604129 Epidermolysis bullosa, pretibial, 131850 Toenail dystrophy, isolated, 607523 Transient bullous of the newborn, 131705 |
| COL8A2 | 28.7 | 87% | 70% | Corneal dystrophy, Fuchs endothelial, 1, 136800 Corneal dystrophy, posterior polymorphous 2, 609140 |

| | | | | |
|---------|-------|------|------|---|
| COL9A1 | 100.3 | 99% | 95% | Stickler syndrome, type IV, 614134 /?Epiphyseal dysplasia, multiple, 6, 614135 |
| COL9A2 | 52.7 | 96% | 88% | Epiphyseal dysplasia, multiple, 2, 600204 ?Stickler syndrome, type V, 614284 {Intervertebral disc disease, susceptibility to}, 603932 |
| COL9A3 | 62.2 | 96% | 87% | Epiphyseal dysplasia, multiple, 3, with or without myopathy, 600969 {Intervertebral disc disease, susceptibility to}, 603932 |
| COLEC11 | 168.0 | 100% | 100% | 3MC syndrome 2, 265050 |
| COLQ | 96.9 | 100% | 94% | Myasthenic syndrome, congenital, 5, 603034 |
| COMP | 114.5 | 93% | 92% | Epiphyseal dysplasia, multiple, 1, 132400 Pseudoachondroplasia, 177170 |
| COQ2 | 68.4 | 96% | 93% | Coenzyme Q10 deficiency, primary, 1, 607426 {Multiple system atrophy, susceptibility to}, 146500 |
| COQ4 | 76.0 | 86% | 83% | Coenzyme Q10 deficiency, primary, 7, 616276 |
| COQ6 | 114.7 | 99% | 96% | Coenzyme Q10 deficiency, primary, 6, 614650 |
| COQ9 | 81.4 | 100% | 94% | Coenzyme Q10 deficiency, primary, 5, 614654 |
| CORIN | 150.7 | 99% | 98% | Preeclampsia/eclampsia 5, 614595 |
| CORO1A | 144.5 | 97% | 92% | Immunodeficiency 8, 615401 |
| COX10 | 194.9 | 100% | 100% | Leigh syndrome due to mitochondrial COX4 deficiency, 256000 Mitochondrial complex IV deficiency, 220110 |
| COX15 | 86.6 | 100% | 98% | Cardioencephalomyopathy, fatal infantile, due to cytochrome c oxidase deficiency 2, 615119 Leigh syndrome due to cytochrome c oxidase deficiency, 256000 |
| COX20 | 42.6 | 89% | 61% | Mitochondrial complex IV deficiency, 220110 |
| COX4I2 | 91.9 | 100% | 100% | Exocrine pancreatic insufficiency, dyserythropoietic anemia, and calvarial hyperostosis, 612714 |
| COX6A1 | 154.4 | 100% | 100% | Charcot-Marie-Tooth disease, recessive intermediate D, 616039 |
| COX6B1 | 126.5 | 100% | 100% | Mitochondrial complex IV deficiency, 220110 |
| COX7B | 52.3 | 77% | 42% | Linear skin defects with multiple congenital anomalies, 300887 |
| CP | 115.4 | 96% | 88% | Cerebellar ataxia, 604290 Hemosiderosis, systemic, due to aceruloplasminemia, 604290 [Hypoceruloplasminemia, hereditary], 604290 |
| CPA6 | 113.8 | 100% | 100% | Epilepsy, familial temporal lobe, 5, 614417 Febrile seizures, familial, 11, 614418 |
| CPN1 | 109.3 | 99% | 97% | Carboxypeptidase N deficiency, 212070 |
| CPOX | 95.3 | 96% | 81% | Coproporphyria, 121300 |

| | | | | |
|--------|-------|------|------|---|
| | | | | Harderoporphiria, 121300 |
| CPS1 | 133.0 | 100% | 99% | Carbamoylphosphate synthetase I deficiency, 237300 {Pulmonary hypertension, neonatal, susceptibility to}, 615371 {Venocclusive disease after bone marrow transplantation} |
| CPT1A | 151.0 | 100% | 97% | CPT deficiency, hepatic, type IA, 255120 |
| CPT2 | 136.9 | 98% | 96% | CPT deficiency, hepatic, type II, 600649 CPT II deficiency, lethal neonatal, 608836 Myopathy due to CPT II deficiency, 255110 {Encephalopathy, acute, infection-induced, 4, susceptibility to}, 614212 |
| CR2 | 145.2 | 100% | 99% | Immunodeficiency, common variable, 7, 614699 {Systemic lupus erythematosus, susceptibility to, 9}, 610927 |
| CRADD | 97.9 | 98% | 95% | Mental retardation, autosomal recessive 34, 614499 |
| CRB1 | 189.4 | 100% | 100% | Leber congenital amaurosis 8, 613835 Pigmented paravenous chorioretinal atrophy, 172870 Retinitis pigmentosa-12, autosomal recessive, 600105 |
| CRB2 | 92.0 | 99% | 93% | Focal segmental glomerulosclerosis 9, 616220 Ventriculomegaly with cystic kidney disease, 219730 |
| CRBN | 126.2 | 100% | 93% | Mental retardation, autosomal recessive 2, 607417 |
| CREB1 | 116.1 | 99% | 86% | Histiocytoma, angiomyomatoid fibrous, somatic, 612160 |
| CREBBP | 115.7 | 99% | 95% | Rubinstein-Taybi syndrome, 180849 |
| CRELD1 | 93.5 | 100% | 100% | Atrioventricular septal defect, partial, with heterotaxy syndrome, 606217 {Atrioventricular septal defect, susceptibility to, 2}, 606217 |
| CRIPT | 34.9 | 93% | 67% | Short stature with microcephaly and distinctive facies, 615789 |
| CRLF1 | 94.7 | 90% | 88% | Cold-induced sweating syndrome 1, 272430 |
| CRTAP | 88.1 | 100% | 92% | Osteogenesis imperfecta, type VII, 610682 |
| CRTC1 | 114.8 | 97% | 89% | Mucoepidermoid salivary gland carcinoma |
| CRX | 93.6 | 99% | 97% | Cone-rod retinal dystrophy-2, 120970 Leber congenital amaurosis 7, 613829 |
| CRYAA | 101.3 | 92% | 83% | Cataract 9, multiple types, 604219 |
| CRYAB | 102.6 | 98% | 93% | Cardiomyopathy, dilated, 1II, 615184 Cataract 16, multiple types, 613763 Myopathy, myofibrillar, 2, 608810 Myopathy, myofibrillar, fatal infantile hypertrophy, alpha-B crystallin-related, 613869 |
| CRYBA1 | 120.6 | 100% | 99% | Cataract 10, multiple types, 600881 |

| | | | | |
|---------|-------|------|------|---|
| CRYBA4 | 97.3 | 100% | 100% | Cataract 23, 610425 |
| CRYBB1 | 100.8 | 100% | 98% | Cataract 17, multiple types, 611544 |
| CRYBB2 | 146.5 | 100% | 100% | Cataract 3, multiple types, 601547 |
| CRYBB3 | 113.2 | 100% | 100% | Cataract 22, autosomal recessive, 609741 |
| CRYGB | 86.9 | 100% | 98% | Cataract 39, multiple types, autosomal dominant, 615188 |
| CRYGC | 109.4 | 100% | 100% | Cataract 2, multiple types, 604307 |
| CRYGD | 77.7 | 100% | 100% | Cataract 4, multiple types, 115700 |
| CRYGS | 112.0 | 94% | 83% | Cataract 20, multiple types, 116100 |
| CRYM | 79.0 | 100% | 98% | Deafness, autosomal dominant 40, 616357 |
| CSF1R | 108.8 | 99% | 97% | Leukoencephalopathy, diffuse hereditary, with spheroids, 221820 |
| CSF2RA | 52.0 | 89% | 85% | Surfactant metabolism dysfunction, pulmonary, 4, 300770 |
| CSF2RB | 78.2 | 100% | 99% | Surfactant metabolism dysfunction, pulmonary, 5, 614370 |
| CSNK1D | 149.8 | 94% | 92% | Advanced sleep-phase syndrome, familial, 2, 615224 |
| CSNK2A1 | 112.5 | 96% | 84% | Okur-Chung neurodevelopmental syndrome, 617062 Glaucoma, primary congenital (Lee (2011) Mol Vis 17,3583) |
| CSPP1 | 97.8 | 99% | 93% | Joubert syndrome 21, 615636 |
| CSRP3 | 100.0 | 100% | 99% | Cardiomyopathy, hypertrophic, 12, 612124 ?Cardiomyopathy, dilated, 1M, 607482 |
| CST3 | 98.8 | 90% | 82% | Cerebral amyloid angiopathy, 105150 {Macular degeneration, age-related, 11}, 611953 |
| CSTA | 92.5 | 100% | 99% | Peeling skin syndrome 4, 607936 |
| CSTB | 90.3 | 100% | 100% | Epilepsy, progressive myoclonic 1A (Unverricht and Lundborg), 254800 |
| CTC1 | 91.6 | 100% | 99% | Cerebroretinal microangiopathy with calcifications and cysts, 612199 |
| CTCF | 139.6 | 97% | 96% | Mental retardation, autosomal dominant 21, 615502 |
| CTDP1 | 92.7 | 87% | 83% | Congenital cataracts, facial dysmorphism, and neuropathy, 604168 |
| CTH | 156.9 | 100% | 99% | Cystathioninuria, 219500 Homocysteine, total plasma, elevated |
| CTHRC1 | 88.4 | 98% | 81% | Barrett esophagus/esophageal adenocarcinoma, 614266 |
| CTLA4 | 176.4 | 100% | 100% | Autoimmune lymphoproliferative syndrome, type V, 616100 {Celiac disease, susceptibility to, 3}, 609755 {Diabetes mellitus, insulin-dependent, 12}, 601388 {Hashimoto thyroiditis}, 140300 {Systemic lupus erythematosus, susceptibility to}, 152700 |

| | | | | |
|--------|-------|------|------|---|
| CTNNA1 | 120.4 | 99% | 96% | Macular dystrophy,patterned,608970 Gastric cancer, diffuse (Majewski (2012) J Pathol epub) |
| CTNNA3 | 136.8 | 100% | 99% | Arrhythmogenic right ventricular dysplasia, familial, 13, 615616 |
| CTNNB1 | 142.1 | 100% | 100% | Colorectal cancer, somatic, 114500 Hepatocellular carcinoma, somatic, 114550 Mental retardation, autosomal dominant 19, 615075 Ovarian cancer, somatic, 167000 Pilomatricoma, somatic, 132600 |
| CTNS | 113.8 | 100% | 100% | Cystinosis, atypical nephropathic, 219800 Cystinosis, late-onset juvenile or adolescent nephropathic, 219900 Cystinosis, nephropathic, 219800 Cystinosis, ocular nonnephropathic, 219750 |
| CTPS1 | 121.0 | 100% | 100% | Immunodeficiency 24, 615897 |
| CTSA | 113.1 | 100% | 100% | Galactosialidosis, 256540 |
| CTSC | 119.9 | 100% | 100% | Haim-Munk syndrome, 245010 Papillon-Lefevre syndrome, 245000 Periodontitis 1, juvenile, 170650 |
| CTSD | 152.1 | 100% | 97% | Ceroid lipofuscinosis, neuronal, 10, 610127 |
| CTSF | 92.5 | 91% | 81% | Ceroid lipofuscinosis, neuronal, 13, Kufs type, 615362 |
| CTSK | 98.4 | 100% | 100% | Pycnodysostosis, 265800 |
| CUBN | 113.0 | 99% | 96% | Megaloblastic anemia-1, Finnish type, 261100 |
| CUL3 | 102.1 | 95% | 90% | Pseudohypoaldosteronism, type IIE, 614496 |
| CUL4B | 89.5 | 98% | 96% | Mental retardation, X-linked, syndromic 15 (Cabezas type), 300354 |
| CUL7 | 122.3 | 100% | 98% | 3-M syndrome 1, 273750 |
| CXCR4 | 149.4 | 100% | 97% | Myelokathexis, isolated WHIM syndrome, 193670 |
| CYB5A | 110.2 | 100% | 100% | Methemoglobinemia, type IV, 250790 |
| CYB5R3 | 157.7 | 98% | 98% | Methemoglobinemia, type I, 250800 Methemoglobinemia, type II, 250800 |
| CYBA | 83.7 | 81% | 72% | Chronic granulomatous disease, autosomal, due to deficiency of CYBA, 233690 |
| CYBB | 141.6 | 100% | 100% | Chronic granulomatous disease, X-linked, 306400 Immunodeficiency 34, mycobacteriosis, X-linked, 300645 |
| CYC1 | 159.5 | 87% | 86% | Mitochondrial complex III deficiency, nuclear type 6, 615453 |
| CYCS | 66.6 | 99% | 99% | Thrombocytopenia 4, 612004 |

| | | | | |
|---------|-------|------|------|---|
| CYLD | 108.2 | 95% | 93% | Brooke-Spiegler syndrome, 605041 Cylindromatosis, familial, 132700 Trichoepithelioma, multiple familial, 1, 601606 |
| CYP11A1 | 101.7 | 99% | 96% | Adrenal insufficiency, congenital, with 46XY sex reversal, partial or complete, 613743 |
| CYP11B1 | 140.1 | 100% | 100% | Adrenal hyperplasia, congenital, due to 11-beta-hydroxylase deficiency, 202010 Aldosteronism, glucocorticoid-remediable, 103900 |
| CYP11B2 | 150.4 | 100% | 100% | Aldosterone to renin ratio raised Hypoaldosteronism, congenital, due to CMO I deficiency, 203400 Hypoaldosteronism, congenital, due to CMO II deficiency, 610600 {Low renin hypertension, susceptibility to} |
| CYP17A1 | 109.4 | 100% | 99% | 17,20-lyase deficiency, isolated, 202110 17-alpha-hydroxylase/17,20-lyase deficiency, 202110 |
| CYP19A1 | 163.6 | 100% | 100% | Aromatase deficiency, 613546 Aromatase excess syndrome, 139300 |
| CYP1B1 | 98.6 | 100% | 94% | Glaucoma 3A, primary open angle, congenital, juvenile, or adult onset, 231300 Peters anomaly, 604229 |
| CYP21A2 | 11.0 | 48% | 9% | Adrenal hyperplasia, congenital, due to 21-hydroxylase deficiency, 201910 Hyperandrogenism, nonclassic type, due to 21-hydroxylase deficiency, 201910 |
| CYP24A1 | 148.9 | 100% | 99% | Hypercalcemia, infantile, 143880 |
| CYP26B1 | 146.7 | 100% | 99% | Craniosynostosis with radiohumeral fusions and other skeletal and craniofacial anomalies, 614416 |
| CYP26C1 | 65.5 | 100% | 97% | Focal facial dermal dysplasia 4, 614974 |
| CYP27A1 | 158.7 | 94% | 93% | Cerebrotendinous xanthomatosis, 213700 |
| CYP27B1 | 98.6 | 99% | 94% | Vitamin D-dependent rickets, type I, 264700 |
| CYP2A6 | 119.3 | 100% | 96% | Coumarin resistance, 122700 {Lung cancer, resistance to}, 211980 {Nicotine addiction, protection from}, 188890 |
| CYP2C8 | 103.4 | 97% | 95% | Rhabdomyolysis, cerivastatin-induced, 601129 |
| CYP2R1 | 119.6 | 96% | 88% | Rickets due to defect in vitamin D 25-hydroxylation, 600081 |
| CYP2U1 | 115.4 | 95% | 92% | Spastic paraparesis 56, autosomal recessive, 615030 |
| CYP4F22 | 103.4 | 100% | 97% | Ichthyosis, congenital, autosomal recessive 5, 604777 |
| CYP4V2 | 152.0 | 100% | 98% | Bietti crystalline corneoretinal dystrophy, 210370 |
| CYP7B1 | 88.0 | 96% | 88% | Bile acid synthesis defect, congenital, 3, 613812 Spastic paraparesis 5A, autosomal recessive, 270800 |
| D2HGDH | 112.5 | 95% | 92% | D-2-hydroxyglutaric aciduria, 600721 |

| | | | | |
|---------|-------|------|------|--|
| DAG1 | 164.9 | 100% | 100% | Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 9, 616538 Muscular dystrophy-dystroglycanopathy (limb-girdle), type C, 9, 613818 |
| DARS | 93.3 | 99% | 93% | Hypomyelination with brainstem and spinal cord involvement and leg spasticity, 615281 |
| DARS2 | 112.2 | 100% | 98% | Leukoencephalopathy with brain stem and spinal cord involvement and lactate elevation, 611105 |
| DBH | 124.5 | 100% | 99% | Dopamine beta-hydroxylase deficiency, 223360 [Dopamine-beta-hydroxylase activity levels, plasma] |
| DBT | 98.9 | 94% | 94% | Maple syrup urine disease, type II, 248600 |
| DCAF17 | 84.2 | 100% | 91% | Woodhouse-Sakati syndrome, 241080 |
| DCC | 130.5 | 100% | 100% | Colorectal cancer, somatic, 114500 Esophageal carcinoma, somatic 133239 Mirror movements 1, 157600 |
| DCDC2 | 125.6 | 100% | 98% | Nephronophthisis 19, 616217 ?Deafness, autosomal recessive 66, 610212 |
| DCHS1 | 126.6 | 98% | 97% | Mitral valve prolapse 2, 607829 Van Maldergem syndrome 1, 601390 |
| DCLRE1C | 117.3 | 96% | 90% | Omenn syndrome, 603554 Severe combined immunodeficiency, Athabascan type, 602450 |
| DCN | 133.0 | 95% | 94% | Corneal dystrophy, congenital stromal, 610048 |
| DCPS | 118.2 | 100% | 99% | Al-Raqad syndrome, 616459 |
| DCTN1 | 110.2 | 100% | 99% | Neuropathy, distal hereditary motor, type VIIB, 607641 Perry syndrome, 168605 {Amyotrophic lateral sclerosis, susceptibility to}, 105400 |
| DCX | 139.7 | 100% | 100% | Lissencephaly, X-linked, 300067 Subcortical laminal heteropia, X-linked, 300067 |
| DDB2 | 127.9 | 100% | 99% | Xeroderma pigmentosum, group E, DDB-negative subtype, 278740 |
| DDC | 97.6 | 100% | 97% | Aromatic L-amino acid decarboxylase deficiency, 608643 |
| DDHD1 | 132.8 | 97% | 93% | Spastic paraplegia 28, autosomal recessive, 609340 |
| DDHD2 | 148.2 | 100% | 99% | Spastic paraplegia 54, autosomal recessive, 615033 |
| DDR2 | 133.7 | 100% | 98% | Spondylometaepiphyseal dysplasia, short limb-hand type, 271665 |
| DDX11 | 76.1 | 76% | 73% | Warsaw breakage syndrome, 613398 |
| DDX3X | 114.8 | 99% | 97% | Mental retardation, X-linked 102, 300958 |
| DDX58 | 124.3 | 99% | 98% | Singleton-Merten syndrome 2, 616298 |
| DDX59 | 143.8 | 99% | 98% | Orofaciodigital syndrome V, 174300 |
| DEAF1 | 126.7 | 87% | 83% | Mental retardation, autosomal dominant 24, 615828 |

| | | | | |
|--------|-------|------|------|--|
| DEPDC5 | 127.2 | 99% | 99% | Epilepsy, familial focal, with variable foci, 604364 |
| DES | 105.1 | 100% | 96% | Cardiomyopathy, dilated, 1I, 604765 Myopathy, myofibrillar, 1, 601419 Scapuloperoneal syndrome, neurogenic, Kaeser type, 181400 ?Muscular dystrophy, limb-girdle, type 2R, 615325 |
| DFNA5 | 96.2 | 100% | 97% | Deafness, autosomal dominant 5, 600994 |
| DFNB59 | 127.4 | 100% | 100% | Deafness, autosomal recessive 59, 610220 |
| DGKE | 126.1 | 96% | 93% | Nephrotic syndrome, type 7, 615008 {Hemolytic uremic syndrome, atypical, susceptibility to, 7}, 615008 |
| DGUOK | 117.3 | 100% | 97% | Mitochondrial DNA depletion syndrome 3 (hepatocerebral type), 251880 |
| DHCR24 | 154.9 | 100% | 100% | Desmosterolosis, 602398 |
| DHCR7 | 147.7 | 100% | 100% | Smith-Lemli-Opitz syndrome, 270400 |
| DHDDS | 89.1 | 96% | 92% | Retinitis pigmentosa 59, 613861 |
| DHFR | 44.3 | 79% | 69% | Megaloblastic anemia due to dihydrofolate reductase deficiency, 613839 |
| DHH | 92.5 | 100% | 100% | 46XY partial gonadal dysgenesis, with minifascicular neuropathy, 607080 46XY sex reversal 7, 233420 |
| DHODH | 91.4 | 100% | 100% | Miller syndrome, 263750 |
| DHTKD1 | 130.2 | 99% | 98% | 2-amino adipic 2-oxoadipic aciduria, 204750 ?Charcot-Marie-Tooth disease, axonal, type 2Q, 615025 |
| DIABLO | 200.7 | 100% | 100% | Deafness, autosomal dominant 64, 614152 |
| DIAPH1 | 108.4 | 99% | 96% | Deafness, autosomal dominant 1, 124900 Seizures, cortical blindness, microcephaly syndrome, 616632 |
| DIAPH2 | 71.6 | 94% | 89% | Premature ovarian failure, 300511 |
| DIAPH3 | 74.5 | 96% | 86% | Auditory neuropathy, autosomal dominant, 1, 609129 |
| DICER1 | 138.0 | 99% | 96% | Goiter, multinodular 1, with or without Sertoli-Leydig cell tumors, 138800 Pleuropulmonary blastoma, 601200 Rhabdomyosarcoma, embryonal, 2, 180295 |
| DIP2B | 146.6 | 99% | 97% | Mental retardation, FRA12A type, 136630 |
| DIS3L2 | 146.8 | 100% | 97% | Perlman syndrome, 267000 |
| DKC1 | 143.3 | 100% | 100% | Dyskeratosis congenita, X-linked, 305000 |
| DLAT | 78.7 | 100% | 91% | Pyruvate dehydrogenase E2 deficiency, 245348 |
| DLC1 | 167.4 | 100% | 98% | Colorectal cancer, somatic, 114500 |
| DLD | 110.9 | 98% | 97% | Dihydrolipoamide dehydrogenase deficiency, 246900 |
| DLG3 | 114.2 | 100% | 98% | Mental retardation, X-linked 90, 300850 |

| | | | | |
|----------|-------|------|------|---|
| DLL3 | 58.5 | 88% | 76% | Spondylocostal dysostosis 1, autosomal recessive, 277300 |
| DLL4 | 170.9 | 99% | 97% | Adams-Oliver syndrome 6, 616589 |
| DLX3 | 102.9 | 100% | 99% | Amelogenesis imperfecta, type IV, 104510 Trichodontoosseous syndrome, 190320 |
| DMD | 152.9 | 99% | 99% | Becker muscular dystrophy, 300376 Cardiomyopathy, dilated, 3B, 302045 Duchenne muscular dystrophy, 310200 |
| DMGDH | 138.4 | 98% | 95% | Dimethylglycine dehydrogenase deficiency, 605850 |
| DMP1 | 138.4 | 97% | 96% | Hypophosphatemic rickets, AR, 241520 |
| DMPK | 98.0 | 97% | 89% | Myotonic dystrophy 1, 160900 |
| DNA2 | 120.1 | 99% | 95% | Progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal dominant 6, 615156 ?Seckel syndrome 8, 615807 |
| DNAAF1 | 109.9 | 100% | 96% | Ciliary dyskinesia, primary, 13, 613193 |
| DNAAF2 | 90.7 | 100% | 94% | Ciliary dyskinesia, primary, 10, 612518 |
| DNAAF3 | 74.5 | 99% | 90% | Ciliary dyskinesia, primary, 2, 606763 |
| DNAH11 | 121.4 | 99% | 97% | Ciliary dyskinesia, primary, 7, with or without situs inversus, 611884 |
| DNAH5 | 114.9 | 99% | 98% | Ciliary dyskinesia, primary, 3, with or without situs inversus, 608644 |
| DNAI1 | 102.1 | 97% | 95% | Ciliary dyskinesia, primary, 1, with or without situs inversus, 244400 |
| DNAI2 | 129.9 | 95% | 93% | Ciliary dyskinesia, primary, 9, with or without situs inversus, 612444 |
| DNAJB2 | 92.7 | 100% | 99% | Spinal muscular atrophy, distal, autosomal recessive, 5, 614881 |
| DNAJB6 | 53.2 | 93% | 78% | Muscular dystrophy, limb-girdle, type 1E, 603511 |
| DNAJC19 | 84.5 | 99% | 98% | 3-methylglutaconic aciduria, type V, 610198 |
| DNAJC21 | 112.7 | 98% | 96% | Bone marrow failure syndrome 3, 617052 |
| DNAJC5 | 166.2 | 100% | 100% | Ceroid lipofuscinosi, neuronal, 4, Parry type, 162350 |
| DNAJC6 | 147.4 | 99% | 98% | Parkinson disease 19, juvenile-onset, 615528 |
| DNAL1 | 92.5 | 99% | 73% | Ciliary dyskinesia, primary, 16, 614017 |
| DNASE1L3 | 121.9 | 100% | 100% | Systemic lupus erythematosus 16, 614420 |
| DNM1 | 138.3 | 93% | 89% | Epileptic encephalopathy, early infantile, 31, 616346 |
| DNM1L | 103.1 | 99% | 91% | Encephalopathy, lethal, due to defective mitochondrial peroxisomal fission, 614388 |
| DNM2 | 110.9 | 96% | 94% | Charcot-Marie-Tooth disease, axonal, type 2M, 606482 Charcot-Marie-Tooth disease, dominant intermediate B, 606482 Lethal congenital contracture syndrome 5, 615368 Myopathy, centronuclear, 160150 |

| | | | | |
|---------|-------|------|------|---|
| DNMT1 | 107.0 | 99% | 99% | Cerebellar ataxia, deafness, and narcolepsy, autosomal dominant, 604121 Neuropathy, hereditary sensory, type IE, 614116 |
| DNMT3A | 95.6 | 96% | 93% | Tatton-Brown-Rahman syndrome, 615879 |
| DNMT3B | 109.3 | 100% | 99% | Immunodeficiency-centromeric instability-facial anomalies syndrome 1, 242860 |
| DOCK2 | 126.7 | 100% | 100% | Immunodeficiency 40, 616433 |
| DOCK6 | 105.3 | 99% | 96% | Adams-Oliver syndrome 2, 614219 |
| DOCK7 | 101.1 | 96% | 93% | Epileptic encephalopathy, early infantile, 23, 615859 |
| DOCK8 | 122.7 | 100% | 99% | Hyper-IgE recurrent infection syndrome, autosomal recessive, 243700 |
| DOK7 | 77.5 | 96% | 91% | Myasthenic syndrome, congenital, 10, 254300 ?Fetal akinesia deformation sequence, 208150 |
| DOLK | 153.7 | 100% | 99% | Congenital disorder of glycosylation, type Im, 610768 |
| DPAGT1 | 96.6 | 100% | 100% | Congenital disorder of glycosylation, type Ij, 608093 Myasthenic syndrome, congenital, 13, with tubular aggregates, 614750 |
| DPH1 | 148.2 | 100% | 99% | Developmental delay with short stature,dysmorphic features and sparse hair,616901 |
| DPM1 | 105.8 | 90% | 86% | Congenital disorder of glycosylation, type Ie, 608799 |
| DPM2 | 94.2 | 100% | 99% | Congenital disorder of glycosylation, type Iu, 615042 |
| DPM3 | 147.7 | 100% | 100% | Congenital disorder of glycosylation, type Io, 612937 |
| DPP6 | 121.7 | 99% | 95% | Mental retardation, autosomal dominant 33, 616311 {Ventricular fibrillation, paroxysmal familial, 2}, 612956 |
| DPY19L2 | 64.2 | 74% | 68% | Spermatogenic failure 9, 613958 |
| DPYD | 145.1 | 95% | 93% | 5-fluorouracil toxicity, 274270 Dihydropyrimidine dehydrogenase deficiency, 274270 |
| DPYS | 109.1 | 100% | 99% | Dihydropyrimidinuria, 222748 |
| DRAM2 | 127.2 | 100% | 100% | Cone-rod dystrophy 21, 616502 |
| DRC1 | 89.0 | 100% | 99% | Ciliary dyskinesia, primary, 21, 615294 |
| DRD4 | 73.3 | 77% | 66% | Autonomic nervous system dysfunction [Novelty seeking personality], 601696 {Attention deficit-hyperactivity disorder}, 143465 |
| DRD5 | 72.7 | 100% | 100% | Dystonia, primary cervical, 126453 {Attention deficit-hyperactivity disorder, susceptibility to}, 143465 {Blepharospasm, primary benign}, 606798 |
| DSC2 | 124.3 | 99% | 95% | Arrhythmogenic right ventricular dysplasia 11 with mild palmoplantar keratoderma and woolly hair, 610476 Arrhythmogenic right ventricular dysplasia 11, 610476 |

| | | | | |
|----------|-------|------|------|---|
| DSG1 | 152.5 | 98% | 97% | Erythroderma, congenital, with palmoplantar keratoderma, hypotrichosis, and hyper IgE, 615508 Keratosis palmoplantaris striata I, AD, 148700 |
| DSG2 | 115.3 | 100% | 99% | Arrhythmogenic right ventricular dysplasia 10, 610193 Cardiomyopathy, dilated, 1BB, 612877 |
| DSG4 | 195.1 | 98% | 94% | Hypotrichosis 6, 607903 |
| DSP | 122.6 | 100% | 98% | Arrhythmogenic right ventricular dysplasia 8, 607450 Cardiomyopathy, dilated, with woolly hair and keratoderma, 605676 Dilated cardiomyopathy with woolly hair, keratoderma, and tooth agenesis, 615821 Epidermolysis bullosa, lethal acantholytic, 609638 Keratosis palmoplantaris striata II, 612908 Skin fragility-woolly hair syndrome, 607655 |
| DSPP | 134.7 | 100% | 100% | Deafness, autosomal dominant 39, with dentinogenesis, 605594 Dentin dysplasia, type II, 125420 Dentinogenesis imperfecta, Shields type II, 125490 Dentinogenesis imperfecta, Shields type III, 125500 |
| DST | 147.6 | 99% | 97% | Epidermolysis bullosa simplex, autosomal recessive 2, 615425 ?Neuropathy, hereditary sensory and autonomic, type VI, 614653 |
| DTNA | 146.8 | 100% | 100% | Left ventricular noncompaction 1, with or without congenital heart defects, 604169 |
| DTNBP1 | 108.5 | 100% | 96% | Hermansky-Pudlak syndrome 7, 614076 |
| DUOX2 | 116.1 | 94% | 92% | Thyroid dyshormonogenesis 6, 607200 |
| DUOXA2 | 112.3 | 100% | 100% | Thyroid dyshormonogenesis 5, 274900 |
| DUSP6 | 133.4 | 100% | 99% | Hypogonadotropic hypogonadism 19 with or without anosmia, 615269 |
| DVL1 | 95.1 | 98% | 91% | Robinow syndrome, autosomal dominant 2, 616331 |
| DVL3 | 129.7 | 100% | 99% | Robinow syndrome, autosomal dominant 3, 616894 |
| DYM | 101.5 | 95% | 90% | Dyggve-Melchior-Claussen disease, 223800 Smith-McCort dysplasia, 607326 |
| DYNC1H1 | 157.8 | 100% | 99% | Charcot-Marie-Tooth disease, axonal, type 20, 614228 Mental retardation, autosomal dominant 13, 614563 Spinal muscular atrophy, lower extremity-predominant 1, AD, 158600 |
| DYNC2H1 | 83.0 | 94% | 83% | Short-rib thoracic dysplasia 3 with or without polydactyly, 613091 |
| DYNC2LI1 | 89.2 | 100% | 95% | Short-rib thoracic dysplasia 15 with polydactyly, 617088 |
| DYRK1A | 136.7 | 100% | 100% | Mental retardation, autosomal dominant 7, 614104 |
| DYRK1B | 86.2 | 94% | 93% | Abdominal obesity-metabolic syndrome 3, 615812 |

| | | | | |
|---------|-------|------|------|---|
| DYSF | 114.2 | 100% | 99% | Miyoshi muscular dystrophy 1, 254130 Muscular dystrophy, limb-girdle, type 2B, 253601 Myopathy, distal, with anterior tibial onset, 606768 |
| DYX1C1 | 65.1 | 99% | 75% | Ciliary dyskinesia, primary, 25, 615482 {Dyslexia, susceptibility to, 1}, 127700 |
| EARS2 | 78.8 | 98% | 96% | Combined oxidative phosphorylation deficiency 12, 614924 |
| EBP | 80.2 | 100% | 96% | Chondrodysplasia punctata, X-linked dominant, 302960 MEND syndrome, 300960 |
| ECE1 | 140.1 | 97% | 93% | Hirschsprung disease, cardiac defects, and autonomic dysfunction, 613870 {Hypertension, essential, susceptibility to}, 145500 |
| ECEL1 | 83.6 | 87% | 83% | Arthrogryposis, distal, type 5D, 615065 |
| ECHS1 | 108.4 | 100% | 100% | Mitochondrial short-chain enoyl-CoA hydratase 1 deficiency, 616277 |
| ECM1 | 141.9 | 100% | 99% | Urbach-Wiethe disease, 247100 |
| EDA | 103.5 | 97% | 80% | Ectodermal dysplasia 1, hypohidrotic, X-linked, 305100 Tooth agenesis, selective, X-linked 1, 313500 |
| EDAR | 110.2 | 98% | 95% | Ectodermal dysplasia 10A, hypohidrotic/hair/nail type, autosomal dominant, 129490 Ectodermal dysplasia 10B, hypohidrotic/hair/tooth type, autosomal recessive, 224900 [Hair morphology 1, hair thickness], 612630 |
| EDARADD | 87.4 | 99% | 90% | Ectodermal dysplasia 11A, hypohidrotic/hair/tooth type, autosomal dominant, 614940 Ectodermal dysplasia 11B, hypohidrotic/hair/tooth type, autosomal recessive, 614941 |
| EDN1 | 122.3 | 100% | 100% | Auriculocondylar syndrome 3, 615706 Question mark ears, isolated, 612798 {High density lipoprotein cholesterol level QTL 7} |
| EDN3 | 108.6 | 100% | 93% | Central hypoventilation syndrome, congenital, 209880 Waardenburg syndrome, type 4B, 613265 {Hirschsprung disease, susceptibility to, 4}, 613712 |
| EDNRA | 166.5 | 100% | 98% | Mandibulofacial dysostosis with alopecia, 616367 {Migraine, resistance to}, 157300 |
| EDNRB | 115.6 | 93% | 93% | ABCD syndrome, 600501 Waardenburg syndrome, type 4A, 277580 {Hirschsprung disease, susceptibility to, 2}, 600155 |
| EEF1A2 | 168.9 | 99% | 90% | Epileptic encephalopathy, early infantile, 33, 616409 Mental retardation, autosomal dominant 38, 616393 |
| EFEMP1 | 166.6 | 100% | 97% | Doyne honeycomb degeneration of retina, 126600 |

| | | | | |
|---------|-------|------|------|--|
| EFEMP2 | 117.6 | 100% | 100% | Cutis laxa, autosomal recessive, type IB, 614437 |
| EFNB1 | 147.4 | 100% | 100% | Craniofrontonasal dysplasia, 304110 |
| EFTUD2 | 100.2 | 100% | 99% | Mandibulofacial dysostosis, Guion-Almeida type, 610536 |
| EGF | 118.4 | 100% | 99% | Hypomagnesemia 4, renal, 611718 |
| EGFR | 137.7 | 100% | 98% | Adenocarcinoma of lung, response to tyrosine kinase inhibitor in, 211980 Non small cell lung cancer, response to tyrosine kinase inhibitor in, 211980 ?Inflammatory skin and bowel disease, neonatal, 2, 616069 {Non small cell lung cancer, susceptibility to}, 211980 |
| EGLN1 | 42.5 | 79% | 60% | Erythrocytosis, familial, 3, 609820 [Hemoglobin, high altitude adaptation], 609070 |
| EGR2 | 111.3 | 100% | 100% | Charcot-Marie-Tooth disease, type 1D, 607678 Dejerine-Sottas disease, 145900 Neuropathy, congenital hypomyelinating, 1, 605253 |
| EHMT1 | 134.6 | 99% | 95% | Kleefstra syndrome, 610253 |
| EIF2AK3 | 132.9 | 95% | 92% | Wolcott-Rallison syndrome, 226980 |
| EIF2AK4 | 137.4 | 100% | 97% | Pulmonary venoocclusive disease 2, 234810 |
| EIF2B1 | 118.8 | 100% | 100% | Leukoencephalopathy with vanishing white matter, 603896 |
| EIF2B2 | 119.2 | 100% | 100% | Leukoencephalopathy with vanishing white matter, 603896 Ovarioleukodystrophy, 603896 |
| EIF2B3 | 139.8 | 100% | 100% | Leukoencephalopathy with vanishing white matter, 603896 |
| EIF2B4 | 114.8 | 99% | 96% | Leukoencephaly with vanishing white matter, 603896 Ovarioleukodystrophy, 603896 |
| EIF2B5 | 105.7 | 100% | 98% | Leukoencephalopathy with vanishing white matter, 603896 Ovarioleukodystrophy, 603896 |
| EIF4A3 | 101.1 | 100% | 99% | Robin sequence with cleft mandible and limb abnormalities, 268305 |
| ELAC2 | 105.4 | 100% | 98% | Combined oxidative phosphorylation deficiency 17, 615440 {Prostate cancer, hereditary, 2, susceptibility to}, 614731 |
| ELANE | 90.8 | 99% | 96% | Neutropenia, cyclic, 162800 Neutropenia, severe congenital 1, autosomal dominant, 202700 |
| ELN | 91.1 | 99% | 96% | Cutis laxa, AD, 123700 Supravalvar aortic stenosis, 185500 |
| ELOVL4 | 74.4 | 98% | 97% | Ichthyosis, spastic quadriplegia, and mental retardation, 614457 Stargardt disease 3, 600110 ?Spinocerebellar ataxia 34, 133190 |

| | | | | |
|--------|-------|------|------|---|
| ELOVL5 | 102.4 | 100% | 99% | Spinocerebellar ataxia 38, 615957 |
| EMC1 | 109.4 | 100% | 99% | Cerebellar atrophy, visual impairment, and psychomotor retardation, 616875 |
| EMD | 128.9 | 100% | 99% | Emery-Dreifuss muscular dystrophy 1, X-linked, 310300 |
| EMG1 | 118.3 | 100% | 100% | Bowen-Conradi syndrome, 211180 |
| EMP2 | 92.3 | 100% | 99% | Nephrotic syndrome, type 10, 615861 |
| EMR2 | 142.1 | 97% | 96% | Vibratory urticaria, 125630 |
| EMX2 | 93.9 | 100% | 99% | Schizencephaly, 269160 |
| ENAM | 125.2 | 100% | 100% | Amelogenesis imperfecta, type IB, 104500 Amelogenesis imperfecta, type IC, 204650 |
| ENG | 111.5 | 94% | 91% | Telangiectasia, hereditary hemorrhagic, type 1, 187300 |
| ENPP1 | 129.9 | 86% | 76% | Arterial calcification, generalized, of infancy, 1, 208000 Cole disease, 615522 Hypophosphatemic rickets, autosomal recessive, 2, 613312 {Diabetes mellitus, non-insulin-dependent, susceptibility to}, 125853 {Obesity, susceptibility to}, 601665 |
| ENTPD1 | 139.2 | 100% | 99% | Spastic paraparesis 64, autosomal recessive, 615683 |
| EOGT | 130.9 | 100% | 96% | Adams-Oliver syndrome 4, 615297 |
| EP300 | 161.4 | 99% | 98% | Colorectal cancer, somatic, 114500 Rubinstein-Taybi syndrome 2, 613684 |
| EPAS1 | 114.8 | 96% | 94% | Erythrocytosis, familial, 4, 611783 |
| EPB41 | 112.5 | 99% | 96% | Elliptocytosis-1, 611804 |
| EPB42 | 133.8 | 100% | 99% | Spherocytosis, type 5, 612690 |
| EPCAM | 52.9 | 94% | 75% | Colorectal cancer, hereditary nonpolyposis, type 8, 613244 Diarrhea 5, with tufting enteropathy, congenital, 613217 |
| EPG5 | 112.9 | 99% | 96% | Vici syndrome, 242840 |
| EPHA2 | 151.5 | 98% | 97% | Cataract 6, multiple types, 116600 |
| EPHX1 | 108.9 | 98% | 96% | Diphenylhydantoin toxicity Hypercholanemia, familial, 607748 ?Fetal hydantoin syndrome {Preeclampsia, susceptibility to}, 189800 |
| EPM2A | 98.4 | 83% | 80% | Epilepsy, progressive myoclonic 2A (Lafora), 254780 |
| ERBB2 | 115.1 | 98% | 97% | Adenocarcinoma of lung, somatic, 211980 Gastric cancer, somatic, 613659 Glioblastoma, somatic, 137800 |

| | | | | |
|---------|-------|------|------|---|
| | | | | Ovarian cancer, somatic, |
| ERBB3 | 114.2 | 99% | 98% | Lethal congenital contractual syndrome 2, 607598 |
| ERBB4 | 131.0 | 99% | 98% | Amyotrophic lateral sclerosis 19, 615515 |
| ERCC1 | 74.2 | 100% | 95% | Cerebrooculofacioskeletal syndrome 4, 610758 |
| ERCC2 | 116.2 | 100% | 100% | Cerebrooculofacioskeletal syndrome 2, 610756 Trichothiodystrophy 1, photosensitive, 601675 Xeroderma pigmentosum, group D, 278730 |
| ERCC3 | 95.9 | 100% | 97% | Trichothiodystrophy 2, photosensitive, 616390 Xeroderma pigmentosum, group B, 610651 |
| ERCC4 | 131.5 | 99% | 97% | Fanconi anemia, complementation group Q, 615272 Xeroderma pigmentosum, group F, 278760 Xeroderma pigmentosum, type F/Cockayne syndrome, 278760 ?XFE progeroid syndrome, 610965 |
| ERCC5 | 124.3 | 100% | 99% | Cerebrooculofacioskeletal syndrome 3, 616570 Xeroderma pigmentosum, group G, 278780 Xeroderma pigmentosum, group G/Cockayne syndrome, 278780 |
| ERCC6 | 147.5 | 100% | 100% | Cerebrooculofacioskeletal syndrome 1, 214150 Cockayne syndrome, type B, 133540 De Sanctis-Cacchione syndrome, 278800 Premature ovarian failure 11, 616946 UV-sensitive syndrome 1, 600630 {Lung cancer, susceptibility to}, 211980 {Macular degeneration, age-related, susceptibility to 5}, 613761 |
| ERCC6L2 | 118.1 | 99% | 97% | Bone marrow failure syndrome 2, 615715 |
| ERCC8 | 78.9 | 98% | 82% | Cockayne syndrome, type A, 216400 UV-sensitive syndrome 2, 614621 |
| ERF | 90.7 | 100% | 95% | Craniosynostosis 4, 600775 |
| ERLIN1 | 151.1 | 100% | 100% | Spastic Paraplegia 62, 615681 |
| ERLIN2 | 132.6 | 100% | 96% | Spastic paraplegia 18, autosomal recessive, 611225 |
| ESCO2 | 102.3 | 91% | 85% | Roberts syndrome, 268300 SC phocomelia syndrome, 269000 |

| | | | | |
|--------|-------|------|------|---|
| ESPN | 36.4 | 65% | 54% | Deafness, autosomal recessive 36, 609006 Deafness, neurosensory, without vestibular involvement, autosomal dominant |
| ESR1 | 101.2 | 98% | 97% | Estrogen resistance, 615363 {Atherosclerosis, susceptibility to} {Breast cancer}, 114480 {HDL response to hormone replacement, augmented} {Migraine, susceptibility to}, 157300 {Myocardial infarction, susceptibility to}, 608446 |
| ESRRB | 98.4 | 100% | 99% | Deafness, autosomal recessive 35, 608565 |
| ETFA | 130.5 | 100% | 100% | Glutaric acidemia IIA, 231680 |
| ETFB | 97.9 | 100% | 100% | Glutaric acidemia IIB, 231680 |
| ETFDH | 93.8 | 99% | 98% | Glutaric acidemia IIC, 231680 |
| ETHE1 | 65.8 | 100% | 87% | Ethylmalonic encephalopathy, 602473 |
| ETV6 | 105.8 | 100% | 100% | Leukemia, acute myeloid, somatic, 601626 Thrombocytopenia 5, 616216 |
| EVC | 95.8 | 90% | 85% | Ellis-van Creveld syndrome, 225500 Weyers acrodental dysostosis, 193530 |
| EVC2 | 95.8 | 96% | 90% | Ellis-van Creveld syndrome, 225500 Weyers acrofacial dysostosis, 193530 |
| EWSR1 | 63.7 | 93% | 86% | Ewing sarcoma, 612219 Neuroepithelioma, 612219 |
| EXOSC3 | 68.1 | 89% | 83% | Pontocerebellar hypoplasia, type 1B, 614678 |
| EXOSC8 | 69.1 | 84% | 68% | Pontocerebellar hypoplasia, type 1C, 616081 |
| EXPH5 | 178.8 | 100% | 100% | Epidermolysis bullosa, nonspecific, autosomal recessive, 615028 |
| EXT1 | 77.9 | 97% | 94% | Chondrosarcoma, 215300 Exostoses, multiple, type 1, 133700 |
| EXT2 | 162.0 | 100% | 98% | Exostoses, multiple, type 2, 133701 ?Seizures, scoliosis, and macrocephaly syndrome, 616682 |
| EYA1 | 132.8 | 100% | 99% | Anterior segment anomalies with or without cataract, 113650 Branchioototic syndrome 1, 602588 Branchiootorenal syndrome 1, with or without cataracts, 113650 ?Otofaciocervical syndrome, 166780 |
| EYA4 | 135.5 | 100% | 100% | Cardiomyopathy, dilated, 1J, 605362 Deafness, autosomal dominant 10, 601316 |

| | | | | |
|---------|-------|------|------|--|
| EYS | 127.3 | 98% | 93% | Retinitis pigmentosa 25, 602772 |
| EZH2 | 122.6 | 99% | 97% | Weaver syndrome, 277590 |
| F10 | 128.4 | 98% | 95% | Factor X deficiency, 227600 |
| F11 | 136.8 | 100% | 99% | Factor XI deficiency, autosomal dominant, 612416 Factor XI deficiency, autosomal recessive, 612416 |
| F12 | 98.4 | 100% | 99% | Angioedema, hereditary, type III, 610618 Factor XII deficiency, 234000 |
| F13A1 | 148.1 | 100% | 98% | Factor XIII A deficiency, 613225 {Myocardial infarction, protection against}, 608446 {Venous thrombosis, protection against}, 188050 |
| F13B | 109.2 | 94% | 84% | Factor XIII B deficiency, 613235 |
| F2 | 101.1 | 100% | 97% | Dysprothrombinemia, 613679 Hypoprothrombinemia, 613679 Thrombophilia due to thrombin defect, 188050 {Pregnancy loss, recurrent, susceptibility to, 2}, 614390 {Stroke, ischemic, susceptibility to}, 601367 |
| F5 | 162.1 | 98% | 97% | Factor V deficiency, 227400 Thrombophilia due to activated protein C resistance, 188055 {Budd-Chiari syndrome}, 600880 {Pregnancy loss, recurrent, susceptibility to, 1}, 614389 {Stroke, ischemic, susceptibility to}, 601367 {Thrombophilia, susceptibility to, due to factor V Leiden}, 188055 |
| F7 | 135.4 | 100% | 100% | Factor VII deficiency, 227500 {Myocardial infarction, decreased susceptibility to}, 608446 |
| F8 | 151.0 | 99% | 99% | Hemophilia A, 306700 |
| F9 | 170.7 | 100% | 95% | Hemophilia B, 306900 Thrombophilia, X-linked, due to factor IX defect, 300807 {Deep venous thrombosis, protection against}, 300807 {Warfarin sensitivity}, 122700 |
| FA2H | 81.6 | 94% | 79% | Spastic paraparesis 35, autosomal recessive, 612319 |
| FADD | 112.5 | 100% | 98% | Infections, recurrent, with encephalopathy, hepatic dysfunction, and cardiovascular malformations, 613759 |
| FAH | 133.7 | 100% | 99% | Tyrosinemia, type I, 276700 |
| FAM105B | 125.2 | 91% | 87% | Autoinflammation, panniculitis, and dermatosis syndrome, 617099 |

| | | | | |
|---------|-------|------|------|--|
| FAM11A | 249.9 | 100% | 100% | Gracile bone dysplasia, 602361 Kenny-Caffey syndrome, type 2, 127000 |
| FAM11B | 134.3 | 100% | 99% | Poikiloderma, hereditary fibrosing, with tendon contractures, myopathy, and pulmonary fibrosis, 615704 |
| FAM126A | 125.0 | 95% | 95% | Leukodystrophy, hypomyelinating, 5, 610532 |
| FAM134B | 98.5 | 95% | 87% | Neuropathy, hereditary sensory and autonomic, type IIB, 613115 |
| FAM161A | 97.9 | 98% | 92% | Retinitis pigmentosa 28, 606068 |
| FAM20A | 96.9 | 99% | 89% | Amelogenesis imperfecta, type IG (enamel-renal syndrome), 204690 |
| FAM20C | 82.4 | 100% | 93% | Raine syndrome, 259775 |
| FAM58A | 88.7 | 80% | 78% | STAR syndrome, 300707 |
| FAM83H | 70.9 | 96% | 87% | Amelogenesis imperfecta, type III, 130900 |
| FAN1 | 131.5 | 100% | 100% | Interstitial nephritis, karyomegalic, 614817 |
| FANCA | 103.4 | 100% | 98% | Fanconi anemia, complementation group A, 227650 |
| FANCB | 87.2 | 99% | 93% | Fanconi anemia, complementation group B, 300514 |
| FANCC | 102.9 | 100% | 100% | Fanconi anemia, complementation group C, 227645 |
| FANCD2 | 116.8 | 97% | 94% | Fanconi anemia, complementation group D2, 227646 |
| FANCE | 99.6 | 84% | 84% | Fanconi anemia, complementation group E, 600901 |
| FANCF | 113.0 | 100% | 100% | Fanconi anemia, complementation group F, 603467 |
| FANCG | 117.3 | 100% | 99% | Fanconi anemia, complementation group G, 614082 |
| FANCI | 154.7 | 99% | 96% | Fanconi anemia, complementation group I, 609053 |
| FANCL | 67.2 | 100% | 96% | Fanconi anemia, complementation group L, 614083 |
| FAR1 | 78.2 | 94% | 90% | Peroxisomal fatty acyl-CoA reductase 1 disorder, 616154 |
| FARS2 | 183.5 | 100% | 100% | Combined oxidative phosphorylation deficiency 14, 614946 ?Spastic paraplegia 77, autosomal recessive, 617046 |
| FAS | 236.0 | 100% | 98% | Autoimmune lymphoproliferative syndrome, type IA, 601859 Squamous cell carcinoma, burn scar-related, somatic {Autoimmune lymphoproliferative syndrome}, 601859 |
| FASLG | 78.1 | 100% | 96% | Autoimmune lymphoproliferative syndrome, type IB, 601859 {Lung cancer, susceptibility to}, 211980 |
| FAT4 | 186.7 | 100% | 99% | Hennekam lymphangiectasia-lymphedema syndrome 2, 616006 Van Maldergem syndrome 2, 615546 |
| FBLN5 | 102.3 | 91% | 91% | Cutis laxa, autosomal dominant 2, 614434 Cutis laxa, autosomal recessive, type IA, 219100 Macular degeneration, age-related, 3, 608895 Neuropathy, hereditary, with or without age-related macular degeneration, 608895 |

| | | | | |
|--------|-------|------|------|--|
| FBN1 | 141.2 | 100% | 98% | Acromicric dysplasia, 102370 Aortic aneurysm, ascending, and dissection Ectopia lentis, familial, 129600 Geleophysic dysplasia 2, 614185 Marfan lipodystrophy syndrome, 616914 Marfan syndrome, 154700 MASS syndrome, 604308 Stiff skin syndrome, 184900 Weill-Marchesani syndrome 2, dominant, 608328 |
| FBN2 | 145.5 | 100% | 99% | Contractural arachnodactyly, congenital, 121050 Macular degeneration, early-onset, 616118 |
| FBP1 | 100.7 | 100% | 100% | Fructose-1,6-bisphosphatase deficiency, 229700 |
| FBXL4 | 180.4 | 100% | 100% | Mitochondrial DNA depletion syndrome 13 (encephalomyopathic type), 615471 |
| FBXO38 | 142.4 | 99% | 98% | Neuronopathy, distal hereditary motor, type IID, 615575 |
| FBXO7 | 192.9 | 100% | 98% | Parkinson disease 15, autosomal recessive, 260300 |
| FCGR3A | 156.8 | 100% | 98% | Immunodeficiency 20, 615707 |
| FCGR3B | 163.0 | 99% | 97% | Neutropenia, alloimmune neonatal |
| FCN3 | 113.1 | 100% | 98% | Immunodeficiency due to ficolin 3 deficiency, 613860 |
| FDPS | 60.9 | 96% | 94% | Porokeratosis 9, multiple types, 616631 |
| FECH | 114.9 | 100% | 100% | Protoporphria, erythropoietic, autosomal recessive, 177000 |
| FERMT1 | 87.6 | 97% | 94% | Kindler syndrome, 173650 |
| FERMT3 | 107.2 | 100% | 100% | Leukocyte adhesion deficiency, type III, 612840 |
| FEZF1 | 125.1 | 100% | 95% | Hypogonadotropic hypogonadism 22, with or without anosmia, 616030 |
| FGA | 142.6 | 98% | 94% | Afibrinogenemia, congenital, 202400 Amyloidosis, familial visceral, 105200 Dysfibrinogenemia, congenital, 616004 Hypodysfibrinogenemia, congenital, 616004 |
| FGB | 168.0 | 100% | 98% | Afibrinogenemia, congenital, 202400 Dysfibrinogenemia, congenital, 616004 Hypofibrinogenemia, congenital, 202400 |
| FGD1 | 102.8 | 97% | 92% | Aarskog-Scott syndrome, 305400 Mental retardation, X-linked syndromic 16, 305400 |
| FGD4 | 92.4 | 97% | 92% | Charcot-Marie-Tooth disease, type 4H, 609311 |
| FGF10 | 122.6 | 100% | 100% | Aplasia of lacrimal and salivary glands, 180920 |

| | | | | |
|-------|-------|------|------|--|
| | | | | LADD syndrome, 149730 |
| FGF14 | 168.9 | 100% | 98% | Spinocerebellar ataxia 27, 609307 |
| FGF16 | 144.6 | 100% | 99% | Metacarpal 4-5 fusion, 309630 |
| FGF17 | 129.7 | 100% | 100% | Hypogonadotropic hypogonadism 20 with or without anosmia, 615270 |
| FGF23 | 95.3 | 98% | 95% | Hypophosphatemic rickets, autosomal dominant, 193100 Osteomalacia, tumor-induced Tumoral calcinosis, hyperphosphatemic, familial, 211900 |
| FGF3 | 68.5 | 97% | 92% | Deafness, congenital with inner ear agenesis, microtia, and microdontia, 610706 |
| FGF5 | 87.2 | 100% | 99% | Trichomegaly, 190330 |
| FGF8 | 121.5 | 82% | 75% | Hypogonadotropic hypogonadism 6 with or without anosmia, 612702 |
| FGFR1 | 127.6 | 97% | 96% | Encephalocranioscutaneous lipomatosis, 613001 Hartsfield syndrome, 615465 Hypogonadotropic hypogonadism 2 with or without anosmia, 147950 Jackson-Weiss syndrome, 123150 Osteoglophonic dysplasia, 166250 Pfeiffer syndrome, 101600 Trigonocephaly 1, 190440 |
| FGFR2 | 121.8 | 96% | 95% | Antley-Bixler syndrome without genital anomalies or disordered steroidogenesis, 207410 Apert syndrome, 101200 Beare-Stevenson cutis gyrata syndrome, 123790 Bent bone dysplasia syndrome, 614592 Craniofacial-skeletal-dermatologic dysplasia, 101600 Craniosynostosis, nonspecific Crouzon syndrome, 123500 Gastric cancer, somatic, 613659 Jackson-Weiss syndrome, 123150 LADD syndrome, 149730 Pfeiffer syndrome, 101600 Saethre-Chotzen syndrome, 101400 Scaphocephaly and Axenfeld-Rieger anomaly Scaphocephaly, maxillary retrusion, and mental retardation, 609579 |

| | | | | |
|--------|-------|------|-----|--|
| FGFR3 | 98.9 | 100% | 99% | Achondroplasia, 100800 Bladder cancer, somatic, 109800 CATSHL syndrome, 610474 Cervical cancer, somatic, 603956 Colorectal cancer, somatic, 114500 Crouzon syndrome with acanthosis nigricans, 612247 Hypochondroplasia, 146000 LADD syndrome, 149730 Muenke syndrome, 602849 Nevus, epidermal, somatic, 162900 SADDAN, 616482 Spermatocytic seminoma, somatic, 273300 Thanatophoric dysplasia, type I, 187600 Thanatophoric dysplasia, type II, 187601 |
| FGG | 131.4 | 98% | 97% | Afibrinogenemia, congenital, 202400 Dysfibrinogenemia, congenital, 616004 Hypodysfibrinogenemia, 616004 Hypofibrinogenemia, congenital, 202400 |
| FH | 139.2 | 89% | 86% | Fumarase deficiency, 606812 Leiomyomatosis and renal cell cancer, 150800 |
| FHL1 | 98.8 | 98% | 93% | Emery-Dreifuss muscular dystrophy 6, X-linked, 300696 Hemophagocytic lymphohistiocytosis, familial, 1 Myopathy, X-linked, with postural muscle atrophy, 300696 Reducing body myopathy, X-linked 1a, severe, infantile or early childhood onset, 300717 Reducing body myopathy, X-linked 1b, with late childhood or adult onset, 300718 Scapuloperoneal myopathy, X-linked dominant, 300695 |
| FIG4 | 147.4 | 100% | 96% | Amyotrophic lateral sclerosis 11, 612577 Charcot-Marie-Tooth disease, type 4J, 611228 Yunis-Varon syndrome, 216340 ?Polymicrogyria, bilateral temporooccipital, 612691 |
| FIGLA | 91.8 | 90% | 85% | Premature ovarian failure 6, 612310 |
| FKBP10 | 137.9 | 97% | 93% | Bruck syndrome 1, 259450 Osteogenesis imperfecta, type XI, 610968 |
| FKBP14 | 75.6 | 99% | 93% | Ehlers-Danlos syndrome with progressive kyphoscoliosis, myopathy, and hearing loss, 614557 |

| | | | | |
|-------|-------|------|------|--|
| FKRP | 74.3 | 100% | 99% | Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 5, 613153 Muscular dystrophy-dystroglycanopathy (congenital with or without mental retardation), type B, 5, 606612 Muscular dystrophy-dystroglycanopathy (limb-girdle), type C, 5, 607155 |
| FKTN | 128.4 | 99% | 93% | Cardiomyopathy, dilated, 1X, 611615 Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 4, 253800 Muscular dystrophy-dystroglycanopathy (congenital without mental retardation), type B, 4, 613152 Muscular dystrophy-dystroglycanopathy (limb-girdle), type C, 4, 611588 |
| FLAD1 | 141.7 | 100% | 100% | Lipid storage myopathy due to flavin adenine dinucleotide synthetase deficiency, 255100 |
| FLCN | 138.8 | 100% | 99% | Birt-Hogg-Dube syndrome, 135150 Colorectal cancer, somatic, 114500 Pneumothorax, primary spontaneous, 173600 Renal carcinoma, chromophobe, somatic, 144700 |
| FLG | 170.8 | 100% | 99% | Ichthyosis vulgaris, 146700 {Dermatitis, atopic, susceptibility to, 2}, 605803 |
| FLNA | 163.8 | 100% | 100% | Cardiac valvular dysplasia, X-linked, 314400 Congenital short bowel syndrome, 300048 FG syndrome 2, 300321 Frontometaphyseal dysplasia, 305620 Heterotopia, periventricular, 300049 Heterotopia, periventricular, ED variant, 300537 Intestinal pseudoobstruction, neuronal, 300048 Melnick-Needles syndrome, 309350 Otopalatodigital syndrome, type I, 311300 Otopalatodigital syndrome, type II, 304120 Terminal osseous dysplasia, 300244 |
| FLNB | 129.5 | 99% | 99% | Atelosteogenesis, type I, 108720 Atelosteogenesis, type III, 108721 Boomerang dysplasia, 112310 Larsen syndrome, 150250 Spondylocarpotarsal synostosis syndrome, 272460 |
| FLNC | 135.4 | 100% | 99% | Cardiomyopathy, familial hypertrophic, 26 Cardiomyopathy, familial restrictive 5, 617047 Myopathy, distal, 4, 614065 Myopathy, myofibrillar, 5, 609524 |

| | | | | |
|--------|-------|------|------|---|
| FLRT3 | 188.9 | 100% | 100% | Hypogonadotropic hypogonadism 21 with anosmia, 615271 |
| FLT3 | 121.0 | 98% | 97% | Leukemia, acute lymphoblastic, somatic, 613065 Leukemia, acute myeloid, reduced survival in, somatic, 601626 Leukemia, acute myeloid, somatic, 601626 |
| FLT4 | 143.6 | 99% | 98% | Hemangioma, capillary infantile, somatic, 602089 Lymphedema, hereditary, IA, 153100 |
| FLVCR1 | 126.5 | 99% | 97% | Ataxia, posterior column, with retinitis pigmentosa, 609033 |
| FLVCR2 | 152.6 | 100% | 100% | Proliferative vasculopathy and hydraencephaly-hydrocephaly syndrome, 225790 |
| FMN2 | 76.9 | 80% | 72% | Mental retardation, autosomal recessive 47, 616193 |
| FMO3 | 138.1 | 99% | 97% | Trimethylaminuria, 602079 |
| FMR1 | 94.5 | 96% | 87% | Fragile X syndrome, 300624 Fragile X tremor/ataxia syndrome, 300623 Premature ovarian failure 1, 311360 |
| FN1 | 126.8 | 100% | 98% | Glomerulopathy with fibronectin deposits 2, 601894 Plasma fibronectin deficiency, 614101 |
| FOLR1 | 107.1 | 100% | 100% | Neurodegeneration due to cerebral folate transport deficiency, 613068 |
| FOXC1 | 32.1 | 97% | 83% | Axenfeld-Rieger syndrome, type 3, 602482 Iridogoniodysgenesis, type 1, 601631 Iris hypoplasia and glaucoma, 601631 Rieger or Axenfeld anomalies, 602482 |
| FOXC2 | 42.2 | 99% | 77% | Lymphedema-distichiasis syndrome with renal disease and diabetes mellitus, 153400 Lymphedema-distichiasis syndrome, 153400 |
| FOXE1 | 24.2 | 70% | 54% | Bamforth-Lazarus syndrome, 241850 {Thyroid cancer, nonmedullary, 4}, 616534 |
| FOXE3 | 16.1 | 57% | 38% | Anterior segment mesenchymal dysgenesis, 107250 Aphakia, congenital primary, 610256 |
| FOXF1 | 61.8 | 96% | 87% | Alveolar capillary dysplasia with misalignment of pulmonary veins, 265380 |
| FOXG1 | 93.6 | 79% | 76% | Rett syndrome, congenital variant, 613454 |
| FOXI1 | 115.2 | 100% | 100% | Enlarged vestibular aqueduct, 600791 |
| FOXL2 | 25.3 | 78% | 55% | Blepharophimosis, epicanthus inversus, and ptosis, type 1, 110100 Blepharophimosis, epicanthus inversus, and ptosis, type 2, 110100 Premature ovarian failure 3, 608996 |
| FOXN1 | 88.2 | 99% | 96% | T-cell immunodeficiency, congenital alopecia, and nail dystrophy, 601705 |
| FOXO1 | 121.1 | 94% | 91% | Rhabdomyosarcoma, alveolar, 268220 |

| | | | | |
|---------|-------|------|------|--|
| FOXP1 | 116.7 | 100% | 99% | Mental retardation with language impairment and with or without autistic features, 613670 |
| FOXP2 | 134.9 | 95% | 94% | Speech-language disorder-1, 602081 |
| FOXP3 | 130.0 | 100% | 90% | Immunodysregulation, polyendocrinopathy, and enteropathy, X-linked, 304790 {Diabetes mellitus, type I, susceptibility to}, 222100 |
| FOXRED1 | 122.6 | 100% | 99% | Leigh syndrome due to mitochondrial complex I deficiency, 256000 Mitochondrial complex I deficiency, 252010 |
| FRAS1 | 124.7 | 99% | 99% | Fraser syndrome, 219000 |
| FREM1 | 124.0 | 99% | 97% | Bifid nose with or without anorectal and renal anomalies, 608980 Manitoba oculotrichoanal syndrome, 248450 Trigonocephaly 2, 614485 |
| FREM2 | 158.3 | 99% | 99% | Fraser syndrome, 219000 |
| FRMD7 | 151.9 | 100% | 100% | Nystagmus 1, congenital, X-linked, 310700 Nystagmus, infantile periodic alternating, X-linked, 310700 |
| FRRS1L | 106.3 | 62% | 62% | Epileptic encephalopathy, early infantile, 37, 616981 |
| FSCN2 | 130.9 | 100% | 100% | Retinitis pigmentosa 30, 607921 |
| FSHB | 118.0 | 100% | 100% | Hypogonadotropic hypogonadism 24 without anosmia, 229070 |
| FSHR | 108.0 | 99% | 97% | Ovarian dysgenesis 1, 233300 Ovarian hyperstimulation syndrome, 608115 Ovarian response to FSH stimulation, 276400 |
| FTCD | 75.8 | 92% | 85% | Glutamate formiminotransferase deficiency, 229100 |
| FTL | 101.3 | 100% | 97% | Hyperferritinemia-cataract syndrome, 600886 L-ferritin deficiency, dominant and recessive, 615604 Neurodegeneration with brain iron accumulation 3, 606159 |
| FTO | 116.7 | 99% | 97% | Growth retardation, developmental delay, facial dysmorphism, 612938 {Obesity, susceptibility to, BMIQ14}, 612460 |
| FTSJ1 | 149.3 | 100% | 98% | Mental retardation, X-linked 9, 309549 |
| FUCA1 | 121.2 | 100% | 99% | Fucosidosis, 230000 |
| FUS | 117.2 | 100% | 93% | Amyotrophic lateral sclerosis 6, with or without frontotemporal dementia, 608030 Tremor, hereditary essential, 4, 614782 |
| FUT6 | 151.4 | 100% | 100% | Fucosyltransferase 6 deficiency, 613852 |
| FUZ | 94.7 | 100% | 100% | Neural tube defects, 182940 |
| FXN | 59.8 | 75% | 71% | Friedreich ataxia with retained reflexes, 229300 Friedreich ataxia, 229300 |
| FXYD2 | 80.6 | 100% | 100% | Hypomagnesemia 2, renal, 154020 |

| | | | | |
|--------|-------|------|------|--|
| FYCO1 | 106.7 | 100% | 100% | Cataract 18, autosomal recessive, 610019 |
| FZD4 | 177.8 | 100% | 98% | Exudative vitreoretinopathy 1, 133780 Retinopathy of prematurity, 133780 |
| FZD6 | 179.4 | 100% | 100% | Nail disorder, nonsyndromic congenital, 10, (claw-shaped nails), 614157 |
| G6PC | 166.9 | 100% | 100% | Glycogen storage disease Ia, 232200 |
| G6PC3 | 115.4 | 100% | 100% | Dursun syndrome, 612541 Neutropenia, severe congenital 4, autosomal recessive, 612541 |
| G6PD | 135.0 | 100% | 99% | Favism, 134700 Hemolytic anemia due to G6PD deficiency, 300908 {Resistance to malaria due to G6PD deficiency}, 611162 |
| GAA | 106.3 | 100% | 99% | Glycogen storage disease II, 232300 |
| GABRA1 | 160.5 | 100% | 100% | Epileptic encephalopathy, early infantile, 19, 615744 {Epilepsy, childhood absence, susceptibility to, 4}, 611136 {Epilepsy, juvenile myoclonic, susceptibility to, 5}, 611136 |
| GABRG2 | 134.8 | 92% | 92% | Epilepsy, generalized, with febrile seizures plus, type 3, 611277 Febrile seizures, familial, 8, 611277 {Epilepsy, childhood absence, susceptibility to, 2}, 607681 |
| GALC | 94.2 | 98% | 91% | Krabbe disease, 245200 |
| GALE | 125.6 | 100% | 100% | Galactose epimerase deficiency, 230350 |
| GALK1 | 95.7 | 98% | 94% | Galactokinase deficiency with cataracts, 230200 |
| GALNS | 84.5 | 100% | 93% | Mucopolysaccharidosis IVA, 253000 |
| GALNT3 | 118.2 | 97% | 91% | Tumoral calcinosis, hyperphosphatemic, familial, 211900 |
| GALT | 137.1 | 100% | 100% | Galactosemia, 230400 |
| GAMT | 91.2 | 98% | 88% | Cerebral creatine deficiency syndrome 2, 612736 |
| GAN | 177.1 | 100% | 97% | Giant axonal neuropathy-1, 256850 |
| GANAB | 103.5 | 99% | 97% | Polycystic kidney disease 3, 600666 |
| GARS | 120.6 | 99% | 96% | Charcot-Marie-Tooth disease, type 2D, 601472 Neuropathy, distal hereditary motor, type VA, 600794 |
| GAS8 | 137.3 | 100% | 99% | Ciliary dyskinesia, primary, 33, 616726 |
| GATA1 | 92.2 | 100% | 99% | Anemia, X-linked, with/without neutropenia and/or platelet abnormalities, 300835 Leukemia, megakaryoblastic, with or without Down syndrome, somatic, 190685 Thrombocytopenia with beta-thalassemia, X-linked, 314050 Thrombocytopenia, X-linked, with or without dyserythropoietic anemia, 300367 |

| | | | | |
|---------|-------|------|------|--|
| GATA2 | 106.1 | 100% | 98% | Emberger syndrome, 614038 Immunodeficiency 21, 614172 {Leukemia, acute myeloid, susceptibility to}, 601626 {Myelodysplastic syndrome, susceptibility to}, 614286 |
| GATA3 | 145.1 | 100% | 99% | Hypoparathyroidism, sensorineural deafness, and renal dysplasia, 146255 |
| GATA4 | 65.1 | 57% | 53% | Atrial septal defect 2, 607941 Atrioventricular septal defect 4, 614430 Tetralogy of Fallot, 187500 Ventricular septal defect 1, 614429 ?Testicular anomalies with or without congenital heart disease, 615542 |
| GATA6 | 47.2 | 77% | 63% | Atrial septal defect 9, 614475 Atrioventricular septal defect 5, 614474 Pancreatic agenesis and congenital heart defects, 600001 Persistent truncus arteriosus, 217095 Tetralogy of Fallot, 187500 |
| GATAD2B | 110.1 | 100% | 99% | Mental retardation, autosomal dominant 18, 615074 |
| GATM | 140.2 | 100% | 100% | Cerebral creatine deficiency syndrome 3, 612718 |
| GBA | 193.2 | 100% | 100% | Gaucher disease, perinatal lethal, 608013 Gaucher disease, type I, 230800 Gaucher disease, type II, 230900 Gaucher disease, type III, 231000 Gaucher disease, type IIIC, 231005 {Lewy body dementia, susceptibility to}, 127750 {Parkinson disease, late-onset, susceptibility to}, 168600 |
| GBA2 | 145.8 | 99% | 98% | Spastic paraplegia 46, autosomal recessive, 614409 |
| GBE1 | 147.0 | 99% | 93% | Glycogen storage disease IV, 232500 Polyglucosan body disease, adult form, 263570 |
| GCDH | 118.5 | 93% | 91% | Glutaricaciduria, type I, 231670 |
| GCH1 | 66.9 | 96% | 79% | Dystonia, DOPA-responsive, with or without hyperphenylalaninemia, 128230 Hyperphenylalaninemia, BH4-deficient, B, 233910 |
| GCK | 126.0 | 100% | 100% | Diabetes mellitus, noninsulin-dependent, late onset, 125853 Diabetes mellitus, permanent neonatal, 606176 Hyperinsulinemic hypoglycemia, familial, 3, 602485 MODY, type II, 125851 |

| | | | | |
|-------|-------|------|------|--|
| GCLC | 121.1 | 99% | 98% | Hemolytic anemia due to gamma-glutamylcysteine synthetase deficiency, 230450 {Myocardial infarction, susceptibility to}, 608446 |
| GCM2 | 127.0 | 100% | 100% | Hypoparathyroidism, familial isolated, 146200 |
| GCNT2 | 157.9 | 100% | 100% | Adult i phenotype without cataract, 110800 Cataract 13 with adult i phenotype, 116700 [Blood group, ii], 110800 |
| GCSH | 29.0 | 60% | 37% | Glycine encephalopathy, 605899 |
| GDAP1 | 153.4 | 100% | 99% | Charcot-Marie-Tooth disease, axonal, type 2K, 607831 Charcot-Marie-Tooth disease, axonal, with vocal cord paresis, 607706 Charcot-Marie-Tooth disease, recessive intermediate, A, 608340 Charcot-Marie-Tooth disease, type 4A, 214400 |
| GDF1 | 27.7 | 69% | 62% | Double-outlet right ventricle, 217095 Right atrial isomerism, 208530 Tetralogy of Fallot, 187500 Transposition of great arteries, dextro-looped 3, 613854 |
| GDF2 | 128.5 | 100% | 100% | Telangiectasia, hereditary hemorrhagic, type 5, 615506 |
| GDF3 | 122.6 | 100% | 100% | Klippel-Feil syndrome 3, autosomal dominant, 613702 Microphthalmia with coloboma 6, 613703 Microphthalmia, isolated 7, 613704 |
| GDF5 | 122.9 | 100% | 100% | Brachydactyly, type A1, C, 615072 Brachydactyly, type A2, 112600 Brachydactyly, type C, 113100 Chondrodysplasia, Grebe type, 200700 Du Pan syndrome, 228900 Multiple synostoses syndrome 2, 610017 Symphalangism, proximal, 1B, 615298 ?Acromesomelic dysplasia, Hunter-Thompson type, 201250 {Osteoarthritis-5}, 612400 |
| GDF6 | 70.3 | 93% | 80% | Klippel-Feil syndrome 1, autosomal dominant, 118100 Leber congenital amaurosis 17, 615360 Microphthalmia with coloboma 6, digenic, 613703 Microphthalmia, isolated 4, 613094 |
| GDI1 | 194.0 | 100% | 100% | Mental retardation, X-linked 41, 300849 |

| | | | | |
|-------|-------|------|------|---|
| GDNF | 155.8 | 100% | 95% | Central hypoventilation syndrome, 209880 {Hirschsprung disease, susceptibility to, 3}, 613711 {Pheochromocytoma, modifier of}, 171300 |
| GFAP | 87.9 | 100% | 100% | Alexander disease, 203450 |
| GFER | 75.1 | 99% | 86% | Myopathy, mitochondrial progressive, with congenital cataract, hearing loss, and developmental delay, 613076 |
| GFI1 | 81.6 | 100% | 92% | Neutropenia, nonimmune chronic idiopathic, of adults, 607847 Neutropenia, severe congenital 2, autosomal dominant, 613107 |
| GFI1B | 132.8 | 100% | 100% | Bleeding disorder, platelet-type, 17, 187900 |
| GFM1 | 85.8 | 98% | 95% | Combined oxidative phosphorylation deficiency 1, 609060 |
| GFPT1 | 126.0 | 99% | 96% | Myasthenia, congenital, 12, with tubular aggregates, 610542 |
| GGCX | 89.8 | 99% | 96% | Pseudoxanthoma elasticum-like disorder with multiple coagulation factor deficiency, 610842 Vitamin K-dependent clotting factors, combined deficiency of, 1, 277450 |
| GH1 | 167.6 | 100% | 100% | Growth hormone deficiency, isolated, type IA, 262400 Growth hormone deficiency, isolated, type IB, 612781 Growth hormone deficiency, isolated, type II, 173100 Kowarski syndrome, 262650 |
| GHR | 185.3 | 100% | 100% | Growth hormone insensitivity, partial, 604271 Increased responsiveness to growth hormone Laron dwarfism, 262500 {Hypercholesterolemia, familial, modifier of}, 143890 |
| GHRHR | 110.8 | 100% | 100% | Growth hormone deficiency, isolated, type IB, 612781 |
| GHSR | 144.6 | 99% | 97% | Growth hormone deficiency, isolated partial, 615925 |
| GIF | 135.4 | 100% | 100% | Intrinsic factor deficiency, 261000 |
| GIPC3 | 100.4 | 90% | 82% | Deafness, autosomal recessive 15, 601869 |
| GJA1 | 182.8 | 100% | 100% | Atrioventricular septal defect 3, 600309 Craniometaphyseal dysplasia, autosomal recessive, 218400 Erythrokeratoderma variabilis et progressiva, 133200 Hypoplastic left heart syndrome 1, 241550 Oculodentodigital dysplasia, 164200 Oculodentodigital dysplasia, autosomal recessive, 257850 Palmoplantar keratoderma with congenital alopecia, 104100 Syndactyly, type III, 186100 |
| GJA3 | 120.9 | 100% | 96% | Cataract 14, multiple types, 601885 |

| | | | | |
|------|-------|------|------|--|
| GJA5 | 224.4 | 100% | 100% | Atrial fibrillation, familial, 11, 614049 Atrial standstill, digenic (GJA5/SCN5A), 108770 |
| GJA8 | 114.0 | 100% | 100% | Cataract 1, multiple types, 116200 |
| GJB1 | 222.4 | 100% | 100% | Charcot-Marie-Tooth neuropathy, X-linked dominant, 1, 302800 |
| GJB2 | 190.3 | 100% | 100% | Bart-Pumphrey syndrome, 149200 Deafness, autosomal dominant 3A, 601544 Deafness, autosomal recessive 1A, 220290 Hystrix-like ichthyosis with deafness, 602540 Keratitis-ichthyosis-deafness syndrome, 148210 Keratoderma, palmoplantar, with deafness, 148350 Vohwinkel syndrome, 124500 |
| GJB3 | 283.3 | 100% | 100% | Deafness, autosomal dominant 2B, 612644 Deafness, autosomal dominant, with peripheral neuropathy Deafness, autosomal recessive Deafness, digenic, GJB2/GJB3, 220290 Erythrokeratoderma variabilis et progressiva, 133200 |
| GJB4 | 330.8 | 100% | 100% | Erythrokeratoderma variabilis with erythema gyratum repens, 133200 |
| GJB6 | 193.1 | 100% | 100% | Deafness, autosomal dominant 3B, 612643 Deafness, autosomal recessive 1B, 612645 Deafness, digenic GJB2/GJB6, 220290 Ectodermal dysplasia 2, Clouston type, 129500 |
| GJC2 | 38.3 | 84% | 57% | Leukodystrophy, hypomyelinating, 2, 608804 Lymphedema, hereditary, IC, 613480 Spastic paraparesis 44, autosomal recessive, 613206 |
| GK | 55.6 | 83% | 67% | Glycerol kinase deficiency, 307030 |
| GLA | 89.1 | 100% | 99% | Fabry disease, 301500 Fabry disease, cardiac variant, 301500 |
| GLB1 | 72.3 | 99% | 95% | GM1-gangliosidosis, type I, 230500 GM1-gangliosidosis, type II, 230600 GM1-gangliosidosis, type III, 230650 Mucopolysaccharidosis type IVB (Morquio), 253010 |
| GLDC | 69.0 | 91% | 81% | Glycine encephalopathy, 605899 |
| GLE1 | 103.5 | 100% | 97% | Arthrogryposis, lethal, with anterior horn cell disease, 611890 Lethal congenital contracture syndrome 1, 253310 |

| | | | | |
|--------|-------|------|------|--|
| GLI2 | 102.9 | 98% | 96% | Culler-Jones syndrome, 615849 Holoprosencephaly-9, 610829 |
| GLI3 | 136.7 | 100% | 99% | Greig cephalopolysyndactyly syndrome, 175700 Pallister-Hall syndrome, 146510 Polydactyly, postaxial, types A1 and B, 174200 Polydactyly, preaxial, type IV, 174700 {Hypothalamic hamartomas, somatic}, 241800 |
| GLIS2 | 92.0 | 100% | 94% | Nephronophthisis 7, 611498 |
| GLIS3 | 124.3 | 100% | 99% | Diabetes mellitus, neonatal, with congenital hypothyroidism, 610199 |
| GLMN | 67.1 | 99% | 85% | Glomuvenous malformations, 138000 |
| GLRA1 | 105.1 | 100% | 100% | Hyperekplexia, hereditary 1, autosomal dominant or recessive, 149400 |
| GLRB | 88.6 | 97% | 89% | Hyperekplexia 2, autosomal recessive, 614619 |
| GLRX5 | 79.2 | 87% | 81% | Anemia, sideroblastic, 3, pyridoxine-refractory, 616860 Spasticity, childhood-onset, with hyperglycinemia, 616859 |
| GLUD1 | 65.2 | 89% | 80% | Hyperinsulinism-hyperammonemia syndrome, 606762 |
| GLUL | 84.2 | 99% | 95% | Glutamine deficiency, congenital, 610015 |
| GLYCTK | 186.0 | 100% | 100% | D-glyceric aciduria, 220120 |
| GM2A | 116.8 | 100% | 100% | GM2-gangliosidosis, AB variant, 272750 |
| GMNN | 93.5 | 93% | 79% | Meier-Gorlin syndrome 6, 616835 |
| GMPPA | 125.4 | 100% | 100% | Alacrima, achalasia, and mental retardation syndrome, 615510 |
| GMPPB | 207.7 | 100% | 100% | Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 14, 615350 Muscular dystrophy-dystroglycanopathy (congenital with mental retardation), type B, 14, 615351 Muscular dystrophy-dystroglycanopathy (limb-girdle), type C, 14, 615352 |
| GNA11 | 136.9 | 100% | 99% | Hypocalcemia, autosomal dominant 2, 615361 Hypocalciuric hypercalcemia, type II, 145981 |
| GNAI2 | 127.8 | 100% | 100% | Pituitary ACTH-secreting adenoma Ventricular tachycardia, idiopathic, 192605 |
| GNAI3 | 99.1 | 100% | 95% | Auriculocondylar syndrome 1, 602483 |
| GNAL | 118.9 | 99% | 91% | Dystonia 25, 615073 |
| GNAO1 | 167.2 | 100% | 100% | Epileptic encephalopathy, early infantile, 17, 615473 |
| GNAQ | 75.9 | 89% | 72% | Capillary malformations, congenital, 1, somatic, mosaic, 163000 Sturge-Weber syndrome, somatic, mosaic, 185300 |

| | | | | |
|----------|-------|------|------|--|
| GNAS | 102.2 | 97% | 95% | Acromegaly, somatic, 102200 ACTH-independent macronodular adrenal hyperplasia, 219080 McCune-Albright syndrome, somatic, mosaic 174800 Osseous heteroplasia, progressive, 166350 Pseudohypoparathyroidism Ia, 103580 Pseudohypoparathyroidism Ib, 603233 Pseudohypoparathyroidism Ic, 612462 Pseudopseudohypoparathyroidism, 612463 |
| GNAS-AS1 | NC | NC | NC | Pseudohypoparathyroidism, type IB, 603233 |
| GNAT1 | 145.8 | 100% | 100% | Night blindness, congenital stationary, autosomal dominant 3, 610444 ?Night blindness, congenital stationary, type 1G, 616389 |
| GNAT2 | 130.2 | 100% | 100% | Achromatopsia-4, 613856 |
| GNB1 | 162.4 | 100% | 100% | Leukemia,acute lymphoblastic,somatic, 613065 Mental retardation, autosomal dominant 42, 616973 |
| GNB3 | 173.2 | 100% | 100% | Night blindness, congenital stationary, type 1H, 617024 {Hypertension, essential, susceptibility to}, 145500 |
| GNB4 | 133.7 | 100% | 100% | Charcot-Marie-Tooth disease, dominant intermediate F, 615185 |
| GNE | 136.1 | 100% | 99% | Nonaka myopathy, 605820 Sialuria, 269921 |
| GNMT | 143.4 | 99% | 96% | Glycine N-methyltransferase deficiency, 606664 |
| GNPAT | 129.1 | 99% | 95% | Rhizomelic chondrodyplasia punctata, type 2, 222765 |
| GNPTAB | 150.5 | 97% | 97% | Mucolipidosis II alpha/beta, 252500 Mucolipidosis III alpha/beta, 252600 |
| GNPTG | 131.6 | 93% | 84% | Mucolipidosis III gamma, 252605 |
| GNRHR | 182.5 | 100% | 100% | Hypogonadotropic hypogonadism 7 without anosmia, 146110 |
| GNS | 95.0 | 97% | 93% | Mucopolysaccharidosis type IIID, 252940 |
| GORAB | 151.7 | 100% | 99% | Geroderma osteodysplasticum, 231070 |
| GOSR2 | 113.6 | 97% | 96% | Epilepsy, progressive myoclonic 6, 614018 |
| GOT1 | 110.1 | 100% | 97% | Aspartate aminotransferase, serum level of, QTL1, 614419 |
| GP1BA | 135.4 | 97% | 94% | Bernard-Soulier syndrome, type A1 (recessive), 231200 Bernard-Soulier syndrome, type A2 (dominant), 153670 von Willebrand disease, platelet-type, 177820 {Nonarteritic anterior ischemic optic neuropathy, susceptibility to}, 258660 |
| GP1BB | 30.6 | 69% | 61% | Bernard-Soulier syndrome, type B, 231200 |

| | | | | |
|---------|-------|------|------|---|
| | | | | Giant platelet disorder, isolated, 231200 |
| GP6 | 110.2 | 100% | 100% | Bleeding disorder, platelet-type, 11, 614201 |
| GP9 | 60.2 | 99% | 85% | Bernard-Soulier syndrome, type C, 231200 |
| GPC3 | 119.5 | 100% | 98% | Simpson-Golabi-Behmel syndrome, type 1, 312870 Wilms tumor, somatic, 194070 |
| GPC6 | 129.8 | 100% | 100% | Omodyplasia 1, 258315 |
| GPD1 | 88.8 | 99% | 92% | Hypertriglyceridemia, transient infantile, 614480 |
| GPD1L | 132.0 | 100% | 99% | Brugada syndrome 2, 611777 |
| GPHN | 152.5 | 98% | 96% | Molybdenum cofactor deficiency C, 615501 |
| GPI | 126.7 | 100% | 100% | Hemolytic anemia, nonspherocytic, due to glucose phosphate isomerase deficiency, 613470 |
| GPIHBP1 | 82.6 | 100% | 99% | Hyperlipoproteinemia, type 1D, 615947 |
| GPR101 | 152.2 | 100% | 100% | Pituitary adenoma, growth hormone-secreting 2, 300943 |
| GPR126 | 142.8 | 99% | 98% | Lethal congenital contracture syndrome 9, 616503 |
| GPR143 | 75.7 | 91% | 87% | Nystagmus 6, congenital, X-linked, 300814 Ocular albinism, type I, Nettleship-Falls type, 300500 |
| GPR179 | 112.0 | 100% | 99% | Night blindness, congenital stationary (complete), 1E, autosomal recessive, 614565 |
| GPR56 | 141.3 | 100% | 100% | Polymicrogyria, bilateral frontoparietal, 606854 Polymicrogyria, bilateral perisylvian, 615752 |
| GPR98 | 129.7 | 99% | 95% | Usher syndrome, type 2C, 605472 Usher syndrome, type 2C, GPR98/PDZD7 digenic, 605472 ?Febrile seizures, familial, 4, 604352 |
| GPSM2 | 99.3 | 98% | 92% | Chudley-McCullough syndrome, 604213 |
| GPX4 | 165.8 | 85% | 85% | Spondylometaphyseal dysplasia, Sedaghatian type, 250220 |
| GRHL2 | 120.8 | 100% | 100% | Deafness, autosomal dominant 28, 608641 Ectodermal dysplasia/short stature syndrome, 616029 |
| GRHL3 | 131.2 | 100% | 99% | Van der Woude syndrome 2, 606713 |
| GRHPR | 96.1 | 83% | 80% | Hyperoxaluria, primary, type II, 260000 |
| GRIA3 | 115.2 | 100% | 98% | Mental retardation, X-linked 94, 300699 |
| GRID2 | 158.7 | 100% | 100% | Spinocerebellar ataxia, autosomal recessive 18, 616204 |
| GRIK2 | 127.9 | 96% | 94% | Mental retardation, autosomal recessive, 6, 611092 |
| GRIN1 | 136.7 | 100% | 99% | Mental retardation, autosomal dominant 8, 614254 |
| GRIN2A | 138.3 | 100% | 99% | Epilepsy, focal, with speech disorder and with or without mental retardation, 245570 |
| GRIN2B | 162.5 | 100% | 99% | Epileptic encephalopathy, early infantile, 27, 616139 |

| | | | | |
|---------|-------|------|------|---|
| | | | | Mental retardation, autosomal dominant 6, 613970 |
| GRIP1 | 123.5 | 100% | 100% | Fraser syndrome, 219000 |
| GRK1 | 108.4 | 100% | 98% | Oguchi disease-2, 613411 |
| GRM1 | 163.4 | 100% | 99% | Spinocerebellar ataxia, autosomal recessive 13, 614831 |
| GRM6 | 130.9 | 88% | 84% | Night blindness, congenital stationary (complete), 1B, autosomal recessive, 257270 |
| GRN | 165.4 | 100% | 100% | Aphasia, primary progressive, 607485 Ceroid lipofuscinosis, neuronal, 11, 614706 Frontotemporal lobar degeneration with ubiquitin-positive inclusions, 607485 |
| GRXCR1 | 173.3 | 100% | 100% | Deafness, autosomal recessive 25, 613285 |
| GSC | 88.5 | 99% | 77% | Short stature, auditory canal atresia, mandibular hypoplasia, skeletal abnormalities, 602471 |
| GSN | 104.7 | 99% | 92% | Amyloidosis, Finnish type, 105120 |
| GSS | 88.9 | 100% | 99% | Glutathione synthetase deficiency, 266130 Hemolytic anemia due to glutathione synthetase deficiency, 231900 |
| GTF2E2 | 75.1 | 99% | 87% | Trichothiodystrophy 6, nonphotosensitive, 616943 |
| GTF2H5 | 132.3 | 100% | 97% | Trichothiodystrophy 3, photosensitive, 616395 |
| GTPBP3 | 98.9 | 100% | 99% | Combined oxidative phosphorylation deficiency 23, 616198 |
| GUCA1A | 128.2 | 100% | 100% | Cone dystrophy-3, 602093 Cone-rod dystrophy 14, 602093 |
| GUCA1B | 132.7 | 100% | 100% | Retinitis pigmentosa 48, 613827 |
| GUCY1A3 | 151.2 | 100% | 97% | Moyamoya 6 with achalasia, 615750 |
| GUCY2C | 127.5 | 100% | 99% | Diarrhea 6, 614616 Meconium ileus, 614665 |
| GUCY2D | 80.3 | 96% | 90% | Cone-rod dystrophy 6, 601777 Leber congenital amaurosis 1, 204000 |
| GUSB | 96.6 | 84% | 81% | Mucopolysaccharidosis VII, 253220 |
| GYG1 | 112.9 | 100% | 97% | Polyglucosan body myopathy 2, 616199 ?Glycogen storage disease XV, 613507 |
| GYS1 | 96.4 | 100% | 98% | Glycogen storage disease 0, muscle, 611556 |
| GYS2 | 147.2 | 100% | 95% | Glycogen storage disease 0, liver, 240600 |
| H19 | NC | NC | NC | Beckwith-Wiedemann syndrome, 130650 Silver-Russell syndrome, 180860 Wilms tumor 2, 194071 |
| H6PD | 136.2 | 99% | 98% | Cortisone reductase deficiency 1, 604931 |

| | | | | |
|-------|-------|------|------|--|
| HACE1 | 123.6 | 98% | 92% | Spastic paraparesis and psychomotor retardation with or without seizures, 616756 |
| HADH | 97.1 | 99% | 95% | 3-hydroxyacyl-CoA dehydrogenase deficiency, 231530 Hyperinsulinemic hypoglycemia, familial, 4, 609975 |
| HADHA | 71.7 | 95% | 90% | Fatty liver, acute, of pregnancy, 609016 HELLP syndrome, maternal, of pregnancy, 609016 LCHAD deficiency, 609016 Trifunctional protein deficiency, 609015 |
| HADHB | 83.9 | 93% | 84% | Trifunctional protein deficiency, 609015 |
| HAMP | 146.2 | 100% | 100% | Hemochromatosis, type 2B, 613313 |
| HARS | 130.7 | 100% | 100% | Charcot-Marie-Tooth disease, axonal, type 2W, 616625 Usher syndrome type 3B, 614504 |
| HAX1 | 117.0 | 100% | 100% | Neutropenia, severe congenital 3, autosomal recessive, 610738 |
| HBA1 | 99.9 | 100% | 99% | Erythremias, alpha- Heinz body anemias, alpha-, 140700 Hemoglobin H disease, nondeletional, 613978 Methemoglobinemias, alpha- Thalassemias, alpha-, 604131 |
| HBA2 | 88.2 | 93% | 85% | Erythrocytosis Heinz body anemia, 140700 Hemoglobin H disease, nondeletional, 613978 Hypochromic microcytic anemia Thalassemia, alpha-, 604131 |
| HBB | 151.8 | 100% | 100% | Delta-beta thalassemia, 141749 Erythremias, beta- Heinz body anemias, beta-, 140700 Hereditary persistence of fetal hemoglobin, 141749 Methemoglobinemias, beta- Sickle cell anemia, 603903 Thalassemia-beta, dominant inclusion-body, 603902 Thalassemias, beta-, 613985 {Malaria, resistance to}, 611162 |
| HBD | 189.4 | 100% | 100% | Thalassemia due to Hb Lepore Thalassemia, delta- |
| HBG1 | 153.0 | 100% | 99% | Fetal hemoglobin quantitative trait locus 1, 141749 |

| | | | | |
|---------|-------|------|------|--|
| HBG2 | 211.3 | 100% | 100% | Cyanosis, transient neonatal, 613977 Fetal hemoglobin quantitative trait locus 1, 141749 |
| HCCS | 116.0 | 100% | 99% | Linear skin defects with multiple congenital anomalies 1, 309801 |
| HCFC1 | 124.7 | 99% | 98% | Mental retardation, X-linked 3 (methylmalonic acidemia and homocysteinemia, cblX type), 309541 |
| HCN1 | 114.5 | 100% | 95% | Epileptic encephalopathy, early infantile, 24, 615871 |
| HCN4 | 77.5 | 98% | 92% | Brugada syndrome 8, 613123 Sick sinus syndrome 2, 163800 |
| HDAC8 | 162.1 | 100% | 100% | Cornelia de Lange syndrome 5, 300882 |
| HEATR2 | 90.6 | 87% | 81% | Ciliary dyskinesia, primary, 18, 614874 |
| HELLS | 85.0 | 91% | 87% | Immunodeficiency-centromeric instability-facial anomalies syndrome 4, 616911 |
| HEPACAM | 113.8 | 92% | 79% | Megalencephalic leukoencephalopathy with subcortical cysts 2A, 613925 Megalencephalic leukoencephalopathy with subcortical cysts 2B, remitting, with or without mental retardation, 613926 |
| HERC1 | 158.5 | 99% | 99% | Macrocephaly, dysmorphic facies, and psychomotor retardation, 617011 |
| HERC2 | 92.4 | 78% | 74% | Mental retardation, autosomal recessive 38, 615516 [Skin/hair/eye pigmentation 1, blond/brown hair], 227220 [Skin/hair/eye pigmentation 1, blue/nonblue eyes], 227220 |
| HES7 | 34.0 | 70% | 63% | Spondylocostal dysostosis 4, autosomal recessive, 613686 |
| HESX1 | 62.8 | 99% | 88% | Growth hormone deficiency with pituitary anomalies, 182230 Pituitary hormone deficiency, combined, 5, 182230 Septooptic dysplasia, 182230 |
| HEXA | 105.8 | 100% | 100% | GM2-gangliosidosis, several forms, 272800 Tay-Sachs disease, 272800 [Hex A pseudodeficiency], 272800 |
| HEXB | 120.7 | 94% | 85% | Sandhoff disease, infantile, juvenile, and adult forms, 268800 |
| HFE | 119.4 | 100% | 100% | Hemochromatosis, 235200 [Transferrin serum level QTL2], 614193 {Alzheimer disease, susceptibility to}, 104300 {Microvascular complications of diabetes 7}, 612635 {Porphyria cutanea tarda, susceptibility to}, 176100 {Porphyria variegata, susceptibility to}, 176200 |
| HFE2 | 106.1 | 100% | 100% | Hemochromatosis type 2A, 602390 |
| HFM1 | 43.9 | 90% | 80% | Premature ovarian failure 9, 615724 |
| HGD | 116.4 | 100% | 100% | Alkaptonuria, 203500 |

| | | | | |
|---------|-------|------|------|--|
| HGF | 128.7 | 99% | 96% | Deafness, autosomal recessive 39, 608265 |
| HGSNAT | 100.1 | 81% | 81% | Mucopolysaccharidosis type IIIC (Sanfilippo C), 252930 Retinitis pigmentosa 73, 616544 |
| HIBCH | 64.0 | 92% | 69% | 3-hydroxyisobutyryl-CoA hydrolase deficiency, 250620 |
| HINT1 | 54.0 | 99% | 88% | Neuromyotonia and axonal neuropathy, autosomal recessive, 137200 |
| HIVEP2 | 168.2 | 100% | 100% | Mental retardation, autosomal dominant 43, 616977 |
| HK1 | 125.2 | 99% | 98% | Hemolytic anemia due to hexokinase deficiency, 235700 Neuropathy, hereditary motor and sensory, Russe type, 605285 |
| HLCS | 142.8 | 100% | 100% | Holocarboxylase synthetase deficiency, 253270 |
| HMBS | 92.7 | 99% | 95% | Porphyria, acute intermittent, 176000 Porphyria, acute intermittent, nonerythroid variant, 176000 |
| HMGCL | 117.1 | 100% | 100% | HMG-CoA lyase deficiency, 246450 |
| HMGCS2 | 122.1 | 100% | 100% | HMG-CoA synthase-2 deficiency, 605911 |
| HMOX1 | 114.0 | 93% | 88% | Heme oxygenase-1 deficiency, 614034 {Pulmonary disease, chronic obstructive, susceptibility to}, 606963 |
| HMX1 | 17.6 | 71% | 36% | Oculoauricular syndrome, 612109 |
| HNF1A | 123.8 | 99% | 96% | Diabetes mellitus, insulin-dependent, 20, 612520 Hepatic adenoma, somatic, 142330 MODY, type III, 600496 Renal cell carcinoma, 144700 {Diabetes mellitus, insulin-dependent}, 222100 {Diabetes mellitus, noninsulin-dependent, 2}, 125853 |
| HNF1B | 111.3 | 100% | 100% | Diabetes mellitus, noninsulin-dependent, 125853 Renal cysts and diabetes syndrome, 137920 {Renal cell carcinoma}, 144700 |
| HNF4A | 126.8 | 98% | 97% | Fanconi renotubular syndrome 4, with maturity-onset diabetes of the young, 616026 MODY, type I, 125850 {Diabetes mellitus, noninsulin-dependent}, 125853 |
| HNMT | 121.7 | 100% | 96% | Mental retardation, autosomal recessive 51, 616739 {Asthma, susceptibility to}, 600807 |
| HNRNPA1 | 65.5 | 90% | 74% | Amyotrophic lateral sclerosis 20, 615426 ?Inclusion body myopathy with early-onset Paget disease without frontotemporal dementia 3, 615424 |
| HNRNPDL | 59.3 | 94% | 79% | Muscular dystrophy, limb-girdle, type 1G, 609115 |
| HNRNPK | 63.9 | 83% | 74% | Au-Kline syndrome, 616580 |

| | | | | |
|--------|-------|------|------|--|
| HOGA1 | 115.2 | 100% | 89% | Hyperoxaluria, primary, type III, 613616 |
| HOXA1 | 127.0 | 100% | 100% | Athabaskan brainstem dysgenesis syndrome, 601536 Bosley-Salih-Alorainy syndrome, 601536 |
| HOXA11 | 89.9 | 92% | 79% | Radioulnar synostosis with amegakaryocytic thrombocytopenia 1, 605432 |
| HOXA13 | 41.5 | 70% | 62% | Guttmacher syndrome, 176305 Hand-foot-uterus syndrome, 140000 |
| HOXB1 | 93.6 | 100% | 100% | Facial paresis, hereditary congenital, 3, 614744 |
| HOXC13 | 81.4 | 95% | 87% | Ectodermal dysplasia 9, hair/nail type, 614931 |
| HOXD10 | 114.7 | 100% | 100% | Charcot-Marie-Tooth disease, foot deformity of, 192950 Vertical talus, congenital, 192950 |
| HOXD13 | 93.2 | 92% | 90% | Brachydactyly, type D, 113200 Brachydactyly, type E, 113300 Syndactyly, type V, 186300 Synpolydactyly 1, 186000 ?Brachydactyly-syndactyly syndrome, 610713 |
| HPCA | 223.2 | 100% | 100% | Dystonia 2, torsion, autosomal recessive, 224500 |
| HPD | 124.9 | 100% | 100% | Hawkinsinuria, 140350 Tyrosinemia, type III, 276710 |
| HPGD | 83.4 | 100% | 97% | Cranioosteopathia, 259100 Digital clubbing, isolated congenital, 119900 Hypertrophic osteoarthropathy, primary, autosomal recessive 1, 259100 |
| HPRT1 | 82.3 | 96% | 89% | HPRT-related gout, 300323 Lesch-Nyhan syndrome, 300322 |
| HPS1 | 104.9 | 100% | 99% | Hermansky-Pudlak syndrome 1, 203300 |
| HPS3 | 122.8 | 100% | 98% | Hermansky-Pudlak syndrome 3, 614072 |
| HPS4 | 124.8 | 100% | 100% | Hermansky-Pudlak syndrome 4, 614073 |
| HPS5 | 129.0 | 99% | 95% | Hermansky-Pudlak syndrome 5, 614074 |
| HPS6 | 107.4 | 98% | 85% | Hermansky-Pudlak syndrome 6, 614075 |
| HPSE2 | 107.3 | 93% | 90% | Urofacial syndrome 1, 236730 |
| HR | 86.3 | 97% | 94% | Alopecia universalis, 203655 Atrichia with papular lesions, 209500 Hypotrichosis 4, 146550 |

| | | | | |
|----------|-------|------|------|---|
| HRAS | 164.2 | 100% | 100% | Congenital myopathy with excess of muscle spindles, 218040 Costello syndrome, 218040 Schimmelpenning-Feuerstein-Mims syndrome, somatic mosaic, 163200 {Bladder cancer, somatic}, 109800 {Nevus sebaceous or woolly hair nevus, somatic}, 162900 {Spitz nevus or nevus spilus, somatic}, 137550 {Thyroid carcinoma, follicular, somatic}, 188470 |
| HRG | 150.9 | 96% | 94% | Thrombophilia due to elevated HRG, 613116 Thrombophilia due to HRG deficiency, 613116 |
| HSD11B1 | 148.7 | 100% | 100% | Cortisone reductase deficiency 2, 614662 |
| HSD11B2 | 128.2 | 89% | 85% | Apparent mineralocorticoid excess, 218030 |
| HSD17B10 | 119.0 | 100% | 100% | 17-beta-hydroxysteroid dehydrogenase X deficiency, 300438 ?Mental retardation, X-linked syndromic 10, 300220 |
| HSD17B3 | 128.7 | 100% | 100% | Pseudohermaphroditism, male, with gynecomastia, 264300 |
| HSD17B4 | 87.3 | 92% | 89% | D-bifunctional protein deficiency, 261515 Perrault syndrome 1, 233400 |
| HSD3B2 | 139.3 | 100% | 100% | 3-beta-hydroxysteroid dehydrogenase, type II, deficiency, 201810 |
| HSD3B7 | 130.4 | 100% | 93% | Bile acid synthesis defect, congenital, 1, 607765 |
| HSF4 | 89.9 | 96% | 92% | Cataract 5, multiple types, 116800 |
| HSPA9 | 79.0 | 86% | 84% | Anemia, sideroblastic, 4, 182170 Even-plus syndrome, 616854 |
| HSPB1 | 39.0 | 94% | 82% | Charcot-Marie-Tooth disease, axonal, type 2F, 606595 Neuropathy, distal hereditary motor, type IIB, 608634 |
| HSPB8 | 128.4 | 100% | 100% | Charcot-Marie-Tooth disease, axonal, type 2L, 608673 Neuropathy, distal hereditary motor, type IIA, 158590 |
| HSPD1 | 74.8 | 93% | 81% | Leukodystrophy, hypomyelinating, 4, 612233 Spastic paraparesis 13, autosomal dominant, 605280 |
| HSPG2 | 101.2 | 99% | 97% | Dyssegmental dysplasia, Silverman-Handmaker type, 224410 Schwartz-Jampel syndrome, type 1, 255800 |
| HTR1A | 161.3 | 100% | 100% | Periodic fever, menstrual cycle dependent, 614674 |
| HTRA1 | 83.5 | 83% | 77% | CARASIL syndrome, 600142 Cerebral arteriopathy, autosomal dominant, with subcortical infarcts and leukoencephalopathy, type 2, 616779 {Macular degeneration, age-related, 7}, 610149 |

| | | | | |
|---------|-------|------|------|---|
| | | | | {Macular degeneration, age-related, neovascular type}, 610149 |
| HTT | 129.6 | 98% | 95% | Huntington disease, 143100 |
| HUWE1 | 117.8 | 99% | 98% | Mental retardation, X-linked syndromic, Turner type, 300706 |
| HYDIN | 114.6 | 99% | 99% | Ciliary dyskinesia, primary, 5, 608647 |
| HYLS1 | 151.8 | 100% | 100% | Hydrocephalus syndrome, 236680 |
| ICK | 125.7 | 100% | 99% | Endocrine-cerebroosteodysplasia, 612651 |
| ICOS | 136.6 | 100% | 100% | Immunodeficiency, common variable, 1, 607594 |
| IDH2 | 81.1 | 100% | 96% | D-2-hydroxyglutaric aciduria 2, 613657 |
| IDH3B | 142.9 | 100% | 100% | Retinitis pigmentosa 46, 612572 |
| IDS | 112.4 | 100% | 98% | Mucopolysaccharidosis II, 309900 |
| IDUA | 85.1 | 89% | 82% | Mucopolysaccharidosis Iih, 607014 Mucopolysaccharidosis Ih/s, 607015 Mucopolysaccharidosis Is, 607016 |
| IER3IP1 | 47.1 | 87% | 77% | Microcephaly, epilepsy, and diabetes syndrome, 614231 |
| IFIH1 | 109.1 | 97% | 95% | Aicardi-Goutieres syndrome 7, 615846 Singleton-Merten syndrome 1, 182250 |
| IFITM5 | 55.8 | 93% | 85% | Osteogenesis imperfecta, type V, 610967 |
| IFNGR1 | 125.0 | 100% | 98% | Immunodeficiency 27A, mycobacteriosis, AR, 209950 Immunodeficiency 27B, mycobacteriosis, AD, 615978 {H. pylori infection, susceptibility to}, 600263 {Hepatitis B virus infection, susceptibility to}, 610424 {Tuberculosis infection, protection against}, 607948 {Tuberculosis, susceptibility to}, 607948 |
| IFNGR2 | 120.8 | 93% | 93% | Immunodeficiency 28, mycobacteriosis, 614889 |
| IFT122 | 130.4 | 100% | 99% | Cranioectodermal dysplasia 1, 218330 |
| IFT140 | 98.2 | 99% | 97% | Short-rib thoracic dysplasia 9 with or without polydactyly, 266920 |
| IFT172 | 102.0 | 99% | 97% | Retinitis pigmentosa 71, 616394 Short-rib thoracic dysplasia 10 with or without polydactyly, 615630 |
| IFT43 | 100.8 | 100% | 100% | Cranioectodermal dysplasia 3, 614099 |
| IFT80 | 48.7 | 78% | 54% | Short-rib thoracic dysplasia 2 with or without polydactyly, 611263 |
| IGBP1 | 119.4 | 99% | 95% | Corpus callosum, agenesis of, with mental retardation, ocular coloboma and micrognathia, 300472 |
| IGF1 | 125.4 | 100% | 100% | Growth retardation with deafness and mental retardation due to IGF1 deficiency, 608747 |

| | | | | |
|----------|-------|------|------|---|
| IGF1R | 121.1 | 100% | 98% | Insulin-like growth factor I, resistance to, 270450 |
| IGF2R | 121.1 | 97% | 96% | Hepatocellular carcinoma, somatic, 114550 |
| IGFALS | 56.4 | 100% | 94% | Acid-labile subunit, deficiency of, 615961 |
| IGFBP7 | 60.2 | 96% | 81% | Retinal arterial macroaneurysm with supravalvular pulmonic stenosis, 614224 |
| IGHG2 | 39.7 | 82% | 60% | IgG2 deficiency, selective |
| IGHM | 176.1 | 100% | 100% | Agammaglobulinemia 1, 601495 |
| IGHMBP2 | 88.4 | 96% | 89% | Charcot-Marie-Tooth disease, axonal, type 2S, 616155 Neuronopathy, distal hereditary motor, type VI, 604320 |
| IGKC | 123.0 | 100% | 100% | Kappa light chain deficiency, 614102 |
| IGLL1 | 60.7 | 99% | 95% | Agammaglobulinemia 2, 613500 |
| IGSF1 | 103.0 | 100% | 99% | Hypothyroidism, central, and testicular enlargement, 300888 |
| IHH | 107.7 | 100% | 100% | Acrocapitofemoral dysplasia, 607778 Brachydactyly, type A1, 112500 |
| IKBKAP | 128.4 | 99% | 98% | Dysautonomia, familial, 223900 |
| IKBKB | 107.5 | 96% | 92% | Immunodeficiency 15, 615592 |
| IKBKG | 51.0 | 90% | 73% | Ectodermal dysplasia, hypohidrotic, with immune deficiency, 300291 Ectodermal, dysplasia, anhidrotic, lymphedema and immunodeficiency, 300301 Immunodeficiency 33, 300636 Immunodeficiency, isolated, 300584 Incontinentia pigmenti, 308300 Invasive pneumococcal disease, recurrent isolated, 2, 300640 |
| IKZF1 | 164.1 | 100% | 100% | Immunodeficiency, common variable, 1, 616873 |
| IL10RA | 125.1 | 100% | 100% | Inflammatory bowel disease 28, early onset, autosomal recessive, 613148 |
| IL10RB | 166.2 | 95% | 95% | Inflammatory bowel disease 25, early onset, autosomal recessive, 612567 {Hepatitis B virus, susceptibility to}, 610424 |
| IL11RA | 122.8 | 100% | 100% | Craniosynostosis and dental anomalies, 614188 |
| IL12B | 99.4 | 100% | 97% | Immunodeficiency 29, mycobacteriosis, 614890 |
| IL12RB1 | 110.8 | 96% | 93% | Immunodeficiency 30, 614891 |
| IL17RC | 79.3 | 99% | 96% | Candidiasis, familial, 9, 616445 |
| IL17RD | 114.4 | 100% | 96% | Hypogonadotropic hypogonadism 18 with or without anosmia, 615267 |
| IL1RAPL1 | 150.3 | 100% | 100% | Mental retardation, X-linked 21/34, 300143 |
| IL1RN | 147.6 | 100% | 100% | Interleukin 1 receptor antagonist deficiency, 612852 {Gastric cancer risk after H. pylori infection}, 137215 {Microvascular complications of diabetes 4}, 612628 |

| | | | | |
|--------|-------|------|------|--|
| IL21R | 116.3 | 100% | 100% | Immunodeficiency, primary, autosomal recessive, IL21R-related, 615207 [IgE, elevated level of], 147050 |
| IL2RA | 104.6 | 100% | 96% | Immunodeficiency 41 with lymphoproliferation and autoimmunity, 606367 {Diabetes, mellitus, insulin-dependent, susceptibility to, 10}, 601942 |
| IL2RG | 83.4 | 100% | 100% | Combined immunodeficiency, X-linked, moderate, 312863 Severe combined immunodeficiency, X-linked, 300400 |
| IL31RA | 124.3 | 100% | 100% | Amyloidosis, primary localized cutaneous, 2, 613955 |
| IL36RN | 74.6 | 100% | 100% | Psoriasis 14, pustular, 614204 |
| IL7R | 120.6 | 100% | 99% | Severe combined immunodeficiency, T-cell negative, B-cell/natural killer cell-positive type, 608971 |
| ILDR1 | 94.1 | 99% | 98% | Deafness, autosomal recessive 42, 609646 |
| IMPA1 | 126.8 | 100% | 99% | Chondrodysplasia with joint dislocations, GPAPP type, 614078 |
| IMPDH1 | 45.0 | 87% | 77% | Leber congenital amaurosis 11, 613837 Retinitis pigmentosa 10, 180105 |
| IMPG1 | 99.8 | 99% | 97% | Macular dystrophy, vitelliform, 4, 616151 |
| IMPG2 | 151.8 | 98% | 96% | Macular dystrophy, vitelliform, 5, 616152 Retinitis pigmentosa 56, 613581 |
| INF2 | 73.6 | 92% | 89% | Charcot-Marie-Tooth disease, dominant intermediate E, 614455 Glomerulosclerosis, focal segmental, 5, 613237 |
| ING1 | 102.6 | 100% | 95% | Squamous cell carcinoma, head and neck, somatic, 275355 |
| INPP5E | 86.6 | 92% | 90% | Joubert syndrome 1, 213300 Mental retardation, truncal obesity, retinal dystrophy, and micropenis, 610156 |
| INPPL1 | 107.8 | 97% | 90% | Opsismodysplasia, 258480 |
| INS | 84.7 | 100% | 100% | Diabetes mellitus, insulin-dependent, 2, 125852 Diabetes mellitus, permanent neonatal, 606176 Hyperproinsulinemia, 616214 Maturity-onset diabetes of the young, type 10, 613370 |
| INSL3 | 80.9 | 80% | 80% | Cryptorchidism, 219050 |
| INSR | 112.2 | 95% | 92% | Diabetes mellitus, insulin-resistant, with acanthosis nigricans, 610549 Hyperinsulinemic hypoglycemia, familial, 5, 609968 Leprechaunism, 246200 Rabson-Mendenhall syndrome, 262190 |
| INVS | 144.1 | 99% | 99% | Nephronophthisis 2, infantile, 602088 |
| IQCB1 | 87.6 | 86% | 71% | Senior-Loken syndrome 5, 609254 |
| IQSEC2 | 72.6 | 95% | 88% | Mental retardation, X-linked 1/78, 309530 |

| | | | | |
|--------|-------|------|------|---|
| IRAK4 | 87.9 | 100% | 85% | Invasive pneumococcal disease, recurrent isolated, 1, 610799 IRAK4 deficiency, 607676 |
| IRF1 | 143.6 | 100% | 98% | Gastric cancer, somatic, 613659 Myelodysplastic syndrome, preleukemic Myelogenous leukemia, acute Nonsmall cell lung cancer, somatic, 211980 |
| IRF6 | 106.9 | 100% | 97% | Popliteal pterygium syndrome 1, 119500 van der Woude syndrome, 119300 {Orofacial cleft 6}, 608864 |
| IRF8 | 94.4 | 97% | 93% | Immunodeficiency 32A, mycobacteriosis, autosomal dominant, 614893 Immunodeficiency 32B, monocyte and dendritic cell deficiency, autosomal recessive, 614894 |
| IRGM | 161.8 | 100% | 100% | Inflammatory bowel disease 19, 612278 {Mycobacterium tuberculosis, protection against}, 607948 |
| IRX5 | 67.0 | 89% | 82% | Hamamy syndrome, 611174 |
| ISCA2 | 61.6 | 98% | 83% | Multiple mitochondrial dysfunctions syndrome 4, 616370 |
| ISCU | 112.0 | 100% | 100% | Myopathy with lactic acidosis, hereditary, 255125 |
| ISG15 | 121.9 | 100% | 100% | Immunodeficiency 38, 616126 |
| ISPD | 97.6 | 99% | 84% | Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 7, 614643 Muscular dystrophy-dystroglycanopathy (limb-girdle), type C, 7, 616052 |
| ITCH | 106.4 | 95% | 95% | Autoimmune disease, multisystem, with facial dysmorphism, 613385 |
| ITGA2B | 99.8 | 98% | 96% | Bleeding disorder, platelet-type, 16, autosomal dominant, 187800 Glanzmann thrombasthenia, 273800 Thrombocytopenia, neonatal alloimmune, BAK antigen related |
| ITGA3 | 118.9 | 98% | 95% | Interstitial lung disease, nephrotic syndrome, and epidermolysis bullosa, congenital, 614748 |
| ITGA6 | 134.2 | 99% | 98% | Epidermolysis bullosa, junctional, with pyloric stenosis, 226730 |
| ITGA7 | 108.9 | 99% | 96% | Muscular dystrophy, congenital, due to ITGA7 deficiency, 613204 |
| ITGA8 | 118.0 | 99% | 97% | Renal hypodysplasia/aplasia 1, 191830 |
| ITGB2 | 148.7 | 100% | 100% | Leukocyte adhesion deficiency, 116920 |
| ITGB3 | 125.5 | 98% | 96% | Bleeding disorder, platelet-type, 16, autosomal dominant, 187800 Glanzmann thrombasthenia, 273800 Purpura, posttransfusion Thrombocytopenia, neonatal alloimmune {Myocardial infarction, susceptibility to}, 608446 |

| | | | | |
|-------|-------|------|------|---|
| ITGB4 | 123.4 | 97% | 94% | Epidermolysis bullosa of hands and feet, 131800 Epidermolysis bullosa, junctional, non-Herlitz type, 226650 Epidermolysis bullosa, junctional, with pyloric atresia, 226730 |
| ITGB6 | 126.9 | 95% | 95% | Amelogenesis imperfecta, type IH, 616221 |
| ITK | 110.8 | 100% | 97% | Lymphoproliferative syndrome 1, 613011 |
| ITM2B | 101.9 | 100% | 94% | Dementia, familial British, 176500 Dementia, familial Danish, 117300 ?Retinal dystrophy with inner retinal dysfunction and ganglion cell abnormalities, 616079 |
| ITPA | 112.5 | 100% | 100% | Epileptic encephalopathy, early infantile, 35, 616647 [Inosine triphosphatase deficiency], 613850 |
| ITPR1 | 135.9 | 100% | 98% | Gillespie syndrome, 206700 Spinocerebellar ataxia 15, 606658 Spinocerebellar ataxia 29, congenital nonprogressive, 117360 |
| IVD | 98.7 | 100% | 97% | Isovaleric acidemia, 243500 |
| IYD | 101.3 | 98% | 96% | Thyroid dyshormonogenesis 4, 274800 |
| JAG1 | 127.4 | 98% | 97% | Alagille syndrome, 118450 Tetralogy of Fallot, 187500 ?Deafness, congenital heart defects, and posterior embryotoxon |
| JAGN1 | 126.1 | 100% | 100% | Neutropenia, severe congenital, 6, autosomal recessive, 616022 |
| JAK2 | 83.3 | 95% | 88% | Erythrocytosis, somatic, 133100 Leukemia, acute myeloid, somatic, 601626 Myelofibrosis, somatic, 254450 Polycythemia vera, somatic, 263300 Thrombocythemia 3, 614521 {Budd-Chiari syndrome, somatic}, 600800 |
| JAK3 | 87.2 | 96% | 93% | SCID, autosomal recessive, T-negative/B-positive type, 600802 |
| JAM3 | 133.8 | 100% | 97% | Hemorrhagic destruction of the brain, subependymal calcification, and cataracts, 613730 |
| JPH2 | 86.5 | 94% | 83% | Cardiomyopathy, hypertrophic, 17, 613873 |
| JPH3 | 117.9 | 100% | 100% | Huntington disease-like 2, 606438 |
| JUP | 126.3 | 99% | 98% | Arrhythmogenic right ventricular dysplasia 12, 611528 Naxos disease, 601214 |
| KAL1 | 100.6 | 89% | 86% | Hypogonadotropic hypogonadism 1 with or without anosmia (Kallmann syndrome 1), 308700 |
| KANK1 | 133.8 | 100% | 100% | Cerebral palsy, spastic quadriplegic, 2, 612900 |
| KANK2 | 130.3 | 100% | 99% | Palmoplantar keratoderma and woolly hair, 616099 |

| | | | | |
|---------|-------|------|------|--|
| KANSL1 | 63.3 | 94% | 85% | Koolen-De Vries syndrome, 610443 |
| KARS | 104.7 | 100% | 99% | Deafness, autosomal recessive 89, 613916 ?Charcot-Marie-Tooth disease, recessive intermediate, B, 613641 |
| KAT6A | 154.1 | 100% | 99% | Mental retardation, autosomal dominant 32, 616268 |
| KAT6B | 150.7 | 99% | 97% | Genitopatellar syndrome, 606170 SBBYSS syndrome, 603736 |
| KATNB1 | 125.5 | 100% | 100% | Lissencephaly 6, with microcephaly, 616212 |
| KBTBD13 | 87.8 | 98% | 92% | Nemaline myopathy 6, autosomal dominant, 609273 |
| KCNA1 | 124.9 | 99% | 98% | Episodic ataxia/myokymia syndrome, 160120 |
| KCNA2 | 130.8 | 100% | 100% | Epileptic encephalopathy, early infantile, 32, 616366 |
| KCNA5 | 130.3 | 100% | 93% | Atrial fibrillation, familial, 7, 612240 |
| KCNB1 | 115.8 | 100% | 100% | Epileptic encephalopathy, early infantile, 26, 616056 |
| KCNC1 | 155.0 | 100% | 100% | Epilepsy, progressive myoclonic 7, 616187 |
| KCNC3 | 132.5 | 66% | 57% | Spinocerebellar ataxia 13, 605259 |
| KCND3 | 168.2 | 100% | 96% | Brugada syndrome 9, 616399 Spinocerebellar ataxia 19, 607346 |
| KCNE1 | 388.5 | 100% | 100% | Jervell and Lange-Nielsen syndrome 2, 612347 Long QT syndrome 5, 613695 |
| KCNE2 | 142.0 | 100% | 94% | Atrial fibrillation, familial, 4, 611493 Long QT syndrome 6, 613693 |
| KCNE3 | 158.2 | 100% | 100% | Brugada syndrome 6, 613119 |
| KCNH1 | 157.5 | 100% | 99% | Temple-Baraitser syndrome, 611816 Zimmermann-Laband syndrome 1, 135500 |
| KCNH2 | 90.3 | 91% | 82% | Long QT syndrome 2, 613688 Short QT syndrome 1, 609620 {Long QT syndrome 2, acquired, susceptibility to}, 613688 |
| KCNJ1 | 205.1 | 100% | 100% | Bartter syndrome, type 2, 241200 |
| KCNJ10 | 171.3 | 100% | 98% | Enlarged vestibular aqueduct, digenic, 600791 SESAME syndrome, 612780 |
| KCNJ11 | 230.5 | 100% | 100% | Diabetes mellitus, permanent neonatal, with neurologic features, 606176 Diabetes mellitus, transient neonatal, 3, 610582 Diabetes, permanent neonatal, 606176 Hyperinsulinemic hypoglycemia, familial, 2, 601820 Maturity-onset diabetes of the young, type 13, 616329 |

| | | | | |
|----------|-------|------|------|--|
| | | | | {Diabetes mellitus, type 2, susceptibility to}, 125853 |
| KCNJ13 | 165.1 | 100% | 100% | Leber congenital amaurosis 16, 614186 Snowflake vitreoretinal degeneration, 193230 |
| KCNJ2 | 172.1 | 100% | 100% | Andersen syndrome, 170390 Atrial fibrillation, familial, 9, 613980 Short QT syndrome 3, 609622 |
| KCNJ5 | 183.2 | 99% | 96% | Hyperaldosteronism, familial, type III, 613677 Long QT syndrome 13, 613485 |
| KCNJ6 | 155.0 | 100% | 100% | Keppen-Lubinsky syndrome, 614098 |
| KCNK3 | 124.7 | 98% | 94% | Pulmonary hypertension, primary, 4, 615344 |
| KCNK9 | 152.4 | 100% | 100% | Birk-Barel mental retardation dysmorphism syndrome, 612292 |
| KCNMA1 | 119.7 | 100% | 100% | Generalized epilepsy and paroxysmal dyskinesia, 609446 |
| KCNN4 | 102.7 | 100% | 100% | Dehydrated hereditary stomatocytosis 2, 616689 |
| KCNQ1 | 102.6 | 93% | 91% | Atrial fibrillation, familial, 3, 607554 Jervell and Lange-Nielsen syndrome, 220400 Long QT syndrome 1, 192500 Short QT syndrome 2, 609621 {Long QT syndrome 1, acquired, susceptibility to}, 192500 |
| KCNQ1OT1 | NC | NC | NC | Beckwith-Wiedemann syndrome, 130650 |
| KCNQ2 | 84.4 | 99% | 98% | Epileptic encephalopathy, early infantile, 7, 613720 Myokymia, 121200 Seizures, benign neonatal, 1, 121200 |
| KCNQ3 | 93.9 | 100% | 95% | Seizures, benign neonatal, type 2, 121201 |
| KCNQ4 | 119.9 | 94% | 85% | Deafness, autosomal dominant 2A, 600101 |
| KCNT1 | 98.7 | 95% | 89% | Epilepsy, nocturnal frontal lobe, 5, 615005 Epileptic encephalopathy, early infantile, 14, 614959 |
| KCNV2 | 106.4 | 100% | 100% | Retinal cone dystrophy 3B, 610356 |
| KCTD1 | 119.4 | 91% | 85% | Scalp-ear-nipple syndrome, 181270 |
| KCTD17 | 90.2 | 97% | 89% | Dystonia 26, myoclonic, 616398 |
| KCTD7 | 117.8 | 94% | 92% | Epilepsy, progressive myoclonic 3, with or without intracellular inclusions, 611726 |

| | | | | |
|----------|-------|------|------|--|
| KDM1A | 121.4 | 97% | 93% | Cleft palate, psychomotor retardation, and distinctive facial features, 616728 |
| KDM5C | 126.4 | 97% | 96% | Mental retardation, X-linked, syndromic, Claes-Jensen type, 300534 |
| KDM6A | 127.3 | 94% | 89% | Kabuki syndrome 2, 300867 |
| KDR | 128.8 | 100% | 99% | Hemangioma, capillary infantile, somatic, 602089 {Hemangioma, capillary infantile, susceptibility to}, 602089 |
| KERA | 173.0 | 100% | 100% | Cornea plana congenita, recessive, 217300 |
| KHDC3L | 125.7 | 100% | 99% | Hydatidiform mole, recurrent, 2, 614293 |
| KIAA0196 | 123.8 | 97% | 95% | Ritscher-Schinzel syndrome 1, 220210 Spastic paraplegia 8, autosomal dominant, 603563 |
| KIAA0586 | 101.5 | 99% | 89% | Joubert syndrome 23, 616490 Short-rib thoracic dysplasia 14 with polydactyly, 616546 |
| KIAA1279 | 165.1 | 100% | 99% | Goldberg-Shprintzen megacolon syndrome, 609460 |
| KIAA2022 | 186.8 | 100% | 99% | Mental retardation, X-linked 98, 300912 |
| KIF11 | 78.5 | 97% | 91% | Microcephaly with or without chorioretinopathy, lymphedema, or mental retardation, 152950 |
| KIF1A | 112.1 | 99% | 95% | Mental retardation, autosomal dominant 9, 614255 Neuropathy, hereditary sensory, type IIC, 614213 Spastic paraplegia 30, autosomal recessive, 610357 |
| KIF1B | 137.7 | 99% | 98% | Pheochromocytoma, 171300 ?Charcot-Marie-Tooth disease, type 2A1, 118210 {Neuroblastoma, susceptibility to, 1}, 256700 |
| KIF1C | 93.5 | 100% | 99% | Spastic ataxia 2, autosomal recessive, 611302 |
| KIF21A | 111.2 | 99% | 95% | Fibrosis of extraocular muscles, congenital, 1, 135700 Fibrosis of extraocular muscles, congenital, 3B, 135700 |
| KIF22 | 127.7 | 99% | 98% | Spondyloepimetaphyseal dysplasia with joint laxity, type 2, 603546 |
| KIF2A | 93.6 | 96% | 82% | Cortical dysplasia, complex, with other brain malformations 3, 615411 |
| KIF5A | 111.5 | 100% | 99% | Spastic paraplegia 10, autosomal dominant, 604187 |
| KIF5C | 98.0 | 99% | 97% | Cortical dysplasia, complex, with other brain malformations 2, 615282 |
| KIF7 | 71.1 | 96% | 84% | Acrocallosal syndrome, 200990 Joubert syndrome 12, 200990 ?Al-Gazali-Bakalinova syndrome, 607131 ?Hydrocephalus syndrome 2, 614120 |
| KIRREL3 | 130.2 | 100% | 98% | Mental retardation, autosomal dominant 4, 612581 |
| KISS1R | 82.5 | 99% | 96% | Hypogonadotropic hypogonadism 8 with or without anosmia, 614837 ?Precocious puberty, central, 1, 176400 |

| | | | | |
|--------|-------|------|------|--|
| KIT | 140.5 | 100% | 99% | Gastrointestinal stromal tumor, familial, 606764 Germ cell tumors, 273300 Leukemia, acute myeloid, 601626 Mast cell disease, 154800 Piebaldism, 172800 |
| KITLG | 75.4 | 92% | 85% | Deafness, congenital, unilateral or asymmetric, 616697 Hyperpigmentation with or without hypopigmentation, 145250 [Skin/hair/eye pigmentation 7, blond/brown hair], 611664 |
| KIZ | 155.9 | 100% | 95% | Retinitis pigmentosa 69, 615780 |
| KL | 150.2 | 95% | 94% | Tumoral calcinosis, hyperphosphatemic, 211900 {Coronary artery disease, susceptibility to} |
| KLC2 | 100.9 | 100% | 98% | Spastic paraparesis, optic atrophy, and neuropathy, 609541 |
| KLF1 | 48.6 | 90% | 83% | Blood group--Lutheran inhibitor, 111150 Dyserythropoietic anemia, congenital, type IV, 613673 [Hereditary persistence of fetal hemoglobin], 613566 |
| KLF11 | 145.5 | 100% | 100% | Maturity-onset diabetes of the young, type VII, 610508 |
| KLF6 | 115.1 | 100% | 96% | Gastric cancer, somatic, 613659 Prostate cancer, somatic, 176807 |
| KLHL10 | 177.6 | 100% | 98% | Spermatogenic failure 11, 615081 |
| KLHL3 | 122.5 | 99% | 99% | Pseudohypoaldosteronism, type IID, 614495 |
| KLHL40 | 113.8 | 100% | 100% | Nemaline myopathy 8, autosomal recessive, 615348 |
| KLHL41 | 173.4 | 100% | 99% | Nemaline myopathy 9, 615731 |
| KLHL7 | 112.9 | 98% | 96% | Cold induced sweating syndrome 3, 617055 Retinitis pigmentosa 42, 612943 |
| KLK4 | 170.7 | 100% | 98% | Amelogenesis imperfecta, type IIA1, 204700 |
| KLKB1 | 142.2 | 93% | 92% | Fletcher factor (prekallikrein) deficiency, 612423 |
| KLLN | 108.6 | 100% | 100% | Cowden syndrome 4, 615107 |
| KMT2A | 141.3 | 99% | 98% | Leukemia, myeloid/lymphoid or mixed-lineage Wiedemann-Steiner syndrome, 605130 |
| KMT2D | 126.4 | 100% | 99% | Kabuki syndrome 1, 147920 |
| KPTN | 96.1 | 100% | 98% | Mental retardation, autosomal recessive 41, 615637 |

| | | | | |
|-------|-------|------|------|---|
| KRAS | 54.9 | 100% | 99% | Bladder cancer, somatic, 109800 Breast cancer, somatic, 114480 Cardiofaciocutaneous syndrome 2, 615278 Gastric cancer, somatic, 137215 Leukemia, acute myeloid, 601626 Lung cancer, somatic, 211980 Noonan syndrome 3, 609942 Pancreatic carcinoma, somatic, 260350 RAS-associated autoimmune leukoproliferative disorder, 614470 Schimmelpenning-Feuerstein-Mims syndrome, somatic mosaic, 163200 |
| KRIT1 | 76.6 | 98% | 90% | Cavernous malformations of CNS and retina, 116860 Cerebral cavernous malformations-1, 116860 Hyperkeratotic cutaneous capillary-venous malformations associated with cerebral capillary malformations, 116860 |
| KRT1 | 121.0 | 100% | 100% | Epidermolytic hyperkeratosis, 113800 Ichthyosis histrix, Curth-Macklin type, 146590 Ichthyosis, cyclic, with epidermolytic hyperkeratosis, 607602 Keratosis palmoplantaris striata III, 607654 Palmoplantar keratoderma, epidermolytic, 144200 Palmoplantar keratoderma, nonepidermolytic, 600962 |
| KRT10 | 89.5 | 99% | 90% | Epidermolytic hyperkeratosis, 113800 Ichthyosis with confetti, 609165 Ichthyosis, cyclic, with epidermolytic hyperkeratosis, 607602 |
| KRT12 | 98.7 | 97% | 93% | Meesmann corneal dystrophy, 122100 |
| KRT13 | 103.3 | 100% | 99% | White sponge nevus 2, 615785 |
| KRT14 | 47.9 | 87% | 78% | Dermatopathia pigmentosa reticularis, 125595 Epidermolysis bullosa simplex, Dowling-Meara type, 131760 Epidermolysis bullosa simplex, Koebner type, 131900 Epidermolysis bullosa simplex, recessive 1, 601001 Epidermolysis bullosa simplex, Weber-Cockayne type, 131800 Naegeli-Franceschetti-Jadassohn syndrome, 161000 |
| KRT16 | 34.1 | 73% | 53% | Pachyonychia congenita 1, 167200 Palmoplantar keratoderma, nonepidermolytic, focal, 613000 |
| KRT17 | 18.5 | 50% | 34% | Pachyonychia congenita 2, 167210 Steatocystoma multiplex, 184500 |

| | | | | |
|--------|-------|------|------|--|
| KRT18 | 27.9 | 64% | 60% | Cirrhosis, cryptogenic, 215600 {Cirrhosis, noncryptogenic, susceptibility to}, 215600 |
| KRT2 | 107.4 | 98% | 97% | Ichthyosis bullosa of Siemens, 146800 |
| KRT25 | 127.7 | 100% | 100% | Woolly hair, autosomal recessive 3, 616760 |
| KRT3 | 83.2 | 100% | 99% | Meesmann corneal dystrophy, 122100 |
| KRT4 | 101.7 | 100% | 100% | White sponge nevus 1, 193900 |
| KRT5 | 103.1 | 100% | 100% | Dowling-Degos disease 1, 179850 Epidermolysis bullosa simplex, Dowling-Meara type, 131760 Epidermolysis bullosa simplex, Koebner type, 131900 Epidermolysis bullosa simplex, recessive 1, 601001 Epidermolysis bullosa simplex, Weber-Cockayne type, 131800 Epidermolysis bullosa simplex-MP, 131960 Epidermylysis bullosa simplex-MCR, 609352 |
| KRT6A | 137.9 | 90% | 83% | Pachyonychia congenita 3, 615726 |
| KRT6B | 136.6 | 88% | 85% | Pachyonychia congenita 4, 615728 |
| KRT6C | 129.4 | 84% | 77% | Palmoplantar keratoderma, nonepidermolytic, focal or diffuse, 615735 |
| KRT74 | 118.7 | 100% | 100% | Woolly hair, autosomal dominant, 194300 ?Ectodermal dysplasia 7, hair/nail type, 614929 ?Hypotrichosis 3, 613981 |
| KRT8 | 31.5 | 89% | 67% | Cirrhosis, cryptogenic, 215600 {Cirrhosis, noncryptogenic, susceptibility to}, 215600 |
| KRT81 | 81.1 | 100% | 92% | Monilethrix, 158000 |
| KRT85 | 90.4 | 99% | 94% | Ectodermal dysplasia 4, hair/nail type, 602032 |
| KRT86 | 88.2 | 100% | 93% | Monilethrix, 158000 |
| KRT9 | 67.1 | 95% | 93% | Palmoplantar keratoderma, epidermolytic, 144200 |
| L1CAM | 153.4 | 100% | 99% | Corpus callosum, partial agenesis of, 304100 CRASH syndrome, 303350 Hydrocephalus due to aqueductal stenosis, 307000 Hydrocephalus with congenital idiopathic intestinal pseudoobstruction, 307000 Hydrocephalus with Hirschsprung disease, 307000 MASA syndrome, 303350 |
| L2HGDH | 116.2 | 97% | 94% | L-2-hydroxyglutaric aciduria, 236792 |
| LAMA1 | 124.1 | 100% | 99% | Poretti-Boltshauser syndrome, 615960 |
| LAMA2 | 134.3 | 99% | 99% | Muscular dystrophy, congenital merosin-deficient, 607855 |

| | | | | |
|---------|-------|------|------|---|
| | | | | Muscular dystrophy, congenital, due to partial LAMA2 deficiency, 607855 |
| LAMA3 | 134.4 | 99% | 98% | Epidermolysis bullosa, generalized atrophic benign, 226650 Epidermolysis bullosa, junctional, Herlitz type, 226700 Laryngoonychocutaneous syndrome, 245660 |
| LAMA4 | 121.3 | 100% | 99% | Cardiomyopathy, dilated, 1JJ, 615235 |
| LAMB1 | 150.6 | 100% | 98% | Lissencephaly 5, 615191 |
| LAMB2 | 162.4 | 99% | 98% | Nephrotic syndrome, type 5, with or without ocular abnormalities, 614199 Pierson syndrome, 609049 |
| LAMB3 | 105.8 | 100% | 98% | Amelogenesis imperfecta, type IA, 104530 Epidermolysis bullosa, junctional, Herlitz type, 226700 Epidermolysis bullosa, junctional, non-Herlitz type, 226650 |
| LAMC2 | 105.1 | 99% | 96% | Epidermolysis bullosa, junctional, Herlitz type, 226700 Epidermolysis bullosa, junctional, non-Herlitz type, 226650 |
| LAMC3 | 101.4 | 97% | 93% | Cortical malformations, occipital, 614115 |
| LAMP2 | 143.8 | 92% | 92% | Danon disease, 300257 |
| LAMTOR2 | 149.8 | 100% | 100% | Immunodeficiency due to defect in MAPBP-interacting protein, 610798 |
| LARGE | 113.7 | 100% | 98% | Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 6, 613154 Muscular dystrophy-dystroglycanopathy (congenital with mental retardation), type B, 6, 608840 |
| LARP7 | 46.0 | 79% | 59% | Alazami syndrome, 615071 |
| LARS2 | 119.8 | 100% | 100% | Perrault syndrome 4, 615300 ?Hydrops, lactic acidosis, and sideroblastic anemia, 617021 |
| LAS1L | 110.5 | 100% | 99% | Wilson-Turner syndrome, 309585 |
| LBR | 72.7 | 93% | 77% | Greenberg skeletal dysplasia, 215140 Pelger-Huet anomaly, 169400 ?Reynolds syndrome, 613471 |
| LCA5 | 112.2 | 99% | 95% | Leber congenital amaurosis 5, 604537 |
| LCAT | 131.8 | 100% | 88% | Fish-eye disease, 136120 Norum disease, 245900 |
| LCT | 111.0 | 99% | 96% | Lactase deficiency, congenital, 223000 |
| LDB3 | 106.8 | 94% | 93% | Cardiomyopathy, dilated, 1C, with or without LVNC, 601493 Cardiomyopathy, hypertrophic, 24, 601493 Left ventricular noncompaction 3, 601493 Myopathy, myofibrillar, 4, 609452 |
| LDHA | 48.5 | 91% | 84% | Glycogen storage disease XI, 612933 |

| | | | | |
|---------|-------|------|------|--|
| LDLR | 147.6 | 97% | 95% | Hypercholesterolemia, familial, 143890 LDL cholesterol level QTL2, 143890 |
| LDLRAP1 | 130.3 | 100% | 90% | Hypercholesterolemia, familial, autosomal recessive, 603813 |
| LEF1 | 103.9 | 100% | 100% | Sebaceous tumors, somatic, 153245 |
| LEFTY2 | 40.2 | 85% | 71% | Left-right axis malformations, 601877 |
| LEMD2 | 60.4 | 95% | 80% | Cataract 46, juvenile-onset, 212500 |
| LEMD3 | 87.9 | 95% | 90% | Buschke-Ollendorff syndrome, 166700 Melorheostosis with osteopoikilosis, 155950 Osteopoikilosis, 166700 |
| LEP | 161.7 | 100% | 96% | Obesity, morbid, due to leptin deficiency, 614962 |
| LEPR | 103.7 | 93% | 89% | Obesity, morbid, due to leptin receptor deficiency, 614963 |
| LEPRE1 | 118.0 | 100% | 100% | Osteogenesis imperfecta, type VIII, 610915 |
| LEPREL1 | 89.1 | 99% | 91% | Myopia, high, with cataract and vitreoretinal degeneration, 614292 |
| LGI1 | 177.4 | 100% | 92% | Epilepsy, familial temporal lobe, 1, 600512 |
| LHB | 26.2 | 99% | 74% | Hypogonadotropic hypogonadism 23 with or without anosmia, 228300 |
| LHCGR | 141.9 | 92% | 92% | Leydig cell adenoma, somatic, with precocious puberty, 176410 Leydig cell hypoplasia with hypergonadotropic hypogonadism, 238320 Leydig cell hypoplasia with pseudohermaphroditism, 238320 Luteinizing hormone resistance, female, 238320 Precocious puberty, male, 176410 |
| LHFPL5 | 215.9 | 100% | 100% | Deafness, autosomal recessive 67, 610265 |
| LHX3 | 88.2 | 100% | 96% | Pituitary hormone deficiency, combined, 3, 221750 |
| LHX4 | 109.6 | 100% | 100% | Pituitary hormone deficiency, combined, 4, 262700 |
| LIAS | 135.1 | 100% | 97% | Hyperglycinemia, lactic acidosis, and seizures, 614462 |
| LIFR | 112.9 | 96% | 89% | Stuve-Wiedemann syndrome/Schwartz-Jampel type 2 syndrome, 601559 |
| LIG1 | 81.7 | 100% | 97% | DNA ligase I deficiency |
| LIG4 | 150.3 | 100% | 100% | LIG4 syndrome, 606593 {Multiple myeloma, resistance to}, 254500 |
| LIM2 | 89.2 | 100% | 98% | Cataract 19, multiple types, 615277 |
| LIMS2 | 99.5 | 93% | 92% | Muscular dystrophy, limb-girdle, type 2W, 616827 |
| LINS | 119.0 | 100% | 97% | Mental retardation, autosomal recessive 27, 614340 |
| LIPA | 104.1 | 95% | 93% | Cholesteryl ester storage disease, 278000 Wolman disease, 278000 |

| | | | | |
|--------|-------|------|------|---|
| LIPC | 101.3 | 100% | 98% | Hepatic lipase deficiency, 614025 [High density lipoprotein cholesterol level QTL 12], 612797 {Diabetes mellitus, noninsulin-dependent}, 125853 |
| LIPE | 93.5 | 98% | 97% | Lipodystrophy, familial partial, type 6, 615980 |
| LIPH | 111.6 | 100% | 100% | Hypotrichosis 7, 604379 Woolly hair, autosomal recessive 2 with or without hypotrichosis, 604379 |
| LIPN | 120.4 | 100% | 92% | Ichthyosis, congenital, autosomal recessive 8, 613943 |
| LIPT1 | 218.4 | 100% | 100% | Lipoyltransferase 1 deficiency, 616299 |
| LITAF | 100.4 | 97% | 90% | Charcot-Marie-Tooth disease, type 1C, 601098 |
| LMAN1 | 116.1 | 96% | 87% | Combined factor V and VIII deficiency, 227300 |
| LMBR1 | 90.2 | 98% | 92% | Acheiropody, 200500 Hypoplastic or aplastic tibia with polydactyly, 188740 Laurin-Sandrow syndrome, 135750 Polydactyly, preaxial type II, 174500 Syndactyly, type IV, 186200 Triphalangeal thumb, type I, 174500 Triphalangeal thumb-polysyndactyly syndrome, 174500 |
| LMBRD1 | 65.8 | 89% | 81% | Methylmalonic aciduria and homocystinuria, cblF type, 277380 |
| LMF1 | 125.2 | 100% | 98% | Lipase deficiency, combined, 246650 |
| LMNA | 69.2 | 91% | 86% | Cardiomyopathy, dilated, 1A, 115200 Charcot-Marie-Tooth disease, type 2B1, 605588 Emery-Dreifuss muscular dystrophy 2, AD, 181350 Emery-Dreifuss muscular dystrophy 3, AR, 616516 Heart-hand syndrome, Slovenian type, 610140 Hutchinson-Gilford progeria, 176670 Lipodystrophy, familial partial, 2, 151660 Malouf syndrome, 212112 Mandibuloacral dysplasia, 248370 Muscular dystrophy, congenital, 613205 Muscular dystrophy, limb-girdle, type 1B, 159001 Restrictive dermopathy, lethal, 275210 |
| LMNB1 | 111.0 | 100% | 97% | Leukodystrophy, adult-onset, autosomal dominant, 169500 |
| LMOD3 | 130.1 | 100% | 99% | Nemaline myopathy 10, 616165 |
| LMX1B | 99.4 | 100% | 88% | Nail-patella syndrome, 161200 |
| LONP1 | 131.6 | 96% | 90% | CODAS syndrome, 600373 |

| | | | | |
|--------|-------|------|------|---|
| LOR | 14.2 | 80% | 25% | Vohwinkel syndrome with ichthyosis, 604117 |
| LOXHD1 | 114.7 | 100% | 98% | Deafness, autosomal recessive 77, 613079 |
| LPAR6 | 97.4 | 96% | 93% | Hypotrichosis 8, 278150 Woolly hair, autosomal recessive 1, with or without hypotrichosis, 278150 |
| LPIN1 | 118.6 | 98% | 90% | Myoglobinuria, acute recurrent, autosomal recessive, 268200 |
| LPIN2 | 109.0 | 100% | 100% | Majeed syndrome, 609628 |
| LPL | 137.8 | 100% | 99% | Combined hyperlipidemia, familial, 144250 Lipoprotein lipase deficiency, 238600 [High density lipoprotein cholesterol level QTL 11] |
| LPP | 112.7 | 100% | 100% | Leukemia, acute myeloid, 601626 Lipoma |
| LRAT | 239.2 | 100% | 100% | Leber congenital amaurosis 14, 613341 Retinal dystrophy, early-onset severe, 613341 Retinitis pigmentosa, juvenile, 613341 |
| LRBA | 120.2 | 98% | 95% | Immunodeficiency, common variable, 8, with autoimmunity, 614700 |
| LRIG2 | 138.6 | 97% | 97% | Urofacial syndrome 2, 615112 |
| LRIT3 | 138.9 | 93% | 92% | Night blindness, congenital stationary (complete), 1F, autosomal recessive, 615058 |
| LRP2 | 154.4 | 100% | 99% | Donnai-Barrow syndrome, 222448 |
| LRP4 | 141.2 | 98% | 98% | Cenani-Lenz syndactyly syndrome, 212780 Sclerosteosis 2, 614305 ?Myasthenic syndrome, congenital, 17, 616304 |
| LRP5 | 155.0 | 99% | 98% | Exudative vitreoretinopathy 4, 601813 Hyperostosis, endosteal, 144750 Osteopetrosis, autosomal dominant 1, 607634 Osteoporosis-pseudoglioma syndrome, 259770 Osteosclerosis, 144750 van Buchem disease, type 2, 607636 [Bone mineral density variability 1], 601884 {Osteoporosis}, 166710 |
| LRP6 | 136.3 | 100% | 99% | Tooth agenesis, selective, 7, 616724 {Coronary artery disease, autosomal dominant, 2}, 610947 |
| LRPAP1 | 121.1 | 97% | 90% | Myopia 23, autosomal recessive, 615431 |
| LRPPRC | 113.0 | 99% | 95% | Leigh syndrome, French-Canadian type, 220111 |
| LRRC6 | 152.6 | 95% | 89% | Ciliary dyskinesia, primary, 19, 614935 |

| | | | | |
|---------|-------|------|------|--|
| LRRC8A | 222.9 | 100% | 99% | Agammaglobulinemia 5, 613506 |
| LRSAM1 | 123.0 | 99% | 98% | Charcot-Marie-Tooth disease, axonal, type 2P, 614436 |
| LRTOMT | 108.8 | 93% | 91% | Deafness, autosomal recessive 63, 611451 |
| LSS | 101.4 | 100% | 98% | Cataract 44, 616509 |
| LTBP2 | 89.0 | 99% | 97% | Glaucoma 3, primary congenital, D, 613086 Microspherophakia and/or megalocornea, with ectopia lentis and with or without secondary glaucoma, 251750 Weill-Marchesani syndrome 3, recessive, 614819 |
| LTBP3 | 99.3 | 97% | 95% | Dental anomalies and short stature, 601216 |
| LTBP4 | 96.2 | 99% | 94% | Cutis laxa, autosomal recessive, type IC, 613177 |
| LYRM7 | 36.1 | 82% | 57% | Mitochondrial complex III deficiency, nuclear type 8, 615838 |
| LYST | 122.8 | 98% | 92% | Chediak-Higashi syndrome, 214500 |
| LYZ | 156.8 | 100% | 100% | Amyloidosis, renal, 105200 |
| LZTFL1 | 111.6 | 99% | 92% | Bardet-Biedl syndrome 17, 615994 |
| LZTR1 | 124.5 | 100% | 97% | Noonan syndrome 10, 616564 {Schwannomatosis-2, susceptibility to}, 615670 |
| LZTS1 | 78.8 | 100% | 100% | Esophageal squamous cell carcinoma, 133239 |
| MAB21L2 | 206.1 | 100% | 100% | Microphthalmia, syndromic 14, 615877 |
| MAD1L1 | 87.0 | 100% | 93% | Lymphoma, somatic Prostate cancer, somatic, 176807 |
| MAF | 48.5 | 74% | 69% | Ayme-Gripp syndrome, 601088 Cataract 21, multiple types, 610202 |
| MAFB | 95.6 | 100% | 98% | Duane retraction syndrome 3, 617041 Multicentric carpotarsal osteolysis syndrome, 166300 |
| MAG | 121.4 | 100% | 99% | Spastic paraparesis 75, autosomal recessive, 616680 |
| MAGED2 | 90.0 | 100% | 99% | Bartter syndrome, type 5, antenatal, transient, 300971 |
| MAGEL2 | 115.5 | 100% | 100% | Schaaf-Yang syndrome, 615547 |
| MAGT1 | 136.6 | 98% | 98% | Immunodeficiency, X-linked, with magnesium defect, Epstein-Barr virus infection and neoplasia, 300853 |
| MAK | 134.3 | 93% | 93% | Retinitis pigmentosa 62, 614181 |
| MALT1 | 125.3 | 90% | 83% | Immunodeficiency 12, 615468 |
| MAML2 | 110.6 | 100% | 100% | Mucoepidermoid salivary gland carcinoma |
| MAMLD1 | 144.7 | 100% | 99% | Hypospadias 2, X-linked, 300758 |
| MAN1B1 | 128.5 | 100% | 99% | Mental retardation, autosomal recessive 15, 614202 |
| MAN2B1 | 108.0 | 98% | 94% | Mannosidosis, alpha-, types I and II, 248500 |

| | | | | |
|----------|-------|------|------|---|
| MANBA | 112.5 | 100% | 93% | Mannosidosis, beta, 248510 |
| MAOA | 148.0 | 100% | 100% | Brunner syndrome, 300615 {Antisocial behavior},300615 |
| MAP2K1 | 86.9 | 100% | 92% | Cardiofaciocutaneous syndrome 3, 615279 |
| MAP2K2 | 92.2 | 94% | 88% | Cardiofaciocutaneous syndrome 4, 615280 |
| MAP3K1 | 143.4 | 92% | 88% | 46XY sex reversal 6, 613762 |
| MAP3K8 | 140.2 | 100% | 100% | Lung cancer, somatic, 211980 |
| MAPRE2 | 175.8 | 100% | 99% | Symmetric circumferential skin creases, congenital, 2, 616734 |
| MAPT | 55.9 | 99% | 87% | Dementia, frontotemporal, with or without parkinsonism, 600274 Pick disease, 172700 Supranuclear palsy, progressive atypical, 260540 Supranuclear palsy, progressive, 601104 {Parkinson disease, susceptibility to}, 168600 |
| MARS | 112.5 | 100% | 96% | Charcot-Marie-Tooth disease, axonal, type 2U, 616280 Interstitial lung and liver disease, 615486 |
| MARS2 | 128.6 | 100% | 100% | Spastic ataxia 3, autosomal recessive, 611390 ?Combined oxidative phosphorylation deficiency 25, 616430 |
| MARVELD2 | 142.2 | 94% | 92% | Deafness, autosomal recessive 49, 610153 |
| MASP1 | 123.7 | 100% | 99% | 3MC syndrome 1, 257920 |
| MASP2 | 125.0 | 99% | 95% | MASP2 deficiency, 613791 |
| MAT1A | 141.9 | 97% | 94% | Hypermethioninemia, persistent, autosomal dominant, due to methionine adenosyltransferase I/III deficiency, 250850 Methionine adenosyltransferase deficiency, autosomal recessive, 250850 |
| MATN3 | 100.1 | 84% | 84% | Epiphyseal dysplasia, multiple, 5, 607078 Spondyloepimetaphyseal dysplasia, 608728 {Osteoarthritis susceptibility 2}, 140600 |
| MATR3 | 74.3 | 95% | 86% | Amyotrophic lateral sclerosis 21, 606070 |
| MBD5 | 160.9 | 100% | 100% | Mental retardation, autosomal dominant 1, 156200 |
| MBTPS2 | 147.4 | 100% | 98% | IFAP syndrome with or without BRESHECK syndrome, 308205 Keratosis follicularis spinulosa decalvans, X-linked, 308800 ?Olmsted syndrome, X-linked, 300918 |
| MC2R | 165.9 | 100% | 98% | Glucocorticoid deficiency, due to ACTH unresponsiveness, 202200 |
| MC4R | 263.3 | 100% | 100% | Obesity, autosomal dominant, 601665 |
| MCC | 125.4 | 99% | 98% | Colorectal cancer, somatic, 114500 |

| | | | | |
|--------|-------|------|------|--|
| MCCC1 | 131.2 | 100% | 99% | 3-Methylcrotonyl-CoA carboxylase 1 deficiency, 210200 |
| MCCC2 | 116.7 | 99% | 97% | 3-Methylcrotonyl-CoA carboxylase 2 deficiency, 210210 |
| MCEE | 89.0 | 100% | 100% | Methylmalonyl-CoA epimerase deficiency, 251120 |
| MCFD2 | 90.9 | 100% | 100% | Factor V and factor VIII, combined deficiency of, 613625 |
| MCM4 | 145.9 | 100% | 99% | Natural killer cell and glucocorticoid deficiency with DNA repair defect, 609981 |
| MCM6 | 150.2 | 100% | 100% | Lactase persistence/nonpersistence, 223100 |
| MCM9 | 128.7 | 100% | 100% | Ovarian dysgenesis 4, 616185 |
| MCOLN1 | 129.3 | 99% | 96% | Mucolipidosis IV, 252650 |
| MCPH1 | 123.8 | 99% | 95% | Microcephaly 1, primary, autosomal recessive, 251200 |
| MECOM | 133.9 | 99% | 97% | Radioulnar synostosis with amegakaryocytic thrombocytopenia 2, 616738 |
| MECP2 | 100.5 | 100% | 97% | Encephalopathy, neonatal severe, 300673 Mental retardation, X-linked syndromic, Lubs type, 300260 Mental retardation, X-linked, syndromic 13, 300055 Rett syndrome, 312750 Rett syndrome, atypical, 312750 Rett syndrome, preserved speech variant, 312750 {Autism susceptibility, X-linked 3}, 300496 |
| MED12 | 118.1 | 100% | 97% | Lujan-Fryns syndrome, 309520 Ohdo syndrome, X-linked, 300895 Opitz-Kaveggia syndrome, 305450 |
| MED13L | 118.3 | 99% | 97% | Mental retardation and distinctive facial features with or without cardiac defects, 616789 Transposition of the great arteries, dextro-looped 1, 608808 |
| MED17 | 116.5 | 98% | 93% | Microcephaly, postnatal progressive, with seizures and brain atrophy, 613668 |
| MED23 | 116.3 | 99% | 97% | Mental retardation, autosomal recessive 18, 614249 |
| MED25 | 90.7 | 98% | 94% | Basel-Vanagait-Smirin-Yosef syndrome, 616449 ?Charcot-Marie-Tooth disease, type 2B2, 605589 |
| MEF2C | 121.4 | 91% | 88% | Chromosome 5q14.3 deletion syndrome, 613443 Mental retardation, stereotypic movements, epilepsy, and/or cerebral malformations, 613443 |
| MEFV | 104.9 | 94% | 89% | Familial Mediterranean fever, AD, 134610 Familial Mediterranean fever, AR, 249100 |
| MEGF10 | 133.4 | 100% | 100% | Myopathy, areflexia, respiratory distress, and dysphagia, early-onset, 614399 Myopathy, areflexia, respiratory distress, and dysphagia, early-onset, mild variant, 614399 |
| MEGF8 | 103.7 | 99% | 96% | Carpenter syndrome 2, 614976 |

| | | | | |
|---------|-------|------|------|---|
| MEN1 | 103.7 | 99% | 92% | Adrenal adenoma, somatic Angiofibroma, somatic Carcinoid tumor of lung Lipoma, somatic Multiple endocrine neoplasia 1, 131100 Parathyroid adenoma, somatic |
| MEOX1 | 82.2 | 95% | 92% | Klippel-Feil syndrome 2, 214300 |
| MERTK | 151.4 | 100% | 98% | Retinitis pigmentosa 38, 613862 |
| MESP2 | 61.2 | 89% | 81% | Spondylocostal dysostosis 2, autosomal recessive, 608681 |
| MET | 169.1 | 100% | 99% | Hepatocellular carcinoma, childhood type, somatic, 114550 Renal cell carcinoma, papillary, 1, familial and somatic, 605074 ?Deafness, autosomal recessive 97, 616705 {Osteofibrous dysplasia,susceptibility to},607278 |
| METTL23 | 119.1 | 100% | 100% | Mental retardation, autosomal recessive 44, 615942 |
| MFAP5 | 107.5 | 100% | 99% | Aortic aneurysm, familial thoracic 9, 616166 |
| MFN2 | 120.8 | 100% | 99% | Charcot-Marie-Tooth disease, type 2A2, 609260 Hereditary motor and sensory neuropathy VIA, 601152 |
| MFRP | 118.7 | 100% | 100% | Microphthalmia, isolated 5, 611040 Nanophthalmos 2, 609549 |
| MFSD2A | 109.3 | 100% | 100% | Microcephaly 15, primary, autosomal recessive, 616486 |
| MFSD8 | 111.8 | 100% | 99% | Ceroid lipofuscinosis, neuronal, 7, 610951 Macular dystrophy with central cone involvement, 616170 |
| MGAT2 | 117.0 | 100% | 99% | Congenital disorder of glycosylation, type IIa, 212066 |
| MGME1 | 161.5 | 100% | 99% | Mitochondrial DNA depletion syndrome 11, 615084 |
| MGP | 139.7 | 91% | 91% | Keutel syndrome, 245150 |
| MIB1 | 131.7 | 100% | 98% | Left ventricular noncompaction 7, 615092 |
| MICU1 | 109.5 | 96% | 92% | Myopathy with extrapyramidal signs, 615673 |
| MID1 | 182.3 | 100% | 100% | Opitz GBBB syndrome, type I, 300000 |
| MINPP1 | 137.6 | 99% | 96% | Thyroid carcinoma, follicular, 188470 |
| MIP | 99.2 | 90% | 85% | Cataract 15, multiple types, 615274 |
| MIR17HG | NC | NC | NC | Feingold syndrome 2, 614326 |
| MIR184 | NC | NC | NC | EDICT syndrome, 614303 |
| MIR96 | NC | NC | NC | Deafness, autosomal dominant 50, 613074 |

| | | | | |
|--------|-------|------|------|---|
| MITF | 128.3 | 100% | 100% | Tietz albinism-deafness syndrome, 103500 Waardenburg syndrome, type 2A, 193510 Waardenburg syndrome/ocular albinism, digenic, 103470 {Melanoma, cutaneous malignant, susceptibility to, 8}, 614456 |
| MKKS | 185.3 | 89% | 89% | Bardet-Biedl syndrome 6, 605231 McKusick-Kaufman syndrome, 236700 |
| MKL1 | 97.5 | 96% | 88% | Megakaryoblastic leukemia, acute |
| MKRN3 | 96.1 | 100% | 98% | Precocious puberty, central, 2, 615346 |
| MKS1 | 87.0 | 99% | 97% | Bardet-Biedl syndrome 13, 615990 Meckel syndrome 1, 249000 |
| MLC1 | 95.3 | 100% | 98% | Megalencephalic leukoencephalopathy with subcortical cysts, 604004 |
| MLH1 | 147.8 | 100% | 99% | Colorectal cancer, hereditary nonpolyposis, type 2, 609310 Mismatch repair cancer syndrome, 276300 Muir-Torre syndrome, 158320 |
| MLH3 | 143.8 | 100% | 99% | Colorectal cancer, hereditary nonpolyposis, type 7, 614385 Colorectal cancer, somatic, 114500 {Endometrial cancer, susceptibility to}, 608089 |
| MLLT10 | 121.2 | 95% | 90% | Leukemia,acute myeloid,601626 |
| MLLT11 | 79.5 | 100% | 97% | Leukemia, acute myelomonocytic, somatic, 607785 |
| MLPH | 85.8 | 100% | 98% | Griselli syndrome, type 3, 609227 |
| MLYCD | 68.7 | 92% | 89% | Malonyl-CoA decarboxylase deficiency, 248360 |
| MMAA | 156.2 | 100% | 100% | Methylmalonic aciduria, vitamin B12-responsive, 251100 |
| MMAB | 88.3 | 100% | 97% | Methylmalonic aciduria, vitamin B12-responsive, due to defect in synthesis of adenosylcobalamin, cblB complementation type, 251110 |
| MMACHC | 159.5 | 100% | 100% | Methylmalonic aciduria and homocystinuria, cblC type, 277400 |
| MMADHC | 58.5 | 82% | 64% | Homocystinuria, cblD type, variant 1, 277410 Methylmalonic aciduria and homocystinuria, cblD type, 277410 Methylmalonic aciduria, cblD type, variant 2, 277410 |
| MME | 88.8 | 96% | 89% | Charcot-Marie-Tooth disease, axonal, type 2T, 617017 ?Spinocerebellar ataxia 43, 617018 |
| MMP1 | 147.3 | 100% | 97% | COPD, rate of decline of lung function in, 606963 {Epidermolysis bullosa dystrophica, autosomal recessive, modifier of}, 226600 |
| MMP13 | 114.2 | 92% | 91% | Metaphyseal anadysplasia 1, 602111 Spondyloepimetaphyseal dysplasia, Missouri type, 602111 |

| | | | | |
|--------|-------|------|------|---|
| MMP19 | 109.2 | 100% | 99% | Cavitory optic disc anomalies, 611543 |
| MMP2 | 132.0 | 100% | 99% | Multicentric osteolysis, nodulosis, and arthropathy, 259600 |
| MMP20 | 90.5 | 100% | 99% | Amelogenesis imperfecta, type IIA2, 612529 |
| MMP21 | 97.7 | 89% | 83% | Heterotaxy, visceral, 7, autosomal, 616749 |
| MMP9 | 97.7 | 100% | 98% | Metaphyseal anadysplasia 2, 613073 |
| MN1 | 85.9 | 96% | 93% | Meningioma, 607174 |
| MNX1 | 28.9 | 73% | 55% | Currarino syndrome, 176450 |
| MOCOS | 152.8 | 100% | 98% | Xanthinuria, type II, 603592 |
| MOCS1 | 76.9 | 93% | 88% | Molybdenum cofactor deficiency A, 252150 |
| MOCS2 | 128.2 | 99% | 98% | Molybdenum cofactor deficiency B, 252160 |
| MOGS | 94.6 | 99% | 98% | Congenital disorder of glycosylation, type IIb, 606056 |
| MORC2 | 120.1 | 100% | 99% | Charcot-Marie-Tooth disease, axonal, type 2Z, 616688 |
| MPC1 | 114.0 | 100% | 98% | Mitochondrial pyruvate carrier deficiency, 614741 |
| MPDU1 | 112.5 | 100% | 98% | Congenital disorder of glycosylation, type If, 609180 |
| MPDZ | 141.4 | 98% | 95% | Hydrocephalus, nonsyndromic, autosomal recessive 2, 615219 |
| MPI | 108.9 | 100% | 99% | Congenital disorder of glycosylation, type Ib, 602579 |
| MPL | 121.9 | 99% | 93% | Myelofibrosis with myeloid metaplasia, somatic, 254450 Thrombocythemia 2, 601977 Thrombocytopenia, congenital amegakaryocytic, 604498 |
| MPLKIP | 73.8 | 98% | 74% | Trichothiodystrophy 4, nonphotosensitive, 234050 |
| MPO | 134.2 | 100% | 99% | Myeloperoxidase deficiency, 254600 {Alzheimer disease, susceptibility to}, 104300 {Lung cancer, protection against, in smokers} |
| MPV17 | 101.4 | 100% | 99% | Mitochondrial DNA depletion syndrome 6 (hepatocerebral type), 256810 |
| MPZ | 92.9 | 100% | 96% | Charcot-Marie-Tooth disease, dominant intermediate D, 607791 Charcot-Marie-Tooth disease, type 1B, 118200 Charcot-Marie-Tooth disease, type 2I, 607677 Charcot-Marie-Tooth disease, type 2J, 607736 Dejerine-Sottas disease, 145900 Neuropathy, congenital hypomyelinating, 605253 Roussy-Levy syndrome, 180800 |
| MRAP | 137.4 | 100% | 100% | Glucocorticoid deficiency 2, 607398 |
| MRE11A | 48.8 | 98% | 85% | Ataxia-telangiectasia-like disorder, 604391 |
| MRPL3 | 54.4 | 94% | 82% | Combined oxidative phosphorylation deficiency 9, 614582 |

| | | | | |
|--------|-------|------|------|---|
| MRPS16 | 117.4 | 100% | 100% | Combined oxidative phosphorylation deficiency 2, 610498 |
| MRPS22 | 125.4 | 98% | 89% | Combined oxidative phosphorylation deficiency 5, 611719 |
| MS4A1 | 106.7 | 100% | 93% | Immunodeficiency, common variable, 5, 613495 |
| MSH2 | 91.8 | 95% | 87% | Colorectal cancer, hereditary nonpolyposis, type 1, 120435 Mismatch repair cancer syndrome, 276300 Muir-Torre syndrome, 158320 |
| MSH3 | 101.5 | 99% | 94% | Endometrial carcinoma, somatic, 608089 Familial adenomatous polyposis 4, 617100 |
| MSH6 | 142.6 | 100% | 99% | Colorectal cancer, hereditary nonpolyposis, type 5, 614350 Endometrial cancer, familial, 608089 Mismatch repair cancer syndrome, 276300 |
| MSMO1 | 35.0 | 85% | 70% | Microcephaly, congenital cataract, and psoriasisiform dermatitis, 616834 |
| MSR1 | 173.3 | 100% | 100% | Barrett esophagus/esophageal adenocarcinoma, 614266 Prostate cancer, hereditary, 176807 |
| MSRB3 | 122.9 | 100% | 95% | Deafness, autosomal recessive 74, 613718 |
| MSTN | 176.7 | 100% | 98% | Muscle hypertrophy, 614160 |
| MSX1 | 56.2 | 96% | 91% | Ectodermal dysplasia 3, Witkop type, 189500 Orofacial cleft 5, 608874 Tooth agenesis, selective, 1, with or without orofacial cleft, 106600 |
| MSX2 | 81.0 | 100% | 84% | Craniosynostosis, type 2, 604757 Parietal foramina 1, 168500 Parietal foramina with cleidocranial dysplasia, 168550 |
| MTAP | 98.3 | 90% | 84% | Diaphyseal medullary stenosis with malignant fibrous histiocytoma, 112250 |
| MTFMT | 122.3 | 98% | 94% | Combined oxidative phosphorylation deficiency 15, 614947 |
| MTHFR | 117.3 | 100% | 100% | Homocystinuria due to MTHFR deficiency, 236250 {Neural tube defects, susceptibility to}, 601634 {Schizophrenia, susceptibility to}, 181500 {Thromboembolism, susceptibility to}, 188050 {Vascular disease, susceptibility to} |
| MTM1 | 115.2 | 99% | 97% | Myotubular myopathy, X-linked, 310400 |
| MTMR2 | 107.3 | 100% | 100% | Charcot-Marie-Tooth disease, type 4B1, 601382 |
| MTO1 | 140.9 | 89% | 85% | Combined oxidative phosphorylation deficiency 10, 614702 |
| MTOR | 117.2 | 99% | 99% | Smith-Kingsmore syndrome, 616638 |
| MTPAP | 108.7 | 97% | 84% | Ataxia, spastic, 4, 613672 |

| | | | | |
|--------|-------|------|------|--|
| MTR | 126.4 | 100% | 99% | Homocystinuria-megaloblastic anemia, cblG complementation type, 250940 {Neural tube defects, folate-sensitive, susceptibility to}, 601634 |
| MTRR | 114.9 | 99% | 97% | Homocystinuria-megaloblastic anemia, cbl E type, 236270 {Neural tube defects, folate-sensitive, susceptibility to}, 601634 |
| MTTP | 122.0 | 100% | 96% | Abetalipoproteinemia, 200100 {Metabolic syndrome, protection against}, 605552 |
| MUC1 | 88.7 | 97% | 92% | Medullary cystic kidney disease 1, 174000 |
| MUSK | 146.2 | 100% | 100% | Fetal akinesia deformation sequence, 208150 Myasthenic syndrome, congenital, 9, associated with acetylcholine receptor deficiency, 616325 |
| MUT | 105.1 | 97% | 91% | Methylmalonic aciduria, mut(0) type, 251000 |
| MUTYH | 126.5 | 100% | 97% | Adenomas, multiple colorectal, 608456 Colorectal adenomatous polyposis, autosomal recessive, with pilomatricomas, 132600 Gastric cancer, somatic, 613659 |
| MVD | 95.0 | 100% | 100% | Porokeratosis 7, multiple types, 614714 |
| MVK | 120.9 | 100% | 100% | Hyper-IgD syndrome, 260920 Mevalonic aciduria, 610377 Porokeratosis 3, multiple types, 175900 |
| MXI1 | 97.9 | 88% | 83% | Neurofibrosarcoma {Prostate cancer, susceptibility to}, 176807 |
| MYBPC1 | 145.0 | 100% | 99% | Arthrogryposis, distal, type 1B, 614335 Lethal congenital contracture syndrome 4, 614915 |
| MYBPC3 | 118.7 | 99% | 94% | Cardiomyopathy, dilated, 1MM, 615396 Cardiomyopathy, hypertrophic, 4, 115197 Left ventricular noncompaction 10, 615396 |
| MYC | 151.5 | 100% | 100% | Burkitt lymphoma, 113970 |
| MYCN | 80.1 | 99% | 89% | Feingold syndrome, 164280 |
| MYD88 | 145.1 | 100% | 98% | Macroglobulinemia, Waldenstrom, somatic, 153600 Pyogenic bacterial infections, recurrent, due to MYD88 deficiency, 612260 |
| MYF6 | 100.2 | 100% | 100% | Myopathy, centronuclear, 3, 614408 |
| MYH11 | 109.2 | 100% | 98% | Aortic aneurysm, familial thoracic 4, 132900 |
| MYH14 | 89.2 | 95% | 85% | Deafness, autosomal dominant 4A, 600652 ?Peripheral neuropathy, myopathy, hoarseness, and hearing loss, 614369 |
| MYH2 | 111.7 | 98% | 96% | Proximal myopathy and ophthalmoplegia, 605637 |

| | | | | |
|--------|-------|------|------|--|
| MYH3 | 96.3 | 99% | 96% | Arthrogryposis, distal, type 2A, 193700 Arthrogryposis, distal, type 2B, 601680 Arthrogryposis, distal, type 8, 178110 |
| MYH6 | 99.9 | 99% | 90% | Atrial septal defect 3, 614089 Cardiomyopathy, dilated, 1EE, 613252 Cardiomyopathy, hypertrophic, 14, 613251 {Sick sinus syndrome 3}, 614090 |
| MYH7 | 98.1 | 97% | 94% | Cardiomyopathy, dilated, 1S, 613426 Cardiomyopathy, hypertrophic, 1, 192600 Left ventricular noncompaction 5, 613426 Liang distal myopathy, 160500 Myopathy, myosin storage, autosomal dominant, 608358 Myopathy, myosin storage, autosomal recessive, 255160 Scapuloperoneal syndrome, myopathic type, 181430 |
| MYH8 | 115.7 | 99% | 98% | Carney complex variant, 608837 Trismus-pseudocamptodactyly syndrome, 158300 |
| MYH9 | 115.9 | 99% | 97% | Deafness, autosomal dominant 17, 603622 Epstein syndrome, 153650 Fechtner syndrome, 153640 Macrothrombocytopenia and progressive sensorineural deafness, 600208 May-Hegglin anomaly, 155100 Sebastian syndrome, 605249 |
| MYL2 | 131.2 | 99% | 94% | Cardiomyopathy, hypertrophic, 10, 608758 |
| MYL3 | 101.8 | 100% | 100% | Cardiomyopathy, hypertrophic, 8, 608751 |
| MYLK | 133.8 | 99% | 99% | Aortic aneurysm, familial thoracic 7, 613780 |
| MYLK2 | 93.5 | 100% | 98% | Cardiomyopathy, hypertrophic, 1, digenic, 192600 |
| MYO15A | 96.8 | 95% | 91% | Deafness, autosomal recessive 3, 600316 |
| MYO18B | 110.7 | 99% | 97% | Klippel-Feil syndrome 4, autosomal recessive, with myopathy and facial dysmorphism, 616549 |
| MYO1E | 118.8 | 97% | 92% | Glomerulosclerosis, focal segmental, 6, 614131 |
| MYO3A | 107.9 | 96% | 91% | Deafness, autosomal recessive 30, 607101 |
| MYO5A | 114.3 | 100% | 98% | Griselli syndrome, type 1, 214450 |
| MYO5B | 124.7 | 97% | 96% | Microvillus inclusion disease, 251850 |
| MYO6 | 78.6 | 95% | 89% | Deafness, autosomal dominant 22, 606346 Deafness, autosomal dominant 22, with hypertrophic cardiomyopathy, 606346 Deafness, autosomal recessive 37, 607821 |

| | | | | |
|--------|-------|------|------|---|
| MYO7A | 120.1 | 98% | 95% | Deafness, autosomal dominant 11, 601317 Deafness, autosomal recessive 2, 600060 Usher syndrome, type 1B, 276900 |
| MYOC | 141.5 | 100% | 99% | Glaucoma 1A, primary open angle, 137750 |
| MYOT | 130.7 | 96% | 88% | Muscular dystrophy, limb-girdle, type 1A, 159000 Myopathy, myofibrillar, 3, 609200 Myopathy, spheroid body, 182920 |
| MYOZ2 | 138.4 | 100% | 100% | Cardiomyopathy, hypertrophic, 16, 613838 |
| MYPN | 129.7 | 99% | 98% | Cardiomyopathy, dilated, 1KK, 615248 Cardiomyopathy, familial restrictive, 4, 615248 Cardiomyopathy, hypertrophic, 22, 615248 |
| MYT1L | 153.0 | 99% | 99% | Mental retardation, autosomal dominant 39, 616521 |
| NAA10 | 112.3 | 100% | 97% | Ogden syndrome, 300855 ?Microphthalmia, syndromic 1, 309800 |
| NAGA | 118.4 | 100% | 100% | Kanzaki disease, 609242 Schindler disease, type I, 609241 Schindler disease, type III, 609241 |
| NAGLU | 97.6 | 94% | 91% | Mucopolysaccharidosis type IIIB (Sanfilippo B), 252920 ?Charcot-Marie-Tooth disease, axonal, type 2V, 616491 |
| NAGS | 61.6 | 100% | 92% | N-acetylglutamate synthase deficiency, 237310 |
| NALCN | 127.0 | 100% | 97% | Congenital contractures of the limbs and face, hypotonia, and developmental delay, 616266 Hypotonia, infantile, with psychomotor retardation and characteristic facies 1, 615419 |
| NANOS1 | 32.3 | 93% | 74% | Spermatogenic failure 12, 615413 |
| NANS | 102.3 | 100% | 100% | Spondyloepimetaphyseal dysplasia, Genevieve type, 610442 |
| NARS2 | 127.1 | 97% | 96% | Combined oxidative phosphorylation deficiency 24, 616239 |
| NBAS | 131.9 | 98% | 96% | Infantile liver failure syndrome 2, 616483 Short stature, optic nerve atrophy, and Pelger-Huet anomaly, 614800 |
| NBEAL2 | 147.3 | 99% | 99% | Gray platelet syndrome, 139090 |
| NBN | 74.3 | 96% | 92% | Aplastic anemia, 609135 Leukemia, acute lymphoblastic, 613065 Nijmegen breakage syndrome, 251260 |
| NCF1 | 14.4 | 25% | 20% | Chronic granulomatous disease due to deficiency of NCF-1, 233700 |
| NCF2 | 104.8 | 98% | 96% | Chronic granulomatous disease due to deficiency of NCF-2, 233710 |
| NCF4 | 138.6 | 100% | 100% | Granulomatous disease, chronic, autosomal recessive, cytochrome b-positive, type III, 613960 |

| | | | | |
|---------|-------|------|------|--|
| NCSTN | 107.4 | 100% | 100% | Acne inversa, familial, 1, 142690 |
| NDE1 | 84.3 | 100% | 100% | Lissencephaly 4 (with microcephaly), 614019 ?Microhydranencephaly, 605013 |
| NDN | 71.3 | 81% | 70% | Prader-Willi syndrome, 176270 |
| NDP | 152.6 | 100% | 100% | Exudative vitreoretinopathy 2, X-linked, 305390 Norrie disease, 310600 |
| NDRG1 | 114.1 | 100% | 100% | Charcot-Marie-Tooth disease, type 4D, 601455 |
| NDST1 | 164.7 | 100% | 100% | Mental retardation, autosomal recessive 46, 616116 |
| NDUFA1 | 215.2 | 100% | 100% | Mitochondrial complex I deficiency, 252010 |
| NDUFA11 | 76.6 | 100% | 90% | Mitochondrial complex I deficiency, 252010 |
| NDUFA12 | 129.1 | 100% | 100% | Leigh syndrome due to mitochondrial complex I deficiency, 256000 |
| NDUFA2 | 112.5 | 100% | 100% | Leigh syndrome due to mitochondrial complex I deficiency, 256000 |
| NDUFA9 | 120.0 | 99% | 95% | Leigh syndrome due to mitochondrial complex I deficiency, 256000 |
| NDUFAF1 | 85.6 | 100% | 99% | Mitochondrial complex I deficiency, 252010 |
| NDUFAF2 | 52.4 | 82% | 70% | Leigh syndrome, 256000 Mitochondrial complex I deficiency, 252010 |
| NDUFAF3 | 96.5 | 100% | 100% | Mitochondrial complex I deficiency, 252010 |
| NDUFAF4 | 85.6 | 99% | 96% | Mitochondrial complex I deficiency, 252010 |
| NDUFAF5 | 96.4 | 94% | 93% | Mitochondrial complex I deficiency, 252010 |
| NDUFAF6 | 73.7 | 99% | 90% | Leigh syndrome due to mitochondrial complex I deficiency, 256000 |
| NDUFB11 | 109.9 | 94% | 87% | Linear skin defects with multiple congenital anomalies 3, 300952 |
| NDUFB3 | 12.3 | 62% | 28% | Mitochondrial complex I deficiency, 252010 |
| NDUFS1 | 122.4 | 100% | 99% | Mitochondrial complex I deficiency, 252010 |
| NDUFS2 | 94.0 | 99% | 98% | Mitochondrial complex I deficiency, 252010 |
| NDUFS3 | 117.1 | 90% | 90% | Leigh syndrome due to mitochondrial complex I deficiency, 256000 Mitochondrial complex I deficiency, 252010 |
| NDUFS4 | 141.6 | 100% | 99% | Leigh syndrome, 256000 Mitochondrial complex I deficiency, 252010 |
| NDUFS6 | 121.3 | 100% | 100% | Mitochondrial complex I deficiency, 252010 |
| NDUFS7 | 113.0 | 100% | 98% | Leigh syndrome, 256000 |
| NDUFS8 | 102.1 | 100% | 100% | Leigh syndrome due to mitochondrial complex I deficiency, 256000 |
| NDUFV1 | 133.9 | 100% | 97% | Mitochondrial complex I deficiency, 252010 |
| NDUFV2 | 58.2 | 83% | 49% | Mitochondrial complex I deficiency, 252010 |
| NEB | 114.4 | 82% | 81% | Nemaline myopathy 2, autosomal recessive, 256030 |

| | | | | |
|---------|-------|------|------|--|
| NEFH | 83.7 | 98% | 97% | Charcot-Marie-Tooth disease,axonal,type 2CC,616924 ?{Amyotrophic lateral sclerosis, susceptibility to}, 105400 |
| NEFL | 127.7 | 99% | 96% | Charcot-Marie-Tooth disease, type 1F, 607734 Charcot-Marie-Tooth disease, type 2E, 607684 |
| NEK1 | 99.1 | 97% | 91% | Short-rib thoracic dysplasia 6 with or without polydactyly, 263520 |
| NEK9 | 123.7 | 99% | 96% | Lethal congenital contracture syndrome 10, 617022 Nevus comedonicus, somatic, 617025 ?Arthrogryposis, Perthes disease, and upward gaze palsy, 614262 |
| NEU1 | 12.2 | 61% | 15% | Sialidosis, type I, 256550 Sialidosis, type II, 256550 |
| NEUROD1 | 139.9 | 100% | 100% | Maturity-onset diabetes of the young 6, 606394 {Diabetes mellitus, noninsulin-dependent}, 125853 |
| NEUROG3 | 85.5 | 100% | 95% | Diarrhea 4, malabsorptive, congenital, 610370 |
| NEXN | 65.0 | 88% | 76% | Cardiomyopathy, dilated, 1CC, 613122 Cardiomyopathy, hypertrophic, 20, 613876 |
| NF1 | 110.4 | 92% | 87% | Leukemia, juvenile myelomonocytic, 607785 Neurofibromatosis, familial spinal, 162210 Neurofibromatosis, type 1, 162200 Neurofibromatosis-Noonan syndrome, 601321 Watson syndrome, 193520 |
| NF2 | 89.6 | 100% | 99% | Meningioma, NF2-related, somatic, 607174 Neurofibromatosis, type 2, 101000 Schwannomatosis, 162091 |
| NFIX | 127.6 | 98% | 97% | Marshall-Smith syndrome, 602535 Sotos syndrome 2, 614753 |
| NFKB1 | 98.2 | 99% | 90% | Immunodeficiency, common variable, 12, 616576 |
| NFKB2 | 109.8 | 96% | 91% | Immunodeficiency, common variable, 10, 615577 |
| NFKBIA | 94.6 | 94% | 91% | Ectodermal dysplasia, anhidrotic, with T-cell immunodeficiency, 612132 |
| NFU1 | 43.5 | 98% | 81% | Multiple mitochondrial dysfunctions syndrome 1, 605711 |
| NGF | 218.4 | 100% | 100% | Neuropathy, hereditary sensory and autonomic, type V, 608654 |
| NGLY1 | 117.1 | 100% | 99% | Congenital disorder of deglycosylation, 615273 |
| NHEJ1 | 67.8 | 100% | 100% | Severe combined immunodeficiency with microcephaly, growth retardation, and sensitivity to ionizing radiation, 611291 |
| NHLRC1 | 126.0 | 100% | 100% | Epilepsy, progressive myoclonic 2B (Lafora), 254780 |

| | | | | |
|--------|-------|------|-----|--|
| NHP2 | 71.0 | 100% | 99% | Dyskeratosis congenita, autosomal recessive 2, 613987 |
| NHS | 144.9 | 95% | 93% | Cataract 40, X-linked, 302200 Nance-Horan syndrome, 302350 |
| NIN | 139.0 | 99% | 97% | Seckel syndrome 7, 614851 |
| NIPA1 | 135.0 | 100% | 97% | Spastic paraplegia 6, autosomal dominant, 600363 |
| NIPAL4 | 129.5 | 100% | 97% | Ichthyosis, congenital, autosomal recessive 6, 612281 |
| NIPBL | 99.7 | 96% | 95% | Cornelia de Lange syndrome 1, 122470 |
| NKX2-1 | 39.2 | 100% | 91% | Chorea, hereditary benign, 118700 Choreoathetosis, hypothyroidism, and neonatal respiratory distress, 610978 {Thyroid cancer, monmedullary, 1}, 188550 |
| NKX2-5 | 76.5 | 99% | 99% | Atrial septal defect 7, with or without AV conduction defects, 108900 Conotruncal heart malformations, variable, 217095 Hypoplastic left heart syndrome 2, 614435 Hypothyroidism, congenital nongoitrous, 5, 225250 Tetralogy of Fallot, 187500 Ventricular septal defect 3, 614432 |
| NKX2-6 | 90.1 | 100% | 99% | Conotruncal heart malformations, 217095 Persistent truncus arteriosus, 217095 |
| NKX3-2 | 42.0 | 79% | 55% | Spondylo-megaepiphyseal-metaphyseal dysplasia, 613330 |
| NLGN4X | 188.3 | 100% | 97% | Mental retardation, X-linked, 300495 {Asperger syndrome susceptibility, X-linked 2}, 300497 {Autism susceptibility, X-linked 2}, 300495 |
| NLRC4 | 146.4 | 100% | 99% | Autoinflammation with infantile enterocolitis, 616050 ?Familial cold autoinflammatory syndrome 4, 616115 |
| NLRP12 | 131.0 | 99% | 99% | Familial cold autoinflammatory syndrome 2, 611762 |
| NLRP3 | 128.6 | 100% | 99% | CINCA syndrome, 607115 Familial cold-induced inflammatory syndrome 1, 120100 Muckle-Wells syndrome, 191900 |
| NLRP7 | 120.9 | 99% | 97% | Hydatidiform mole,recurrent, 1,231090 |
| NME1 | 80.5 | 100% | 96% | Neuroblastoma, 256700 |
| NME8 | 95.6 | 96% | 90% | Ciliary dyskinesia, primary, 6, 610852 |
| NMNAT1 | 114.7 | 100% | 96% | Leber congenital amaurosis 9, 608553 |
| NNT | 127.7 | 97% | 96% | Glucocorticoid deficiency 4, 614736 |
| NOBOX | 67.3 | 100% | 95% | Premature ovarian failure 5, 611548 |

| | | | | |
|--------|-------|------|------|---|
| NOD2 | 122.6 | 100% | 99% | Blau syndrome, 186580 Sarcoidosis, early-onset, 609464 {Inflammatory bowel disease 1}, 266600 {Psoriatic arthritis, susceptibility to}, 607507 |
| NODAL | 131.2 | 100% | 100% | Heterotaxy, visceral, 5, 270100 |
| NOG | 148.2 | 100% | 100% | Brachydactyly, type B2, 611377 Multiple synostoses syndrome 1, 186500 Stapes ankylosis with broad thumb and toes, 184460 Symphalangism, proximal, 1A, 185800 Tarsal-carpal coalition syndrome, 186570 |
| NOL3 | 71.2 | 91% | 80% | Myoclonus, familial cortical, 614937 |
| NONO | 110.2 | 100% | 98% | Mental retardation, X-linked, syndromic 34, 300967 |
| NOP10 | 148.8 | 100% | 100% | Dyskeratosis congenita, autosomal recessive 1, 224230 |
| NOP56 | 111.5 | 98% | 95% | Spinocerebellar ataxia 36, 614153 |
| NOTCH1 | 125.3 | 99% | 97% | Adams-Oliver syndrome 5, 616028 Aortic valve disease 1, 109730 |
| NOTCH2 | 150.5 | 100% | 99% | Alagille syndrome 2, 610205 Hajdu-Cheney syndrome, 102500 |
| NOTCH3 | 98.3 | 94% | 89% | Cerebral arteriopathy with subcortical infarcts and leukoencephalopathy 1, 125310 Lateral meningocele syndrome, 130720 ?Myofibromatosis, infantile 2, 615293 |
| NPC1 | 126.2 | 99% | 97% | Niemann-Pick disease, type C1, 257220 Niemann-Pick disease, type D, 257220 {Nasopharyngeal carcinoma 1} |
| NPC2 | 121.9 | 100% | 100% | Niemann-pick disease, type C2, 607625 |
| NPHP1 | 118.5 | 98% | 97% | Joubert syndrome 4, 609583 Nephronophthisis 1, juvenile, 256100 Senior-Loken syndrome-1, 266900 |
| NPHP3 | 105.0 | 97% | 91% | Meckel syndrome 7, 267010 Nephronophthisis 3, 604387 Renal-hepatic-pancreatic dysplasia 1, 208540 |
| NPHP4 | 122.1 | 100% | 99% | Nephronophthisis 4, 606966 Senior-Loken syndrome 4, 606996 |
| NPHS1 | 90.7 | 99% | 96% | Nephrotic syndrome, type 1, 256300 |

| | | | | |
|-------|-------|------|------|---|
| NPHS2 | 93.3 | 100% | 98% | Nephrotic syndrome, type 2, 600995 |
| NPM1 | 63.2 | 88% | 77% | Leukemia, acute myeloid, somatic, 601626 |
| NPPA | 89.2 | 100% | 99% | Atrial fibrillation, familial, 6, 612201 Atrial standstill 2, 615745 |
| NPR2 | 148.3 | 100% | 100% | Acromesomelic dysplasia, Maroteaux type, 602875 Epiphyseal chondrodysplasia, Miura type, 615923 Short stature with nonspecific skeletal abnormalities, 616255 |
| NR0B1 | 131.4 | 100% | 100% | 46XY sex reversal 2, dosage-sensitive, 300018 Adrenal hypoplasia, congenital, with hypogonadotropic hypogonadism, 300200 |
| NR0B2 | 78.4 | 100% | 100% | Obesity, mild, early-onset, 601665 |
| NR1H4 | 138.6 | 96% | 89% | Cholestasis, progressive familial intrahepatice 5, 617049 |
| NR2E3 | 84.7 | 100% | 100% | Enhanced S-cone syndrome, 268100 Retinitis pigmentosa 37, 611131 |
| NR2F1 | 164.3 | 100% | 100% | Bosch-Boonstra-Schaaf optic atrophy syndrome, 615722 |
| NR2F2 | 170.2 | 94% | 91% | Congenital heart defects, multiple types, 4, 615779 |
| NR3C1 | 134.1 | 100% | 99% | Glucocorticoid resistance, 615962 |
| NR3C2 | 149.9 | 99% | 95% | Hypertension, early-onset, autosomal dominant, with exacerbation in pregnancy, 605115 Pseudohypoaldosteronism type I, autosomal dominant, 177735 |
| NR4A3 | 88.5 | 99% | 87% | Chondrosarcoma,extraskeletal myxoid,612237 |
| NR5A1 | 74.8 | 100% | 99% | 46XY sex reversal 3, 612965 Adrenocortical insufficiency Premature ovarian failure 7, 612964 Spermatogenic failure 8, 613957 |
| NRAS | 175.3 | 100% | 100% | Colorectal cancer, somatic, 114500 Epidermal nevus, somatic, 162900 Melanocytic nevus syndrome, congenital, somatic, 137550 Neurocutaneous melanosis, somatic, 249400 Noonan syndrome 6, 613224 Schimmelpenning-Feuerstein-Mims syndrome, somatic mosaic, 163200 Thyroid carcinoma, follicular, somatic, 188470 ?RAS-associated autoimmune lymphoproliferative syndrome type IV, somatic, 614470 |
| NRL | 61.3 | 99% | 85% | Retinal degeneration, autosomal recessive, clumped pigment type Retinitis pigmentosa 27, 613750 |
| NRXN1 | 142.9 | 98% | 97% | Pitt-Hopkins-like syndrome 2, 614325 |

| | | | | |
|--------|-------|------|------|--|
| | | | | {Schizophrenia, susceptibility to, 17}, 614332 |
| NSD1 | 139.4 | 100% | 100% | Beckwith-Wiedemann syndrome, 130650 Leukemia, acute myeloid, 601626 Sotos syndrome 1, 117550 |
| NSDHL | 204.8 | 100% | 100% | CHILD syndrome, 308050 CK syndrome, 300831 |
| NSMF | 91.7 | 96% | 94% | Hypogonadotropic hypogonadism 9 with or without anosmia, 614838 |
| NSUN2 | 98.8 | 94% | 87% | Mental retardation, autosomal recessive 5, 611091 |
| NT5C2 | 126.3 | 96% | 94% | Spastic paraparesis 45, autosomal recessive, 613162 |
| NT5C3A | 57.0 | 84% | 66% | Anemia, hemolytic, due to UMPH1 deficiency, 266120 |
| NT5E | 150.7 | 100% | 98% | Calcification of joints and arteries, 211800 |
| NTF4 | 49.9 | 92% | 81% | Glaucoma 1, open angle, 1O, 613100 |
| NTHL1 | 99.3 | 96% | 93% | Familial adenomatous polyposis 3, 616415 |
| NTRK1 | 111.1 | 100% | 97% | Insensitivity to pain, congenital, with anhidrosis, 256800 Medullary thyroid carcinoma, familial, 155240 |
| NUBPL | 81.5 | 90% | 82% | Mitochondrial complex I deficiency, 252010 |
| NUMA1 | 103.7 | 100% | 99% | Leukemia, acute promyelocytic, somatic, 612376 |
| NUP107 | 104.8 | 98% | 90% | Nephrotic syndrome, type 11, 616730 |
| NUP214 | 139.0 | 100% | 99% | Leukemia, acute myeloid, somatic, 601626 Leukemia, T-cell acute lymphoblastic, somatic, 613065 |
| NUP62 | 109.3 | 100% | 100% | Striatonigral degeneration, infantile, 271930 |
| NUP93 | 121.0 | 96% | 93% | Nephrotic syndrome, type 12, 616892 |
| NYX | 86.7 | 97% | 96% | Night blindness, congenital stationary (complete), 1A, X-linked, 310500 |
| OAT | 73.4 | 70% | 65% | Gyrate atrophy of choroid and retina with or without ornithinemia, 258870 |
| OBSL1 | 115.8 | 98% | 95% | 3-M syndrome 2, 612921 |
| OCA2 | 120.2 | 97% | 96% | Albinism, brown oculocutaneous, 203200 Albinism, oculocutaneous, type II, 203200 [Skin/hair/eye pigmentation 1, blond/brown hair], 227220 [Skin/hair/eye pigmentation 1, blue/nonblue eyes], 227220 |
| OCLN | 218.4 | 100% | 100% | Band-like calcification with simplified gyration and polymicrogyria, 251290 |
| OCRL | 164.3 | 100% | 99% | Dent disease 2, 300555 Lowe syndrome, 309000 |

| | | | | |
|--------|-------|------|------|--|
| OFD1 | 57.7 | 88% | 78% | Joubert syndrome 10, 300804 Orofaciodigital syndrome I, 311200 Simpson-Golabi-Behmel syndrome, type 2, 300209 ?Retinitis pigmentosa 23, 300424 |
| OGG1 | 121.4 | 100% | 100% | Renal cell carcinoma, clear cell, somatic, 144700 |
| OPA1 | 113.8 | 97% | 92% | Behr syndrome, 210000 Optic atrophy 1, 165500 Optic atrophy plus syndrome, 125250 ?Mitochondrial DNA depletion syndrome 14 (encephalocardiomyopathic type), 616896 {Glaucoma, normal tension, susceptibility to}, 606657 |
| OPA3 | 90.6 | 97% | 94% | 3-methylglutaconic aciduria, type III, 258501 Optic atrophy 3 with cataract, 165300 |
| OPHN1 | 117.6 | 100% | 99% | Mental retardation, X-linked, with cerebellar hypoplasia and distinctive facial appearance, 300486 |
| OPLAH | 94.3 | 100% | 97% | 5-oxoprolinase deficiency, 260005 |
| OPN1LW | 78.3 | 71% | 66% | Blue cone monochromacy, 303700 Colorblindness, protan, 303900 |
| OPN1MW | 40.7 | 66% | 62% | Blue cone monochromacy, 303700 Colorblindness, deutan, 303800 |
| OPN1SW | 103.4 | 100% | 100% | Colorblindness, tritan, 190900 |
| OPTN | 95.5 | 100% | 99% | Amyotrophic lateral sclerosis 12, 613435 Glaucoma 1, open angle, E, 137760 {Glaucoma, normal tension, susceptibility to}, 606657 |
| ORAI1 | 175.4 | 93% | 89% | Immunodeficiency 9, 612782 Myopathy, tubular aggregate, 2, 615883 |
| ORC1 | 95.7 | 98% | 93% | Meier-Gorlin syndrome 1, 224690 |
| ORC4 | 59.1 | 95% | 85% | Meier-Gorlin syndrome 2, 613800 |
| ORC6 | 122.8 | 100% | 100% | Meier-Gorlin syndrome 3, 613803 |
| OSBPL2 | 130.3 | 100% | 100% | Deafness, autosomal dominant 67, 616340 |
| OSMR | 120.9 | 100% | 99% | Amyloidosis, primary localized cutaneous, 1, 105250 |
| OSTM1 | 53.7 | 90% | 83% | Osteopetrosis, autosomal recessive 5, 259720 |
| OTC | 139.1 | 100% | 100% | Ornithine transcarbamylase deficiency, 311250 |
| OTOA | 99.5 | 98% | 95% | Deafness, autosomal recessive 22, 607039 |
| OTOF | 116.6 | 99% | 98% | Auditory neuropathy, autosomal recessive, 1, 601071 Deafness, autosomal recessive 9, 601071 |

| | | | | |
|----------|-------|------|------|--|
| OTOG | 119.0 | 99% | 97% | Deafness, autosomal recessive 18B, 614945 |
| OTOGL | 110.8 | 98% | 93% | Deafness, autosomal recessive 84B, 614944 |
| OTX2 | 119.3 | 100% | 98% | Microphthalmia, syndromic 5, 610125 Pituitary hormone deficiency, combined, 6, 613986 Retinal dystrophy, early-onset, with or without pituitary dysfunction, 610125 |
| OVOL2 | 105.3 | 100% | 97% | Corneal dystrophy, posterior polymorphous, 1, 122000 |
| OXCT1 | 106.0 | 100% | 96% | Succinyl CoA:3-oxoacid CoA transferase deficiency, 245050 |
| P2RX1 | 104.9 | 99% | 97% | Bleeding disorder due to P2RX1 defect, somatic, 609821 |
| P2RX2 | 108.6 | 100% | 97% | Deafness, autosomal dominant 41, 608224 |
| P2RY12 | 187.5 | 100% | 100% | Bleeding disorder, platelet-type, 8, 609821 |
| P4HB | 102.1 | 94% | 94% | Cole-Carpenter syndrome 1, 112240 |
| PABPN1 | 70.4 | 65% | 58% | Oculopharyngeal muscular dystrophy, 164300 |
| PACS1 | 102.2 | 97% | 95% | Schuss-Hoeijmakers-syndrome, 615009 |
| PAFAH1B1 | 93.5 | 88% | 78% | Lissencephaly 1, 607432 Subcortical laminar heterotopia, 607432 |
| PAH | 153.3 | 100% | 100% | Phenylketonuria, 261600 [Hyperphenylalaninemia, non-PKU mild], 261600 |
| PAK3 | 104.5 | 97% | 92% | Mental retardation, X-linked 30/47, 300558 |
| PALB2 | 149.2 | 100% | 100% | Fanconi anemia, complementation group N, 610832 {Breast cancer, susceptibility to}, 114480 {Pancreatic cancer, susceptibility to, 3}, 613348 |
| PAM16 | 43.8 | 65% | 64% | Spondylometaphyseal dysplasia, Megarbane-Dagher-Melike type, 613320 |
| PANK2 | 147.7 | 98% | 93% | HARP syndrome, 607236 Neurodegeneration with brain iron accumulation 1, 234200 |
| PAPSS2 | 86.8 | 100% | 98% | Brachyolmia 4 with mild epiphyseal and metaphyseal changes, 612847 |
| PARK2 | 109.5 | 100% | 100% | Adenocarcinoma of lung, somatic, 211980 Adenocarcinoma, ovarian, somatic, 167000 Parkinson disease, juvenile, type 2, 600116 {Leprosy, susceptibility to}, 607572 |
| PARK7 | 74.2 | 100% | 97% | Parkinson disease 7, autosomal recessive early-onset, 606324 |
| PARN | 114.7 | 100% | 96% | Dyskeratosis congenita, autosomal recessive 6, 616353 Pulmonary fibrosis and/or bone marrow failure, telomere-related, 4, 616371 |
| PAX2 | 149.3 | 100% | 100% | Glomerulosclerosis, focal segmental, 7, 616002 Papillorenal syndrome, 120330 |

| | | | | |
|--------|-------|------|------|--|
| PAX3 | 100.8 | 100% | 99% | Craniofacial-deafness-hand syndrome, 122880 Rhabdomyosarcoma 2, alveolar, 268220 Waardenburg syndrome, type 1, 193500 Waardenburg syndrome, type 3, 148820 |
| PAX4 | 83.3 | 100% | 98% | Diabetes mellitus, type 2, 125853 Maturity-onset diabetes of the young, type IX, 612225 {Diabetes mellitus, ketosis-prone, susceptibility to}, 612227 |
| PAX6 | 123.5 | 100% | 100% | Aniridia, 106210 Cataract with late-onset corneal dystrophy, 106210 Coloboma of optic nerve, 120430 Coloboma, ocular, 120200 Foveal hypoplasia 1, 136520 Keratitis, 148190 Optic nerve hypoplasia, 165550 Peters anomaly, 604229 ?Morning glory disc anomaly, 120430 |
| PAX7 | 93.8 | 100% | 99% | Rhabdomyosarcoma 2, alveolar, 268220 |
| PAX8 | 89.5 | 100% | 99% | Hypothyroidism, congenital, due to thyroid dysgenesis or hypoplasia, 218700 |
| PAX9 | 201.1 | 99% | 95% | Tooth agenesis, selective, 3, 604625 |
| PC | 126.0 | 97% | 93% | Pyruvate carboxylase deficiency, 266150 |
| PCBD1 | 99.4 | 99% | 99% | Hyperphenylalaninemia, BH4-deficient, D, 264070 |
| PCCA | 91.1 | 95% | 88% | Propionicacidemia, 606054 |
| PCCB | 124.7 | 96% | 94% | Propionicacidemia, 606054 |
| PCDH15 | 146.8 | 99% | 99% | Deafness, autosomal recessive 23, 609533 Usher syndrome, type 1D/F digenic, 601067 Usher syndrome, type 1F, 602083 |
| PCDH19 | 215.0 | 100% | 100% | Epileptic encephalopathy, early infantile, 9, 300088 |
| PCNT | 99.7 | 97% | 94% | Microcephalic osteodysplastic primordial dwarfism, type II, 210720 |
| PCSK1 | 130.7 | 100% | 98% | Obesity with impaired prohormone processing, 600955 {Obesity, susceptibility to, BMIQ12}, 612362 |
| PCSK9 | 87.0 | 93% | 91% | Hypercholesterolemia, familial, 3, 603776 {Low density lipoprotein cholesterol level QTL 1}, 603776 |
| PCYT1A | 92.9 | 99% | 95% | Spondylometaphyseal dysplasia with cone-rod dystrophy, 608940 |
| PDCD10 | 77.7 | 98% | 74% | Cerebral cavernous malformations 3, 603285 |

| | | | | |
|--------|-------|------|------|--|
| PDE10A | 133.5 | 100% | 99% | Dyskinesia,limb and orofacial,infantile-onset,616921 Striatal degeneration,autosomal dominant,616922 |
| PDE11A | 138.7 | 100% | 100% | Pigmented nodular adrenocortical disease, primary, 2, 610475 |
| PDE3A | 104.0 | 99% | 98% | Hypertension and brachydactyly syndrome, 112410 |
| PDE4D | 101.0 | 98% | 94% | Acrodysostosis 2, with or without hormone resistance, 614613 {Stroke, susceptibility to, 1}, 606799 |
| PDE6A | 104.9 | 100% | 100% | Retinitis pigmentosa 43, 613810 |
| PDE6B | 133.6 | 100% | 100% | Night blindness, congenital stationary, autosomal dominant 2, 163500 Retinitis pigmentosa-40, 613801 |
| PDE6C | 124.1 | 97% | 96% | Cone dystrophy 4, 613093 |
| PDE6G | 77.3 | 96% | 92% | Retinitis pigmentosa 57, 613582 |
| PDE6H | 51.2 | 74% | 48% | Achromatopsia 6, 610024 Retinal cone dystrophy 3, 610024 |
| PDE8B | 99.4 | 100% | 99% | Pigmented nodular adrenocortical disease, primary, 3, 614190 Striatal degeneration, autosomal dominant, 609161 |
| PDGFB | 90.8 | 100% | 100% | Basal ganglia calcification, idiopathic, 5, 615483 Dermatofibrosarcoma protuberans, 607907 Meningioma, SIS-related, 607174 |
| PDGFRA | 135.8 | 100% | 99% | Gastrointestinal stromal tumor, somatic, 606764 Hypereosinophilic syndrome, idiopathic, resistant to imatinib, 607685 |
| PDGFRB | 131.1 | 98% | 95% | Basal ganglia calcification, idiopathic, 4, 615007 Kosaki overgrowth syndrome, 616592 Myeloproliferative disorder with eosinophilia, 131440 Myofibromatosis, infantile, 1, 228550 Premature aging syndrome, Penttinen type, 601812 |
| PDGFRL | 122.3 | 100% | 98% | Colorectal cancer, somatic, 114500 Hepatocellular cancer, somatic, 114550 |
| PDHA1 | 125.5 | 99% | 92% | Pyruvate dehydrogenase E1-alpha deficiency, 312170 |
| PDHB | 118.6 | 97% | 94% | Pyruvate dehydrogenase E1-beta deficiency, 614111 |
| PDHX | 112.0 | 97% | 95% | Lacticacidemia due to PDX1 deficiency,245349 |
| PDP1 | 148.8 | 100% | 100% | Pyruvate dehydrogenase phosphatase deficiency, 608782 |
| PDSS1 | 104.5 | 89% | 82% | Coenzyme Q10 deficiency, primary, 2, 614651 |
| PDSS2 | 99.7 | 94% | 94% | Coenzyme Q10 deficiency, primary, 3, 614652 |

| | | | | |
|--------|-------|------|------|--|
| PDX1 | 20.5 | 69% | 46% | MODY, type IV, 606392 Pancreatic agenesis 1, 260370 {Diabetes mellitus, type II, susceptibility to}, 125853 |
| PDYN | 100.0 | 100% | 100% | Spinocerebellar ataxia 23, 610245 |
| PDZD7 | 84.8 | 100% | 97% | Usher syndrome, type IIC, GPR98/PDZD7 digenic, 605472 {Retinal disease in Usher syndrome type IIA, modifier of}, 276901 |
| PEPD | 99.1 | 100% | 100% | Prolidase deficiency, 170100 |
| PER2 | 88.0 | 100% | 99% | Advanced sleep phase syndrome, familial, 1, 604348 |
| PET100 | 114.0 | 84% | 72% | Mitochondrial complex IV deficiency, 220110 |
| PEX1 | 101.0 | 98% | 97% | Heimler syndrome 1, 234580 Peroxisome biogenesis disorder 1A (Zellweger), 214100 Peroxisome biogenesis disorder 1B (NALD/IRD), 601539 |
| PEX10 | 99.1 | 96% | 90% | Peroxisome biogenesis disorder 6A (Zellweger), 614870 Peroxisome biogenesis disorder 6B, 614871 |
| PEX11B | 94.0 | 100% | 100% | Peroxisome biogenesis disorder 14B, 614920 |
| PEX12 | 113.8 | 99% | 98% | Peroxisome biogenesis disorder 3A (Zellweger), 614859 Peroxisome biogenesis disorder 3B, 266510 |
| PEX13 | 172.4 | 98% | 95% | Peroxisome biogenesis disorder 11A (Zellweger), 614883 Peroxisome biogenesis disorder 11B, 614885 |
| PEX14 | 116.0 | 99% | 96% | Peroxisome biogenesis disorder 13A (Zellweger), 614887 |
| PEX16 | 112.6 | 99% | 93% | Peroxisome biogenesis disorder 8A, (Zellweger), 614876 Peroxisome biogenesis disorder 8B, 614877 |
| PEX19 | 98.2 | 100% | 99% | Peroxisome biogenesis disorder 12A (Zellweger), 614886 |
| PEX2 | 134.9 | 100% | 100% | Peroxisome biogenesis disorder 5A (Zellweger), 614866 Peroxisome biogenesis disorder 5B, 614867 |
| PEX26 | 63.5 | 100% | 98% | Peroxisome biogenesis disorder 7A (Zellweger), 614872 Peroxisome biogenesis disorder 7B, 614873 |
| PEX3 | 83.4 | 95% | 92% | Peroxisome biogenesis disorder 10A (Zellweger), 614882 |
| PEX5 | 92.3 | 100% | 96% | Peroxisome biogenesis disorder 2A (Zellweger), 214110 Peroxisome biogenesis disorder 2B, 202370 Rhizomelic chondrodysplasia punctata, type 5, 616716 |
| PEX6 | 68.5 | 90% | 81% | Heimler syndrome 2, 616617 Peroxisome biogenesis disorder 4A (Zellweger), 614862 Peroxisome biogenesis disorder 4B, 614863 |

| | | | | |
|--------|-------|------|------|--|
| PEX7 | 114.5 | 89% | 84% | Peroxisome biogenesis disorder 9B, 614879 Rhizomelic chondrodysplasia punctata, type 1, 215100 |
| PFKM | 140.3 | 100% | 99% | Glycogen storage disease VII, 232800 |
| PFN1 | 139.1 | 100% | 100% | Amyotrophic lateral sclerosis 18, 614808 |
| PGAM2 | 122.8 | 100% | 100% | Glycogen storage disease X, 261670 |
| PGAP1 | 90.9 | 91% | 88% | Mental retardation, autosomal recessive 42, 615802 |
| PGAP2 | 134.1 | 100% | 99% | Hyperphosphatasia with mental retardation syndrome 3, 614207 |
| PGAP3 | 109.3 | 96% | 92% | Hyperphosphatasia with mental retardation syndrome 4, 615716 |
| PGK1 | 60.9 | 90% | 84% | Phosphoglycerate kinase 1 deficiency, 300653 |
| PGM1 | 119.6 | 100% | 100% | Congenital disorder of glycosylation, type Ia, 614921 |
| PGM3 | 171.0 | 100% | 100% | Immunodeficiency 23, 615816 |
| PHEX | 153.1 | 98% | 96% | Hypophosphatemic rickets, X-linked dominant, 307800 |
| PHF6 | 79.4 | 91% | 91% | Borjeson-Forssman-Lehmann syndrome, 301900 |
| PHF8 | 112.2 | 100% | 99% | Mental retardation syndrome, X-linked, Siderius type, 300263 |
| PHGDH | 105.9 | 100% | 99% | Neu-Laxova syndrome 1, 256520 Phosphoglycerate dehydrogenase deficiency, 601815 |
| PHKA1 | 134.7 | 99% | 97% | Muscle glycogenosis, 300559 |
| PHKA2 | 130.2 | 100% | 100% | Glycogen storage disease, type IXa1, 306000 Glycogen storage disease, type IXa2, 306000 |
| PHKB | 126.0 | 100% | 100% | Phosphorylase kinase deficiency of liver and muscle, autosomal recessive, 261750 |
| PHKG2 | 132.3 | 100% | 100% | Cirrhosis due to liver phosphorylase kinase deficiency Glycogen storage disease IXc, 613027 |
| PHOX2A | 33.9 | 49% | 22% | Fibrosis of extraocular muscles, congenital, 2, 602078 |
| PHOX2B | 94.3 | 93% | 87% | Central hypoventilation syndrome, congenital, with or without Hirschsprung disease, 209880 Neuroblastoma with Hirschsprung disease, 613013 {Neuroblastoma, susceptibility to, 2}, 613013 |
| PHYH | 63.6 | 97% | 88% | Refsum disease, 266500 |
| PI4KA | 99.2 | 91% | 83% | Polymicrogyria, perisylvian, with cerebellar hypoplasia and arthrogryposis, 616531 |
| PICALM | 99.7 | 100% | 93% | Leukemia, acute myeloid, somatic, 601626 |
| PIEZ01 | 128.6 | 99% | 97% | Dehydrated hereditary stomatocytosis with or without pseudohyperkalemia and/or perinatal edema, 194380 Lymphedema, hereditary, III, 616843 |
| PIEZ02 | 112.2 | 99% | 98% | Arthrogryposis, distal, type 3, 114300 Arthrogryposis, distal, type 5, 108145 |

| | | | | |
|---------|-------|------|------|---|
| | | | | ?Marden-Walker syndrome, 248700 |
| PIGA | 104.0 | 98% | 87% | Multiple congenital anomalies-hypotonia-seizures syndrome 2, 300868 Paroxysmal nocturnal hemoglobinuria, somatic, 300818 |
| PIGG | 151.5 | 100% | 96% | Mental retardation, autosomal recessive 53,616917 |
| PIGL | 111.8 | 100% | 100% | CHIME syndrome, 280000 |
| PIGM | 128.6 | 100% | 100% | Glycosylphosphatidylinositol deficiency, 610293 |
| PIGN | 104.4 | 95% | 86% | Multiple congenital anomalies-hypotonia-seizures syndrome 1, 614080 |
| PIGO | 103.3 | 100% | 99% | Hyperphosphatasia with mental retardation syndrome 2, 614749 |
| PIGT | 127.6 | 100% | 97% | Multiple congenital anomalies-hypotonia-seizures syndrome 3, 615398 ?Paroxysmal nocturnal hemoglobinuria 2, 615399 |
| PIGV | 144.4 | 100% | 100% | Hyperphosphatasia with mental retardation syndrome 1, 239300 |
| PIGY | 86.2 | 100% | 99% | Hyperphosphatasia with mental retardation syndrome 6, 616809 |
| PIK3CA | 109.9 | 99% | 97% | Breast cancer, somatic, 114480 CLOVE syndrome, somatic, 612918 Colorectal cancer, somatic, 114500 Cowden syndrome 5, 615108 Gastric cancer, somatic, 613659 Hepatocellular carcinoma, somatic, 114550 Keratosis, seborrheic, somatic, 182000 Megalencephaly-capillary malformation-polymicrogyria syndrome, somatic, 602501 Nevus, epidermal, somatic, 162900 Non-small cell lung cancer, somatic, 211980 Ovarian cancer, somatic, 167000 |
| PIK3CD | 112.7 | 98% | 95% | Immunodeficiency 14, 615513 |
| PIK3R1 | 120.6 | 100% | 97% | Immunodeficiency 36, 616005 SHORT syndrome, 269880 ?Agammaglobulinemia 7, autosomal recessive, 615214 |
| PIK3R2 | 80.1 | 88% | 86% | Megalencephaly-polymicrogyria-polydactyly-hydrocephalus syndrome 1, 603387 |
| PIK3R5 | 99.6 | 99% | 98% | Ataxia-oculomotor apraxia 3, 615217 |
| PIKFYVE | 128.3 | 99% | 93% | Corneal fleck dystrophy, 121850 |
| PINK1 | 86.3 | 93% | 89% | Parkinson disease 6, early onset, 605909 |
| PIP5K1C | 106.0 | 97% | 93% | Lethal congenital contractural syndrome 3, 611369 |
| PITPNM3 | 93.0 | 98% | 95% | Cone-rod dystrophy 5, 600977 |

| | | | | |
|---------|-------|------|------|---|
| PITX1 | 122.9 | 92% | 88% | Clubfoot, congenital, with or without deficiency of long bones and/or mirror-image polydactyly, 119800 Liebenberg syndrome, 186550 |
| PITX2 | 122.4 | 98% | 95% | Axenfeld-Rieger syndrome, type 1, 180500 Iridogoniodysgenesis, type 2, 137600 Peters anomaly, 604229 Ring dermoid of cornea, 180550 |
| PITX3 | 51.9 | 100% | 95% | Anterior segment mesenchymal dysgenesis, 107250 Cataract 11, multiple types, 610623 Cataract 11, syndromic, 610623 |
| PKD1 | 22.7 | 40% | 29% | Polycystic kidney disease, adult type I, 173900 |
| PKD2 | 96.7 | 90% | 86% | Polycystic kidney disease 2, 613095 |
| PKHD1 | 138.4 | 100% | 99% | Polycystic kidney and hepatic disease, 263200 |
| PKLR | 142.0 | 100% | 99% | Adenosine triphosphate, elevated, of erythrocytes, 102900 Pyruvate kinase deficiency, 266200 |
| PKP1 | 107.5 | 100% | 98% | Ectodermal dysplasia/skin fragility syndrome, 604536 |
| PKP2 | 88.1 | 96% | 89% | Arrhythmogenic right ventricular dysplasia 9, 609040 |
| PLA2G4A | 125.3 | 100% | 99% | Phospholipase A2, group IV A, deficiency of, 600522 |
| PLA2G6 | 99.6 | 99% | 97% | Infantile neuroaxonal dystrophy 1, 256600 Neurodegeneration with brain iron accumulation 2B, 610217 Parkinson disease 14, autosomal recessive, 612953 |
| PLA2G7 | 121.1 | 100% | 96% | Platelet-activating factor acetylhydrolase deficiency, 614278 {Asthma, susceptibility to}, 600807 {Atopy, susceptibility to}, 147050 |
| PLAG1 | 194.8 | 100% | 100% | Adenomas, salivary gland pleomorphic, somatic, 181030 |
| PLAU | 102.6 | 100% | 95% | Quebec platelet disorder, 601709 {Alzheimer disease, late-onset, susceptibility to}, 104300 |
| PLCB1 | 138.5 | 100% | 99% | Epileptic encephalopathy, early infantile, 12, 613722 |
| PLCB4 | 123.4 | 99% | 93% | Auriculocondylar syndrome 2, 614669 |
| PLCD1 | 103.2 | 99% | 95% | Nail disorder, nonsyndromic congenital, 3, (leukonychia), 151600 |
| PLCE1 | 134.0 | 99% | 98% | Nephrotic syndrome, type 3, 610725 |
| PLCG2 | 102.0 | 99% | 98% | Autoinflammation, antibody deficiency, and immune dysregulation syndrome, 614878 Familial cold autoinflammatory syndrome 3, 614468 |

| | | | | |
|---------|-------|------|------|---|
| PLEC | 92.8 | 99% | 98% | Epidermolysis bullosa simplex with muscular dystrophy, 226670 Epidermolysis bullosa simplex with pyloric atresia, 612138 Epidermolysis bullosa simplex, Ogna type, 131950 Muscular dystrophy, limb-girdle, type 2Q, 613723 ?Epidermolysis bullosa simplex with nail dystrophy, 616487 |
| PLEKHG2 | 105.7 | 100% | 99% | Leukodystrophy and acquired microcephaly with or without dystonia, 616763 |
| PLEKHG5 | 77.0 | 93% | 86% | Charcot-Marie-Tooth disease, recessive intermediate C, 615376 Spinal muscular atrophy, distal, autosomal recessive, 4, 611067 |
| PLEKHM1 | 51.0 | 100% | 94% | Osteopetrosis, autosomal recessive 6, 611497 |
| PLG | 102.8 | 87% | 85% | Dysplasminogenemia, 217090 Plasminogen deficiency, type I, 217090 |
| PLIN1 | 74.6 | 97% | 84% | Lipodystrophy, familial partial, type 4, 613877 |
| PLK4 | 131.0 | 98% | 95% | Microcephaly and chorioretinopathy, autosomal recessive, 2, 616171 |
| PLN | 188.8 | 100% | 100% | Cardiomyopathy, dilated, 1P, 609909 Cardiomyopathy, hypertrophic, 18, 613874 |
| PLOD1 | 119.0 | 99% | 97% | Ehlers-Danlos syndrome, type VI, 225400 |
| PLOD2 | 102.5 | 98% | 90% | Bruck syndrome 2, 609220 |
| PLOD3 | 101.8 | 100% | 99% | Lysyl hydroxylase 3 deficiency, 612394 |
| PLP1 | 160.9 | 100% | 100% | Pelizaeus-Merzbacher disease, 312080 Spastic paraparesis 2, X-linked, 312920 |
| PLS3 | 181.2 | 100% | 100% | Bone mineral density QTL18, osteoporosis, 300910 |
| PML | 96.4 | 100% | 99% | Leukemia, acute promyelocytic, PML/RARA type |
| PMM2 | 153.5 | 100% | 100% | Congenital disorder of glycosylation, type Ia, 212065 |
| PMP22 | 91.6 | 90% | 88% | Charcot-Marie-Tooth disease, type 1A, 118220 Charcot-Marie-Tooth disease, type 1E, 118300 Dejerine-Sottas disease, 145900 Neuropathy, inflammatory demyelinating, 139393 Neuropathy, recurrent, with pressure palsies, 162500 Roussy-Levy syndrome, 180800 |
| PMPCA | 111.3 | 94% | 91% | Spinocerebellar ataxia, autosomal recessive 2, 213200 |
| PMS2 | 76.8 | 83% | 81% | Colorectal cancer, hereditary nonpolyposis, type 4, 614337 Mismatch repair cancer syndrome, 276300 |
| PMVK | 104.6 | 100% | 96% | Porokeratosis 1, multiple types, 175800 |
| PNKD | 90.2 | 100% | 96% | Paroxysmal nonkinesigenic dyskinesia, 118800 |

| | | | | |
|---------|-------|------|------|---|
| PNKP | 81.0 | 100% | 96% | Ataxia-oculomotor apraxia 4, 616267 Microcephaly, seizures, and developmental delay, 613402 |
| PNP | 122.8 | 100% | 100% | Immunodeficiency due to purine nucleoside phosphorylase deficiency, 613179 |
| PNPLA1 | 146.1 | 99% | 98% | Ichthyosis, congenital, autosomal recessive 10, 615024 |
| PNPLA2 | 101.3 | 100% | 96% | Neutral lipid storage disease with myopathy, 610717 |
| PNPLA6 | 112.6 | 99% | 98% | Boucher-Neuhauser syndrome, 215470 Oliver-McFarlane syndrome, 275400 Spastic paraparesis 39, autosomal recessive, 612020 ?Laurence-Moon syndrome, 245800 |
| PNPO | 63.0 | 100% | 96% | Pyridoxamine 5'-phosphate oxidase deficiency, 610090 |
| PNPT1 | 46.4 | 93% | 81% | Combined oxidative phosphorylation deficiency 13, 614932 Deafness, autosomal recessive 70, 614934 |
| POC1A | 112.9 | 100% | 100% | Short stature, onychodysplasia, facial dysmorphism, and hypotrichosis, 614813 |
| POC1B | 81.2 | 96% | 91% | Cone-rod dystrophy 20, 615973 |
| POF1B | 100.9 | 93% | 88% | Premature ovarian failure 2B, 300604 |
| POFUT1 | 118.6 | 100% | 100% | Dowling-Degos disease 2, 615327 |
| POGLUT1 | 121.5 | 100% | 91% | Dowling-Degos disease 4, 615696 |
| POGZ | 141.2 | 99% | 97% | White-Sutton syndrome, 616364 |
| POLA1 | 147.9 | 100% | 98% | Pigmentary disorder, reticulate, with systemic manifestations, X-linked, 301220 |
| POLD1 | 88.8 | 95% | 90% | Mandibular hypoplasia, deafness, progeroid features, and lipodystrophy syndrome, 615381 {Colorectal cancer, susceptibility to, 10}, 612591 |
| POLE | 129.0 | 99% | 98% | FILS syndrome, 615139 {Colorectal cancer, susceptibility to, 12}, 615083 |
| POLG | 100.7 | 100% | 100% | Mitochondrial DNA depletion syndrome 4A (Alpers type), 203700 Mitochondrial DNA depletion syndrome 4B (MNGIE type), 613662 Mitochondrial recessive ataxia syndrome (includes SANDO and SCAE), 607459 Progressive external ophthalmoplegia, autosomal dominant 1, 157640 Progressive external ophthalmoplegia, autosomal recessive 1, 258450 |
| POLG2 | 143.0 | 99% | 97% | Progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal dominant 4, 610131 |
| POLH | 135.1 | 100% | 98% | Xeroderma pigmentosum, variant type, 278750 |
| POLR1A | 108.0 | 99% | 97% | Acrofacial dysostosis, Cincinnati type, 616462 |
| POLR1C | 108.2 | 99% | 95% | Leukodystrophy, hypomyelinating, 11, 616494 Treacher Collins syndrome 3, 248390 |
| POLR1D | 162.2 | 100% | 100% | Treacher Collins syndrome 2, 613717 |

| | | | | |
|---------|-------|------|------|---|
| POLR3A | 126.0 | 100% | 99% | Leukodystrophy, hypomyelinating, 7, with or without oligodontia and/or hypogonadotropic hypogonadism, 607694 |
| POLR3B | 135.8 | 100% | 97% | Leukodystrophy, hypomyelinating, 8, with or without oligodontia and/or hypogonadotropic hypogonadism, 614381 |
| POMC | 84.6 | 100% | 100% | Obesity, adrenal insufficiency, and red hair due to POMC deficiency, 609734 {Obesity, early-onset, susceptibility to}, 601665 |
| POMGNT1 | 100.3 | 98% | 92% | Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 3, 253280 Muscular dystrophy-dystroglycanopathy (congenital with mental retardation), type B, 3, 613151 Muscular dystrophy-dystroglycanopathy (limb-girdle), type C, 3, 613157 |
| POMGNT2 | 216.4 | 100% | 100% | Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies, type A, 8, 614830 |
| POMK | 163.3 | 100% | 100% | Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 12, 615249 ?Muscular dystrophy-dystroglycanopathy (limb-girdle), type C, 12, 616094 |
| POMP | 118.1 | 86% | 85% | Keratosis linearis with ichthyosis congenita and sclerosing keratoderma, 601952 |
| POMT1 | 143.7 | 98% | 95% | Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 1, 236670 Muscular dystrophy-dystroglycanopathy (congenital with mental retardation), type B, 1, 613155 Muscular dystrophy-dystroglycanopathy (limb-girdle), type C, 1, 609308 |
| POMT2 | 96.3 | 97% | 95% | Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 2, 613150 Muscular dystrophy-dystroglycanopathy (congenital with mental retardation), type B, 2, 613156 Muscular dystrophy-dystroglycanopathy (limb-girdle), type C, 2, 613158 |
| POR | 126.9 | 100% | 100% | Antley-Bixler syndrome with genital anomalies and disordered steroidogenesis, 201750 Disordered steroidogenesis due to cytochrome P450 oxidoreductase, 613571 |
| PORCN | 142.7 | 100% | 100% | Focal dermal hypoplasia, 305600 |
| POU1F1 | 107.3 | 99% | 90% | Pituitary hormone deficiency, combined, 1, 613038 |
| POU3F4 | 141.1 | 100% | 100% | Deafness, X-linked 2, 304400 |
| POU4F3 | 204.9 | 100% | 100% | Deafness, autosomal dominant 15, 602459 |
| PPARG | 132.1 | 100% | 100% | Carotid intimal medial thickness 1, 609338 Insulin resistance, severe, digenic, 604367 Lipodystrophy, familial partial, type 3, 604367 Obesity, severe, 601665 [Obesity, resistance to] {Diabetes, type 2}, 125853 |
| PPIB | 102.0 | 100% | 100% | Osteogenesis imperfecta, type IX, 259440 |
| PPM1D | 133.2 | 100% | 97% | Breast cancer, 114480 |
| PPOX | 89.5 | 98% | 96% | Porphyria variegata, 176200 |

| | | | | |
|----------|-------|------|------|--|
| PPP1R15B | 120.5 | 99% | 97% | Microcephaly, short stature, and impaired glucose metabolism 2, 616817 |
| PPP1R3A | 135.7 | 99% | 97% | Insulin resistance, severe, digenic, 604367 |
| PPP2R1A | 119.7 | 93% | 91% | Mental retardation, autosomal dominant 36, 616362 |
| PPP2R1B | 152.0 | 100% | 100% | Lung cancer, 211980 |
| PPP2R2B | 136.1 | 100% | 99% | Spinocerebellar ataxia 12, 604326 |
| PPP2R5D | 129.8 | 100% | 100% | Mental retardation, autosomal dominant 35, 616355 |
| PPT1 | 153.9 | 100% | 100% | Ceroid lipofuscinosis, neuronal, 1, 256730 |
| PQBP1 | 181.6 | 97% | 97% | Renpenning syndrome, 309500 |
| PRCC | 108.6 | 98% | 90% | Renal cell carcinoma, papillary, 605074 |
| PRCD | 86.5 | 100% | 100% | Retinitis pigmentosa 36, 610599 |
| PRDM12 | 92.4 | 88% | 80% | Neuropathy, hereditary sensory and autonomic, type VIII, 616488 |
| PRDM16 | 136.9 | 99% | 98% | Cardiomyopathy, dilated, 1LL, 615373 Left ventricular noncompaction 8, 615373 |
| PRDM5 | 113.6 | 97% | 91% | Brittle cornea syndrome 2, 614170 |
| PRDM6 | 78.4 | 81% | 73% | Patent ductus arteriosus 3, 617039 |
| PRF1 | 102.5 | 100% | 98% | Aplastic anemia, 609135 Hemophagocytic lymphohistiocytosis, familial, 2, 603553 Lymphoma, non-Hodgkin, 605027 |
| PRG4 | 123.9 | 95% | 83% | Camptodactyly-arthropathy-coxa vara-pericarditis syndrome, 208250 |
| PRICKLE1 | 109.8 | 100% | 100% | Epilepsy, progressive myoclonic 1B, 612437 |
| PRIMPOL | 98.1 | 94% | 90% | Myopia 22,autosomal dominant,615420 |
| PRKAG2 | 122.6 | 97% | 86% | Cardiomyopathy, hypertrophic 6, 600858 Glycogen storage disease of heart, lethal congenital, 261740 Wolff-Parkinson-White syndrome, 194200 |
| PRKAR1A | 82.3 | 100% | 91% | Acrodysostosis 1, with or without hormone resistance, 101800 Adrenocortical tumor, somatic, Carney complex, type 1, 160980 Myxoma, intracardiac, 255960 Pigmented nodular adrenocortical disease, primary, 1, 610489 |
| PRKCA | 153.3 | 100% | 100% | Pituitary tumor, invasive |
| PRKCD | 164.2 | 100% | 100% | Autoimmune lymphoproliferative syndrome, type III, 615559 |
| PRKCG | 101.6 | 97% | 92% | Spinocerebellar ataxia 14, 605361 |
| PRKCSH | 113.8 | 99% | 87% | Polycystic liver disease, 174050 |
| PRKDC | 94.7 | 97% | 92% | Immunodeficiency 26, with or without neurologic abnormalities, 615966 |

| | | | | |
|--------|-------|------|------|--|
| PRKG1 | 105.8 | 99% | 86% | Aortic aneurysm, familial thoracic 8, 615436 |
| PRKRA | 127.6 | 100% | 99% | Dystonia 16, 612067 |
| PRLR | 130.5 | 100% | 100% | Multiple fibroadenomas of the breast, 615554 ?Hyperprolactinemia, 615555 |
| PRNP | 140.1 | 100% | 100% | Cerebral amyloid angiopathy, PRNP-related, 137440 Creutzfeldt-Jakob disease, 123400 Gerstmann-Straussler disease, 137440 Huntington disease-like 1, 603218 Insomnia, fatal familial, 600072 Prion disease with protracted course, 606688 {Kuru, susceptibility to}, 245300 |
| PROC | 111.4 | 99% | 94% | Thrombophilia due to protein C deficiency, autosomal dominant, 176860 Thrombophilia due to protein C deficiency, autosomal recessive, 612304 |
| PRODH | 102.3 | 84% | 82% | Hyperprolinemia, type I, 239500 {Schizophrenia, susceptibility to, 4}, 600850 |
| PROK2 | 74.9 | 97% | 89% | Hypogonadotropic hypogonadism 4 with or without anosmia, 610628 |
| PROKR2 | 284.6 | 100% | 100% | Hypogonadotropic hypogonadism 3 with or without anosmia, 244200 |
| PROM1 | 111.1 | 96% | 92% | Cone-rod dystrophy 12, 612657 Macular dystrophy, retinal, 2, 608051 Retinitis pigmentosa 41, 612095 Stargardt disease 4, 603786 |
| PROP1 | 92.5 | 91% | 87% | Pituitary hormone deficiency, combined, 2, 262600 |
| PROS1 | 68.4 | 96% | 91% | Thrombophilia due to protein S deficiency, autosomal dominant, 612336 Thrombophilia due to protein S deficiency, autosomal recessive, 614514 |
| PRPF3 | 74.7 | 97% | 92% | Retinitis pigmentosa 18, 601414 |
| PRPF31 | 99.2 | 100% | 94% | Retinitis pigmentosa 11, 600138 |
| PRPF4 | 137.2 | 100% | 97% | Retinitis pigmentosa 70, 615922 |
| PRPF6 | 114.3 | 100% | 100% | Retinitis pigmentosa 60, 613983 |
| PRPF8 | 121.5 | 99% | 97% | Retinitis pigmentosa 13, 600059 |
| PRPH2 | 202.7 | 100% | 100% | Choroidal dystrophy, central areolar 2, 613105 Leber congenital amaurosis 18, 608133 Macular dystrophy, patterned, 1, 169150 Macular dystrophy, vitelliform, 3, 608161 Retinitis pigmentosa 7 and digenic, 608133 |

| | | | | |
|--------|-------|------|------|---|
| | | | | Retinitis punctata albescens, 136880 |
| PRPS1 | 200.6 | 100% | 100% | Arts syndrome, 301835 Charcot-Marie-Tooth disease, X-linked recessive, 5, 311070 Deafness, X-linked 1, 304500 Gout, PRPS-related, 300661 Phosphoribosylpyrophosphate synthetase superactivity, 300661 |
| PRRT2 | 66.3 | 97% | 96% | Convulsions, familial infantile, with paroxysmal choreoathetosis, 602066 Episodic kinesigenic dyskinesia 1, 128200 Seizures, benign familial infantile, 2, 605751 |
| PRRX1 | 75.6 | 100% | 100% | Agnathia-otocephaly complex, 202650 |
| PRSS1 | 166.1 | 100% | 100% | Pancreatitis, hereditary, 167800 Trypsinogen deficiency, 614044 |
| PRSS12 | 122.2 | 99% | 96% | Mental retardation, autosomal recessive 1, 249500 |
| PRSS56 | 45.7 | 92% | 81% | Microphthalmia, isolated 6, 613517 |
| PRX | 86.4 | 100% | 99% | Charcot-Marie-Tooth disease, type 4F, 614895 Dejerine-Sottas disease, 145900 |
| PSAP | 96.8 | 99% | 95% | Combined SAP deficiency, 611721 Gaucher disease, atypical, 610539 Krabbe disease, atypical, 611722 Metachromatic leukodystrophy due to SAP-b deficiency, 249900 |
| PSAT1 | 40.7 | 80% | 70% | Neu-Laxova syndrome 2, 616038 ?Phosphoserine aminotransferase deficiency, 610992 |
| PSEN1 | 129.3 | 100% | 99% | Acne inversa, familial, 3, 613737 Alzheimer disease, type 3, 607822 Alzheimer disease, type 3, with spastic paraparesis and apraxia, 607822 Alzheimer disease, type 3, with spastic paraparesis and unusual plaques, 607822 Cardiomyopathy, dilated, 1U, 613694 Dementia, frontotemporal, 600274 Pick disease, 172700 |
| PSEN2 | 114.1 | 100% | 100% | Alzheimer disease-4, 606889 |

| | | | | |
|---------|-------|------|------|---|
| | | | | Cardiomyopathy, dilated, 1V, 613697 |
| PSENEN | 60.7 | 100% | 100% | Acne inversa, familial, 2, 613736 |
| PSMB8 | 15.1 | 45% | 32% | Autoinflammation, lipodystrophy, and dermatosis syndrome, 256040 |
| PSMC3IP | 98.4 | 100% | 94% | Ovarian dysgenesis 3, 614324 |
| PSPH | 109.0 | 100% | 96% | Phosphoserine phosphatase deficiency, 614023 |
| PSTPIP1 | 78.4 | 100% | 91% | Pyogenic sterile arthritis, pyoderma gangrenosum, and acne, 604416 |
| PTCH1 | 109.5 | 98% | 95% | Basal cell carcinoma, somatic, 605462 Basal cell nevus syndrome, 109400 Holoprosencephaly-7, 610828 |
| PTCH2 | 95.5 | 98% | 95% | Basal cell carcinoma, somatic, 605462 Basal cell nevus syndrome, 109400 Medulloblastoma, 155255 |
| PTDSS1 | 121.7 | 100% | 100% | Lenz-Majewski hyperostotic dwarfism, 151050 |
| PTEN | 120.7 | 100% | 99% | Bannayan-Riley-Ruvalcaba syndrome, 153480 Cowden syndrome 1, 158350 Endometrial carcinoma, somatic, 608089 Lhermitte-Duclos syndrome, 158350 Macrocephaly/autism syndrome, 605309 Malignant melanoma, somatic, 155600 PTEN hamartoma tumor syndrome Squamous cell carcinoma, head and neck, somatic, 275355 VATER association with macrocephaly and ventriculomegaly, 276950 {Glioma susceptibility 2}, 613028 {Meningioma}, 607174 {Prostate cancer, somatic}, 176807 |
| PTF1A | 67.3 | 83% | 74% | Pancreatic agenesis 2, 615935 Pancreatic and cerebellar agenesis, 609069 |
| PTGIS | 104.9 | 97% | 95% | Hypertension, essential, 145500 |
| PTH | 105.6 | 100% | 99% | Hypoparathyroidism, autosomal dominant, 146200 Hypoparathyroidism, autosomal recessive, 146200 |
| PTH1R | 87.2 | 99% | 98% | Chondrodysplasia, Blomstrand type, 215045 Eiken syndrome, 600002 Failure of tooth eruption, primary, 125350 Metaphyseal chondrodysplasia, Murk Jansen type, 156400 |

| | | | | |
|--------|-------|------|------|--|
| PTHLH | 117.9 | 100% | 82% | Brachydactyly, type E2, 613382 Humoral hypercalcemia of malignancy |
| PTPN11 | 74.9 | 96% | 86% | LEOPARD syndrome 1, 151100 Leukemia, juvenile myelomonocytic, somatic, 607785 Metachondromatosis, 156250 Noonan syndrome 1, 163950 |
| PTPN12 | 122.5 | 95% | 90% | Colon cancer, somatic, 114500 |
| PTPN14 | 158.2 | 98% | 97% | Choanal atresia and lymphedema, 613611 |
| PTPRC | 91.6 | 89% | 80% | Severe combined immunodeficiency, T cell-negative, B-cell/natural killer-cell positive, 608971 {Hepatitis C virus, susceptibility to}, 609532 |
| PTPRJ | 150.7 | 96% | 95% | Colon cancer, somatic, 114500 |
| PTPRO | 137.0 | 99% | 98% | Nephrotic syndrome, type 6, 614196 |
| PTPRQ | 98.6 | 90% | 87% | Deafness, autosomal recessive 84A, 613391 |
| PTRF | 107.4 | 100% | 98% | Lipodystrophy, congenital generalized, type 4, 613327 |
| PTRH2 | 237.1 | 100% | 100% | Infantile-onset multisystem neurologic, endocrine, and pancreatic disease, 616263 |
| PTS | 94.2 | 94% | 83% | Hyperphenylalaninemia, BH4-deficient, A, 261640 |
| PUF60 | 142.8 | 100% | 96% | Verheij syndrome, 615583 |
| PURA | 117.2 | 100% | 91% | Mental retardation, autosomal dominant 31, 616158 |
| PUS1 | 126.0 | 100% | 95% | Myopathy, lactic acidosis, and sideroblastic anemia 1, 600462 |
| PVRL1 | 130.8 | 100% | 100% | Cleft lip/palate-ectodermal dysplasia syndrome, 225060 Orofacial cleft 7, 225060 |
| PVRL4 | 118.8 | 100% | 98% | Ectodermal dysplasia-syndactyly syndrome 1, 613573 |
| PXDN | 143.0 | 99% | 98% | Corneal opacification and other ocular anomalies, 269400 |
| PYCR1 | 82.7 | 97% | 95% | Cutis laxa, autosomal recessive, type IIB, 612940 Cutis laxa, autosomal recessive, type IIIB, 614438 |
| PYCR2 | 113.8 | 100% | 95% | Leukodystrophy, hypomyelinating, 10, 616420 |
| PYGL | 148.1 | 100% | 100% | Glycogen storage disease VI, 232700 |
| PYGM | 123.6 | 100% | 99% | McArdle disease, 232600 |
| QARS | 128.6 | 100% | 99% | Microcephaly, progressive, seizures, and cerebral and cerebellar atrophy, 615760 |
| QDPR | 65.9 | 100% | 100% | Hyperphenylalaninemia, BH4-deficient, C, 261630 |
| RAB18 | 81.2 | 99% | 78% | Warburg micro syndrome 3, 614222 |
| RAB23 | 105.2 | 100% | 99% | Carpenter syndrome, 201000 |
| RAB27A | 137.7 | 100% | 100% | Griselli syndrome, type 2, 607624 |
| RAB28 | 49.9 | 99% | 85% | Cone-rod dystrophy 18, 615374 |

| | | | | |
|----------|-------|------|------|--|
| RAB33B | 206.0 | 100% | 100% | Smith-McCort dysplasia 2, 615222 |
| RAB39B | 144.1 | 100% | 100% | Mental retardation, X-linked 72, 300271 ?Waisman syndrome, 311510 |
| RAB3GAP1 | 112.3 | 99% | 96% | Warburg micro syndrome 1, 600118 |
| RAB3GAP2 | 84.5 | 97% | 91% | Martolf syndrome, 212720 Warburg micro syndrome 2, 614225 |
| RAB7A | 135.9 | 100% | 100% | Charcot-Marie-Tooth disease,type 2B, 600882 |
| RAC2 | 106.4 | 100% | 100% | Neutrophil immunodeficiency syndrome, 608203 |
| RAD21 | 84.4 | 99% | 94% | Cornelia de Lange syndrome 4, 614701 |
| RAD50 | 88.5 | 93% | 88% | Nijmegen breakage syndrome-like disorder, 613078 |
| RAD51 | 122.7 | 89% | 89% | Mirror movements 2, 614508 {Breast cancer, susceptibility to}, 114480 |
| RAD51C | 121.9 | 100% | 100% | Fanconi anemia, complementation group O, 613390 {Breast-ovarian cancer, familial, susceptibility to, 3}, 613399 |
| RAD54B | 87.9 | 95% | 85% | Colon cancer, somatic, 114500 Lymphoma, non-Hodgkin, somatic, 605027 |
| RAD54L | 97.9 | 99% | 97% | Adenocarcinoma, colonic, somatic Lymphoma, non-Hodgkin, somatic, 605027 {Breast cancer, invasive ductal}, 114480 |
| RAF1 | 105.4 | 100% | 100% | Cardiomyopathy, dilated, 1NN, 615916 LEOPARD syndrome 2, 611554 Noonan syndrome 5, 611553 |
| RAG1 | 183.4 | 100% | 100% | Alpha/beta T-cell lymphopenia with gamma/delta T-cell expansion, severe cytomegalovirus infection, and autoimmunity, 609889 Combined cellular and humoral immune defects with granulomas, 233650 Omenn syndrome, 603554 Severe combined immunodeficiency, B cell-negative, 601457 |
| RAG2 | 214.7 | 100% | 100% | Combined cellular and humoral immune defects with granulomas, 233650 Omenn syndrome, 603554 Severe combined immunodeficiency, B cell-negative, 601457 |
| RAI1 | 111.0 | 99% | 99% | Smith-Magenis syndrome, 182290 |
| RAP1GDS1 | 81.5 | 98% | 86% | Lymphocytic leukemia, acute T-cell |
| RAPSN | 105.8 | 93% | 93% | Fetal akinesia deformation sequence, 208150 Myasthenic syndrome, congenital, 11, associated with acetylcholine receptor deficiency, 616326 |

| | | | | |
|--------|-------|------|------|--|
| RARB | 118.7 | 100% | 100% | Microphtalmia, syndromic 12, 615524 |
| RARS | 76.7 | 98% | 92% | Leukodystrophy, hypomyelinating, 9, 616140 |
| RARS2 | 100.2 | 99% | 96% | Pontocerebellar hypoplasia, type 6, 611523 |
| RASA1 | 88.7 | 93% | 79% | Basal cell carcinoma, somatic, 605462 Capillary malformation-arteriovenous malformation, 608354 Parkes Weber syndrome, 608355 |
| RAX | 73.4 | 91% | 81% | Microphtalmia, isolated 3, 611038 |
| RAX2 | 51.9 | 99% | 78% | Macular degeneration, age-related, 6, 613757 ?Cone-rod dystrophy 11, 610381 |
| RB1 | 75.2 | 90% | 75% | Bladder cancer, somatic, 109800 Osteosarcoma, somatic, 259500 Retinoblastoma, 180200 Retinoblastoma, trilateral, 180200 Small cell cancer of the lung, somatic, 182280 |
| RB1CC1 | 104.7 | 94% | 87% | Breast cancer, somatic, 114480 |
| RBBP8 | 95.8 | 99% | 94% | Jawad syndrome, 251255 Pancreatic carcinoma, somatic Seckel syndrome 2, 606744 |
| RBCK1 | 92.4 | 98% | 94% | Polyglucosan body myopathy 1 with or without immunodeficiency, 615895 |
| RBM10 | 122.1 | 100% | 99% | TARP syndrome, 311900 |
| RBM20 | 154.3 | 99% | 95% | Cardiomyopathy, dilated, 1DD, 613172 |
| RBM8A | 100.8 | 100% | 95% | Thrombocytopenia-absent radius syndrome, 274000 |
| RBP4 | 93.1 | 93% | 89% | Microphtalmia, isolated, with coloboma 10, 616428 Retinal dystrophy, iris coloboma, and comedogenic acne syndrome, 615147 |
| RBPJ | 67.2 | 87% | 76% | Adams-Oliver syndrome 3, 614814 |
| RD3 | 142.0 | 100% | 100% | Leber congenital amaurosis 12, 610612 |
| RDH12 | 78.5 | 97% | 91% | Leber congenital amaurosis 13, 612712 |
| RDH5 | 148.7 | 100% | 100% | Fundus albipunctatus, 136880 |
| RDX | 35.3 | 66% | 55% | Deafness, autosomal recessive 24, 611022 |
| RECQL4 | 127.6 | 97% | 96% | Baller-Gerold syndrome, 218600 RAPADILINO syndrome, 266280 Rothmund-Thomson syndrome, 268400 |
| REEP1 | 91.3 | 100% | 95% | Spastic paraparesis 31, autosomal dominant, 610250 ?Neuronopathy, distal hereditary motor, type VB, 614751 |

| | | | | |
|--------|-------|------|------|---|
| RELN | 147.0 | 100% | 99% | Lissencephaly 2 (Norman-Roberts type), 257320 {Epilepsy, familial temporal lobe, 7}, 616436 |
| REN | 134.0 | 100% | 100% | Hyperuricemic nephropathy, familial juvenile 2, 613092 Renal tubular dysgenesis, 267430 [Hyperproreninemia] |
| RERE | 67.5 | 96% | 91% | Neurodevelopmental disorder with or without anomalies of the brain, eye or heart, 616975 |
| RET | 127.8 | 98% | 96% | Central hypoventilation syndrome, congenital, 209880 Medullary thyroid carcinoma, 155240 Multiple endocrine neoplasia IIA, 171400 Multiple endocrine neoplasia IIB, 162300 Pheochromocytoma, 171300 {Hirschsprung disease, susceptibility to, 1}, 142623 |
| RFT1 | 97.6 | 100% | 95% | Congenital disorder of glycosylation, type In, 612015 |
| RFX5 | 93.9 | 98% | 95% | Bare lymphocyte syndrome, type II, complementation group C, 209920 Bare lymphocyte syndrome, type II, complementation group E, 209920 |
| RFX6 | 135.6 | 100% | 100% | Mitchell-Riley syndrome, 615710 |
| RFXANK | 97.7 | 100% | 100% | MHC class II deficiency, complementation group B, 209920 |
| RFXAP | 100.9 | 94% | 93% | Bare lymphocyte syndrome, type II, complementation group D, 209920 |
| RGR | 111.5 | 100% | 100% | Retinitis pigmentosa 44, 613769 |
| RGS9 | 91.2 | 100% | 94% | Bradyopsia, 608415 |
| RGS9BP | 65.8 | 100% | 99% | Bradyopsia, 608415 |
| RHAG | 147.5 | 100% | 96% | Anemia, hemolytic, Rh-null, regulator type, 268150 Overhydrated hereditary stomatocytosis, 185000 Rh-mod syndrome |
| RHBDF2 | 92.3 | 97% | 95% | Tylosis with esophageal cancer, 148500 |
| RHCE | 153.0 | 99% | 99% | Rh-null disease, amorph type, 111700 [Blood group, Rhesus], 111690 |
| RHO | 186.4 | 100% | 100% | Night blindness, congenital stationary, autosomal dominant 1, 610445 Retinitis pigmentosa 4, autosomal dominant or recessive, 613731 Retinitis punctata albescens, 136880 |
| RIMS1 | 102.9 | 99% | 94% | Cone-rod dystrophy 7, 603649 |
| RIN2 | 96.2 | 100% | 99% | Macrocephaly, alopecia, cutis laxa, and scoliosis, 613075 |
| RIPK4 | 125.9 | 100% | 99% | Popliteal pterygium syndrome, Bartsocas-Papas type, 263650 |
| RIT1 | 145.2 | 100% | 100% | Noonan syndrome 8, 615355 |

| | | | | |
|----------|-------|------|------|--|
| RLBP1 | 109.6 | 100% | 100% | Bothnia retinal dystrophy, 607475 Fundus albipunctatus, 136880 Newfoundland rod-cone dystrophy, 607476 Retinitis punctata albescens, 136880 |
| RLIM | 140.4 | 100% | 100% | Mental Retardation, X-linked 61, 300978 |
| RMND1 | 117.8 | 99% | 96% | Combined oxidative phosphorylation deficiency 11, 614922 |
| RMRP | NC | NC | NC | Anauxetic dysplasia, 607095 Cartilage-hair hypoplasia, 250250 Metaphyseal dysplasia without hypotrichosis, 250460 |
| RNASEH1 | 92.0 | 94% | 91% | Progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal recessive 2, 616479 |
| RNASEH2A | 111.1 | 100% | 99% | Aicardi-Goutieres syndrome 4, 610333 |
| RNASEH2B | 101.2 | 90% | 87% | Aicardi-Goutieres syndrome 2, 610181 |
| RNASEH2C | 156.2 | 100% | 99% | Aicardi-Goutieres syndrome 3, 610329 |
| RNASEL | 121.7 | 99% | 98% | Prostate cancer 1, 601518 |
| RNASET2 | 73.7 | 93% | 85% | Leukoencephalopathy, cystic, without megalencephaly, 612951 |
| RNF125 | 148.2 | 100% | 98% | Tenorio syndrome, 616260 |
| RNF135 | 69.0 | 93% | 87% | Macrocephaly, macrosomia, facial dysmorphism syndrome, 614192 |
| RNF139 | 199.9 | 100% | 100% | Renal cell carcinoma, 144700 |
| RNF168 | 202.2 | 100% | 98% | RIDDLE syndrome, 611943 |
| RNF170 | 112.1 | 96% | 93% | Ataxia, sensory, 1, autosomal dominant, 608984 |
| RNF212 | 100.9 | 99% | 95% | Recombination rate QTL 1, 612042 |
| RNF216 | 122.4 | 99% | 95% | Cerebellar ataxia and hypogonadotropic hypogonadism, 212840 |
| RNF6 | 175.3 | 100% | 100% | Esophageal carcinoma, somatic, 133239 |
| RNU4ATAC | NC | NC | NC | Microcephalic osteodysplastic primordial dwarfism, type I, 210710 Roifman syndrome, 616651 |
| ROBO2 | 127.4 | 97% | 96% | Vesicoureteral reflux 2, 610878 |
| ROBO3 | 84.9 | 98% | 93% | Gaze palsy, horizontal, with progressive scoliosis, 607313 |
| ROGDI | 106.5 | 95% | 94% | Kohlschutter-Tonz syndrome, 226750 |
| ROM1 | 100.9 | 100% | 98% | Retinitis pigmentosa 7, digenic, 608133 |
| ROR2 | 153.6 | 99% | 98% | Brachydactyly, type B1, 113000 Robinow syndrome, autosomal recessive, 268310 |
| RORC | 114.0 | 100% | 99% | Immunodeficiency 42, 616622 |
| RP1 | 112.7 | 100% | 98% | Retinitis pigmentosa 1, 180100 |
| RP1L1 | 86.7 | 100% | 99% | Occult macular dystrophy, 613587 |

| | | | | |
|----------|-------|------|------|---|
| RP2 | 213.4 | 100% | 100% | Retinitis pigmentosa 2, 312600 |
| RPE65 | 122.8 | 99% | 98% | Leber congenital amaurosis 2, 204100 Retinitis pigmentosa 20, 613794 |
| RPGR | 108.1 | 85% | 78% | Cone-rod dystrophy, X-linked, 1, 304020 Macular degeneration, X-linked atrophic, 300834 Retinitis pigmentosa 3, 300029 Retinitis pigmentosa, X-linked, and sinorespiratory infections, with or without deafness, 300455 |
| RPGRIP1 | 132.6 | 100% | 99% | Cone-rod dystrophy 13, 608194 Leber congenital amaurosis 6, 613826 |
| RPGRIP1L | 128.5 | 96% | 93% | COACH syndrome, 216360 Joubert syndrome 7, 611560 Meckel syndrome 5, 611561 |
| RPL11 | 83.9 | 100% | 99% | Diamond-Blackfan anemia 7, 612562 |
| RPL21 | 72.1 | 80% | 65% | Hypotrichosis 12, 615885 |
| RPL35A | 59.2 | 93% | 81% | Diamond-Blackfan anemia 5, 612528 |
| RPL5 | 30.2 | 69% | 55% | Diamond-Blackfan anemia 6, 612561 |
| RPS10 | 97.4 | 99% | 89% | Diamond-Blackfan anemia 9, 613308 |
| RPS14 | 111.1 | 96% | 92% | Macrocytic anemia, refractory, due to 5q deletion, somatic, 153550 |
| RPS17 | 40.6 | 69% | 69% | Diamond-Blackfan anemia 4, 612527 |
| RPS19 | 66.2 | 100% | 99% | Diamond-Blackfan anemia 1, 105650 |
| RPS24 | 88.7 | 87% | 87% | Diamond-blackfan anemia 3, 610629 |
| RPS26 | 77.0 | 99% | 91% | Diamond-Blackfan anemia 10, 613309 |
| RPS28 | 34.8 | 93% | 82% | Diamond Blackfan anemia 15 with mandibulofacial dysostosis, 606164 |
| RPS29 | 57.5 | 99% | 93% | Diamond-Blackfan anemia 13, 615909 |
| RPS6KA3 | 98.8 | 98% | 93% | Coffin-Lowry syndrome, 303600 Mental retardation, X-linked 19, 300844 |
| RPS7 | 89.7 | 86% | 63% | Diamond-Blackfan anemia 8, 612563 |
| RPSA | 62.0 | 100% | 100% | Asplenia, isolated congenital, 271400 |
| RRAS2 | 70.8 | 81% | 75% | Ovarian carcinoma |
| RRM2B | 133.1 | 99% | 97% | Mitochondrial DNA depletion syndrome 8A (encephalomyopathic type with renal tubulopathy), 612075 Mitochondrial DNA depletion syndrome 8B (MNGIE type), 612075 Progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal dominant 5, 613077 |
| RS1 | 64.1 | 99% | 95% | Retinoschisis, 312700 |
| RSPH1 | 148.3 | 100% | 100% | Ciliary dyskinesia, primary, 24, 615481 |

| | | | | |
|---------|-------|------|------|---|
| RSPH3 | 110.8 | 98% | 96% | Ciliary dyskinesia, primary, 32, 616481 |
| RSPH4A | 123.7 | 96% | 94% | Ciliary dyskinesia, primary, 11, 612649 |
| RSPH9 | 130.2 | 100% | 99% | Ciliary dyskinesia, primary, 12, 612650 |
| RSPO1 | 97.9 | 100% | 100% | Palmoplantar hyperkeratosis and true hermaphroditism, 610644 Palmoplantar hyperkeratosis with squamous cell carcinoma of skin and sex reversal, 610644 |
| RSPO4 | 103.6 | 100% | 100% | Anonychia congenita, 206800 |
| RSPRY1 | 141.3 | 100% | 99% | Spondyloepimetaphyseal dysplasia, Faden-Alkuraya type, 616723 |
| RTEL1 | 110.0 | 99% | 96% | Dyskeratosis congenita, autosomal dominant 4, 615190 Dyskeratosis congenita, autosomal recessive 5, 615190 Pulmonary fibrosis and/or bone marrow failure, telomere-related, 3, 616373 |
| RTN2 | 97.1 | 96% | 90% | Spastic paraplegia 12, autosomal dominant, 604805 |
| RTN4IP1 | 82.5 | 98% | 96% | Optic atrophy 10 with or without ataxia, mental retardation, and seizures, 616732 |
| RTTN | 121.2 | 97% | 94% | Microcephaly, short stature, and polymicrogyria with seizures, 614833 |
| RUNX1 | 95.2 | 95% | 91% | Leukemia, acute myeloid, 601626 Platelet disorder, familial, with associated myeloid malignancy, 601399 |
| RUNX2 | 82.1 | 74% | 74% | Cleidocranial dysplasia, 119600 Cleidocranial dysplasia, forme fruste, dental anomalies only, 119600 Cleidocranial dysplasia, forme fruste, with brachydactyly, 119600 Metaphyseal dysplasia with maxillary hypoplasia with or without brachydactyly, 156510 |
| RYR1 | 102.9 | 96% | 92% | Central core disease, 117000 King-Denborough syndrome, 145600 Minicore myopathy with external ophthalmoplegia, 255320 Neuromuscular disease, congenital, with uniform type 1 fiber, 117000 {Malignant hyperthermia susceptibility 1}, 145600 |
| RYR2 | 124.4 | 99% | 97% | Arrhythmogenic right ventricular dysplasia 2, 600996 Ventricular tachycardia, catecholaminergic polymorphic, 1, 604772 |
| S1PR2 | 191.7 | 90% | 88% | Deafness, autosomal recessive 68, 610419 |
| SACS | 142.5 | 99% | 99% | Spastic ataxia, Charlevoix-Saguenay type, 270550 |
| SAG | 119.9 | 100% | 100% | Oguchi disease-1, 258100 Retinitis pigmentosa 47, 613758 |
| SALL1 | 115.3 | 98% | 98% | Townes-Brocks branchiootorenal-like syndrome, 107480 Townes-Brocks syndrome, 107480 |
| SALL4 | 120.3 | 97% | 95% | Duane-radial ray syndrome, 607323 IVIC syndrome, 147750 |

| | | | | |
|--------|-------|------|------|--|
| SAMD9 | 158.1 | 100% | 99% | MIRAGE syndrome, 617053 Tumoral calcinosis, familial, normophosphatemic, 610455 |
| SAMD9L | 145.2 | 100% | 100% | Ataxia-pancytopenia syndrome, 159550 |
| SAMHD1 | 120.6 | 100% | 98% | Aicardi-Goutieres syndrome 5, 612952 ?Chilblain lupus 2, 614415 |
| SAR1B | 125.6 | 89% | 88% | Chylomicron retention disease, 246700 |
| SARS2 | 97.2 | 96% | 95% | Hyperuricemia, pulmonary hypertension, renal failure, and alkalosis, 613845 |
| SATB2 | 97.5 | 97% | 86% | Glass syndrome, 612313 |
| SBDS | 163.6 | 100% | 99% | Shwachman-Diamond syndrome, 260400 {Aplastic anemia, susceptibility to}, 609135 |
| SBF1 | 85.1 | 99% | 94% | Charcot-Marie-Tooth disease, type 4B3, 615284 |
| SBF2 | 112.7 | 98% | 96% | Charcot-Marie-Tooth disease, type 4B2, 604563 |
| SC5D | 169.7 | 100% | 97% | Lathosterolosis, 607330 |
| SCARB2 | 113.4 | 100% | 97% | Epilepsy, progressive myoclonic 4, with or without renal failure, 254900 |
| SCARF2 | 62.8 | 88% | 73% | Van den Ende-Gupta syndrome, 600920 |
| SCN10A | 155.0 | 100% | 99% | Episodic pain syndrome, familial, 2, 615551 |
| SCN11A | 127.1 | 99% | 97% | Episodic pain syndrome, familial, 3, 615552 Neuropathy, hereditary sensory and autonomic, type VII, 615548 |
| SCN1A | 122.5 | 99% | 96% | Dravet syndrome, 607208 Epilepsy, generalized, with febrile seizures plus, type 2, 604403 Febrile seizures, familial, 3A, 604403 Migraine, familial hemiplegic, 3, 609634 |
| SCN1B | 146.7 | 100% | 96% | Atrial fibrillation, familial, 13, 615377 Brugada syndrome 5, 612838 Cardiac conduction defect, nonspecific, 612838 Epilepsy, generalized, with febrile seizures plus, type 1, 604233 |
| SCN2A | 132.4 | 99% | 96% | Epileptic encephalopathy, early infantile, 11, 613721 Seizures, benign familial infantile, 3, 607745 |
| SCN2B | 170.4 | 100% | 100% | Atrial fibrillation, familial, 14, 615378 |
| SCN3B | 132.4 | 100% | 100% | Atrial fibrillation, familial, 16, 613120 Brugada syndrome 7, 613120 |

| | | | | |
|--------|-------|------|------|---|
| SCN4A | 188.5 | 100% | 99% | Hyperkalemic periodic paralysis, type 2, 170500 Hypokalemic periodic paralysis, type 2, 613345 Myasthenic syndrome, congenital, 16, 614198 Myotonia congenita, atypical, acetazolamide-responsive, 608390 Paramyotonia congenita, 168300 |
| SCN4B | 64.3 | 100% | 97% | Atrial fibrillation, familial, 17, 611819 Long QT syndrome-10, 611819 |
| SCN5A | 145.7 | 100% | 100% | Atrial fibrillation, familial, 10, 614022 Brugada syndrome 1, 601144 Cardiomyopathy, dilated, 1E, 601154 Heart block, nonprogressive, 113900 Heart block, progressive, type IA, 113900 Long QT syndrome-3, 603830 Sick sinus syndrome 1, 608567 Ventricular fibrillation, familial, 1, 603829 {Sudden infant death syndrome, susceptibility to}, 272120 |
| SCN8A | 180.8 | 100% | 99% | Epileptic encephalopathy, early infantile, 13, 614558 ?Cognitive impairment with or without cerebellar ataxia, 614306 |
| SCN9A | 128.5 | 98% | 94% | Epilepsy, generalized, with febrile seizures plus, type 7, 613863 Erythermalgia, primary, 133020 Febrile seizures, familial, 3B, 613863 HSAN2D, autosomal recessive, 243000 Insensitivity to pain, congenital, 243000 Paroxysmal extreme pain disorder, 167400, Small fiber neuropathy, 133020 {Dravet syndrome, modifier of}, 607208 |
| SCNN1A | 109.4 | 97% | 93% | Bronchiectasis with or without elevated sweat chloride 2, 613021 Pseudohypoaldosteronism, type I, 264350 |
| SCNN1B | 138.5 | 100% | 100% | Bronchiectasis with or without elevated sweat chloride 1, 211400 Liddle syndrome, 177200 Pseudohypoaldosteronism, type I, 264350 |
| SCNN1G | 120.5 | 97% | 93% | Bronchiectasis with or without elevated sweat chloride 3, 613071 Liddle syndrome, 177200 Pseudohypoaldosteronism, type I, 264350 |
| SCO1 | 98.1 | 96% | 93% | Mitochondrial complex IV deficiency, 220110 |

| | | | | |
|----------|-------|------|------|---|
| SCO2 | 87.8 | 100% | 98% | Cardioencephalomyopathy, fatal infantile, due to cytochrome c oxidase deficiency 1, 604377 Myopia 6, 608908 |
| SCP2 | 94.1 | 100% | 97% | Leukoencephalopathy with dystonia and motor neuropathy, 613724 |
| SCYL1 | 138.3 | 100% | 97% | Spinocerebellar ataxia, autosomal recessive 21, 616719 |
| SDCCAG8 | 109.1 | 99% | 91% | Bardet-Biedl syndrome 16, 615993 Senior-Loken syndrome 7, 613615 |
| SDHA | 80.2 | 82% | 77% | Cardiomyopathy, dilated, 1GG, 613642 Leigh syndrome, 256000 Mitochondrial respiratory chain complex II deficiency, 252011 Paragangliomas 5, 614165 |
| SDHAF1 | 44.3 | 100% | 99% | Mitochondrial complex II deficiency, 252011 |
| SDHAF2 | 122.6 | 94% | 92% | Paragangliomas 2, 601650 |
| SDHB | 123.6 | 100% | 100% | Cowden syndrome 2, 612359 Gastrointestinal stromal tumor, 606764 Paraganglioma and gastric stromal sarcoma, 606864 Paragangliomas 4, 115310 Pheochromocytoma, 171300 |
| SDHC | 83.8 | 100% | 93% | Gastrointestinal stromal tumor, 606764 Paraganglioma and gastric stromal sarcoma, 606864 Paragangliomas 3, 605373 |
| SDHD | 50.5 | 59% | 59% | Carcinoid tumors, intestinal, 114900 Cowden syndrome 3, 615106 Merkel cell carcinoma, somatic Mitochondrial complex II deficiency, 252011 Paraganglioma and gastric stromal sarcoma, 606864 Paragangliomas 1, with or without deafness, 168000 Pheochromocytoma, 171300 |
| SEC23A | 116.6 | 98% | 93% | Craniolenticulosutural dysplasia, 607812 |
| SEC23B | 146.5 | 97% | 95% | Cowden syndrome 7, 616858 Dyserythropoietic anemia, congenital, type II, 224100 |
| SEC24D | 122.0 | 99% | 96% | Cole-Carpenter syndrome 2, 616294 |
| SEC61A1 | 119.6 | 100% | 100% | Hyperuricemic nephropathy, familial juvenile, 4, 617056 |
| SEC63 | 57.2 | 80% | 72% | Polycystic liver disease, 174050 |
| SECISBP2 | 109.8 | 99% | 87% | Thyroid hormone metabolism, abnormal, 609698 |

| | | | | |
|----------|-------|------|------|--|
| SEMA4A | 110.3 | 99% | 98% | Cone-rod dystrophy 10, 610283 Retinitis pigmentosa 35, 610282 |
| SEPN1 | 96.0 | 84% | 83% | Muscular dystrophy, rigid spine, 1, 602771 Myopathy, congenital, with fiber-type disproportion, 255310 |
| SEPSECS | 150.6 | 100% | 100% | Pontocerebellar hypoplasia type 2D, 613811 |
| SEPT12 | 84.6 | 98% | 94% | Spermatogenic failure 10, 614822 |
| SEPT9 | 107.3 | 99% | 95% | Amyotrophy, hereditary neuralgic, 162100 Leukemia, acute myeloid, therapy-related Ovarian carcinoma |
| SERAC1 | 96.7 | 100% | 93% | 3-methylglutaconic aciduria with deafness, encephalopathy, and Leigh-like syndrome, 614739 |
| SERPINA1 | 127.0 | 100% | 100% | Emphysema due to AAT deficiency, 613490 Emphysema-cirrhosis, due to AAT deficiency, 613490 Hemorrhagic diathesis due to \'antithrombin\' Pittsburgh, 613490 {Pulmonary disease, chronic obstructive, susceptibility to}, 606963 |
| SERPINA3 | 114.1 | 100% | 100% | Alpha-1-antichymotrypsin deficiency Cerebrovascular disease, occlusive |
| SERPINA6 | 172.6 | 100% | 100% | Corticosteroid-binding globulin deficiency, 611489 |
| SERPINB7 | 114.4 | 100% | 99% | Palmoplantar keratoderma, Nagashima type, 615598 |
| SERPINC1 | 118.5 | 100% | 100% | Thrombophilia due to antithrombin III deficiency, 613118 |
| SERPIND1 | 138.8 | 100% | 100% | Thrombophilia due to heparin cofactor II deficiency, 612356 |
| SERPINE1 | 133.8 | 100% | 100% | Plasminogen activator inhibitor-1 deficiency, 613329 {Transcription of plasminogen activator inhibitor, modulator of} |
| SERPINF1 | 83.9 | 100% | 98% | Osteogenesis imperfecta, type VI, 613982 |
| SERPINF2 | 114.9 | 99% | 95% | Alpha-2-plasmin inhibitor deficiency, 262850 |
| SERPING1 | 85.3 | 96% | 93% | Angioedema, hereditary, types I and II, 106100 Complement component 4, partial deficiency of, 120790 |
| SERPINI1 | 98.9 | 100% | 95% | Encephalopathy, familial, with neuroserpin inclusion bodies, 604218 |
| SETBP1 | 110.7 | 96% | 95% | Mental retardation, autosomal dominant 29, 616078 Schinzel-Giedion midface retraction syndrome, 269150 |
| SETD2 | 131.5 | 100% | 99% | Luscan-Lumish syndrome, 616831 |
| SETD5 | 154.3 | 100% | 99% | Mental retardation, autosomal dominant 23, 615761 |
| SETX | 147.8 | 100% | 98% | Amyotrophic lateral sclerosis 4, juvenile, 602433 Spinocerebellar ataxia, autosomal recessive 1, 606002 |
| SF3B1 | 125.6 | 98% | 96% | Myelodysplastic syndrome, somatic, 614286 |

| | | | | |
|----------|-------|------|------|--|
| SF3B4 | 65.3 | 100% | 94% | Acrofacial dysostosis 1, Nager type, 154400 |
| SFRP4 | 129.8 | 100% | 97% | Pyle disease, 265900 |
| SFTPA2 | 121.3 | 100% | 100% | Pulmonary fibrosis, idiopathic, 178500 |
| SFTPB | 84.5 | 100% | 99% | Surfactant metabolism dysfunction, pulmonary, 1, 265120 |
| SFTPC | 80.5 | 100% | 95% | Surfactant metabolism dysfunction, pulmonary, 2, 610913 |
| SFXN4 | 126.2 | 100% | 99% | Combined oxidative phosphorylation deficiency 18, 615578 |
| SGCA | 129.3 | 100% | 99% | Muscular dystrophy, limb-girdle, type 2D, 608099 |
| SGCB | 147.1 | 99% | 96% | Muscular dystrophy, limb-girdle, type 2E, 604286 |
| SGCD | 83.4 | 100% | 98% | Cardiomyopathy, dilated, 1L, 606685 Muscular dystrophy, limb-girdle, type 2F, 601287 |
| SGCE | 81.9 | 95% | 89% | Dystonia-11, myoclonic, 159900 |
| SGCG | 120.4 | 100% | 100% | Muscular dystrophy, limb-girdle, type 2C, 253700 |
| SGOL1 | 93.9 | 99% | 89% | Chronic atrial and intestinal dysrhythmia, 616201 |
| SGSH | 111.1 | 94% | 94% | Mucopolysaccharidosis type IIIA (Sanfilippo A), 252900 |
| SH2B3 | 82.3 | 84% | 74% | Erythrocytosis, somatic, 133100 Myelofibrosis, somatic, 254450 Thrombocythemia, somatic, 187950 |
| SH2D1A | 137.8 | 89% | 89% | Lymphoproliferative syndrome, X-linked, 1, 308240 |
| SH3BP2 | 93.8 | 91% | 89% | Cherubism, 118400 |
| SH3PXD2B | 123.4 | 100% | 100% | Frank-ter Haar syndrome, 249420 |
| SH3TC2 | 87.6 | 99% | 96% | Charcot-Marie-Tooth disease, type 4C, 601596 Mononeuropathy of the median nerve, mild, 613353 |
| SHANK3 | 61.7 | 76% | 70% | Phelan-McDermid syndrome, 606232 {Schizophrenia 15}, 613950 |
| SHH | 90.0 | 99% | 93% | Holoprosencephaly-3, 142945 Microphthalmia with coloboma 5, 611638 Schizencephaly, 269160 Single median maxillary central incisor, 147250 |
| SHOC2 | 124.7 | 100% | 99% | Noonan-like syndrome with loose anagen hair, 607721 |
| SHOX | 18.3 | 70% | 48% | Langer mesomelic dysplasia, 249700 Leri-Weill dyschondrosteosis, 127300 Short stature, idiopathic familial, 300582 |
| SI | 92.9 | 96% | 86% | Sucrase-isomaltase deficiency, congenital, 222900 |
| SIK1 | 84.9 | 96% | 92% | Epileptic encephalopathy, early infantile, 30, 616341 |

| | | | | |
|----------|-------|------|------|--|
| SIL1 | 134.6 | 99% | 97% | Marinesco-Sjogren syndrome, 248800 |
| SIM1 | 127.2 | 100% | 99% | Obesity, severe, 601665 |
| SIX1 | 96.2 | 100% | 99% | Brachiootic syndrome 3, 608389 Deafness, autosomal dominant 23, 605192 |
| SIX3 | 118.5 | 99% | 96% | Holoprosencephaly-2, 157170 Schizencephaly, 269160 |
| SIX5 | 38.0 | 83% | 70% | Branchiootorenal syndrome 2, 610896 |
| SIX6 | 179.8 | 100% | 99% | Optic disc anomalies with retinal and/or macular dystrophy, 212550 |
| SKI | 73.7 | 99% | 96% | Shprintzen-Goldberg syndrome, 182212 |
| SKIV2L | 21.0 | 69% | 42% | Trichohepatoenteric syndrome 2, 614602 |
| SLC10A2 | 127.1 | 100% | 100% | Bile acid malabsorption, primary, 613291 |
| SLC11A2 | 115.8 | 100% | 99% | Anemia, hypochromic microcytic, with iron overload 1, 206100 |
| SLC12A1 | 154.5 | 100% | 99% | Bartter syndrome, type 1, 601678 |
| SLC12A3 | 125.7 | 100% | 99% | Gitelman syndrome, 263800 |
| SLC12A5 | 139.4 | 99% | 96% | Epileptic encephalopathy, early infantile, 34, 616645 {Epilepsy, idiopathic generalized, susceptibility to, 14}, 616685 |
| SLC12A6 | 134.2 | 100% | 100% | Agenesis of the corpus callosum with peripheral neuropathy, 218000 |
| SLC13A5 | 141.5 | 100% | 100% | Epileptic encephalopathy, early infantile, 25, 615905 |
| SLC16A1 | 126.9 | 99% | 94% | Erythrocyte lactate transporter defect, 245340 Hyperinsulinemic hypoglycemia, familial, 7, 610021 Monocarboxylate transporter 1 deficiency, 616095 |
| SLC16A12 | 168.9 | 100% | 100% | Cataract, juvenile, with microcornea and glucosuria, 612018 |
| SLC16A2 | 72.1 | 98% | 89% | Allan-Herndon-Dudley syndrome, 300523 |
| SLC17A5 | 103.5 | 100% | 92% | Salla disease, 604369 Sialic acid storage disorder, infantile, 269920 |
| SLC17A8 | 122.7 | 100% | 100% | Deafness, autosomal dominant 25, 605583 |
| SLC17A9 | 102.3 | 95% | 94% | Porokeratosis 8, disseminated superficial actinic type, 616063 |
| SLC19A2 | 102.3 | 99% | 95% | Thiamine-responsive megaloblastic anemia syndrome, 249270 |
| SLC19A3 | 151.6 | 100% | 100% | Thiamine metabolism dysfunction syndrome 2 (biotin- or thiamine-responsive encephalopathy type 2), 607483 |
| SLC1A1 | 170.5 | 100% | 100% | Dicarboxylic aminoaciduria, 222730 {?Schizophrenia susceptibility 18}, 615232 |
| SLC1A3 | 116.2 | 100% | 100% | Episodic ataxia, type 6, 612656 |
| SLC1A4 | 141.2 | 100% | 99% | Spastic tetraplegia, thin corpus callosum, and progressive microcephaly, 616657 |

| | | | | |
|----------|-------|------|------|---|
| SLC20A2 | 83.6 | 98% | 90% | Basal ganglia calcification, idiopathic, 1, 213600 |
| SLC22A12 | 96.3 | 100% | 99% | Hypouricemia, renal, 220150 |
| SLC22A18 | 82.0 | 96% | 77% | Breast cancer, somatic, 114480 Lung cancer, somatic, 211980 Rhabdomyosarcoma, somatic, 268210 |
| SLC22A5 | 131.0 | 100% | 100% | Carnitine deficiency, systemic primary, 212140 |
| SLC24A1 | 174.9 | 100% | 100% | Night blindness, congenital stationary (complete), 1D, autosomal recessive, 613830 |
| SLC24A4 | 106.9 | 99% | 96% | Amelogenesis imperfecta, type IIA5, 615887 [Skin/hair/eye pigmentation 6, blond/brown hair], 210750 [Skin/hair/eye pigmentation 6, blue/green eyes], 210750 |
| SLC24A5 | 99.7 | 98% | 87% | Albinism, oculocutaneous, type VI, 113750 [Skin/hair/eye pigmentation 4, fair/dark skin], 113750 |
| SLC25A1 | 64.3 | 96% | 88% | Combined D-2- and L-2-hydroxyglutaric aciduria, 615182 |
| SLC25A12 | 126.8 | 96% | 95% | Epileptic encephalopathy, early infantile, 39, 612949 |
| SLC25A13 | 104.9 | 99% | 91% | Citrullinemia, adult-onset type II, 603471 Citrullinemia, type II, neonatal-onset, 605814 |
| SLC25A15 | 179.4 | 99% | 96% | Hyperornithinemia-hyperammonemia-homocitrullinemia syndrome, 238970 |
| SLC25A19 | 61.8 | 95% | 85% | Microcephaly, Amish type, 607196 Thiamine metabolism dysfunction syndrome 4 (progressive polyneuropathy type), 613710 |
| SLC25A20 | 82.6 | 100% | 95% | Carnitine-acylcarnitine translocase deficiency, 212138 |
| SLC25A22 | 93.7 | 100% | 97% | Epileptic encephalopathy, early infantile, 3, 609304 |
| SLC25A26 | 79.7 | 96% | 93% | Combined oxidative phosphorylation deficiency 28, 616794 |
| SLC25A3 | 125.0 | 96% | 90% | Mitochondrial phosphate carrier deficiency, 610773 |
| SLC25A38 | 93.8 | 100% | 93% | Anemia, sideroblastic, 2, pyridoxine-refractory, 205950 |
| SLC25A4 | 122.5 | 100% | 100% | Mitochondrial DNA depletion syndrome 12 (cardiomyopathic type), 615418 Progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal dominant 2, 609283 |
| SLC25A46 | 149.0 | 92% | 81% | Neuropathy, hereditary motor and sensory, type VIB, 616505 |
| SLC26A2 | 206.3 | 100% | 100% | Achondrogenesis Ib, 600972 Atelosteogenesis II, 256050 De la Chapelle dysplasia, 256050 Diastrophic dysplasia, 222600 Diastrophic dysplasia, broad bone-platyspondylic variant, 222600 Epiphyseal dysplasia, multiple, 4, 226900 |
| SLC26A3 | 144.5 | 98% | 96% | Diarrhea 1, secretory chloride, congenital, 214700 |

| | | | | |
|----------|-------|------|------|--|
| SLC26A4 | 117.9 | 100% | 97% | Deafness, autosomal recessive 4, with enlarged vestibular aqueduct, 600791 Pendred syndrome, 274600 |
| SLC26A8 | 118.9 | 100% | 100% | Spermatogenic failure 3, 606766 |
| SLC27A4 | 123.7 | 100% | 97% | Ichthyosis prematurity syndrome, 608649 |
| SLC29A3 | 171.4 | 100% | 98% | Histiocytosis-lymphadenopathy plus syndrome, 602782 |
| SLC2A1 | 143.3 | 100% | 100% | Dystonia 9, 601042 GLUT1 deficiency syndrome 1, infantile onset, severe, 606777 GLUT1 deficiency syndrome 2, childhood onset, 612126 Stomatin-deficient cryohydrocytosis with neurologic defects, 608885 {Epilepsy, idiopathic generalized, susceptibility to, 12}, 614847 |
| SLC2A10 | 138.3 | 100% | 100% | Arterial tortuosity syndrome, 208050 |
| SLC2A2 | 151.5 | 100% | 99% | Fanconi-Bickel syndrome, 227810 {Diabetes mellitus, noninsulin-dependent}, 125853 |
| SLC2A9 | 124.1 | 100% | 96% | Hypouricemia, renal, 2, 612076 {Uric acid concentration, serum, QTL 2}, 612076 |
| SLC30A10 | 135.4 | 100% | 100% | Hypermanganesemia with dystonia 1, 613280 |
| SLC30A2 | 115.4 | 100% | 95% | Zinc deficiency, transient neonatal, 608118 |
| SLC33A1 | 117.8 | 95% | 87% | Congenital cataracts, hearing loss, and neurodegeneration, 614482 Spastic paraparesis 42, autosomal dominant, 612539 |
| SLC34A1 | 121.3 | 100% | 99% | Fanconi renotubular syndrome 2, 613388 Hypercalcemia, infantile 2, 616963 Nephrolithiasis/osteoporosis, hypophosphatemic, 1, 612286 |
| SLC34A2 | 139.9 | 100% | 100% | Pulmonary alveolar microlithiasis, 265100 |
| SLC34A3 | 96.3 | 94% | 91% | Hypophosphatemic rickets with hypercalciuria, 241530 |
| SLC35A1 | 123.3 | 100% | 99% | Congenital disorder of glycosylation, type II α , 603585 |
| SLC35A2 | 118.5 | 100% | 99% | Congenital disorder of glycosylation, type II β , 300896 |
| SLC35C1 | 172.5 | 97% | 93% | Congenital disorder of glycosylation, type II γ , 266265 |
| SLC35D1 | 110.7 | 93% | 87% | Schneckenbecken dysplasia, 269250 |
| SLC36A2 | 97.7 | 100% | 99% | Hyperglycinuria, 138500 Iminoglycinuria, digenic, 242600 |
| SLC37A4 | 114.9 | 100% | 99% | Glycogen storage disease Ib, 232220 Glycogen storage disease Ic, 232240 |
| SLC38A8 | 71.9 | 99% | 94% | Foveal hypoplasia 2, with or without optic nerve misrouting and/or anterior segment dysgenesis, 609218 |
| SLC39A13 | 102.5 | 100% | 98% | Spondylocheirodysplasia, Ehlers-Danlos syndrome-like, 612350 |

| | | | | |
|----------|-------|------|------|--|
| SLC39A14 | 86.1 | 97% | 94% | Hypermanganesemia with dystonia 2, 617013 |
| SLC39A4 | 66.8 | 98% | 91% | Acrodermatitis enteropathica, 201100 |
| SLC39A5 | 106.0 | 100% | 98% | Myopia 24, autosomal dominant, 615946 |
| SLC39A8 | 114.6 | 100% | 99% | Congenital disorder of glycosylation, type IIIn, 616721 |
| SLC3A1 | 148.1 | 100% | 99% | Cystinuria, 220100 |
| SLC40A1 | 118.7 | 98% | 97% | Hemochromatosis, type 4, 606069 |
| SLC45A2 | 103.8 | 100% | 98% | Albinism, oculocutaneous, type IV, 606574 [Skin/hair/eye pigmentation 5, black/nonblack hair], 227240 [Skin/hair/eye pigmentation 5, dark/fair skin], 227240 [Skin/hair/eye pigmentation 5, dark/light eyes], 227240 |
| SLC46A1 | 80.2 | 99% | 92% | Folate malabsorption, hereditary, 229050 |
| SLC4A1 | 120.5 | 100% | 99% | Cryohydrocytosis, 185020 Ovalocytosis, SA type, 166900 Renal tubular acidosis, distal, AD, 179800 Renal tubular acidosis, distal, AR, 611590 Spherocytosis, type 4, 612653 [Blood group, Diego], 110500 [Blood group, Froese], 601551 [Blood group, Swann], 601550 [Blood group, Waldner], 112010 [Blood group, Wright], 112050 [Malaria, resistance to], 611162 |
| SLC4A11 | 125.4 | 100% | 100% | Corneal dystrophy, Fuchs endothelial, 4, 613268 Corneal endothelial dystrophy 2, autosomal recessive, 217700 Corneal endothelial dystrophy and perceptive deafness, 217400 |
| SLC4A4 | 123.1 | 100% | 98% | Renal tubular acidosis, proximal, with ocular abnormalities, 604278 |
| SLC52A1 | 173.3 | 100% | 100% | Riboflavin deficiency, 615026 |
| SLC52A2 | 154.0 | 100% | 100% | Brown-Vialetto-Van Laere syndrome 2, 614707 |
| SLC52A3 | 99.7 | 100% | 100% | Brown-Vialetto-Van Laere syndrome 1, 211530 Fazio-Londe disease, 211500 |
| SLC5A1 | 120.1 | 100% | 100% | Glucose/galactose malabsorption, 606824 |
| SLC5A2 | 106.8 | 100% | 94% | Renal glucosuria, 233100 |
| SLC5A5 | 91.9 | 100% | 91% | Thyroid dyshormonogenesis 1, 274400 |
| SLC5A7 | 107.1 | 100% | 99% | Neuronopathy, distal hereditary motor, type VIIA, 158580 |

| | | | | |
|----------|-------|------|------|---|
| SLC6A1 | 127.1 | 100% | 100% | Myoclonic-atonic epilepsy, 616421 |
| SLC6A17 | 172.0 | 100% | 100% | Mental retardation, autosomal recessive 48, 616269 |
| SLC6A19 | 144.9 | 100% | 99% | Hartnup disorder, 234500 Hyperglycinuria, 138500 Iminoglycinuria, digenic, 242600 |
| SLC6A2 | 123.9 | 100% | 99% | Orthostatic intolerance, 604715 |
| SLC6A20 | 135.5 | 99% | 96% | Hyperglycinuria, 138500 Iminoglycinuria, digenic, 242600 |
| SLC6A3 | 120.0 | 100% | 98% | Parkinsonism-dystonia, infantile, 613135 {Nicotine dependence, protection against}, 188890 |
| SLC6A5 | 127.5 | 100% | 100% | Hyperekplexia 3, 614618 |
| SLC6A8 | 57.9 | 92% | 88% | Cerebral creatine deficiency syndrome 1, 300352 |
| SLC7A14 | 149.1 | 100% | 100% | Retinitis pigmentosa 68, 615725 |
| SLC7A7 | 105.9 | 100% | 100% | Lysinuric protein intolerance, 222700 |
| SLC7A9 | 125.8 | 100% | 98% | Cystinuria, 220100 |
| SLC9A3 | 145.6 | 98% | 96% | Diarrhea 8, secretory sodium, congenital, 616868 |
| SLC9A3R1 | 104.1 | 100% | 100% | Nephrolithiasis/osteoporosis, hypophosphatemic, 2, 612287 |
| SLC9A6 | 131.6 | 99% | 88% | Mental retardation, X-linked syndromic, Christianson type, 300243 |
| SLCO1B1 | 41.1 | 93% | 87% | Hyperbilirubinemia, Rotor type, digenic, 237450 |
| SLCO1B3 | 44.3 | 95% | 72% | Hyperbilirubinemia, Rotor type, digenic, 237450 |
| SLCO2A1 | 86.8 | 100% | 98% | Hypertrophic osteoarthropathy, primary, autosomal recessive 2, 614441 |
| SLFN14 | 177.8 | 100% | 100% | Bleeding disorder, platelet-type, 20, 616913 |
| SLTRK1 | 113.2 | 100% | 100% | Tourette syndrome, 137580 ?Trichotillomania, 613229 |
| SLTRK6 | 193.5 | 100% | 100% | Deafness and myopia, 221200 |
| SLURP1 | 83.3 | 98% | 86% | Meleda disease, 248300 |
| SLX4 | 97.2 | 99% | 98% | Fanconi anemia, complementation group P, 613951 |
| SMAD3 | 109.5 | 100% | 98% | Loeys-Dietz syndrome 3, 613795 |
| SMAD4 | 97.9 | 99% | 98% | Juvenile polyposis/hereditary hemorrhagic telangiectasia syndrome, 175050 Myhre syndrome, 139210 Pancreatic cancer, somatic, 260350 Polyposis, juvenile intestinal, 174900 |
| SMAD6 | 83.5 | 88% | 75% | Aortic valve disease 2, 614823 |

| | | | | |
|----------|-------|------|------|---|
| SMAD9 | 124.3 | 100% | 100% | Pulmonary hypertension,primary,615342 Polyposis & gastrointestinal ganglioneuromas (Ngeow (2015) Gastroenterology 149,886) |
| SMARCA2 | 103.2 | 95% | 93% | Nicolaides-Baraitser syndrome, 601358 |
| SMARCA4 | 121.2 | 99% | 95% | Coffin-Siris syndrome 4, 614609 {Rhabdoid tumor predisposition syndrome 2}, 613325 |
| SMARCAD1 | 72.7 | 98% | 92% | Adermatoglyphia, 136000 |
| SMARCAL1 | 120.5 | 100% | 99% | Schimke immunoosseous dysplasia, 242900 |
| SMARCB1 | 195.8 | 100% | 100% | Coffin-Siris syndrome 3, 614608 Rhabdoid tumors, somatic, 609322 {Rhabdoid predisposition syndrome 1}, 609322 {Schwannomatosis-1, susceptibility to}, 162091 |
| SMARCE1 | 68.7 | 96% | 82% | Coffin-Siris syndrome 5,616938 {Meningioma, familial, susceptibility to}, 607174 |
| SMC1A | 116.2 | 100% | 100% | Cornelia de Lange syndrome 2,300590 |
| SMC3 | 81.5 | 92% | 82% | Cornelia de Lange syndrome 3, 610759 |
| SMCHD1 | 83.5 | 96% | 87% | Fascioscapulohumeral muscular dystrophy 2, digenic, 158901 |
| SMN1 | 90.1 | 100% | 92% | Spinal muscular atrophy-1, 253300 Spinal muscular atrophy-2, 253550 Spinal muscular atrophy-3, 253400 Spinal muscular atrophy-4, 271150 |
| SMO | 132.5 | 96% | 92% | Basal cell carcinoma, somatic, 605462 Curry-Jones syndrome,somatic mosaic, 601707 |
| SMOC1 | 104.0 | 98% | 93% | Microphthalmia with limb anomalies, 206920 |
| SMOC2 | 99.3 | 97% | 93% | Dentin dysplasia, type I, with microdontia and misshapen teeth, 125400 |
| SMPD1 | 104.5 | 98% | 95% | Niemann-Pick disease, type A, 257200 Niemann-Pick disease, type B, 607616 |
| SMPX | 101.8 | 100% | 99% | Deafness, X-linked 4, 300066 |
| SMS | 69.7 | 84% | 78% | Mental retardation, X-linked, Snyder-Robinson type, 309583 |
| SNAI2 | 124.1 | 100% | 97% | Piebaldism, 172800 Waardenburg syndrome, type 2D, 608890 |
| SNAP29 | 119.6 | 100% | 100% | Cerebral dysgenesis, neuropathy, ichthyosis, and palmoplantar keratoderma syndrome, 609528 |
| SNCA | 113.5 | 100% | 100% | Dementia, Lewy body, 127750 Parkinson disease 1, 168601 Parkinson disease 4, 605543 |

| | | | | |
|----------|-------|------|------|---|
| SNCB | 63.3 | 100% | 100% | Dementia, Lewy body, 127750 |
| SNIP1 | 122.2 | 100% | 97% | Psychomotor retardation, epilepsy, and craniofacial dysmorphism, 614501 |
| SNRNP200 | 130.9 | 99% | 97% | Retinitis pigmentosa 33, 610359 |
| SNRPB | 71.8 | 100% | 94% | Cerebrocostomandibular syndrome, 117650 |
| SNRPE | 90.3 | 99% | 96% | Hypotrichosis 11, 615059 |
| SNRPN | 101.9 | 100% | 98% | Prader-Willi syndrome, 176270 |
| SNTA1 | 79.2 | 86% | 79% | Long QT syndrome 12, 612955 |
| SNX10 | 96.8 | 100% | 96% | Osteopetrosis, autosomal recessive 8, 615085 |
| SNX14 | 66.5 | 89% | 79% | Spinocerebellar ataxia, autosomal recessive 20, 616354 |
| SOBP | 87.7 | 96% | 86% | Mental retardation, anterior maxillary protrusion, and strabismus, 613671 |
| SOD1 | 138.7 | 100% | 100% | Amyotrophic lateral sclerosis 1, 105400 |
| SOS1 | 85.5 | 92% | 89% | Noonan syndrome 4, 610733 ?Fibromatosis, gingival, 1, 135300 |
| SOS2 | 86.7 | 98% | 91% | Noonan syndrome 9, 616559 |
| SOST | 113.1 | 100% | 100% | Craniodiaphyseal dysplasia, autosomal dominant, 122860 Sclerosteosis 1, 269500 Van Buchem disease, 239100 |
| SOX10 | 61.5 | 97% | 90% | PCWH syndrome, 609136 Waardenburg syndrome, type 2E, with or without neurologic involvement, 611584 Waardenburg syndrome, type 4C, 613266 |
| SOX11 | 99.5 | 100% | 95% | Mental retardation, autosomal dominant, 27, 615866 |
| SOX17 | 50.7 | 96% | 83% | Vesicoureteral reflux 3, 613674 |
| SOX18 | 19.8 | 74% | 49% | Hypotrichosis-lymphedema-telangiectasia syndrome, 607823 Hypotrichosis-lymphedema-telangiectasia-renal defect syndrome, 137940 |
| SOX2 | 83.7 | 100% | 97% | Microphthalmia, syndromic 3, 206900 Optic nerve hypoplasia and abnormalities of the central nervous system, 206900 |
| SOX3 | 51.9 | 94% | 88% | Mental retardation, X-linked, with isolated growth hormone deficiency, 300123 Panhypopituitarism, X-linked, 312000 |
| SOX5 | 88.3 | 99% | 96% | Lamb-Shaffer syndrome, 616803 |
| SOX9 | 95.7 | 95% | 89% | Acampomelic campomelic dysplasia, 114290 Campomelic dysplasia with autosomal sex reversal, 114290 Campomelic dysplasia, 114290 |
| SP110 | 113.6 | 100% | 99% | Hepatic venoocclusive disease with immunodeficiency, 235550 {Mycobacterium tuberculosis, susceptibility to}, 607948 |

| | | | | |
|---------|-------|------|------|---|
| SPAG1 | 74.2 | 96% | 86% | Ciliary dyskinesia, primary, 28, 615505 |
| SPARC | 148.4 | 100% | 100% | Osteogenesis imperfecta, type XVII, 616507 |
| SPAST | 54.8 | 87% | 72% | Spastic paraplegia 4, autosomal dominant, 182601 |
| SPATA5 | 116.5 | 99% | 98% | Epilepsy, hearing loss, and mental retardation syndrome, 616577 |
| SPATA7 | 116.6 | 97% | 92% | Leber congenital amaurosis 3, 604232 Retinitis pigmentosa, juvenile, autosomal recessive, 604232 |
| SPECC1L | 132.3 | 100% | 100% | Opitz GBBB syndrome, type II, 145410 ?Facial clefting, oblique, 1, 600251 |
| SPEG | 85.3 | 92% | 84% | Centronuclear myopathy 5, 615959 |
| SPG11 | 117.4 | 98% | 96% | Amyotrophic lateral sclerosis 5, juvenile, 602099 Charcot-Marie-Tooth disease, axonal, type 2X, 616668 Spastic paraplegia 11, autosomal recessive, 604360 |
| SPG20 | 131.7 | 97% | 96% | Troyer syndrome, 275900 |
| SPG21 | 116.4 | 100% | 99% | Mast syndrome, 248900 |
| SPG7 | 98.1 | 95% | 91% | Spastic paraplegia 7, autosomal recessive, 607259 |
| SPINK1 | 64.0 | 100% | 95% | Pancreatitis, hereditary, 167800 Tropical calcific pancreatitis, 608189 {Fibrocalculous pancreatic diabetes, susceptibility to}, 608189 |
| SPINK5 | 134.0 | 99% | 92% | Atopy, 147050 Netherton syndrome, 256500 |
| SPINT2 | 55.0 | 99% | 88% | Diarrhea 3, secretory sodium, congenital, syndromic, 270420 |
| SPR | 150.6 | 95% | 87% | Dystonia, dopa-responsive, due to sepiapterin reductase deficiency, 612716 |
| SPRED1 | 135.7 | 96% | 96% | Legius syndrome, 611431 |
| SPRTN | 142.9 | 100% | 100% | Ruijs-Aalfs syndrome, 616200 |
| SPRY4 | 123.7 | 100% | 100% | Hypogonadotropic hypogonadism 17 with or without anosmia, 615266 |
| SPTA1 | 110.7 | 99% | 98% | Elliptocytosis-2, 130600 Pyropoikilocytosis, 266140 Spherocytosis, type 3, 270970 |
| SPTAN1 | 108.8 | 99% | 97% | Epileptic encephalopathy, early infantile, 5, 613477 |
| SPTB | 126.3 | 100% | 99% | Anemia, neonatal hemolytic, fatal and near-fatal Elliptocytosis-3 Spherocytosis, type 2, 616649 |
| SPTBN2 | 100.1 | 99% | 98% | Spinocerebellar ataxia 5, 600224 |

| | | | | |
|---------|-------|------|------|--|
| | | | | Spinocerebellar ataxia, autosomal recessive 14, 615386 |
| SPTLC1 | 104.4 | 96% | 90% | Neuropathy, hereditary sensory and autonomic, type IA, 162400 |
| SPTLC2 | 139.9 | 100% | 100% | Neuropathy, hereditary sensory and autonomic, type IC, 613640 |
| SQSTM1 | 102.7 | 94% | 91% | Frontotemporal dementia and/or amyotrophic lateral sclerosis 3, 616437 Paget disease of bone 3, 167250 |
| SRC | 99.7 | 100% | 99% | Colon cancer, advanced, somatic, 114500 ?Thrombocytopenia 6,616937 |
| SRCAP | 123.0 | 98% | 97% | Floating-Harbor syndrome, 136140 |
| SRD5A2 | 71.9 | 100% | 99% | Pseudovaginal perineoscrotal hypospadias, 264600 |
| SRD5A3 | 133.5 | 100% | 97% | Congenital disorder of glycosylation, type Iq, 612379 Kahrizi syndrome, 612713 |
| SRP72 | 61.4 | 92% | 85% | Bone marrow failure syndrome 1, 614675 |
| SRY | 1.7 | 1% | 1% | 46XX sex reversal, 400045 46XY sex reversal, 400044 |
| SSTR5 | 144.7 | 99% | 97% | Somatostatin analog, resistance to |
| ST14 | 130.8 | 100% | 98% | Ichthyosis, congenital, autosomal recessive 11, 602400 |
| ST3GAL3 | 152.1 | 100% | 100% | Epileptic encephalopathy, early infantile, 15, 615006 Mental retardation, autosomal recessive 12, 611090 |
| ST3GAL5 | 109.5 | 94% | 94% | Amish infantile epilepsy syndrome, 609056 |
| STAC3 | 113.2 | 100% | 98% | Native American myopathy, 255995 |
| STAMBP | 103.4 | 100% | 97% | Microcephaly-capillary malformation syndrome, 614261 |
| STAR | 103.0 | 100% | 100% | Lipoid adrenal hyperplasia, 201710 |
| STAT1 | 122.1 | 97% | 96% | Immunodeficiency 31A, mycobacteriosis, autosomal dominant, 614892 Immunodeficiency 31B, mycobacterial and viral infections, autosomal recessive, 613796 Immunodeficiency 31C, autosomal dominant, 614162 |
| STAT2 | 100.3 | 100% | 100% | Immunodeficiency 44, 616636 |
| STAT3 | 110.2 | 100% | 97% | Autoimmune disease, multisystem, infantile-onset, 615952 Hyper-IgE recurrent infection syndrome, 147060 |
| STAT5B | 113.3 | 100% | 95% | Growth hormone insensitivity with immunodeficiency, 245590 Leukemia, acute promyelocytic, somatic, 102578 |
| STIL | 140.8 | 98% | 98% | Microcephaly 7, primary, autosomal recessive, 612703 |
| STIM1 | 107.5 | 96% | 92% | Immunodeficiency 10, 612783 Myopathy, tubular aggregate, 1 160565 Stormorken syndrome, 185070 |

| | | | | |
|--------|-------|------|------|--|
| STK11 | 112.5 | 100% | 91% | Melanoma, malignant, somatic Pancreatic cancer, 260350 Peutz-Jeghers syndrome, 175200 Testicular tumor, somatic, 273300 |
| STK4 | 133.0 | 100% | 98% | T-cell immunodeficiency, recurrent infections, autoimmunity, and cardiac malformations, 614868 |
| STOX1 | 171.4 | 89% | 89% | Preeclampsia/eclampsia 4, 609404 |
| STRA6 | 107.1 | 100% | 99% | Microphthalmia, isolated, with coloboma 8, 601186 Microphthalmia, syndromic 9, 601186 |
| STRADA | 119.6 | 100% | 100% | Polyhydramnios, megalencephaly, and symptomatic epilepsy, 611087 |
| STRC | 95.5 | 100% | 96% | Deafness, autosomal recessive 16, 603720 |
| STS | 113.2 | 100% | 99% | Ichthyosis, X-linked, 308100 |
| STUB1 | 139.6 | 100% | 100% | Spinocerebellar ataxia, autosomal recessive 16, 615768 |
| STX11 | 249.5 | 100% | 100% | Hemophagocytic lymphohistiocytosis, familial, 4, 603552 |
| STX16 | 129.4 | 98% | 96% | Pseudohypoparathyroidism, type IB, 603233 |
| STX1B | 142.2 | 100% | 100% | Generalized epilepsy with febrile seizures plus, type 9, 616172 |
| STXBP1 | 121.9 | 100% | 100% | Epileptic encephalopathy, early infantile, 4, 612164 |
| STXBP2 | 111.7 | 100% | 99% | Hemophagocytic lymphohistiocytosis, familial, 5, 613101 |
| SUCLA2 | 54.7 | 93% | 79% | Mitochondrial DNA depletion syndrome 5 (encephalomyopathic with or without methylmalonic aciduria), 612073 |
| SUCLG1 | 80.5 | 100% | 89% | Mitochondrial DNA depletion syndrome 9 (encephalomyopathic type with methylmalonic aciduria), 245400 |
| SUFU | 112.8 | 100% | 97% | Basal cell nevus syndrome, 109400 Medulloblastoma, desmoplastic, 155255 {Meningioma, familial, susceptibility to}, 607174 |
| SUMF1 | 103.2 | 97% | 86% | Multiple sulfatase deficiency, 272200 |
| SUMO1 | 12.4 | 57% | 21% | Orofacial cleft 10, 613705 |
| SUOX | 171.4 | 100% | 100% | Sulfite oxidase deficiency, 272300 |
| SYCP3 | 86.5 | 95% | 67% | Pregnancy loss, recurrent, 4, 270960 Spermatogenic failure 4, 270960 |
| SYN1 | 87.5 | 99% | 80% | Epilepsy, X-linked, with variable learning disabilities and behavior disorders, 300491 |
| SYNE1 | 125.0 | 99% | 98% | Emery-Dreifuss muscular dystrophy 4, autosomal dominant, 612998 Spinocerebellar ataxia, autosomal recessive 8, 610743 |
| SYNE2 | 108.7 | 97% | 95% | Emery-Dreifuss muscular dystrophy 5, autosomal dominant, 612999 |
| SYNE4 | 67.1 | 98% | 90% | Deafness, autosomal recessive 76, 615540 |

| | | | | |
|---------|-------|------|------|--|
| SYNGAP1 | 63.3 | 93% | 84% | Mental retardation, autosomal dominant 5, 612621 |
| SYNJ1 | 114.6 | 99% | 96% | Parkinson disease 20, early-onset, 615530 |
| SYP | 85.2 | 100% | 99% | Mental retardation, X-linked 96, 300802 |
| SYT14 | 147.1 | 87% | 84% | Spinocerebellar ataxia, autosomal recessive 11, 614229 |
| SYT2 | 89.4 | 100% | 98% | Myasthenic syndrome, congenital, 7, presynaptic, 616040 |
| SZT2 | 121.0 | 99% | 99% | Epileptic encephalopathy, early infantile, 18, 615476 |
| T | 142.4 | 100% | 97% | Sacral agenesis with vertebral anomalies, 615709 {Neural tube defects, susceptibility to}, 182940 |
| TAB2 | 176.7 | 99% | 95% | Congenital heart defects, nonsyndromic, 2, 614980 |
| TAC3 | 75.4 | 83% | 75% | Hypogonadotropic hypogonadism 10 with or without anosmia, 614839 |
| TACO1 | 90.8 | 94% | 90% | Mitochondrial complex IV deficiency, 220110 |
| TACR3 | 136.4 | 100% | 99% | Hypogonadotropic hypogonadism 11 with or without anosmia, 614840 |
| TACSTD2 | 186.9 | 98% | 94% | Corneal dystrophy, gelatinous drop-like, 204870 |
| TAF1 | 140.0 | 100% | 98% | Dystonia-Parkinsonism, X-linked, 314250 Mental retardation, X-linked, syndromic 33, 300966 |
| TAF2 | 113.6 | 99% | 93% | Mental retardation, autosomal recessive 40, 615599 |
| TAL1 | 50.8 | 89% | 62% | Leukemia, T-cell acute lymphocytic, somatic, 613065 |
| TAL2 | 89.0 | 100% | 100% | Leukemia, T-cell acute lymphocytic, somatic, 613065 |
| TALDO1 | 112.8 | 100% | 96% | Transaldolase deficiency, 606003 |
| TANGO2 | 134.3 | 100% | 100% | Metabolic encephalomyopathic crises, recurrent, with rhabdomyolysis, cardiac arrhythmias and neurodegeneration, 616878 |
| TAP1 | 9.3 | 38% | 4% | Bare lymphocyte syndrome, type I, 604571 |
| TAP2 | 8.8 | 29% | 11% | Bare lymphocyte syndrome, type I, due to TAP2 deficiency, 604571 Wegener-like granulomatosis |
| TAPBP | 16.4 | 72% | 26% | Bare lymphocyte syndrome, type I, 604571 |
| TAPT1 | 84.6 | 88% | 85% | Osteochondrodysplasia, complex lethal, Symoens-Barnes-Gistelinck type, 616897 |
| TARDBP | 130.7 | 100% | 100% | Amyotrophic lateral sclerosis 10, with or without FTD, 612069 Frontotemporal lobar degeneration, TARDBP-related, 612069 |
| TAT | 103.4 | 100% | 100% | Tyrosinemia, type II, 276600 |
| TAZ | 118.5 | 100% | 100% | Barth syndrome, 302060 |
| TBC1D20 | 128.0 | 94% | 92% | Warburg micro syndrome 4, 615663 |

| | | | | |
|---------|-------|------|------|---|
| TBC1D24 | 144.6 | 100% | 99% | Deafness , autosomal recessive 86, 614617 Deafness, autosomal dominant 65, 616044 DOOR syndrome, 220500 Epileptic encephalopathy, early infantile, 16, 615338 Myoclonic epilepsy, infantile, familial, 605021 |
| TBC1D7 | 94.9 | 93% | 92% | Macrocephaly/megalencephaly syndrome, autosomal recessive, 248000 |
| TBCE | 125.3 | 99% | 98% | Hypoparathyroidism-retardation-dysmorphism syndrome, 241410 Kenny-Caffey syndrome, type 1, 244460 |
| TBCK | 82.2 | 97% | 87% | Hypotonia, infantile, with psychomotor retardation and characteristic facies 3,616900 |
| TBK1 | 95.5 | 97% | 87% | Frontotemporal dementia and/or amyotrophic lateral sclerosis 4, 616439 |
| TBL1XR1 | 79.9 | 93% | 69% | Mental retardation, autosomal dominant 41,616944 Piermont syndrome, 602342 |
| TBP | 88.5 | 100% | 98% | Spinocerebellar ataxia 17, 607136 {Parkinson disease, susceptibility to}, 168600 |
| TBX1 | 65.9 | 74% | 61% | Conotruncal anomaly face syndrome, 217095 DiGeorge syndrome, 188400 Tetralogy of Fallot, 187500 Velocardiofacial syndrome, 192430 |
| TBX15 | 105.8 | 100% | 94% | Cousin syndrome, 260660 |
| TBX18 | 84.2 | 97% | 92% | Congenital anomalies of kidney and urinary tract 2, 143400 |
| TBX19 | 134.5 | 100% | 100% | Adrenocorticotrophic hormone deficiency, 201400 |
| TBX20 | 110.0 | 100% | 100% | Atrial septal defect 4, 611363 |
| TBX21 | 71.4 | 95% | 84% | Asthma and nasal polyps, 208550 {Asthma, aspirin-induced, susceptibility to}, 208550 |
| TBX22 | 142.7 | 100% | 99% | Cleft palate with ankyloglossia, 303400 ?Abruzzo-Erickson syndrome, 302905 |
| TBX3 | 76.7 | 97% | 92% | Ulnar-mammary syndrome, 181450 |
| TBX4 | 140.5 | 96% | 94% | Ischiocoxopodopatellar syndrome, 147891 |
| TBX5 | 119.2 | 100% | 99% | Holt-Oram syndrome, 142900 |
| TBX6 | 112.8 | 99% | 87% | Spondylocostal dysostosis 5, 122600 |
| TBXAS1 | 119.9 | 100% | 100% | Ghosal hematodiaphyseal syndrome, 231095 ?Thromboxane synthase deficiency, 614158 |
| TCAP | 85.2 | 100% | 100% | Cardiomyopathy, hypertrophic, 25, 607487 Muscular dystrophy, limb-girdle, type 2G, 601954 |

| | | | | |
|--------|-------|------|------|--|
| TCF12 | 136.1 | 100% | 99% | Craniosynostosis 3, 615314 |
| TCF3 | 67.8 | 99% | 95% | Agammaglobulinemia 8, autosomal dominant, 616941 |
| TCF4 | 127.3 | 100% | 99% | Corneal dystrophy, Fuchs endothelial, 3, 613267 Pitt-Hopkins syndrome, 610954 |
| TCIRG1 | 102.5 | 96% | 89% | Osteopetrosis, autosomal recessive 1, 259700 |
| TCN2 | 155.3 | 100% | 100% | Transcobalamin II deficiency, 275350 |
| TCOF1 | 75.8 | 98% | 96% | Treacher Collins syndrome 1, 154500 |
| TCTN1 | 94.0 | 95% | 91% | Joubert syndrome 13, 614173 |
| TCTN2 | 123.8 | 99% | 93% | Joubert syndrome 24, 616654 ?Meckel syndrome 8, 613885 |
| TCTN3 | 110.4 | 99% | 97% | Joubert syndrome 18, 614815 Orofaciodigital syndrome IV, 258860 |
| TDGF1 | 115.7 | 86% | 81% | Forebrain defects, 187395 |
| TDP1 | 100.5 | 94% | 92% | Spinocerebellar ataxia, autosomal recessive with axonal neuropathy, 607250 |
| TDP2 | 142.3 | 100% | 100% | Spinocerebellar ataxia, autosomal recessive, 616949 |
| TDRD7 | 149.8 | 99% | 97% | Cataract 36, 613887 |
| TEAD1 | 139.7 | 97% | 93% | Sveinsson choreoretinal atrophy, 108985 |
| TECPR2 | 128.9 | 100% | 100% | Spastic paraparesis 49, autosomal recessive, 615031 |
| TECR | 75.1 | 99% | 94% | Mental retardation, autosomal recessive 14, 614020 |
| TECTA | 184.7 | 100% | 100% | Deafness, autosomal dominant 8/12, 601543 Deafness, autosomal recessive 21, 603629 |
| TEK | 168.9 | 100% | 99% | Venous malformations, multiple cutaneous and mucosal, 600195 |
| TELO2 | 86.0 | 98% | 87% | You-Hoover-Fong syndrome, 616954 |
| TENM3 | 172.2 | 99% | 98% | Microphthalmia, isolated, with coloboma 9, 615145 |
| TENM4 | 131.5 | 99% | 98% | Tremor, hereditary essential, 5, 616736 |
| TERC | NC | NC | NC | Dyskeratosis congenita, autosomal dominant 1, 127550 {Aplastic anemia}, 614743 {Pulmonary fibrosis, idiopathic, susceptibility to}, 614743 |
| TET2 | 178.3 | 100% | 100% | Myelodysplastic syndrome, somatic, 614286 |
| TEX11 | 104.9 | 94% | 86% | Spermatogenic failure, X-linked, 2, 309120 |
| TF | 114.6 | 100% | 100% | Atransferrinemia, 209300 |
| TFAP2A | 97.1 | 100% | 99% | Branchiooculofacial syndrome, 113620 |
| TFAP2B | 106.5 | 98% | 95% | Char syndrome, 169100 Patent ductus arteriosus 2, 617035 |

| | | | | |
|--------|-------|------|------|---|
| TFE3 | 80.4 | 100% | 98% | Renal cell carcinoma, papillary, 1, 300854 |
| TFG | 96.4 | 93% | 92% | Hereditary motor and sensory neuropathy, Okinawa type, 604484 ?Spastic paraplegia 57, autosomal recessive, 615658 |
| TFR2 | 84.2 | 98% | 90% | Hemochromatosis, type 3, 604250 |
| TFRC | 146.3 | 100% | 98% | Immunodeficiency 46, 616740 |
| TG | 116.7 | 99% | 98% | Thyroid dyshormonogenesis 3, 274700 {Autoimmune thyroid disease, susceptibility to, 3}, 608175 |
| TGDS | 91.1 | 99% | 97% | Catel-Manzke syndrome, 616145 |
| TGFB1 | 73.8 | 100% | 95% | Camurati-Engelmann disease, 131300 {Cystic fibrosis lung disease, modifier of}, 219700 |
| TGFB2 | 140.0 | 100% | 98% | Loeys-Dietz syndrome 4, 614816 |
| TGFB3 | 138.7 | 100% | 100% | Arrhythmogenic right ventricular dysplasia 1, 107970 Loeys-Dietz syndrome 5, 615582 |
| TGFB1 | 118.1 | 97% | 89% | Corneal dystrophy, Avellino type, 607541 Corneal dystrophy, epithelial basement membrane, 121820 Corneal dystrophy, Groenouw type I, 121900 Corneal dystrophy, lattice type I, 122200 Corneal dystrophy, lattice type IIIA, 608471 Corneal dystrophy, Reis-Bucklers type, 608470 Corneal dystrophy, Thiel-Behnke type, 602082 |
| TGFBR1 | 169.6 | 94% | 93% | Loeys-Dietz syndrome 1, 609192 {Multiple self-healing squamous epithelioma, susceptibility to}, 132800 |
| TGFBR2 | 165.3 | 100% | 100% | Colorectal cancer, hereditary nonpolyposis, type 6, 614331 Esophageal cancer, somatic, 133239 Loeys-Dietz syndrome 2, 610168 |
| TGIF1 | 122.9 | 100% | 100% | Holoprosencephaly-4, 142946 |
| TGM1 | 144.1 | 100% | 100% | Ichthyosis, congenital, autosomal recessive 1, 242300 |
| TGM5 | 140.5 | 100% | 100% | Peeling skin syndrome 2, 609796 |
| TGM6 | 118.9 | 100% | 94% | Spinocerebellar ataxia 35, 613908 |
| TH | 71.1 | 93% | 89% | Segawa syndrome, recessive, 605407 |
| THAP1 | 119.1 | 100% | 100% | Dystonia 6, torsion, 602629 |
| THBD | 96.4 | 100% | 93% | Thrombophilia due to thrombomodulin defect, 614486 {Hemolytic uremic syndrome, atypical, susceptibility to, 6}, 612926 |
| THOC2 | 94.5 | 98% | 91% | Mental retardation, X-linked 12/35, 300957 |

| | | | | |
|----------|-------|------|------|--|
| THOC6 | 206.9 | 100% | 100% | Beaulieu-Boycott-Innes syndrome, 613680 |
| THPO | 88.6 | 100% | 100% | Thrombocythemia 1, 187950 |
| THRA | 159.3 | 100% | 99% | Hypothyroidism, congenital, nongoitrous, 6, 614450 |
| THRΒ | 149.6 | 100% | 100% | Thyroid hormone resistance, 188570 Thyroid hormone resistance, autosomal recessive, 274300 Thyroid hormone resistance, selective pituitary, 145650 |
| TIA1 | 108.4 | 92% | 83% | Welander distal myopathy, 604454 |
| TIMM8A | 42.4 | 93% | 74% | Jensen syndrome, 311150 Mohr-Tranebjærg syndrome, 304700 |
| TIMP3 | 134.5 | 100% | 100% | Sorsby fundus dystrophy, 136900 |
| TINF2 | 159.6 | 100% | 100% | Dyskeratosis congenita, autosomal dominant 3, 613990 Revesz syndrome, 268130 |
| TJP2 | 108.0 | 99% | 98% | Cholestasis, progressive familial intrahepatic 4, 615878 Hypercholanemia, familial, 607748 |
| TK2 | 85.5 | 92% | 88% | Mitochondrial DNA depletion syndrome 2 (myopathic type), 609560 |
| TKT | 104.7 | 98% | 96% | Short stature, developmental delay, and congenital heart defects, 617044 |
| TLE6 | 91.8 | 100% | 98% | Preimplantation embryonic lethality, 616814 |
| TLL1 | 129.5 | 100% | 100% | Atrial septal defect 6, 613087 |
| TMC1 | 119.9 | 96% | 93% | Deafness, autosomal dominant 36, 606705 Deafness, autosomal recessive 7, 600974 |
| TMC6 | 67.0 | 99% | 95% | Epidermolytic hyperkeratosis, 226400 |
| TMC8 | 98.3 | 98% | 89% | Epidermolytic hyperkeratosis, 226400 |
| TMCO1 | 86.9 | 100% | 99% | Craniofacial dysmorphism, skeletal anomalies, and mental retardation syndrome, 213980 |
| TMEM126A | 101.9 | 98% | 77% | Optic atrophy 7, 612989 |
| TMEM126B | 79.1 | 97% | 95% | Mitochondrial complex I deficiency, 252010 |
| TMEM138 | 106.2 | 100% | 100% | Joubert syndrome 16, 614465 |
| TMEM165 | 97.2 | 99% | 94% | Congenital disorder of glycosylation, type IIk, 614727 |
| TMEM173 | 86.6 | 100% | 97% | STING-associated vasculopathy, infantile-onset, 615934 |
| TMEM199 | 112.3 | 100% | 99% | Congenital disorder of glycosylation, type IIp, 616829 |
| TMEM216 | 144.8 | 100% | 100% | Joubert syndrome 2, 608091 Meckel syndrome 2, 603194 |
| TMEM231 | 84.9 | 100% | 96% | Joubert syndrome 20, 614970 Meckel syndrome 11, 615397 |
| TMEM237 | 90.8 | 97% | 97% | Joubert syndrome 14, 614424 |

| | | | | |
|-----------|-------|------|------|---|
| TMEM240 | 108.2 | 100% | 100% | Spinocerebellar ataxia 21, 607454 |
| TMEM38B | 104.6 | 100% | 100% | Osteogenesis imperfecta, type XIV, 615066 |
| TMEM43 | 107.2 | 100% | 96% | Arrhythmogenic right ventricular dysplasia 5, 604400 Emery-Dreifuss muscular dystrophy 7, AD, 614302 |
| TMEM5 | 125.4 | 91% | 89% | Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 10, 615041 |
| TMEM67 | 63.7 | 92% | 81% | COACH syndrome, 216360 Joubert syndrome 6, 610688 Meckel syndrome 3, 607361 Nephronophthisis 11, 613550 {Bardet-Biedl syndrome 14, modifier of}, 615991 |
| TMEM70 | 113.2 | 91% | 83% | Mitochondrial complex V (ATP synthase) deficiency, nuclear type 2, 614052 |
| TMEM98 | 116.0 | 99% | 95% | Nanophthalmos 4, 615972 |
| TMIE | 97.0 | 97% | 91% | Deafness, autosomal recessive 6, 600971 |
| TMPRSS15 | 114.8 | 95% | 85% | Enterokinase deficiency, 226200 |
| TMPRSS3 | 103.4 | 99% | 97% | Deafness, autosomal recessive 8/10, 601072 |
| TMPRSS6 | 93.0 | 100% | 100% | Iron-refractory iron deficiency anemia, 206200 |
| TNC | 148.0 | 100% | 98% | Deafness, autosomal dominant 56, 615629 |
| TNFAIP3 | 106.8 | 100% | 100% | Autoinflammatory syndrome, familial, Behcet-like, 616744 |
| TNFRSF10B | 111.0 | 100% | 100% | Squamous cell carcinoma, head and neck, 275355 |
| TNFRSF11A | 121.3 | 92% | 90% | Osteolysis, familial expansile, 174810 Osteopetrosis, autosomal recessive 7, 612301 {Paget disease of bone 2, early-onset}, 602080 |
| TNFRSF11B | 221.2 | 100% | 100% | Paget disease of bone 5, juvenile-onset, 239000 |
| TNFRSF13B | 87.9 | 100% | 100% | Immunodeficiency, common variable, 2, 240500 Immunoglobulin A deficiency 2, 609529 |
| TNFRSF13C | 45.5 | 91% | 58% | Immunodeficiency, common variable, 4, 613494 |
| TNFRSF1A | 77.4 | 91% | 86% | Periodic fever, familial, 142680 {Multiple sclerosis, susceptibility to, 5}, 614810 |
| TNFSF11 | 138.9 | 100% | 84% | Osteopetrosis, autosomal recessive 2, 259710 |
| TNIK | 105.1 | 100% | 97% | Mental retardation, autosomal recessive 54, 617028 |
| TNNC1 | 185.5 | 100% | 100% | Cardiomyopathy, dilated, 1Z, 611879 Cardiomyopathy, hypertrophic, 13, 613243 |
| TNNI2 | 121.0 | 100% | 100% | Arthrogryposis multiplex congenita, distal, type 2B, 601680 |

| | | | | |
|--------|-------|------|------|--|
| TNNI3 | 88.5 | 94% | 80% | Cardiomyopathy, dilated, 1FF, 613286 Cardiomyopathy, familial restrictive, 1, 115210 Cardiomyopathy, hypertrophic, 7, 613690 ?Cardiomyopathy, dilated, 2A, 611880 |
| TNNT1 | 79.1 | 98% | 96% | Nemaline myopathy 5, Amish type, 605355 |
| TNNT2 | 87.2 | 100% | 100% | Cardiomyopathy, dilated, 1D, 601494 Cardiomyopathy, familial restrictive, 3, 612422 Cardiomyopathy, hypertrophic, 2, 115195 Left ventricular noncompaction 6, 601494 |
| TNNT3 | 99.9 | 99% | 95% | Arthrogryposis, distal, type 2B, 601680 |
| TNPO3 | 127.9 | 100% | 99% | Muscular dystrophy, limb-girdle, type 1F, 608423 |
| TNXB | 13.0 | 50% | 24% | Ehlers-Danlos syndrome due to tenascin X deficiency, 606408 Vesicoureteral reflux 8, 615963 |
| TOPORS | 199.0 | 100% | 100% | Retinitis pigmentosa 31, 609923 |
| TOR1A | 196.2 | 100% | 98% | Dystonia-1, torsion, 128100 {Dystonia-1, modifier of} |
| TP53 | 89.1 | 97% | 91% | Adrenal cortical carcinoma, 202300 Breast cancer, 114480 Choroid plexus papilloma, 260500 Colorectal cancer, 114500 Hepatocellular carcinoma, 114550 Li-Fraumeni syndrome, 151623 Nasopharyngeal carcinoma, 607107 Osteosarcoma, 259500 Pancreatic cancer, 260350 {Basal cell carcinoma 7}, 614740 {Glioma susceptibility 1}, 137800 |
| TP63 | 170.5 | 100% | 100% | ADULT syndrome, 103285 Ectrodactyly, ectodermal dysplasia, and cleft lip/palate syndrome 3, 604292 Hay-Wells syndrome, 106260 Limb-mammary syndrome, 603543 Orofacial cleft 8, 129400 Rapp-Hodgkin syndrome, 129400 Split-hand/foot malformation 4, 605289 |
| TPI1 | 82.2 | 99% | 94% | Hemolytic anemia due to triosephosphate isomerase deficiency, 615512 |

| | | | | |
|-----------|-------|------|------|---|
| TPK1 | 106.4 | 100% | 94% | Thiamine metabolism dysfunction syndrome 5 (episodic encephalopathy type), 614458 |
| TPM1 | 135.1 | 100% | 99% | Cardiomyopathy, dilated, 1Y, 611878 Cardiomyopathy, hypertrophic, 3, 115196 Left ventricular noncompaction 9, 611878 |
| TPM2 | 94.4 | 100% | 97% | Arthrogryposis multiplex congenita, distal, type 1, 108120 Arthrogryposis, distal, type 2B, 601680 CAP myopathy 2, 609285 Nemaline myopathy 4, autosomal dominant, 609285 |
| TPM3 | 75.2 | 86% | 84% | CAP myopathy 1, 609284 Myopathy, congenital, with fiber-type disproportion, 255310 Nemaline myopathy 1, autosomal dominant or recessive, 609284 |
| TPO | 113.8 | 98% | 92% | Thyroid dyshormonogenesis 2A, 274500 |
| TPP1 | 130.9 | 100% | 100% | Ceroid lipofuscinosis, neuronal, 2, 204500 Spinocerebellar ataxia, autosomal recessive 7, 609270 |
| TPRN | 61.2 | 83% | 76% | Deafness, autosomal recessive 79, 613307 |
| TRAC | 170.5 | 100% | 100% | Immunodeficiency 7, TCR-alpha/beta deficient, 615387 |
| TRAF3IP1 | 63.4 | 94% | 92% | Senior-Loken syndrome 9, 616629 |
| TRAIP | 115.8 | 100% | 100% | Seckel syndrome 9, 616777 |
| TRAPP C11 | 110.1 | 97% | 94% | Muscular dystrophy, limb-girdle, type 2S, 615356 |
| TRAPP C2 | 117.9 | 85% | 73% | Spondyloepiphyseal dysplasia tarda, 313400 |
| TRAPP C9 | 123.3 | 100% | 100% | Mental retardation, autosomal recessive 13, 613192 |
| TRDN | 62.6 | 83% | 68% | Ventricular tachycardia, catecholaminergic polymorphic, 5, with or without muscle weakness, 615441 |
| TREM2 | 110.7 | 100% | 99% | Nasu-Hakola disease, 221770 |
| TREX1 | 216.3 | 100% | 100% | Aicardi-Goutieres syndrome 1, dominant and recessive, 225750 Chilblain lupus, 610448 Vasculopathy, retinal, with cerebral leukodystrophy, 192315 {Systemic lupus erythematosus, susceptibility to}, 152700 |
| TRIM2 | 138.7 | 99% | 95% | Charcot-Marie-Tooth disease, type 2R, 615490 |
| TRIM32 | 114.5 | 100% | 100% | Muscular dystrophy, limb-girdle, type 2H, 254110 ?Bardet-Biedl syndrome 11, 615988 |
| TRIM37 | 106.6 | 99% | 96% | Mulibrey nanism, 253250 |
| TRIO | 123.7 | 97% | 94% | Mental retardation, autosomal dominant 44, 617061 |
| TRIOBP | 102.5 | 97% | 94% | Deafness, autosomal recessive 28, 609823 |
| TRIP11 | 74.0 | 93% | 83% | Achondrogenesis, type IA, 200600 |

| | | | | |
|---------|-------|------|------|--|
| TRIP4 | 99.7 | 100% | 98% | Spinal muscular atrophy with congenital bone fractures 1, 616866 ?Muscular dystrophy, congenital, Davignon-Chauveau type, 617066 |
| TRMT10A | 121.7 | 100% | 100% | Microcephaly, short stature, and impaired glucose metabolism 1, 616033 |
| TRMT10C | 90.7 | 99% | 95% | Combined oxidative phosphorylation deficiency 30, 616974 |
| TRMT5 | 189.1 | 94% | 86% | Combined oxidative phosphorylation deficiency 26, 616539 |
| TRMU | 94.2 | 100% | 100% | Liver failure, transient infantile, 613070 {Deafness, mitochondrial, modifier of}, 580000 |
| TRNT1 | 91.9 | 95% | 89% | Retinitis pigmentosa and erythrocytic microcytosis, 616959 Sideroblastic anemia with B-cell immunodeficiency, periodic fevers, and developmental delay, 616084 |
| TRPA1 | 88.2 | 87% | 75% | Episodic pain syndrome, familial, 615040 |
| TRPC6 | 108.9 | 98% | 96% | Glomerulosclerosis, focal segmental, 2, 603965 |
| TRPM1 | 141.7 | 99% | 97% | Night blindness, congenital stationary (complete), 1C, autosomal recessive, 613216 |
| TRPM4 | 99.4 | 100% | 97% | Progressive familial heart block, type IB, 604559 |
| TRPM6 | 132.6 | 100% | 98% | Hypomagnesemia 1, intestinal, 602014 |
| TRPS1 | 160.1 | 100% | 100% | Trichorhinophalangeal syndrome, type I, 190350 Trichorhinophalangeal syndrome, type III, 190351 |
| TRPV3 | 140.7 | 100% | 97% | Olmsted syndrome, 614594 ?Palmoplantar keratoderma, nonepidermolytic, focal 2, 616400 |
| TRPV4 | 159.5 | 100% | 99% | Brachyolmia type 3, 113500 Digital arthropathy-brachydactyly, familial, 606835 Hereditary motor and sensory neuropathy, type IIc, 606071 Metatropic dysplasia, 156530 Parastremmatic dwarfism, 168400 Scapuloperoneal spinal muscular atrophy, 181405 SED, Maroteaux type, 184095 Spinal muscular atrophy, distal, congenital nonprogressive, 600175 Spondylometaphyseal dysplasia, Kozlowski type, 184252 [Sodium serum level QTL 1], 613508 |
| TSC1 | 120.4 | 99% | 97% | Lymphangiomyomatosis, 606690 Tuberous sclerosis-1, 191100 |
| TSC2 | 118.0 | 100% | 100% | Lymphangiomyomatosis, somatic, 606690 Tuberous sclerosis-2, 613254 |
| TSEN15 | 65.7 | 97% | 84% | Pontocerebellar hypoplasia, type 2F, 617026 |
| TSEN2 | 101.7 | 100% | 99% | Pontocerebellar hypoplasia type 2B, 612389 |

| | | | | |
|---------|-------|------|------|--|
| TSEN34 | 49.3 | 87% | 85% | Pontocerebellar hypoplasia type 2C, 612390 |
| TSEN54 | 77.1 | 94% | 90% | Pontocerebellar hypoplasia type 2A, 277470 Pontocerebellar hypoplasia type 4, 225753 ?Pontocerebellar hypoplasia type 5, 610204 |
| TSFM | 121.3 | 100% | 97% | Combined oxidative phosphorylation deficiency 3, 610505 |
| TSG101 | 85.4 | 98% | 95% | Breast cancer, somatic, 114480 |
| TSHB | 281.4 | 100% | 100% | Hypothyroidism, congenital, nongoitrous 4, 275100 |
| TSHR | 176.5 | 99% | 94% | Hyperthyroidism, familial gestational, 603373 Hyperthyroidism, nonautoimmune, 609152 Hypothyroidism, congenital, nongoitrous, 1 275200 Thyroid adenoma, hyperfunctioning, somatic Thyroid carcinoma with thyrotoxicosis |
| TSHZ1 | 134.7 | 98% | 98% | Aural atresia, congenital, 607842 |
| TSPAN12 | 117.5 | 100% | 99% | Exudative vitreoretinopathy 5, 613310 |
| TSPAN7 | 139.5 | 100% | 100% | Mental retardation, X-linked 58, 300210 |
| TSPEAR | 125.7 | 100% | 99% | Deafness, autosomal recessive 98, 614861 |
| TSPYL1 | 116.6 | 100% | 95% | Sudden infant death with dysgenesis of the testes syndrome, 608800 |
| TTBK2 | 131.2 | 100% | 99% | Spinocerebellar ataxia 11, 604432 |
| TTC19 | 82.0 | 85% | 79% | Mitochondrial complex III deficiency, nuclear type 2, 615157 |
| TTC21B | 92.0 | 99% | 97% | Nephronophthisis 12, 613820 Short-rib thoracic dysplasia 4 with or without polydactyly, 613819 |
| TTC25 | 81.9 | 100% | 99% | Ciliary dyskinesia, primary, 35, 617092 |
| TTC37 | 113.5 | 98% | 95% | Trichohepatoenteric syndrome 1, 222470 |
| TTC7A | 95.7 | 99% | 97% | Gastrointestinal defects and immunodeficiency syndrome, 243150 |
| TTC8 | 89.5 | 97% | 89% | Bardet-Biedl syndrome 8, 615985 ?Retinitis pigmentosa 51, 613464 |
| TTI2 | 91.0 | 98% | 95% | Mental retardation, autosomal recessive 39, 615541 |
| TTLL5 | 131.1 | 98% | 94% | Cone-rod dystrophy 19, 615860 |
| TTN | 171.1 | 98% | 97% | Cardiomyopathy, dilated, 1G, 604145 Cardiomyopathy, familial hypertrophic, 9, 613765 Muscular dystrophy, limb-girdle, type 2J, 608807 Myopathy, early-onset, with fatal cardiomyopathy, 611705 Myopathy, proximal, with early respiratory muscle involvement, 603689 Tibial muscular dystrophy, tardive, 600334 |

| | | | | |
|---------|-------|------|------|---|
| TTPA | 108.9 | 90% | 78% | Ataxia with isolated vitamin E deficiency, 277460 |
| TTR | 170.6 | 100% | 100% | Amyloidosis, hereditary, transthyretin-related, 105210 Carpal tunnel syndrome, familial, 115430 [Dystransthyretinemic hyperthyroxinemia], 145680 |
| TUBA1A | 73.8 | 100% | 92% | Lissencephaly 3, 611603 |
| TUBA4A | 169.1 | 100% | 100% | Amyotrophic lateral sclerosis 22 with or without frontotemoral dementia, 616208 |
| TUBA8 | 129.0 | 100% | 96% | Polymicrogyria with optic nerve hypoplasia, 613180 |
| TUBB | 16.5 | 67% | 39% | Cortical dysplasia, complex, with other brain malformations 6, 615771 Symmetric circumferential skin creases, congenital, 1, 156610 |
| TUBB1 | 128.1 | 100% | 100% | Macrothrombocytopenia, autosomal dominant, TUBB1-related, 613112 |
| TUBB2A | 85.4 | 100% | 96% | Cortical dysplasia, complex, with other brain malformations 5, 615763 |
| TUBB2B | 85.1 | 100% | 100% | Polymicrogyria, symmetric or asymmetric, 610031 |
| TUBB3 | 160.9 | 98% | 97% | Cortical dysplasia, complex, with other brain malformations 1, 614039 Fibrosis of extraocular muscles, congenital, 3A, 600638 |
| TUBB4A | 111.6 | 96% | 96% | Dystonia 4, torsion, autosomal dominant, 128101 Leukodystrophy, hypomyelinating, 6, 612438 |
| TUBB8 | 30.0 | 81% | 59% | Oocyte maturation defect 2, 616780 |
| TUBG1 | 127.6 | 100% | 100% | Cortical dysplasia, complex, with other brain malformations 4, 615412 |
| TUBGCP4 | 123.1 | 96% | 93% | Microcephaly and chorioretinopathy, autosomal recessive, 3, 616335 |
| TUBGCP6 | 134.6 | 100% | 99% | Microcephaly and chorioretinopathy, autosomal recessive, 1, 251270 |
| TUFM | 117.0 | 100% | 99% | Combined oxidative phosphorylation deficiency 4, 610678 |
| TULP1 | 84.0 | 97% | 91% | Leber congenital amaurosis 15, 613843 Retinitis pigmentosa 14, 600132 |
| TUSC3 | 128.3 | 100% | 99% | Mental retardation, autosomal recessive 7, 611093 |
| TWIST1 | 119.9 | 90% | 79% | Craniosynostosis, type 1, 123100 Robinow-Sorauf syndrome, 180750 Saethre-Chotzen syndrome with eyelid anomalies, 101400 Saethre-Chotzen syndrome, 101400 |
| TWIST2 | 101.2 | 100% | 98% | Ablepharon-macrostomia syndrome, 200110 Barber-Say syndrome, 209885 Focal facial dermal dysplasia 3, Setleis type, 227260 |
| TXNL4A | 108.6 | 100% | 99% | Burn-McKeown syndrome, 608572 |
| TYK2 | 98.8 | 100% | 99% | Immunodeficiency 35, 611521 |
| TYMP | 76.8 | 98% | 85% | Mitochondrial DNA depletion syndrome 1 (MNGIE type), 603041 |

| | | | | |
|--------|-------|------|------|---|
| TYR | 162.3 | 100% | 100% | Albinism, oculocutaneous, type IA, 203100 Albinism, oculocutaneous, type IB, 606952 Waardenburg syndrome/albinism, digenic, 103470 [Skin/hair/eye pigmentation 3, blue/green eyes], 601800 [Skin/hair/eye pigmentation 3, light/dark/freckling skin], 601800 {Melanoma, cutaneous malignant, susceptibility to, 8}, 601800 |
| TYROBP | 68.6 | 100% | 100% | Nasu-Hakola disease, 221770 |
| TYRP1 | 170.1 | 100% | 100% | Albinism, oculocutaneous, type III, 203290 [Skin/hair/eye pigmentation, variation in, 11 (Melanesian blond hair)], 612271 |
| UBA1 | 181.1 | 99% | 98% | Spinal muscular atrophy, X-linked 2, infantile, 301830 |
| UBE2A | 123.4 | 100% | 99% | Mental retardation, X-linked syndromic, Nascimento-type, 300860 |
| UBE2T | 106.2 | 100% | 100% | Fanconi anemia, complementation group T, 616435 |
| UBE3A | 84.2 | 98% | 92% | Angelman syndrome, 105830 |
| UBE3B | 115.2 | 100% | 98% | Kaufman oculocerebrofacial syndrome, 244450 |
| UBIAD1 | 199.8 | 100% | 96% | Corneal dystrophy, Schnyder type, 121800 |
| UBQLN2 | 145.1 | 99% | 97% | Amyotrophic lateral sclerosis 15, with or without frontotemporal dementia, 300857 |
| UBR1 | 116.3 | 99% | 95% | Johanson-Blizzard syndrome, 243800 |
| UGT1A1 | 188.5 | 100% | 100% | Crigler-Najjar syndrome, type I, 218800 Crigler-Najjar syndrome, type II, 606785 Hyperbilirubinemia, familial transient neonatal, 237900 [Bilirubin, serum level of, QTL1], 601816 [Gilbert syndrome], 143500 |
| UMOD | 109.1 | 97% | 96% | Glomerulocystic kidney disease with hyperuricemia and isosthenuria, 609886 Hyperuricemic nephropathy, familial juvenile 1, 162000 Medullary cystic kidney disease 2, 603860 |
| UMPS | 164.2 | 100% | 100% | Orotic aciduria, 258900 |
| UNC13D | 85.4 | 98% | 96% | Hemophagocytic lymphohistiocytosis, familial, 3, 608898 |
| UNC80 | 115.8 | 99% | 98% | Hypotonia, infantile, with psychomotor retardation and characteristic facies 2, 616801 |
| UNG | 60.3 | 95% | 90% | Immunodeficiency with hyper IgM, type 5, 608106 |
| UPB1 | 143.6 | 100% | 100% | Beta-ureidopropionase deficiency, 613161 |
| UPF3B | 57.5 | 94% | 85% | Mental retardation, X-linked, syndromic 14, 300676 |
| UQCRB | 90.7 | 99% | 93% | Mitochondrial complex III deficiency, nuclear type 3, 615158 |
| UQCRC2 | 124.5 | 100% | 100% | Mitochondrial complex III deficiency, nuclear type 5, 615160 |
| UQCRRQ | 131.9 | 100% | 100% | Mitochondrial complex III deficiency, nuclear type 4, 615159 |

| | | | | |
|--------|-------|------|------|---|
| UROD | 135.0 | 100% | 100% | Porphyria cutanea tarda, 176100 Porphyria, hepatoerythropoietic, 176100 |
| UROS | 91.7 | 100% | 100% | Porphyria, congenital erythropoietic, 263700 |
| USB1 | 112.9 | 100% | 97% | Poikiloderma with neutropenia, 604173 |
| USH1C | 92.2 | 100% | 99% | Deafness, autosomal recessive 18A, 602092 Usher syndrome, type 1C, 276904 |
| USH1G | 147.7 | 98% | 96% | Usher syndrome, type 1G, 606943 |
| USH2A | 136.1 | 100% | 99% | Retinitis pigmentosa 39, 613809 Usher syndrome, type 2A, 276901 |
| USP9X | 142.0 | 99% | 96% | Mental retardation, X-linked 99, 300919 Mental retardation, X-linked 99, syndromic, female-restricted, 300968 |
| USP9Y | .2 | 0% | 0% | Spermatogenic failure, Y-linked, 2, 415000 |
| UVSSA | 111.5 | 100% | 99% | UV-sensitive syndrome 3, 614640 |
| VAC14 | 104.5 | 100% | 99% | Striatonigral degeneration, childhood-onset, 617054 |
| VAMP1 | 123.8 | 100% | 100% | Spastic ataxia 1, autosomal dominant, 108600 |
| VANGL1 | 148.7 | 100% | 99% | Caudal regression syndrome, 600145 {Neural tube defects, susceptibility to}, 182940 |
| VANGL2 | 140.1 | 99% | 98% | Neural tube defects, 182940 |
| VAPB | 96.3 | 99% | 92% | Amyotrophic lateral sclerosis 8, 608627 Spinal muscular atrophy, late-onset, Finkel type, 182980 |
| VARS2 | 12.2 | 48% | 18% | Combined oxidative phosphorylation deficiency 20, 615917 |
| VCAN | 164.8 | 100% | 100% | Wagner syndrome 1, 143200 |
| VCL | 98.4 | 100% | 99% | Cardiomyopathy, dilated, 1W, 611407 Cardiomyopathy, hypertrophic, 15, 613255 |
| VCP | 124.6 | 100% | 99% | Amyotrophic lateral sclerosis 14, with or without frontotemporal dementia, 613954 Charcot-Marie-Tooth disease, type 2Y, 616687 Inclusion body myopathy with early-onset Paget disease and frontotemporal dementia 1, 167320 |
| VDR | 103.3 | 99% | 95% | Rickets, vitamin D-resistant, type IIA, 277440 ?Osteoporosis, involutional, 166710 |
| VEGFC | 150.2 | 100% | 97% | Lymphedema, hereditary, ID, 615907 |
| VHL | 95.9 | 92% | 81% | Erythrocytosis, familial, 2, 263400 Hemangioblastoma, cerebellar, somatic Pheochromocytoma, 171300 Renal cell carcinoma, somatic, 144700 |

| | | | | |
|---------|-------|------|------|--|
| | | | | von Hippel-Lindau syndrome, 193300 |
| VIPAS39 | 132.1 | 100% | 100% | Arthrogryposis, renal dysfunction, and cholestasis 2, 613404 |
| VKORC1 | 124.5 | 100% | 100% | Vitamin K-dependent clotting factors, combined deficiency of, 2, 607473 Warfarin resistance, 122700 |
| VLDLR | 191.3 | 100% | 100% | Cerebellar hypoplasia and mental retardation with or without quadrupedal locomotion 1, 224050 |
| VMA21 | 52.2 | 98% | 85% | Myopathy, X-linked, with excessive autophagy, 310440 |
| VPS11 | 134.7 | 99% | 98% | Leukodystrophy, hypomyelinating, 12, 616683 |
| VPS13A | 64.0 | 93% | 81% | Choreoacanthocytosis, 200150 |
| VPS13B | 126.1 | 99% | 96% | Cohen syndrome, 216550 |
| VPS13C | 100.6 | 96% | 88% | Parkinson disease 23, autosomal recessive, early onset, 616840 |
| VPS33B | 123.6 | 100% | 100% | Arthrogryposis, renal dysfunction, and cholestasis 1, 208085 |
| VPS37A | 63.8 | 86% | 66% | Spastic paraplegia 53, autosomal recessive, 614898 |
| VPS45 | 116.3 | 95% | 94% | Neutropenia, severe congenital, 5, autosomal recessive, 615285 |
| VPS53 | 118.9 | 90% | 89% | Pontocerebellar hypoplasia, type 2E, 615851 |
| VRK1 | 117.3 | 99% | 92% | Pontocerebellar hypoplasia type 1A, 607596 |
| VSX1 | 52.7 | 77% | 70% | Keratoconus 1, 148300 ?Craniofacial anomalies and anterior segment dysgenesis syndrome, 614195 |
| VSX2 | 59.5 | 100% | 92% | Microphthalmia with coloboma 3, 610092 Microphthalmia, isolated 2, 610093 |
| VWF | 96.5 | 98% | 96% | von Willebrand disease, type 1, 193400 von Willebrand disease, types 2A, 2B, 2M, and 2N, 613554 von Willibrand disease, type 3, 277480 |
| WAC | 151.8 | 98% | 97% | Desanto-Shinawi syndrome, 616708 |
| WAS | 67.0 | 88% | 79% | Neutropenia, severe congenital, X-linked, 300299 Thrombocytopenia, X-linked, 313900 Thrombocytopenia, X-linked, intermittent, 313900 Wiskott-Aldrich syndrome, 301000 |
| WDR11 | 120.8 | 96% | 96% | Hypogonadotropic hypogonadism 14 with or without anosmia, 614858 |
| WDR19 | 126.0 | 99% | 96% | Nephronophthisis 13, 614377 Senior-Loken syndrome 8, 616307 ?Cranioectodermal dysplasia 4, 614378 |

| | | | | |
|---------|-------|------|------|--|
| | | | | ?Short-rib thoracic dysplasia 5 with or without polydactyly, 614376 |
| WDR34 | 89.3 | 100% | 91% | Short-rib thoracic dysplasia 11 with or without polydactyly, 615633 |
| WDR35 | 138.1 | 99% | 94% | Cranioectodermal dysplasia 2, 613610 Short-rib thoracic dysplasia 7 with or without polydactyly, 614091 |
| WDR36 | 104.6 | 96% | 86% | Glaucoma 1, open angle, G, 609887 |
| WDR45 | 97.2 | 97% | 92% | Neurodegeneration with brain iron accumulation 5, 300894 |
| WDR60 | 96.0 | 97% | 93% | Short-rib thoracic dysplasia 8 with or without polydactyly, 615503 |
| WDR62 | 128.8 | 99% | 98% | Microcephaly 2, primary, autosomal recessive, with or without cortical malformations, 604317 |
| WDR72 | 131.1 | 99% | 98% | Amelogenesis imperfecta, type IIA3, 613211 |
| WDR73 | 116.6 | 100% | 99% | Galloway-Mowat syndrome, 251300 |
| WDR81 | 133.7 | 99% | 98% | Cerebellar ataxia, mental retardation, and dysequilibrium syndrome 2, 610185 |
| WFS1 | 193.9 | 99% | 98% | Deafness, autosomal dominant 6/14/38, 600965 Wolfram syndrome, 222300 Wolfram-like syndrome, autosomal dominant, 614296 ?Cataract 41, 116400 {Diabetes mellitus, noninsulin-dependent, association with}, 125853 |
| WHSC1L1 | 113.4 | 99% | 98% | Leukemia, acute myeloid, 601626 |
| WISP3 | 96.0 | 100% | 100% | Arthropathy, progressive pseudorheumatoid, of childhood, 208230 Spondyloepiphyseal dysplasia tarda with progressive arthropathy, 208230 |
| WNK1 | 137.9 | 99% | 97% | Neuropathy, hereditary sensory and autonomic, type II, 201300 Pseudohypoaldosteronism, type IIC, 614492 |
| WNK4 | 102.4 | 99% | 97% | Pseudohypoaldosteronism, type IIB, 614491 |
| WNT1 | 174.9 | 100% | 99% | Osteogenesis imperfecta, type XV, 615220 {Osteoporosis, early-onset, susceptibility to, autosomal dominant}, 615221 |
| WNT10A | 99.1 | 100% | 99% | Odontoonychodermal dysplasia, 257980 Schopf-Schulz-Passarge syndrome, 224750 Tooth agenesis, selective, 4, 150400 |
| WNT10B | 109.4 | 100% | 100% | Split-hand/foot malformation 6, 225300 |
| WNT4 | 204.8 | 92% | 92% | Mullerian aplasia and hyperandrogenism, 158330 SERKAL syndrome, 611812 |
| WNT5A | 145.5 | 100% | 100% | Robinow syndrome, autosomal dominant 1, 180700 |

| | | | | |
|---------|-------|------|------|--|
| WNT7A | 175.2 | 100% | 100% | Fuhrmann syndrome, 228930 Ulna and fibula, absence of, with severe limb deficiency, 276820 |
| WRAP53 | 136.1 | 100% | 100% | Dyskeratosis congenita, autosomal recessive 3, 613988 |
| WRN | 116.6 | 97% | 93% | Werner syndrome, 277700 |
| WT1 | 78.9 | 93% | 85% | Denys-Drash syndrome, 194080 Frasier syndrome, 136680 Meacham syndrome, 608978 Mesothelioma, somatic, 156240 Nephrotic syndrome, type 4, 256370 Wilms tumor, type 1, 194070 |
| WWOX | 121.4 | 100% | 100% | Epileptic encephalopathy, early infantile, 28, 616211 Esophageal squamous cell carcinoma, somatic, 133239 Spinocerebellar ataxia, autosomal recessive 12, 614322 |
| XDH | 93.7 | 100% | 99% | Xanthinuria, type I, 278300 |
| XIAP | 125.8 | 91% | 91% | Lymphoproliferative syndrome, X-linked, 2, 300635 |
| XIST | NC | NC | NC | X-inactivation,familial skewed,300087 |
| XK | 115.7 | 100% | 100% | McLeod syndrome with or without chronic granulomatous disease, 300842 |
| XPA | 46.1 | 92% | 69% | Xeroderma pigmentosum, group A, 278700 |
| XPC | 123.2 | 100% | 99% | Xeroderma pigmentosum, group C, 278720 |
| XPNPEP3 | 116.3 | 97% | 97% | Nephronophthisis-like nephropathy 1, 613159 |
| XPR1 | 124.9 | 99% | 97% | Basal ganglia calcification, idiopathic, 6, 616413 |
| XRCC4 | 83.0 | 100% | 91% | Short stature, microcephaly, and endocrine dysfunction, 616541 |
| XYLT1 | 114.7 | 93% | 88% | Desbuquois dysplasia 2, 615777 {Pseudoxanthoma elasticum, modifier of severity of}, 264800 |
| XYLT2 | 115.2 | 98% | 95% | Spondyloocular syndrome, 605822 {Pseudoxanthoma elasticum, modifier of severity of}, 264800 |
| YAP1 | 84.4 | 83% | 72% | Coloboma, ocular, 120433 Coloboma, ocular, with or without hearing impairment, cleft lip/palate, and/or mental retardation, 120433 |
| YARS | 112.2 | 100% | 98% | Charcot-Marie-Tooth disease, dominant intermediate C, 608323 |
| YARS2 | 144.8 | 100% | 96% | Myopathy, lactic acidosis, and sideroblastic anemia 2, 613561 |
| ZAP70 | 165.6 | 99% | 98% | Autoimmune disease,multisystem,infantile-onset,2,617006 Immunodeficiency 48,269840 |
| ZBTB16 | 128.0 | 100% | 99% | Leukemia, acute promyelocytic, PL2F/RARA type |

| | | | | |
|----------|-------|------|------|--|
| | | | | Skeletal defects, genital hypoplasia, and mental retardation, 612447 |
| ZBTB20 | 185.2 | 100% | 100% | Primrose syndrome, 259050 |
| ZBTB24 | 156.7 | 100% | 100% | Immunodeficiency-centromeric instability-facial anomalies syndrome-2, 614069 |
| ZC4H2 | 93.7 | 100% | 99% | Wieacker-Wolff syndrome, 314580 |
| ZDHHC9 | 80.9 | 100% | 99% | Mental retardation, X-linked syndromic, Raymond type, 300799 |
| ZEB1 | 170.3 | 100% | 98% | Corneal dystrophy, Fuchs endothelial, 6, 613270 Corneal dystrophy, posterior polymorphous, 3, 609141 |
| ZEB2 | 145.2 | 100% | 99% | Mowat-Wilson syndrome, 235730 |
| ZFP57 | 10.3 | 46% | 9% | Diabetes mellitus, transient neonatal, 1, 601410 |
| ZFPM2 | 175.8 | 100% | 100% | 46XY sex reversal 9, 616067 Diaphragmatic hernia 3, 610187 Tetralogy of Fallot, 187500 |
| ZFYVE26 | 101.8 | 99% | 98% | Spastic paraplegia 15, autosomal recessive, 270700 |
| ZFYVE27 | 106.0 | 100% | 100% | Spastic paraplegia 33, autosomal dominant, 610244 |
| ZIC1 | 147.0 | 100% | 100% | Craniosynostosis 6, 616602 |
| ZIC2 | 87.0 | 92% | 78% | Holoprosencephaly-5, 609637 |
| ZIC3 | 125.7 | 100% | 100% | Congenital heart defects, nonsyndromic, 1, X-linked, 306955 Heterotaxy, visceral, 1, X-linked 306955 VACTERL association, X-linked, 314390 |
| ZMPSTE24 | 110.8 | 100% | 97% | Mandibuloacral dysplasia with type B lipodystrophy, 608612 Restrictive dermopathy, lethal, 275210 |
| ZMYND10 | 119.9 | 100% | 100% | Ciliary dyskinesia, primary, 22, 615444 |
| ZMYND11 | 112.1 | 100% | 99% | Mental retardation, autosomal dominant 30, 616083 |
| ZNF408 | 100.6 | 100% | 100% | Retinitis pigmentosa 72, 616469 ?Exudative vitreoretinopathy 6, 616468 |
| ZNF41 | 137.3 | 100% | 100% | Mental retardation, X-linked 89, 300848 |
| ZNF423 | 218.5 | 100% | 100% | Joubert syndrome 19, 614844 Nephronophthisis 14, 614844 |
| ZNF469 | 76.0 | 99% | 96% | Brittle cornea syndrome 1, 229200 |
| ZNF513 | 95.9 | 100% | 100% | Retinitis pigmentosa 58, 613617 |
| ZNF644 | 143.8 | 100% | 99% | Myopia 21, autosomal dominant, 614167 |
| ZNF674 | 152.0 | 100% | 100% | Mental retardation, X-linked 92, 300851 |
| ZNF687 | 135.8 | 100% | 100% | Paget disease of bone 6, 616833 |

| | | | | |
|--------|-------|------|------|--|
| ZNF711 | 162.4 | 100% | 99% | Mental retardation, X-linked 97, 300803 |
| ZNF750 | 126.2 | 100% | 99% | Seborrhea-like dermatitis with psoriasiform elements, 610227 |
| ZNF81 | 127.1 | 100% | 98% | Mental retardation, X-linked 45, 300498 |
| ZP1 | 166.7 | 100% | 100% | Oocyte maturation defect 1, 615774 |
| ZSWIM6 | 137.9 | 95% | 90% | Acromelic frontonasal dysostosis, 603671 |

Gene symbols used follow HGNC guidelines: Gray KA, Yates B, Seal RL, Wright MW, Bruford EA. Nucleic Acids Res. 2015 Jan;43(Database issue):D1079-85.

Median Coverage describes the average number of reads seen across 50 exomes.

% Covered 10x describes the percentage of a gene's coding sequence that is covered at least 10x.

% Covered 20x describes the percentage of a gene's coding sequence that is covered at least 20x.

Genes with Median Coverage and % Covered 10x/20x denoting NC are non-coding genes for which coverage statistics could not be generated.

OMIM release used for OMIM disease identifiers and descriptions : October 1st, 2016.

This list is accurate for panel versions DG 2.7 and DG 2.8 From DG 2.7 to DG 2.8 no changes were made to the content of the gene panels.

Ad 1. "No OMIM phenotype" signifies a gene without a current OMIM association Ad 2. OMIM phenotype descriptions between {} signify risk factors
